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Chitin, a linear polymer of N-acetylglucosamine, is an essential structural component of fungal, 
nematode and insect pathogens but is not found in human physiology. Chitinases, which 
hydrolyze this polymer, play a key role in life cycle of these pathogens and associated 
pathogenesis. Consequently chitinase inhibitors have generated a lot of interest given their 
potential as insectides, fungicides and antimalarials. 
Herein, approaches are reported to the synthesis of some non-sugar based chitinase inhibitors: 
the cyclic pentapeptide natural products argifin, banyasin A and diketopiperazines related to 
the natural product CI-4.  
In order to improve the efficiency of production of argifin and facilitate SAR on analogues of 
the natural product, a revised synthesis of argifin has been developed. 
The synthesis of argifin was carried out by a combination of solid-phase and solution chemistry. 
The assembly of the linear peptide was carried out by SPPS and the cyclisation was performed 
in solution. The protecting groups chosen for the Asp and Arg residues were removable by 
hydrogenolysis, as this allowed aspartimide formation under acidic conditions to be avoided. 
Only one HPLC purification was required at the final step; argifin was isolated in 19% yield, 
compared to 18% yield for the first synthesis by Dixon et al. 
Banyasin A contains the same essential Arg(MC)-MePhe dipeptide motif as argifin and so it is 
of considerable interest as a potential Family 18 chitinase inhibitor. The synthesis of Amoa (3-
amino-2-methyl-5E-octenoic acid) a rare amino-acid present in banyasin A was investigated. 
An advanced intermediate for the synthesis of Amoa was successfully obtained via chiral pool 
chemistry in an 8 step sequence from L-Asp. This involved preparation of a selectively 
protected β-methyl-substituted Asp derivative, which was then homologated to the β-amino-
acid via Arndt-Eistert chemistry to give (3R,4R)-3-(((benzyloxy)carbonyl)amino)-4-methyl-5-
oxo-5-allyloxypentanoic acid in 27% yield for the final step. 
 
The cyclic dipeptide CI-4, cyclo (L-Arg-D-Pro) is a weak inhibitor (IC50 = 1.2 mM) of Family 
18 chitinases, however its binding efficiency index (BEI) is comparable to more potent 
inhibitors such as argifin. Some analogues of CI-4 show promising activity against a typical 
bacterial type Family 18 chitinase, SmChiB1 from Serratia marcescens. The cyclic dipeptide 
should therefore be a useful starting point for the development of more effective and selective 
inhibitors of this enzyme class. A series of cyclo (Xaa-Pro)-based dipeptides were synthesized, 
iii 
 
with different Xaa such as L/D-Pro, Gly, L-Ser, L/D-Arg, D-His, D-Phe, with yields ranging 
from 12 to 84%. Preliminary biological data confirm that cyclo (D-Xaa-D-Pro) may be a novel 





























First of all I would like to thank the University of Bath for funding my PhD scholarship. 
 
I would like to take this opportunity to express all my gratitude and appreciation to my 
supervisor Dr. Ian Eggleston for the support, encouragement, through these four years. Thank 
you for your guidance and patience that allowed me to complete my PhD. I would like to thank 
Dr. Gustav Vaaje-Kolstad (Norwegian University of Life Sciences, Ǻs, Norway) for testing a 
series of CI-4 chitinase inhibitors against the bacterial chitinase SmChB1.  
I would like to acknowledge Dr. Tim Woodman for running the NMR spectra and Dr. Anneka 
Lubben for her technical support regarding mass spectrometry data processing. Also I would 
like to thank Christian Rehbein for running some of my mass spectrometry samples. I would 
like to thank Linda Humphreys for helping me to solve issues on Endnote Web. 
I would like to thank Dr. Andy Riley, Dr. Steve Mills and Dr. Matthew Lloyd for their 
contributions throughout this project. Your support with ideas has been highly appreciated. 
Thank you to all members of Lab 3.11 past and present for being friendly and making this place 
full of warmth. Thank you  to Dr. Emma Casey and Dr. Joanna Swarbrick for the “Thursday 
literature sessions” that allowed us to practice reaction mechanisms in organic chemistry as 
well to get a deeper knowledge in medicinal chemistry. 
I would like to thank Dr. Olivier Reelfs, Dr. Amit Nathubhai and Pascal Loizeau for their 
encouragement through my writing up. Special thanks go to Dr. Elvis Twum for his valuable 
help through my PhD, his patience to explain Endnote and encouragement. 
To my group, I would like to thank Dr. Benjamin Young for the enjoyable time that we had in 
the laboratory. Also my thanks to Dr. Ruggero Dondi and Kunal Tewari for their help about 
extracting the HPLC data. 
When I lived in Bath, I found very nice people at Sladebrook community; I would like to thank 
all of them for their love, support and encouragement. I would like to thank John Martin for 
reviewing this work. Special mention goes to Bonnett’s family, for helping me through these 
long years, providing me “a tasty homemade dinner”, thank you for being there for me. 
v 
 
Back home in France, I would like to thank all my family and friends for making this happen, 













































Abstract ....................................................................................................................................... ii 
Acknowledgements ................................................................................................................... iv 
List of Schemes ....................................................................................................................... xiv 
List of Tables .......................................................................................................................... xvii 
List of abbreviations .............................................................................................................. xviii 
1. Introduction ....................................................................................................................................... 1 
1.1. Chitin ............................................................................................................................... 1 
1.2. Role of chitin in insects .................................................................................................. 2 
1.3. Chitin metabolism in insects and microorganisms ..................................................... 3 
1.4. Chitin biosynthesis ......................................................................................................... 4 
2. Chitinases and their classification ................................................................................................... 6 
2.1. Family 18 chitinases: structural biology and catalytic mechanism ........................... 8 
2. 2. Chitinases: occurrence and regulation ....................................................................... 9 
2.2.1. Importance of chitinases in metabolism .............................................................. 10 
2.2.2. Chitinases in insects .............................................................................................. 10 
2.2.3. Chitinases in plants ............................................................................................... 13 
2.2.4. Role of chitinases in other microorganisms (bacteria, nematodes and fungi) . 15 
2.2.5. Chitinases in Humans ........................................................................................... 16 
2.3. Targeting chitinases ................................................................................................. 18 
2.4. Bacterial and plant chitinases classes ..................................................................... 19 
3. Existence of natural product chitinase inhibitors ........................................................................ 22 
3.1. Allosamidin ................................................................................................................... 22 
3.3. Styloguanidines ............................................................................................................ 26 
3.4. Cyclic Dipeptides .......................................................................................................... 27 
3.4.1. CI-4, cyclo(L-Arg-D-Pro) ..................................................................................... 28 
3.5. Cyclopentapeptides ...................................................................................................... 30 
3.5.1. Argifin .................................................................................................................... 31 
3.5.2. Banyasin A ............................................................................................................. 33 
3.5.3. Argadin ................................................................................................................... 34 
3.6. Methylxanthines ........................................................................................................... 34 
4. Synthetic chitinase inhibitors ......................................................................................................... 35 
vii 
 
4.1. Bacterial-type chitinase inhibitors ............................................................................. 35 
4.1.2. Closantel plus related derivatives ........................................................................ 39 
4.1.3. AMCase inhibitors from high throughput screening ........................................ 40 
4.2. Plant chitinase inhibitors ............................................................................................. 42 
4.2.1. Guanylurea and derivatives ................................................................................. 43 
4.3. Objectives of the project: ............................................................................................ 45 
5. Results and discussion ..................................................................................................................... 46 
5.1. Approaches to argifin and related peptides .............................................................. 46 
5.1.1 Strategy avoiding aspartimide formation ............................................................ 46 
5.1.2. Introducing the guanylurea group of argifin; strategy avoiding the double 
acylation ........................................................................................................................... 57 
5.1.3. Approaches to alternative reagents for the direct conversion of Orn to 
Arg(MC) ........................................................................................................................... 64 
5.1.4. Conclusion and future work: ............................................................................... 70 
5.2. Approaches to Amoa: key component of banyasin A ............................................... 72 
5.2.5. Approaches to Amoa synthesis using displacement reactions for introduction 
of the amino function ...................................................................................................... 83 
5.2.6. Synthesis of (123) via a tosylate ............................................................................ 86 
5.2.7 Synthesis of (122) via the mesylate ........................................................................ 87 
5.2.8. Synthesis of (123) via the triflate .......................................................................... 87 
5.3. Chiral pool approach towards the synthesis of Amoa .............................................. 88 
5.3.1. Summary on the aldol strategy ............................................................................ 89 
5.3.2. Aspartic and glutamic acid starting scaffolds .................................................... 89 
5.3.3. Aspartic acid as a scaffold in alkaloid synthesis ................................................. 91 
5.3.4. Aspartic acid for formation of lactams ............................................................... 92 
5.3.5. Aspartic acid in the synthesis of the novel amino acid NMeOHIle .................. 92 
5.3.6. Aspartic acid used in our strategy towards the synthesis of Amoa .................. 93 
5.3.7. Conclusion and future work ............................................................................... 120 
5.4. 2,5-Diketopiperazines : proline-containing cyclodipeptides as potential Family 18  
chitinase inhibitors. ........................................................................................................... 121 
5.4.1. DKP in nature ...................................................................................................... 121 
5.4.3. Proline-containing DKP derivatives and their biological activities ................ 125 
5.4.4. Approaches to the synthesis of 2,5-diketopiperazines...................................... 128 
5.4.5.  Biological data .................................................................................................... 136 
viii 
 
5.4.6. Conclusion and future work ............................................................................... 138 
6. Overall conclusions ....................................................................................................................... 142 
7. Experimental ................................................................................................................................. 142 
7.1 General ......................................................................................................................................... 142 
7.2. Approaches to argifin and related peptides. ............................................................... 145 
7.2.1. Improved synthesis of argifin by use of hydrogenolysable protecting groups.
 ......................................................................................................................................... 145 
H-Asp(OBn)-D-Ala-Arg(Z)2-MePhe-Asp-OBn (59) ................................................ 145 
Cyclo (βAsp(OBn)-D-Ala-Arg(Z2)-MePhe- β Asp(OBn)) (60) .................................. 146 
Cyclo(βAsp-D-Ala-Arg-MePhe-βAsp) (61) ................................................................. 146 
Cyclo(βAsp-D-Ala-Arg(MC)-MePhe-βAsp)161 (72) .................................................... 149 
7.2.2.  Approaches to alternative reagents for the direct conversion of Orn to 
Arg(MC) ......................................................................................................................... 149 
N,N’-di-Boc-N’’-benzylguanidine (65)161 .................................................................... 149 
N,N’-di-Z-guanidine (68)161 .......................................................................................... 150 
N,N’-di-Z-N’’-trifluoromethanesulfonylguanidine (69) ............................................ 152 
N’’-benzyl-N,N’-di-Z-guanidine (70)164 ....................................................................... 152 
(E)-Benzyl (benzylamino) (3-methylureido) methylenecarbamate (71) ................... 153 
Attempted conversion of cyclic peptide (60) into guanylurea derivative (72) ......... 154 
Ac-Arg(Z)2-MePhe-Asp-OH (74) ................................................................................. 154 
Ac-Arg(Z)2-MePhe-Asp-OBn (77) ............................................................................... 155 
Attempted preparation of Ac-Arg( Z, CONHMe)-MePhe-Asp-OBn (75) ............... 156 
Attempted preparation of Ac-Arg(Z, CONHMe)-MePhe-Asp-CONHMe (78) ...... 157 
Nδ-Nε-Bis(benxyloxycarbonyl)-Nα-(fluorine-9-ylmethoxycarbonyl)-L-arginine-N-
methlamide (80) ............................................................................................................. 157 
Nα-Acetyl-Nδ,Nε-bis(benzyloxycarbonyl)-L-arginine-N-methylamide (81) .............. 158 
Attempted preparation of Nα-Acetyl-Nε-(benzylaminocarbonyl)-Nδ-
benzyloxycarbonyl-L-arginine-N-methylamide (83) .................................................. 159 
Attempted preparation of  Nα-Acetyl-Nδ-benzyloxycarbonyl-Nε-
(methylaminocarbonyl)-L-arginine-N-methylamide (82) .......................................... 160 
7.2.3. Approaches to alternative reagents for the direct conversion of Orn (or simple 
amines) to Arg(MC) and analogues ............................................................................. 161 
N-Benzyl-N-methylcarbamoyl chloride (90)170 ........................................................... 161 
Attempted preparation of benzyl -((benzyl(methyl)carbamoyl)imino)(1H-pyrazol-1-
yl)methyl)carbamate (92) ............................................................................................. 162 
ix 
 
1,3-di-Boc-guanidine (95)164.......................................................................................... 164 
tert-Butoxy(3-methylureido)carbamide (96) ............................................................... 164 
tert-Butyl (N-benzyl(methyl)carbamoyl]carbamimidoyl)carbamate (97) ................ 165 
tert-Butyl (N-4-methoxybenzyl)methyl)carbamoylcarbamimidoyl)carbamate (98)166 
Attempted preparation of benzyl [N-(methylcarbamoyl)carbamimidoyl]carbamate 
(99) .................................................................................................................................. 166 
Benzyl (N-[benzyl(methyl)carbamoyl]cabamimidoyl)carbamate (100) ................... 167 
Benzyl (N-[(4-methoxybenzyl)methyl)carbamoyl]carbamimidoyl)carbamate (101)
 ......................................................................................................................................... 168 
tert-butyl(N-(tert-butoxycarbonyl)-N’-[(4-methoxybenzyl)(methyl)carbamoyl] 
carbamimidoyl)carbamate (103) .................................................................................. 169 
Attempted preparation of tert-butyl (N-(4-methoxybenzyl)(methyl)carbamoyl-N’-
(trifluoromethyl)sulfonyl carbamimidoyl)carbamate (102) ...................................... 170 
7.3. Approaches to Amoa – key component of banyasin A. .............................................. 145 
   7.3.1. Investigation of Ti aldol route towards saturated Amoa ................................. 171 
(4R,5S)-4-Methyl-5-phenyl-3-propanoyloxazolidin-2-one (107) ............................... 171 
(4R,5S)-3-[(2R,3S)-3-Hydroxy-2-methyloctanoyl]-4-methyl-5-phenyl-1,3-oxazolidin-
2-one (122)184 .................................................................................................................. 172 
7.3.2.Displacement reactions ........................................................................................ 173 
Attempted preparation of (4R,5S)-3-(2R,3R)-3-azido-2-methyloctanoyl)-4-methyl-5-
phenyloxazolidin-2-one (123) ....................................................................................... 173 
Attempted preparation of (2R,3S)-2-methyl-1-((4R,5S)-4-methyl-2-oxo-5-
phenyloxazolidin-3-yl)-1-oxooctan-3-yl 4-methylbenzenesulfonate (129) ................ 174 
(2R,3S)-2-Methyl-1-((4R,5S)-4-methyl-2-oxo-5-phenyloxazolidin-3-yl)-1-oxooctan-3-
yl methanesulfonate (130) ............................................................................................. 175 
Attempted preparation of (4R,5S)-3-((2R,3R)-3-azido-2-methyloctanoyl)-4-methyl-5-
phenyloxazolidin-2-one (123) ....................................................................................... 176 
(2R,3S)-2-methyl-1-((4R,5S)-4-methyl-2-oxo-5-phenyloxazolidin-3-yl)-1-oxooctan-3-
yl trifluoromethanesulfonate (132) .............................................................................. 177 
Attempted preparation of (4R,5S)-3-((2R,3R)-3-azido-2-methyloctanoyl)-4-methyl-5-
phenyloxazolidin-2-one (123) ....................................................................................... 178 
7.3.3. Aldol route towards unsaturated Amoa ............................................................ 178 
3-(Benzyloxy)propanol253 (121) .................................................................................... 178  
3-(Benzyloxy)propanal (112)179, 180 ............................................................................... 179 
(4R,5S)-3-[(2R,3S)-5-(Benzyloxy)-3-hydroxy-2-methylpentanoyl]-4-methyl-5-phenyl-
1,3-oxazolidin-2-one (113) ............................................................................................. 180 
x 
 
7.4. Chiral pool route towards synthesis of Amoa .......................................................................... 181 
Boc-Asp(OMe)-OMe (158)254 ....................................................................................... 182 
(2S,3R) and (2S,3S)-dimethyl-2-((tert-butoxycarbonyl)amino)-3-methylsuccinate198 
(159a) and (159b) ........................................................................................................... 182 
Attempted preparation of (2S,3R)-2-amino-4-methoxy-3-methyl-4-oxobutanoic 
acid200 (162) .................................................................................................................... 183 
(2S)-4-(Allyloxy)-2-amino-4-oxobutanoic acid (180)203, 204 ........................................ 184 
(2S)-4-(Allyloxy)-2-(benzyloxycarbonylamino)-4-oxobutanoic acid204 (181) ........... 185 
(2S)-4-Allyl-1-tert-butyl-2-(((benzyloxy)carbonyl)amino)succinate (150) 204 ........... 186  
(2R,3S)-1-Allyl 4-tert-butyl 3-(benzyloxycarbonylamino)-2-
methylbutanedioate193(171) .......................................................................................... 189 
Preparation of (2S,3R)-4-(allyloxy)-2-((benzyloxy)carbonyl)amino)-3-methyl-4-
oxobutanoic acid   (173)185 ............................................................................................ 192 
(2R,3S)-Allyl-3-((benzyloxy)carbonyl)amino)-4-(methoxy(methyl)amino)-2-methyl-
4-oxobutanoate (174) ..................................................................................................... 194 
Attempted preparation of (2R,3S)-allyl-3-(((benzyloxy)carbonyl)amino)-2-methyl-4-
oxobutanoate (176) ........................................................................................................ 195 
(2R,3S)-Allyl-3-(((benzyloxy)carbonyl)amino)-4-(ethylthio)-2-methyl-4-
oxobutanoate (175) ........................................................................................................ 196 
(2R,3S)-Allyl-3-((benzyloxy)carbonyl)amino-5-diazo-2-methyl-4-oxopentanoate 
(192) ................................................................................................................................ 200 
(3R,4R)-3-(Benzyloxycarbonylamino)-4-methyl-5-oxo-5-allyloxypentanoic acid (193)
 ......................................................................................................................................... 201 
7.5. Synthesis of diketopiperazines. ..................................................................................... 202 
Fmoc-D-Pro-D-Pro-OMe (224) .................................................................................... 202 
Fmoc-L-Pro-L-Pro-OMe (227)..................................................................................... 203 
Fmoc-Gly-D-Pro-OMe (229) ........................................................................................ 204 
Boc-L-Pro-L-Pro-OMe (231)256 .................................................................................... 205 
Boc-D-Pro-D-Pro-OMe (233) ....................................................................................... 206 
Boc-Gly-D-Pro-OMe (235) ........................................................................................... 207 
Boc-D-Ser(OBn)-D-Pro-OMe (237) ............................................................................. 207 
Boc-L-Ser(OBn)-L-Pro-OMe (239)262,263 ..................................................................... 208 
Fmoc-D-His(Trt)-D-Pro-OMe (241) ............................................................................ 209 
Fmoc-D-Phe-D-Pro-OMe (243) .................................................................................... 210 
Boc-D-Tyr(OBn)-D-Pro (245) ...................................................................................... 211 
xi 
 
Fmoc-L-Arg(Pmc)-L-Pro-OMe (247) .......................................................................... 212 
Fmoc-D-Arg(Pmc)-L-Pro-OMe (250) .......................................................................... 214 
Fmoc-D-Arg(Pmc)-D-Pro-OMe (251) ......................................................................... 215 
Attempted preparation of cyclo(D-Pro-D-Pro) (252) ................................................. 216 
Cyclo(D-Pro-D-Pro) (252)222......................................................................................... 217 
Attempted preparation of cyclo(L-Pro-L-Pro) (215) ................................................. 217 
Cyclo(L-Pro-L-Pro) (215)258 ......................................................................................... 218 
Attempted preparation of cyclo (Gly-D-Pro) (253) .................................................... 219 
Cyclo (Gly-D-Pro) (253)265 ............................................................................................ 219 
Cyclo(D-Ser(OBn)-D-Pro) (254) .................................................................................. 220 
Cyclo(D-His(Trt)-D-Pro) (256)..................................................................................... 222 
Cyclo(D-Phe-D-Pro) (213)239 ........................................................................................ 223 
Cyclo (D-Tyr(OBn)-D-Pro) (257) ................................................................................. 224 
Cyclo (L-Arg(Pmc)-L-Pro) (258) ................................................................................. 224 
Cyclo (L-Arg(Pmc)-D-Pro) (259) ................................................................................. 225 
Cyclo (D-Arg(Pmc)-L-Pro) (260) ................................................................................. 227 
Cyclo (D-Arg(Pmc)-D-Pro) (261) ................................................................................. 228 
Cyclo(D-Arg-D-Pro) (262) ............................................................................................ 229 
Cyclo (D-His-D-Pro) (263) ............................................................................................ 229 



















List of Figures 
 
Figure 1: Structure of chitin ...................................................................................................... 1 
Figure 2: Microstructure of lobster cuticle as shown by by SEM.7........................................... 1 
Figure 3: Biosynthesis of chitin in insects. Images adapted  from Merzendorfer.5 .................. 5 
Figure 4: (a) The active site of a bacterial-type exo-chitinase, Serratia marcescens chitinase B 
SmChiB, (b) a plant-type endo-chitinase, hevamine, (Image courtesy of Prof. D. M. F. van 
Aalten, University of Dundee).................................................................................................. 20 
Figure 5.  Sequence alignment of chitinase ChiB from Serratia marcescens, ChiA from 
Serratia marcescens and hevamine  from Hevea brasiliensis. The catalytic regions of TIM 
barrel β-strands are indicated by β1–8. Glu144 is part of the Family 18 DxxDxDxE motif. The 
following definitions of loops and domains are: the α/β-domain (residues 295–373), the linker 
(residues 425–450) and the ChBD (residues 451–498), the porch loop (residues 14–27), the 
support loop (residues 233–262), the flexible loop (residues 315–325).123 ............................. 22 
Figure 6. Structure of allosamidin. .......................................................................................... 23 
Figure 7. Structure of allosamizoline....................................................................................... 24 
Figure 8. Allosamidin and its derivatives. ............................................................................... 24 
Figure 9. Structures of Psammaplins. ...................................................................................... 26 
Figure 10. Styloguanidine structures. ...................................................................................... 27 
Figure 11. Structure of CI-4..................................................................................................... 28 
Figure 12. Comparison of the SmChiB with allosamidin, CI-4 and cyclo-(L-Arg-L-Pro)...... 30 
Figure 13. Structure of argifin. ................................................................................................ 32 
Figure 14.  X-ray crystal structure of Argifin-AfChiB1 complex. ........................................... 33 
Figure 15.  Banyasin A. ........................................................................................................... 34 
Figure 16. Argadin structure. ................................................................................................... 35 
Figure 17. Structures of methylxanthines. ............................................................................... 36 
Figure 18. 3-Methylxanthine scaffolds as potential inhibitors of AfChiB1. ............................ 38 
Figure 19. Structures of bisdionins. ......................................................................................... 39 
Figure 20. Structure of closantel (28) and its derivative (29). ................................................. 40 
Figure 21. Structure of OvCHT1 inhibitors. ............................................................................ 41 
Figure 22. Structure of AMCase inhibitors. ............................................................................ 42 
Figure 23. Structures of AMCase inhibitors identified by FBS. ............................................. 42 
Figure 24. Competitive inhibitors of ScCTS1. ........................................................................ 43 
Figure 25. Structure of alkylguanylureas. ............................................................................... 44 
Figure 26. Sunazuka’s guanidination reagent. ......................................................................... 52 
Figure 27. HPLC trace of isolated cyclic pentapeptide (60) and the linear peptide (59). ....... 54 
Figure 28. Compounds resulting from the hydrogenolysis of protected cyclic peptide (60). . 55 
Figure 29. HPLC trace of the partially deprotected cyclic pentapeptides (62) and  (63). ....... 56 
Figure 30. HPLC trace of the fully deprotected cyclic pentapeptide (61). .............................. 57 
Figure 31. HPLC trace of argifin (16). .................................................................................... 58 
Figure 32.  HPLC trace of the  aminolysis reaction with (60) after 72 h. ................................ 62 
Figure 33. (102) and (103); potential reagents for the direct conversion of amines to protected 
methylguanylureas. ................................................................................................................... 70 
xiii 
 
Figure 34. Structure of banyasin A (104). ............................................................................... 73 
Figure 35. 3-Amino-2-methyl-5E-octenoic acid (Amoa) (105) – the -amino acid component 
of banyasin A. ........................................................................................................................... 73 
Figure 36.  Compound (150) ................................................................................................. 100 
Figure 37.  Proposed chelated transition state in alkylation of (171).210 ............................... 111 
Figure 38. Trimethylsilylmethyl ester derivative formed during attempted Arndt-Eistert 
synthesis.220 ............................................................................................................................ 120 
Figure 39. Natural  2,5-DKP- and  epithiodiketopiperazines ................................................ 122 
Figure 40. Spirodiketopiperazine (198) and its derivatives. .................................................. 123 
Figure 41. Spirodiketopiperazine derivatives. ....................................................................... 124 
Figure 42. Tryprostatins A and B. ......................................................................................... 124 
Figure 43. Tryprostatin C with D-Pro-L-Trp stereochemistry. ............................................. 125 
Figure 44. Trypostatin A analogues   modification at the indole ring. .................................. 125 
Figure 45. Trypostatin A analogues  modification of the L-proline ring. ............................. 125 
Figure 46. DKP structure in natural peptide antibiotics. ....................................................... 126 
Figure 47. Proline based DKPs with antimicrobial activity. ................................................. 127 
Figure 48. Proline-based DKPs examined as neuroprotective agents. .................................. 127 
Figure 49. Antifungal chitinase inhibitors. ............................................................................ 128 
Figure 50. (a) HPLC trace of (259) plus epimer from the reaction at 65 °C in MeOH; (b) pure 























List of Schemes 
 
Scheme 1.  The catalytic cycle of Family18 exo-chitinases. ..................................................... 9 
Scheme 2. Degradation of chitin by bacterial chitin-processing enzymes, adapted from 
Aronson et al.53 ......................................................................................................................... 20 
Scheme 3. Synthesis of Psammaplin A. ................................................................................... 26 
Scheme 4. First total synthesis of argifin. ................................................................................ 48 
Scheme 5. Dixon’s on-resin synthesis of argifin.146 ................................................................ 50 
Scheme 6.  Aspartimide formation from β-Asp peptides. ........................................................ 51 
Scheme 7. Improved synthesis of argifin – synthesis of protected cyclic peptide (60). .......... 54 
Scheme 8. Hydrogenolysis of (60). .......................................................................................... 55 
Scheme 9. Aminolysis of  the Boc-protected guanidine (65) to give guanylurea (66). ........... 58 
Scheme 10. Aminolysis of the Z-protected guanidine (70). .................................................... 59 
Scheme 11.  Mechanism of aminolysis via an isocyanate proposed by Miel and Rault.162 ..... 59 
Scheme 12. Attempted conversion of  (60) to guanylurea (72), using methylamine............... 60 
Scheme 13. Investigation of aminolysis reaction on the tripeptides. ....................................... 62 
Scheme 14. Synthesis of model compound (81) and attempted aminolyses. .......................... 63 
Scheme 15. Pyrazole-based guanidinylating reagent (87) developed by Sunazuka.144 ........... 64 
Scheme 16. First attempted preparation of pyrazole-based guanidinylating agent (92) with 
hydrogenolysable protecting groups. ........................................................................................ 65 
Scheme 17. Second attempted preparation of (93). ................................................................. 66 
Scheme 18. Diprotected triflylguanidine reagents for guanidinylation of amines................... 66 
Scheme 19. Formation of guanidines or guanylureas from tri-Boc guanidine. ....................... 67 
Scheme 20. Boc-protected guanidine derivatives. ................................................................... 67 
Scheme 21. Synthesis of guanylureas (99)-(101): precursors for guanidinylating agents. ...... 68 
Scheme 22. Attempted preparation of potential guanidinylating agents (102) and (103). ...... 70 
Scheme 23. Transition states to access  (A) “non-Evans syn” aldol adducts, (B) “Evans syn” 
aldol adducts  via chlorotitanium enolates. .............................................................................. 73 
Scheme 24. Synthesis of one diastereoisomer of (105) based on diastereoselective aldol 
chemistry. ................................................................................................................................. 75 
Scheme 25. Synthesis of (2S, 3S) and (2S, 3R)-3-amino-2-methylhexanoic acids.173 ............. 76 
Scheme 26. Synthesis of (2R, 3R) and  (2R, 3S)-3-amino-2-methylhexanoic acids.173 ........... 76 
Scheme 27. Proposed synthetic approach for the preparation of one single diastereoisomer of 
(105) as the Fmoc-protected derivative. ................................................................................... 78 
Scheme 28. Synthesis of aldehyde (112). ................................................................................ 78 
Scheme 29. Synthesis of the syn aldol product (113). ............................................................. 79 
Scheme 30. Synthetic approach to reduced Amoa analogue (122) and banyasin A analogue 
(126). ........................................................................................................................................ 81 
Scheme 31. Synthesis of the syn aldol product (122). ............................................................. 82 
Scheme 32. Conversion of (122) to dolabellin-derived material.184 ........................................ 82 
Scheme 33. Mitsunobu reaction between an alcohol and nucleophilic species, Nu (Nu = N3).
 .................................................................................................................................................. 83 
Scheme 34. Mitsunobu reaction  mechanism. .......................................................................... 84 
xv 
 
Scheme 35. Mechanism of the Mitsunobu reaction occuring on (122) with DPPA. ............... 85 
Scheme 36. Mitsunobu reactions with (122) and DPPA as azide source. ............................... 85 
Scheme 37. Attempted conversion of aldol (123) to tosylate (129). ....................................... 86 
Scheme 38. Preparation and attempted displacement of mesylate (130). ................................ 87 
Scheme 39. Synthesis and attempted displacement of triflate (132). ...................................... 88 
Scheme 40. Synthesis of an S-(N-Aryl-N-hydroxamate) analogue of glutathione.189 ............. 90 
Scheme 41. Synthetic route to (+)-vincamine, based on  L-Asp diesters.190 ........................... 91 
Scheme 42. Preparation of a lactam inhibitor (149) of tumor necrosis factor-α converting 
enzyme from L-Asp.191 ............................................................................................................. 92 
Scheme 43. Synthesis of NMeOHIle from L-Asp.193 .............................................................. 93 
Scheme 44. Planned retrosynthesis of compound (119). ......................................................... 94 
Scheme 45. Wittig reaction, using an enol ylide for aldehyde homologation.196 .................... 94 
Scheme 46. Modified Julia-Kocienski olefination by Pospisil.197 ........................................... 95 
Scheme 47. Synthesis of the β-methyl-L-Asp derivatives (159a) and (159b).198 .................... 95 
Scheme 48. Proof of the stereochemistry of (159a).198 ............................................................ 96 
Scheme 50. Alkylation of aspartic acid derivatives under Hanessian’s conditions.199 ............ 97 
Scheme 51. Planned synthesis for Amoa from L-aspartic acid. .............................................. 99 
Scheme 52. Attempted preparation of (180) – Method A.203 ................................................... 99 
Scheme 53. Preparation of Z-Asp(OAll)-OH - Method B.204 ................................................ 100 
Scheme 54. β-Esterification of  Z-Asp-OMe.205 .................................................................... 100 
Scheme 55. α-Esterification of (181).205 ................................................................................ 101 
Scheme 56. Mechanism of synthesis of α-aspartate esters via Boc2O/DMAP. ..................... 102 
Scheme 57. α-Esterification of Z-Asp(OAll)-OH.206 ............................................................. 102 
Scheme 58. Mechanism of synthesis of α-aspartate esters via IPCC/DMAP method. .......... 103 
Scheme 59. α-Esterification of Z-Asp(OAll)-OH.207 ............................................................. 103 
Scheme 60. α-Esterification of Z-Asp(OAll)-OH.208 ............................................................. 104 
Scheme 61. α-Esterification using DCC-DMAP. .................................................................. 105 
Scheme 62. Attempted α-esterification of (181) using DCC-DMAP. ................................... 105 
Scheme 63. Mechanism of esterification with DCC-HOBt. .................................................. 105 
Scheme 64. Attempted α-esterification of (181) with DCC-HOBt. ....................................... 106 
Scheme 65. Boc anhydride-promoted esterification of (181). ............................................... 106 
Scheme 66.  β-Alkylation reaction on (150) according to Park et al.198 ................................ 107 
Scheme 67. β-Alkylation reaction on (150) according to Yu et al.193 ................................... 107 
Scheme 68. β-Alkylation reaction on (150) – modification of Yu’s method. ....................... 108 
Scheme 69. β-Alkylation reaction of (150) – repeat of Method C with purified reagents. ... 109 
Scheme 70. Proof of stereochemistry of (171).193 ................................................................. 109 
Scheme 71. β-Alkylation reaction of (150) according to Yu et al.,193 without HMPA. ........ 110 
Scheme 72. Large scale β-alkylation reaction of (171) under optimised conditions. ............ 111 
Scheme 73. Removal of tert-butyl ester of (171). .................................................................. 112 
Scheme 74. Reduction of an ester by DIBAL-H.................................................................... 112 
Scheme 75. Weinreb amide reduction by DIBAL-H. ............................................................ 113 
Scheme 76. Preparation of the aldehyde using Weinreb amide.194 ........................................ 113 
Scheme 77. Preparation of the Weinreb amide (174).194 ....................................................... 114 
Scheme 78. Attempted reduction of the Weinreb amide (174) with DIBAL-H.194 ............... 114 
xvi 
 
Scheme 79. Reduction of a  thiol ester to the α-aminoaldehyde using Et3SiH and Pd/C.215 . 115 
Scheme 80. Preparation of thiol ester (175) using DCC/DMAP activation. ......................... 115 
Scheme 81. Preparation  of the thiol ester (175)  using EDC.HCl, DMAP.215 ...................... 115 
Scheme 82. Attempted reductions of the thiol ester (175).215 ................................................ 116 
Scheme 83. Selective reduction of a thiol ester in the presence of an alkene according to 
Evans.195 ................................................................................................................................. 116 
Scheme 84. Attempted eduction of (175) according to Evans’ procedure.195 ....................... 117 
Scheme 85. Further attempted selective reduction of (175). ................................................. 117 
Scheme 86. Attempted Arndt-Eistert homologation of (173) using TBTU as coupling reagent.
 ................................................................................................................................................ 118 
Scheme 87. Arndt-Eistert synthesis with (173) using ClCOOEt/DIPEA as a coupling 
reagent.217 ............................................................................................................................... 119 
Scheme 88. Planned synthetic route to protected Amoa diastereoisomer. ............................ 120 
Scheme 89. Dipeptide formation and microwave-assisted cyclization to DKPs. .................. 129 
Scheme 90. DKP formation upon cleavage-induced cyclization. .......................................... 129 
Scheme 91. Preparation of DKPs by Ugi reaction. ................................................................ 130 
Scheme 92. Aza-Wittig cyclization route to DKPs. ............................................................... 130 
Scheme 93. Synthesis of dipeptide intermediates for CI-4 derivatives. ................................ 131 
Scheme 94. Cyclisation of dipeptides to CI-4 analogues. ...................................................... 133 


















List of Tables 
 
Table 1: Structure of allosamidin and its derivatives............................................................... 24 
Table 2. IC50 values of  allosamidin derivatives against chitinases from different species. .... 25 
Table 3. Alkylguanylurea biological activities against AfChiA1............................................. 45 
Table 4. Methylation of aspartate derivatives199 ...................................................................... 99 
Table 5. Preparation of dipeptides ......................................................................................... 133 
Table 6. Preparation of cyclic dipeptides ............................................................................... 135 
Table 7. Synthesis of cyclo(Arg(Pmc)-Pro) .......................................................................... 136 
Table 8. Deprotection of cyclic dipeptides ............................................................................ 137 





List of abbreviations 
 
Ac   acetyl 
AcOH   acetic acid 
ALLO                         allosamidin 
Aq   aqueous 
Ar aryl       
Arg   arginine 
Asp   aspartic acid 
BEI binding efficiency indices 
Boc   tert-butoxycarbonyl 
BnOCOCl  benzyl chloroformate 
CSA   10-camphorsulfonic acid 
Da   Dalton 
DBU   1,8-diazabicycloundec-7-ene 
DCC   N,N’-dicyclohexylcarbodiimide 
DCM   dichloromethane 
Dde   1-(4,4-dimethyl-2,6-dioxohexylidene)ethyl 
DEAD   diethyl azodicarboxylate 
DEME                        demethylallosamidin 
DIBAL-H diisobutylaluminium hydride 
DIC  N,N’-diisopropylcarbodiimide 
DIPEA  N,N-diisopropylethylamine 
DKP   diketopiperazine 
DMAP   4-(dimethylaminopyridine) 
DMF   N,N-dimethylformamide 
DMSO   dimethylsulfoxide 
DNA   deoxyribonucleic acid 
DPPA   diphenylphosphoryl azide 
EDC   1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
Eq   equivalent(s) 
EMS   electrospray mass spectrometry 
Et2O   diethyl ether 
EtOAc   ethyl acetate 
xix 
 
EtOH   ethanol 
ETP   epipothiodioxopiperazine 
ESI   electrospray ionisation 
FBS   fragment-based screening 
Fmoc   9-fluorenylmethoxycarbonyl 
Fig   figure 
g   grams 
Glu                             glutamic acid 
GLCB                        glucoallosamidin 
Gly                              glycine 
h   hour 
HATU                       (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxide hexafluorophosphate 
His   histidine 
HTS   high-throughput screening 
HOBt   1-hydroxybenzotriazole 
HPLC   high performance liquid chromatography 
Hz   Hertz 
IC50   concentration required for 50% inhibition of activity 
IP   isoelectric point 
IPCC   isopropenyl chlorocarbonate 
IR   infra-red 
J   coupling constant 
Ki   inhibition constant 
LE   ligand effiency 
LLE   ligand-lipophilic effiency 
Lit   literature 
M   molar 
METH                        methylallosamidin 
Mp   melting point 
m/z   mass to charge ratio (mass spectrometry) 
MC   methylcarbamoyl 
Me   methyl 
MeOH   methanol 
xx 
 
MePhe   N-methylphenylalanine 
Min   minutes 
mL   millilitres 
NMM   N-methylmorpholine 
mmol   millimoles 
mol   moles 
MU   4-methylumbelliferone 
mRNA   messenger ribonucleic acid 
MsCl   methanesulfonyl chloride 
NAG   N-acetylglucosamine 
NEM   N-ethylmorpholine 
n-BuLi   n-butyl lithium 
nM   nanomolar 
NMP   N-methyl-2-pyrrolidinone 
NMR   nuclear magnetic resonance 
OAll   O-allyl 
OBn   O-benzyl 
Orn   ornithine 
PCR   polymerase chain reaction 
PPA   propane phosphonic acid anhydride 
PEST              proline (P), glutamic acid (E), serine (S), threonine (T)-rich sequence 
Petrol   petroleum ether 40-60 °C 
Ph   phenyl 
Phe   phenylalanine 
PhFl   9-phenylfluoren-9-yl  
PMB  para-methoxybenzyl  
Pmc   2,2,5,7,8-pentamethylchroman-6-sulfonyl 
PMN   polymorphonuclear neutrophils 
ppm   parts per million 
PR                               pathogenesis-related proteins 
Pro   proline 
p-TsCl   para-toluenesulfonyl chloride 
PyBOP            (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
PyBrOP  bromotripyrrolidinophosphonium hexafluorophosphate 
xxi 
 
QS quorum sensing 
Rf   retention factor 
Rt   retention time 
RNA              ribonucleic acid 
RP-HPLC  reversed-phase high-perfomance chromatography 
ROS                            reactive oxygen species 
SAR   structure activity relationship 
Ser   serine 
SPPS   solid-phase peptide synthesis 
TBAI   tetrabutylammonium iodide 
TBTU 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethylaminium      
tetrafluoroborate 
Tert tertiary 
TFA             trifluoroacetic acid 
TFAA             trifluoroacetic acid anhydride 
THF             tetrahydrofuran 
THP tetrahydropyranyl  
TIM                            triosephosphate isomerase 
TIPS              triisopropylsilyl 
TLC   thin layer chromatography 
TMEDA  tetramethylethylenediamine 
TMSCHN2  trimethylsilyldiazomethane 
TMSE   2-(trimethylsilyl)ethyl 
Trp   tryptophan 
Tyr   tyrosine  
UV   ultraviolet 
VS   virtual screening 
Xaa   amino-acid 





Chitin is a linear polymer of β-1,4-linked N-acetyl-glucosamine (Figure 1),1 which is, after 
cellulose, the most abundant polysaccharide in nature. It is present as a structural component in 
the coatings of many species, such as the cell wall of most fungi2, the microfilarial sheath of 
parasitic nematodes3, sheaths of crustaceans and exoskeletons of all types of arthropods.4  
Chitin is also a part of the the cuticle of the epidermis and trachea, stomodeum and proctodeum 
of many insects.5 
 
Figure 1: Structure of chitin 
 
Chitin is a significant component of the integument or exoskeleton of insects. Various analyses 
show that the chitin content of the cuticle, the main part of the integument, may be at least 40%, 
with the exact figure varying according to the insect species.6 Chitin provides a light but strong 
scaffold material which is associated with cuticle proteins that determine the mechanical 
properties of the cuticle itself.4 Within the cuticle, there are two main chitin-containing layers 
with distinct structural features. These are the outer exocuticle and the inner endocuticle.7 
                
(a) exocuticle                                                         (b)  endocuticle 
 
Figure 2: Microstructure of lobster cuticle as shown by by SEM.7 
 
In the exocuticle (Figure 2) the mineralized chitin-proteins fibres are thin and arranged in 
parallel, whereas in the endocuticle (Figure 2) the chitin-protein fibres are stacked in horizontal 
2 
 
planes. The fibre direction (white arrows) rotates around the normal axis of the cuticle. Every 
stack of planes rotated 180° is referred to as one Bouligand layer.7 
 
1.2. Role of chitin in insects 
Chitin is also found in insect peritrophic matrices, where it provides an absorbent membrane 
between the food bolus and the midgut epithelium. This helps digestion and protects the midgut 
from mechanical damage and harmful organisms.8 Insect peritrophic matrices are usually 
composed of between 3-13% chitin,9 although studies on the tobacco hornworm Manduca sexta 
reported a chitin content of 40%.6 The rate of matrix formation often varies depending on 
physiological conditions.9 The peritrophic matrix itself is formed by the association of chitin 
microfibrils with highly hydrated proteoglycan material secreted by the insect gut cells, and the 
rest of the non-chitin content is a complex mixture of proteins and glycoproteins.8 This includes 
proteins called peritrophins that bind to chitin microfibrils via multiple chitin-binding domains 
and also mediate binding to other glycoproteins.10 In this way they may add significant 
mechanical strength to the peritrophic matrix. 
 
Chitin polymers are cross-linked by hydrogen bonds between the amine and carbonyl groups, 
which usually leads to the formation of  chitin microfibrils of ~ 3 nm.11 In peritrophic matrices 
however, the chitin microfibrils may be more than 0.5 μm in length with 10 or more of these 
single microfibrils associated together as parallel bundles .9 Analysis by x-ray diffraction has 
shown that chitin in general is a polymorphic substance that occurs in three different crystalline 
modifications, termed α-, β- and γ- chitin.7, 11 The degree of hydration, the size of the unit cell 
and the number of chitin chains per cell, determine the polymorphic state of the chitin.11 In α-
chitin, all chains are laid out in an anti-parallel orientation, whereas in the β-form the chains are 
arranged in a parallel fashion. In γ-chitin, sets of two parallel strands interchange with single 
antiparallel strands.4, 7 All three polymorphic states of chitin are found in insects, while in fungal 
systems non-crystalline, transient states have also been reported.12 In insects, α-chitin is mostly 
found in chitinous cuticles,13 as well as peritophic matrices.9 β-Chitin also occurs in peritophic 
matrices,  and is  often found in cocoons, as is γ-chitin.10, 11  
 
The physiochemical properties of the insect cuticle such as mechanical strength and stability13, 
14 rely upon the anti-parallel arrangement of α-chitin chains. This allows tight packaging into 
chitin microfibrils, in which around 20 chitin units are held together by inter-chain hydrogen 
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bonds.9,11 Insect body parts that are used to hold prey, and should therefore ideally be hard and 
strong also tend to be composed of α-chitin; for instance, the grasping spines of the arrow worm 
Sagitta are made of pure α-chitin,15 although the pen of Cephalopoda is β-chitin.  In general, 
flexible and softer chitinous structures such as peritrophic matrices or cocoons tend to contain 
more β- and γ-chitin.9 In the β- and γ-forms, there are fewer inter-chain hydrogen bonds, an 
increased number of hydrogen bonds with water,17 and overall the chains are less tightly packed.  
 
The association of chitin with proteins and minerals plays a key role in providing properties of 
resistance and flexibility throughout the anatomy of arthropods.4 Chitin-protein complexes are 
responsible for exoskeleton elements such as trachea, cuticle, stomodeum and the peripheral 
membrane of arthropods.18, 19 The colouration of the cuticles has its origin from the binding of 
chitin with carotenoids.4  
 
1.3. Chitin metabolism in insects and microorganisms 
Insects need to periodically replace their old cuticle with a new and loose one during moulting 
(ecdysis).11 The new synthesized cuticle can only be expanded when moulting is complete.5 
After ecdysis occurs, the old endocuticle is digested by proteases and chitinases.20, 21 This means  
that insect growth and development depends on the capability to remodel chitinous structures,22 
and so insects must consistently synthesize and degrade chitin in a highly controlled manner to 
allow ecdysis and regeneration of the peritrophic matrices.9  
 
Chitin metabolism plays a crucial role in the life cycle of metazoan and protozoan parasites that 
affect humans.23 In some parasites chitin is a structural component of these organisms, whereas 
in others, parasites interact with the chitin-containing structure, which they come upon during 
development, e.g. Entamoeba parasites.24 The eggshell and sheath integument of microfilarial 
worms contains chitin.3 Also chitin is a component of the cyst wall of the intestinal pathogens 
Entamoeba and Giardia.25, 26 These parasites secrete chitinases in order to modulate their 
chitinous structure. The fungal cell wall is also composed of chitin, which protects these 
organisms from the environment.2  
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1.4. Chitin biosynthesis 
The biosynthetic pathway to chitin involves the conversion of glucose to uridine diphosphate 
N-acetylglucosamine (UDP-GlcNAc).5, 11 It was suggested that seven enzymes catalyse the 
reactions in the synthesis of chitin, as shown in Figure 3.  
 
The formation of glucosamine-6-phosphate occurs from glucose and is catalysed by 
hexokinase. Fructose-6-phosphate is obtained by the action of glucose-6-phosphate isomerase, 
which reacts with glutamine and glutamine transaminase to transfer an amino group from 
glutamine to fructose-6-phosphate to give glucosamine-6-phosphate. By the action of 
phosphoglucosamine transacetylase and acetyl coenzyme-A, acetylglucosamine-6-phosphate is 
obtained and then acetylglucosamine-1-phosphate is obtained by the action of 
phosphoacetylglucosamine mutase. Uridine diphosphate acetylglucosamine (UDPAG) is 
formed from uridine triphosphate and acetylglucosamine-1-phosphate, which is the substrate 






Figure 3: Biosynthesis of chitin in insects. Reproduced  from Merzendorfer.5 
 
Many subsequent studies conducted with preparations from various insects support the general 
pathway, which is shown in Figure 3. Chitin synthase (CS) converts cytosolic uridine 
diphosphoryl-N-acetylglucosamine (UDP-GlcNAc) to chitin. However, little is known about 
the final steps in chitin synthesis in any organism.5  
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The pathway from UDPGlcNAc to chitin was determined by using the cell-free extracts from 
the southern armyworm and also using microsomal fractions from the blue crab and the brine 
shrimp.5, 27 UDPGlcNAc and primer chitin oligosaccharides are precursors utilized by the 
synthase enzyme for chitin. Several carbohydrates, besides glucose, serve as precursors for 
chitin, including trehalose, fructose, glucosamine and N-acetylglucosamine.5 The common 
features of chitin synthases from yeast, fungi and insect are their localization on vesicular 
membranes and slight activation after treatment with proteases such as trypsin.28, 29  
 
Chitin synthase activity is  inhibited by  UDP-GlcNAc analogues such as polyoxins and 
nikkomycin, 5 and seems to be confined to membrane-containing fractions. 29 Chitin synthase 
has been found  in the membranes of Golgi complexes30 and intracellular vesicles, and also  in 
plasma membranes, which suggests that the enzyme follows an exocytotic pathway, 
accumulating in cytoplasmic organelles during its transport to the cell surface.28 Analysis on 
the  imaginal discs of the Indian mealmoth Plodia interpunctella, showed that chitin synthesis 
is inhibited with colchine and vinblastine.5 In fungal systems, the activity of one chitin synthase 
isoform (CHS3p) has been shown to be associated with intracellular microvesicles, known as 
chitosomes.31 Electron microscopy studies of the chitosomes showed that they synthesise chitin 
microfibrils that crystallize in the lumen of these vesicles.5 Similar results were obtained when 
chitin synthase activity in crude extracts of the red flour beetle Tribolium castaneum was 
examined. Electron micrographs showed that the chitin synthase products were arranged in 
parallel microfibrils with a thickness from 10 nm to 80 nm .32 These microfibrils were 
associated with other particles of 50-250 nm which could be regarded as “insect chitosomes”.30 
Currently, little is known about the role of such insect chitosomes in chitin synthesis, and 
studies  on both  the Brazilian skipper butterfly Calpodes ethlius and the Australian sheep 
blowfly Lucilia cuprina29 have shown an absence of these types of structures. Electron 
microscopy studies instead indicated areas at the tips of microvilli from the epidermal cells to 
the clusters of chitin synthesising enzymes.29   
 
2. Chitinases and their classification 
The hydrolysis of chitin is catalysed by chitinases which convert the carbohydrate polymer into 
simple mono- and oligosaccharides. Chitinases can be classified into two different groups of 
enzymes -  endochitinases and exochitinases – according to where they act on the polymer 
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chain.11 Exochitinases act on the non-reducing end of the chitin polymer and be further divided 
two different groups of enzymes. These are chitobiosidases, which progressively cleave off 
diacetylchitobiose units, and β-(1,4)-acetylglucosaminidases (NAGase),  which cleave off only 
terminal, non-reducing N-acetylglucosamine (NAG) units, to generate NAG monomers.33 
Endochitinases in contrast, cleave random β-(1,4)-glycosidic bonds within the chitin polymer, 
giving a variety of low molecular weight NAG oligomers, such as diacetylchitobiose, as well 
as NAG trimers and tetramers.33-35   
Chitinases are classified into Family 18 and 19 glycoside hydrolases (GH) according to their 
amino acid sequence similarity.36 Members of the two distinct families differ both in their three 
dimensional structures and also the mechanisms by which they catalyse chitin hydrolysis.37, 38  
Family 18 chitinases have catalytic domains with  triosephosphate isomerase (TIM-barrel) 
folds,39 with a conserved motif of DxDxE residues, and hydrolyse chitin  by a substrate-assisted 
mechanism.40-44 On the other hand, the three dimensional structures of Family 19 chitinases 
have a significant degree of  α-helicity, and chitin hydrolysis is catalysed via  a single 
displacement mechanism.45 Family 18 contains chitinases from mammals, insects, plants, 
nematodes, fungi and bacteria, whereas Family 19 chitinases are only found in plants and 
Streptomyces species.46 Family 18 chitinases have been well characterised, with information 
available on their three-dimensional (3-D) protein structures and their reaction mechanisms. 
The catalytic domain of known Family 18 chitinases consists of an (α/β)8 barrel fold with a long 
deep substrate-binding cleft containing six binding subsites -4, -3, -2, -1, +1  and +2, with the 
cleavage site located between subsites -1 and +1.47  Based on crystal structures, the catalytic 
reaction of Family 18 chitinases takes place through a substrate-assisted, double displacement 
mechanism with a geometrically deformed oxazolinium intermediate.44 This has been 
demonstrated in structural analysis of hevamine and Serratia marcescens chitinase A. In 
contrast, the catalytic domain of Family 19 chitinases has a high α-helical content and has 
structural similarity, including a conserved core, with chitosanase and lysozyme.46, 48 
In addition to their 3D structure, chitinases of the two families show several important 
differences in their biological properties. For example, Family 18 chitinases hydrolyse the 
glycosidic bond with retention of the anomeric configuration,49 whereas Family 19 chitinases 
hydrolyse with inversion.45, 50 Family 18 are sensitive to allosamidin, but Family 19 from higher 
plants has been shown to be insensitive. Family 18 chitinases hydrolyse also GlcNAc-GlcNAc 
and GlcNAc-GlcN linkages, whereas Family 19 chitinases cleave GlcNAc-GlcNAc and GlcN-
GlcNAc.48 These differences are common between all members of the two families and arise 
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from the differences in their catalytic mechanisms. Substrate-assisted catalysis is the most 
widely accepted model for the catalytic mechanism of Family 18 chitinases, whereas a general 
acid and base mechanism has been suggested for the catalytic mechanism of Family 19 
chitinases.50, 51 
 
2.1. Family 18 chitinases: structural biology and catalytic mechanism 
The reaction mechanism of Family 18 chitinases is well established. Chitooligosaccharides bind 
to the active site groove of Family 18 chitinases with the N-acetylglucosamine (GlcNAc) units 
stacking on solvent-exposed hydrophobic residues, with the -1 sugar assuming a boat 
conformation, as outlined in Scheme 1 for Aspergillus fumigatus chitinase B1 (AfChiB1), a 
typical bacterial-type chitinase. In the Family 18 chitinases, the amino-acid motif DXEDXE 
which is involved in catalysis is strongly conserved.41, 44, 49, 52 Chitin binding also results in a 
reorientation of the Asp-175 side chain, replacing its hydrogen bonds to the carboxyl group of 
the catalytic acid Glu-177 and the -1 sugar C2 acetamido group of the substrate. Nucleophilic 
attack of the carbonyl oxygen of the acetamido group on the anomeric C1 carbon of the same 
pyranose ring occurs concurrently with protonation of the glycosidic oxygen by the catalytic 
acid, generating the leaving group from the reducing end of chitin as well as an oxazolinium 
ion intermediate (step (ii), Scheme 1).44, 45, 52 Family 18 enzymes thus catalyse hydrolysis 
through the “substrate-assisted” mechanism, in which the essential steps are the generation of 
the oxazolinium intermediate by attack on the polymer of its own N-acetamido group and the 
retention of the β-glycosidic configuration after the glycosidic cleavage. 
Like all TIM-barrel enzymes, in the Family 18 chitinases, the two catalytic residues Asp and 
Glu are located just beyond the carboxyl-ends of two of the eight β-strands making the (α/β)8 
barrel.53 Thus evolution has led to substrate specificity for hydrolysis of the carbohydrate 
structure. For example, endochitinases hydrolyze a reducing end GlcNAc, while in contrast, 































Scheme 1.  The catalytic cycle of Family18 exo-chitinases. 
Arrows indicate electron transfer of the subsequent step, while dashed lines represent hydrogen bonds. (i) Binding 
of GlcNAc; (ii) cleavage of GlcNAc releasing product from the reducing end; (iii) release of product form non-
reducing end. This figure is based on reaction schemes from Tews et al.44 and van Aalten et al.40 This reaction 
results in the retention of the stereochemistry at the anomeric carbon of the product, in contrast to the inversion 
mechanism of Family 19 chitinase. The soluble products of this catalytic mechanism are chitotetraose, chitobiose. 
These steps differ from the classical retaining mechanism of glycosyl hydrolases such as lysozyme, cellulose and 






2. 2. Chitinases: occurrence and regulation 
Chitinases play a role in the life cycle of many organisms including bacteria, fungi, plants, 
insects and animals. In insects and crustaceans, chitinases partipate in the moulting process to 
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renew the  cuticle,11 while chitinases from bacteria and fungi help to  maintain a balance 
between the large amount of carbon and nitrogen trapped in the biomass as insoluble chitin in 
nature.55 In fungi, chitinases are needed for cell separation,56 and chitinases from some plants 
play a protective role against   fungal pathogens.57 The human chitotriosidase may also be 
important as a defence against chitin-containing  pathogens such as Candida albicans.58  
 
2.2.1. Importance of chitinases in metabolism 
The roles of chitinases in organisms are diverse. In fungi, chitinases are thought to have 
autolytic, nutritional and morphogenetic roles.56, 59 Chitinases in bacteria have been shown to 
play a role in the digestion of chitin for utilization as a carbon and energy source and recycling 
chitin in nature.60 In insects, chitinases are associated with sclerotized proteins to allow growth 
and development.5 Plant chitinases are involved in defence and development.61 In the human 
genome, chitinases have been suggested to play a role in defence against chitinous human 
pathogens.62  
 
2.2.2. Chitinases in insects  
It is known that arthropods consistently synthesize and degrade chitin using proteases and 
chitinases to allow ecdysis and regeneration of the peritrophic matrices.5, 9  
 
Insect chitinases belong to the sub-class of Family 18 chitinases and share a high degree of 
amino acid similarity.38 The most remarkable difference among chitinases from different 
kingdoms is the large range in their sizes. The smallest chitinases consist primarily of a catalytic 
domain, whereas the larger chitinases often are organized into multiple domains with distinct 
functions. Insect chitinases obey these rules, thus they have theoretical molecular masses 
ranging between 40 kDa and 85 kDa. The basic structure consists of three different domains: a 
catalytic domain possessing one or more chitin-binding domains which can be either C-terminal 
or N-terminal, a binding domain with one or more fibronectin type 3, a PEST-like region, 
enriched in proline, glutamate, serine and threonine and a cysteine-rich region.22 All these 
domains play a role in glycosylation and protein turnover. 
Chitinases also differ in their pH optima (pH 4-8) and isoelectric points (IP 5-7). This 
contributes to their catalytic parameters, affinity for chitin and stability.5 The tobacco hornworm 
(Manduca sexta) has an insect chitinase responsible for the moulting process.22 This enzyme 
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possesses multiple domains, including an N-terminal catalytic domain, a middle 
serine/threonine and a C-terminal cysteinerich domain. In the moulting secretions, three 
different forms of this protein with sizes 50 kDa, 62 kDa, 85 kDa have been detected. They all 
are enzymatically active and cross-related immunologically.11 In all insect chitinases, the 
PEST-like region acts as a signal peptide for the glycopolymer degradation.22 The signal peptide 
transfers secretion of the chitinase to the endoplasmic reticulum, which is released by a signal 
peptidase after the protein has been transported across the membrane.63  
 
It is known that, as similarities of amino acid sequences are present in different glycosyl 
hydrolase families, the catalytic mechanism within each family is highly conserved.38, 39 
Members of sequence-related families will have similar folds and this can direct the choice of 
appropriate search models for molecular replacement and gives potential for homology 
modelling of related sequences.53 The catalytic domain of Family 18 chitinases has a (α/β)8 
TIM-barrel which consists of a cylindrical, barrel-like structure made from eight parallel β-
strands, that are alternately connected with eight α-helices.64 A full crystal structure of an insect 
chitinase is not yet available but homology modelling using crystal structures of bacterial and 
plant chitinases has provided three-dimensional models of the catalytic domain.65 The Manduca 
chitinase showed a partial signature of the (α/β)8 folding and a  crystal structure showed β-
sheets and four complete and several incomplete α-helices.22 Like some fungal chitinases, the 
chitinases found in insect moulting fluids are glycosylated. Additionally, the PEST-like region 
of Manduca chitinase is mostly modified by O-glycosylation.66 
 
Insect chitinases contain a  C-terminal chitin-binding region,  whose three-dimensional 
structure includes a six-cysteine motif that is also seen in nematode chitinases.67 The cysteine 
motif targets the chitinase  towards  its substrate and and so helps facilitate chitin hydrolysis.68 
This structural feature also occurs in peritrophic matrix proteins, as well as in receptors and 
other proteins that are involved in cellular adhesion.22, 68  
 
Enzymatic glycosidase reactions normally require the presence of two catalytic groups which 
in most cases have been observed to be either aspartic acid or glutamate residues.39 The Family 
18 chitinases utilise conserved acidic amino acids, in their hydrolysis mechanism, similar to 
those observed in other glycosidases.43 Chitinases from insects have the conserved  active site 
sequence YDFDGLDLDWEYP , which identifies them as Family 18 chitinases,69-71 and this is 
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confirmed by the fact that mutation of the glutamic acid residue site leads to a loss of enzymatic 
activity.72 
 
Many of the sequence-related Family 18 chitinases from insects are polyspecific, which means 
they contain enzymes of different substrate specificities, suggesting an evolutionary 
divergence. Chitin degradation in M. sexta is carried out by chitinase and β-N-
acetylglucosaminidase,20 while the chitinases from Manduca, Bombyx and fall webworn moth 
Hyphantria cunea display the three basic domains (a catalytic domain, chitin-binding, PEST-
like region and cysteine-rich region).66, 73 Some other chitinases lack the PEST-like or the 
typical chitin-binding regions.74 Enzymes with similar specificities are sometimes found in the 
different chitinase families which raises the possibilities of convergent evolution. In Aedes, for 
example, chitinases are encoded by two different genes. Nucleotide sequencing has revealed 
that one of the genes encodes three separate chitinases, each containing a catalytic and also a 
chitin-binding domain.71 The beetle Tenebrio molitor encodes 5 chitinases TmChit5, which also 
displays an unusual structure, since 5 chitinases contain units of approximately 480 amino acids 
that are separated by PEST-like, chitin-binding and mucin-like domains.75 
 
Chitin in arthropods plays a key role in  development and growth, and so its  hydrolysis is as 
tightly regulated as its synthesis.11 Monitored transcription or enzyme activities have shown 
that the expression or activity of the integument chitinases is restricted to periods of moult and 
pupation,11 whereas gut chitinases are expressed after feeding.76 Interestingly, chitinase 
expression in the moulting fluid appears after β-N-acetylglucosaminidase expression.66 In 
epidermal cells, 20-hydroxyecdysone stimulates the secretion of the molting fluid containing 
chitinases and proteases, indicating that this hormone may also be involved in the regulation of 
chitinase expression and activity. For example,  the chitinases of Bombyx and Manduca are 
induced at high haemolymph levels of 20-hydroxyecdysone, while β-N-acetylglucosaminidases 
are induced at low levels of this  ecdysteroid.77 Consistent with this, β-N-acetylglucosaminidase 
expression was found to start before chitinase expression in the larvae of the yellow fever 
mosquito, Aedes aegypti.76 
 
Cuticles from arthropods are associated with proteins such as resillin, a glycine-proline rich 
protein that confers rigidity properties.4 In order for the cuticle to be degraded by chitinases, 
proteases are needed, not only to break down this structural material directly,   but also to cleave 
inactive chitinase precursors and release the active enzymes, as suggested for Manduca or 
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Tenebrio chitinases. This kind of proteolytic activation of chitinases  may also occur in insect 
gut systems, so in the case of blood-sucking insects, the activities of gut chitinase and β-N-
acetylglucosaminidases are found to rise shortly after feeding.76 For instance, the gut-specific 
chitinase of Anopheles needs to be trypsinized in order to develop chitinase activity.78  The 
malaria parasite Plasmodium falciparum also makes use of the protease-rich environment in 
the mid-gut of the mosquito host in order to induce the enzymatic activity of its own chitinase 
which allows it to penetrate the peritrophic matrix.79 
 
2.2.3. Chitinases in plants 
Plant chitinases are divided into classes I-V within which classes III and V belong to Family 18 
and classes I, II and IV belong to Family 19 chitinases.48 Three classes of plant chitinase have 
been identified based on the primary structure. These classes I, II and IV chitinases all have a 
signal peptide domain and possess similarities in the catalytic domain.80 Class I chitinases are 
enzymes with N-terminal cysteine-rich domains linked by a proline/glycine-rich region (signal 
peptide region) to the catalytic domain. The cysteine-rich domain is also called a wheat-germ 
agglutinin domain, which is important for chitin binding, but not for catalytic activity.81 Most 
of the class I chitinases contain a C-terminal signal peptide that is essential for targeting the 
plant cell vacuole.81 Class II chitinases, mainly found in dicotyledons, lack the N-terminal 
cysteine-rich domain and C-terminal signal peptide, indicating that these chitinases do not bind 
chitin and they are secreted to be apoplastic.82 Class IV are also found in dicotyledons, contain 
a cysteine-rich domain and a conserved main structure which resemble to those of class I 
chitinases but are significantly smaller due to four delections.57, 81 Class III are mainly found in 
plants and fungi; they possess bifunctional lysozyme/chitinase activity, such as the enzyme of 
Havea brasiliensis.83  
 
Plant chitinases are classified as pathogenesis-related proteins (PR), which are expressed upon 
attacks by viruses, bacteria and fungi as well as pest attack.57 It has been found that PR proteins 
are induced by various stress factors such as drought, salinity, wounding, heavy metals in their 
environment, endogenous and exogenous elicitor treatment and plant growth regulators.84-86 
The induction of chitinase in plants is often co-ordinated with the induction of specific β-1,3-




The role of chitinases in plants is as a defence mechanism against chitin-containing organisms, 
such as insects and fungi.87 A plant pathogenic fungus Rhizoctonia solani, is known to cause 
serious plant losses, by attacking primarily the roots and lower stems and its hosts are 
herbaceous plants.88 The levels of chitinases are upregulated in rice cultivars when there is an 
attack by the pathogen Rhizoctonia solani. Chitinases in plants are associated with β-1,3-
glucanases, which inhibit the growth of chitin-containing fungi by causing decomposition of 
hyphal tips in juvenile cells containing exposed nascent chitin chains that are accessible to 
hydrolysis. The chitin layer in the mature cell wall is cross-linked with polysaccharides forming 
mixed chitin-glucan fibres and is therefore, relatively inaccessible to hydrolysis.89 
 
Plant cellular and secretory chitinases are suggested to have different roles in defence reactions. 
Apoplastic chitinases are considered to be part of an early, induced response as these chitinases 
act directly by blocking the growth of the hyphae invading the intracellular space.90 During the 
infection process, cellular chitinases are released when hyphae penetrate and affect cell 
integrity.57 Class I vacuolar chitinases are strongly induced by jasmonate/ethylene pathways.61 
Both class I and class II chitinases are induced as part of the local hypersensitive response. On 
the other hand, class II chitinases are induced as a response to the pathogen attack.91 Cellular 
chitinases inhibit pathogen growth more efficiently, due to their rapid mutation occurring in the 
active site. This faster mutation allows for following of evolutionary changes in fungal cell 
structure, whereas the active site of apoplastic chitinases is more conserved and most of the 
evolutionary changes occur in the non-catalytic domain.61  
 
Most saprophytic pathogens live and survive in the soil and attack the parts of their host that 
reside there. Consequently chitinase mRNAs accumulate at elevated levels in seeds in different 
plant species. Seed chitinases act in a synergistic way with ribosome-inactivating proteins and 
β-glucanase proteins to provide antifungal properties. 92 The role of chitinases in plant defence 
against fungi has been established with genetic transformation experiments. The transgenic 
plants have been produced using chitinase genes of diverse classes and by employing a range 
of donor and recipient host plant species.93 Transgenic tobacco plants constitutively expressing 
a bean class I chitinase gene showed an enhanced resistance to the fungal root pathogen 
Rhizoctonia solani.94 A partial resistance against Fusarium species in tomato was demonstrated 
by simultaneous expression of a class I chitinase and a class I β-1,3-glucanase gene from 
tobacco. Transgenic plants that overexpress either chitinases singly or chitinase in combination 
with other antifungal proteins have also been developed. 
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Chitinases are induced by a range of different abiotic stresses such as osmotic, salt, cold, 
wounding and heavy metal stress.87  For instance, to heal wounds, Class I chitinases in fig tree 
latex are induced. Brassica juncea chitinase (BjCHI) expression is also highly induced by 
methyl jasmonate, wounding, NaCl and polyethylene glycol stresses,95 while class I chitinases 
from tall fescue turf grass are overexpressed by dehydration and ethylene.96 Additionally, 
chitinases have roles in protecting against the toxicity of heavy metals, such as lead, arsenic 
and cadmium that occurs in faba beans, barley, maize and soybean.97 
 
Chitinase activity is induced in Arabidopsis by UV light, heat, shock and wounding.90 While 
class I and IV chitinase genes were expressed in most organs of Arabidopsis under normal 
growth conditions, class III genes were expressed exclusively when the plants were exposed to 
environmental stresses, notably salt and wound stresses.98 
  
Chitinases have been shown to be expressed during cold hardening in rye, indicating their 
antifreeze activity and the ability to inhibit and modify ice crystal growth in plant apoplasts.  In 
Cynodon species, a class II chitinase gene was induced during cold conditions and 
dehydration.99 Cold-responsive extracellular chitinase was also found to have antifreeze activity 
in bromegrass cell cultures. Chitinases are also expressed under drought conditions in wheat. 
Transgenic tobacco plants that overexpressed chitinase from Trichoderma harzianum also 
conferred resistance against salinity and heavy metals.100 
 
Chitinases also regulate processes of growth and development by generating or degrading signal 
molecules, as during nodulating processes, where the bacterial lipochitooligosaccharides (Nod 
factors) are degraded by chitinases.61 
  
2.2.4. Role of chitinases in other microorganisms (bacteria, nematodes and fungi) 
 The fungal human pathogen Candida albicans utilizes chitinases during cell division to 
separate daughter cells.101 The eggs of the nematode gastrointestinal parasite of mice, 
Helimosomoides polygyrus, express increasing levels of chitinases with age up to hatching and 
Entamoeba invadens, a model for pathogenic amoebic encystations, produces chitinases during 
encystation.102 Vertebrates are therefore exposed to chitin through ingested food or when 




Chitinases are present in various non-chitin containing organisms, where chitin is used as a 
source of nutrients for growth. Some bacteria produce chitinases for processing and digestion 
of GlcNAc-containing macromolecules found in nature, which are sources of their nutrients.60 
Streptomyces species are soil bacteria and some of the main decomposers of chitin. They use 
chitin as carbon and nitrogen sources and so play a major role in the turnover of chitin in natural 
ecosystems. Baculoviruses, such as Bombyx mori nucleopolyhedrovirus, express chitinases and 
cathepsin, which cause dissolution of the insect cell host, resulting in the complete loss of all 
insect tissues, permitting mature viruses to escape into the environment and promoting 
horizontal virus transmission.103 Malaria parasites (ookinetes) digest the peritrophic membrane 
in the mosquito midgut during penetration.104 Parasites also degrade chitin-containing host 
organisms in order to facilitate their further growth and transmission. Leishmania parasites and 
those causing Chagas disease also do not contain chitin but secrete chitinases to degrade the 
internal chitin-containing structures of their insect vectors.79 Chitinases in the reptilian parasite 
Entamoeba invadens encyst parasites within a cell wall, allowing resistance to environmental 
conditions.24 Serratia marcescens chitinases digest a chitinous peritrophic membrane, leading 
to the release of N-acetylglucosamine and fragments of the membrane.36 
 
2.2.5. Chitinases in Humans 
Despite the absence of endogenous chitin, humans express two active chitinases, designated 
chitotriosidase (CHIT1),62, 105 and a second, given its acidic pH optimum, named acid 
mammalian chitinase (AMCase).105 AMCase is expressed mainly in salivary glands and in the 
stomach,106 whereas CHIT1 is expressed by phagocytic cells in humans and extremely high 
levels are seen in lysosomal storage diseases, such as Gaucher’s disease.107 Both are endo-β-
1,4-N-acetylglucosaminidases that are believed to be involved in food digestion and the 
immune response.108 Zhu et al. showed that AMCase expression was increased in the lungs of 
ovalbumin-sensitized mice compared with the control group, suggesting a key role of this 
enzyme in asthma pathophysiology.109 In this asthma model, AMCase does not directly induce 
Th2 cytokine response but mediates the effector response of interleukin-13 (a cytokine 
produced by Th2 cells). AMCase possesses the ability to exacerbate local inflammation by the 
activation of the IL-13 pathway and facilitating the production of chemical mediators, 
suggesting that AMCase inhibitors are a potential target in Th2- mediated inflammation.1 More 




Chitotriosidase was first discovered in the plasma of patients suffering from Gaucher’s 
disorder.62 The protein activity was strongly elevated because of its high production and 
secretion by the lipid-laden macrophages that accumulate in these patients. Subsequently it has 
been purified from the spleen of a Gaucher patient and its cDNA was cloned from a human 
macrophage cDNA library. Analysis revealed that the enzyme belongs to the Family 18 
chitinases and shares significant sequence identity with chitinases from non-mammalian 
species. Chitotriosidase is known to exist in two forms, a 50-kDa protein and a 39-kDa enzyme 
that are produced therefore by proteolytic processing. The 50-kDa protein exhibits a C-terminal 
chitin-binding region and a hinge region and the 39-kDa enzyme consists of an N-terminal 
domain that has chitinase activity.62  
 
The established antifungal action of chitinases in plants and the tightly regulated expression of 
chitotriosidase in phagocytes suggest that this protein might fulfil a role in the degradation of 
chitin-containing pathogens.58 Chitotriosidase is also expressed in human polymorphonuclear 
neutrophils (PMNs) and macrophages.62 The enzyme is selectively expressed and released upon 
specific stimuli by human PMNs as well as macrophages. In PMNs the protein is found to be 
stored in the specific granules from which it is released by appropriate stimuli.62 Studies in vivo 
have showed that chitotriosidase inhibits growth of C. neoformans, causes hyphal tip lysis in 
Mucor rouxii and prevents Candida albicans switching from the yeast to a hyphal morphology, 
which is important for pathogenicity and virulence. On the other hand, studies in vitro carried 
out with a model of mice affected with neutropenia-imposed infections from C. albicans and 
Aspergillus fumigatus have shown that recombinant human chitotriosidase improves the 
survival in these models. Preliminary investigations have showed that chitotriosidase activity 
was overexpressed in plasma of neonates with C. albicans infections. These results showed that 
chitotriosidase possesses an activity or anti-fungal role similar to chitinases in plants.58 
Additionally, recombinant chitotriosidase might be used to treat life-threatening fungal 
infections and Gaucher disease (a glycolipidic disorder). Chitotriosidase was also found to be 
at high levels in plasma of African children infected with acute Plasmodium falciparum malaria.  
As it is known that two active chitinases are expressed in the human genome, with AMCase 
implicated in asthma109 and chitotriosidase being shown to target chitin-containing pathogens,58 
this opens a route to design new drugs for fungal diseases.  
 
Interestingly, human cartilage family glycoprotein 39 (HCgp39/YKL-40), a chitin-binding 
lectin, has sequence homology with Family 18 chitinases but lacks enzymatic activity, due to a 
18 
 
critical amino acid replacement in the active site.111 YKL-40 is present in specific granules of 
human neutrophils.112 Many of the chitinase family proteins are expressed in macrophages and 
epithelial cells of the lung and digestive tracts, consisting of the body’s first line of defence 
against exogenous chitin-containing pathogens. It has been shown in humans that levels of 
YKL-40/BRP39 in sera and lung tissues were significantly correlated with asthma development 
and even severity of the disease.113 A significant role of these proteins in the generation of 
intestinal bowel disease (IBD) as an active mediator in acute colitis has also been suggested.114 
 
2.3. Targeting chitinases 
Since chitin metabolism is crucial for fungal2 and arthropod development,5 inhibition or 
deregulation of chitinases are important objectives for the development of fungicides115 and 
also for the treatment of inflammatory diseases such as asthma and neglected tropical diseases. 
 
Chitin metabolism plays a crucial role in the life cycle of parasites. Chitinases allow parasites 
to remodel their structures, develop and grow. The expression of stage–specific chitinases in 
parasites represents a potential target for blocking the development and the transmission of 
these parasites, particularly as chitin polymers are absent in vertebrates.60 
 
The strategies for developing chitinase inhibitors would be dependent on the parasites. For some 
parasites, a chitinase inhibitor can act as a drug; for some others a vaccine can be prepared 
against the vertebrate stage of the parasite, in some other cases, a transmission-blocking vaccine 
against the vector would be suitable.  
 
Various chitinase genes from human parasites have been identified, such as filarial nematodes 
(Brugia malayi, Wuchereria bancrofti and Onchecerca volvulus).116 Plasmodium gallicenaum, 
an avian parasite similar to the human malaria parasite P. falciparum, has also been identified. 
 
The potent chitinase inhibitor allosamidin delays the cyst formation of Entamoeba invadens, so 
allosamidin acts as a drug.24 Chitinase antibodies were detected in sera of immunologically 
protected individuals with recombinant B.malayi chitinase and antigen of the monoclonal 
antibody MF1. This suggests that interfering with chitinase activity would block the 
establishment of filarial infection. Therefore chitinase inhibitors would be prophylactic agents 
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in this case. The hatching of filarial eggs and separation of mature nematodes in humans also 
suggests that a chitinase inhibitor could be used as a drug against microfilarial infection.74  
 
2.4. Bacterial and plant chitinases classes 
There are two sub-classifications amongst Family 18 chitinases, which are bacterial-type and 
plant-type.47 The plant-type Family 18 enzymes are endo-chitinases (EC 3.2.1.14) and cleave 
chitin randomly at β-(1,4)-glycosidic bonds in internal sites, generating soluble low-molecular-
mass multimers of GlcNAc, giving oligosaccharide products of varying length such as 
chitotetraose, chitotriose and diacetylchitobiose. The bacterial-type enzymes are usually exo-
chitinases (EC 3.2.1.19), meaning that specific β-(1,4)-glycosidic bonds are cleaved along the 
oligosaccharide chain such that di-acetylchitiobiose (GlcNAc2) or acetylchitotriose (GlcNAc3) 
is progressively released from the non-reducing end of chitin. 1,4-β-Acetyl-glucosaminidases 
(EC 3.2.1.30) then cleave the oligomeric products of endochitinases and chitobiosidases 
generating monomers of GlcNAc, as outlined in Scheme 2.47, 53 
 
 
Scheme 2. Degradation of chitin by bacterial chitin-processing enzymes, adapted from Aronson et al.53 
 
 
A key difference between the bacterial and the plant-type enzymes is that in the former there is 
a well-defined active site groove, lined with conserved aromatic residues to which chitin binds. 
The plant-type Family 18 chitinases, however, are generally smaller and usually contain less 
clearly identifiable sub-sites compared to the bacterial type-enzymes. This is an important 






Figure 4: (a) The active site of a bacterial-type exo-chitinase, Serratia marcescens chitinase B SmChiB, (b) a 
plant-type endo-chitinase, hevamine, (Image courtesy of Prof. D. M. F. van Aalten, University of Dundee).  
 
The bacterial type chitinase B1 from AfChiB1 is the most secreted protein by this saprophytic 
pathogen. It possesses a (β/α)8 barrel fold but lacks helix α1 similar to other proteins from 
Family 18 glycoside hydrolases. Asp-175 and Glu-177 at the end of β4 represent the signature 
of the Family 18 chitinases, which is the DxE motif, with the glutamate residue being the 
catalytic acid. The active site groove is lined by several solvent-exposed aromatic residues, 
including Trp-137 and Phe-251. The crystal structure of an inhibitor, argifin, in complex with 
AfChiB1 indicates that a N-methylphenylalanine is inserted tightly between these two 
hydrophobic residues, with a guanidinylurea moiety stacking on the amine of the oxazolinium 
ion intermediate and on the conserved Trp-384 and interacting with Asp-175 and Glu-177.117 
In plant-type chitinases such as AfChiA1 which have the (β/α)8 fold, most of the loops 
connecting the helices and strands are relatively short. Helix α8 is interrupted by a minimal β 
sheet comprising strands β9 and β10. The active site is defined by the very short β/α-loops and 
lies at the C-terminal opening of the β-barrel.118 In contrast, AfChiB1 contains larger β/α-loops 
including an entire α/β domain that forms a shallow active site groove, lined by several solvent-
exposed aromatic residues such as Trp-137.118 The differences in the construction of the active 
site cleft are reflected in different affinities for the substrate.  
 
The chitinase SmChiA, a Family 18 chitinase from the Gram-negative soil bacterium Serratia 
marcescens is the most studied bacterial chitinase, on account of its physio-biological 




is diacetylchitobiose and free NAG at higher enzyme or substrate concentrations. The enzyme 
acts as an exochitinase and cleaves the oligosaccharide from the non-reducing end of chitin.54 
A Michaelis constant (Km) of 4.4 mM (expressed in NAG equivalents) was reported for the 
enzyme, which was shown to be highly specific for chitin, over all other yeast cell-wall 
components.54 The structure of SmChiA consists of three domains. The amino-terminal domain 
(residues 24–137), which consists only of β–strands, connects through a hinge region (residues 
138–158) to the main α/β–barrel domain (residues 159–442 and 517–563). The third domain, 
which has an α +β fold, is formed by an insertion in the barrel motif (residues 443–516), as 
shown in Figure 5.119  
  
Microbial chitinases, such as SmChiA, are important agents in resistance against fungal 
infection of plants, including some infections of major economic interest.120 For example 
infection of bean and cotton plants by the soil fungi Rhizoctonia solani and Sclerotium rolfsii 
was effectively reduced by the presence of the E. coli ChiA-overproducing strain. In transgenic 
tobacco plants, expression of the ChiA gene improved resistance of the plants to fungal 
infection.121, 122 
The bacterial type chitinase B from S. marcescens (SmChiB) is composed of a catalytic domain 
(residues 1-425), a linker (residues 426-450) and a small C-terminal (residues 451-499) domain 
referred as ChBD. This domain is formed by three antiparallel β-strands connected by long β/α-
loops. The catalytic domain consists of (α/β)8 and an extra β/α domain (residues 292-379), 
which provides a flexible loop (residues 310-325) near the active site. The active site is formed 







Figure 5.  Sequence alignment of chitinase ChiB from S. marcescens, ChiA from S. marcescens and hevamine 
from Hevea brasiliensis. The catalytic regions of TIM barrel β-strands are indicated by β1–8. Glu144 is part of the 
Family 18 DxxDxDxE motif. The following definitions of loops and domains are: the α/β-domain (residues 295–
373), the linker (residues 425–450) and the ChBD (residues 451–498), the porch loop (residues 14–27), the support 








3. Existence of natural product chitinase inhibitors 
Most known chitinase inhibitors compete with the substrate by blocking its binding site, 
whether they mimic the reaction intermediate by their structure, or they mimic the key 







Figure 6. Structure of allosamidin. 
 
The pseudotrisaccharide allosamidin (Figure 6) is the most extensively studied chitinase 
inhibitor and inhibits many Family 18 chitinases in the nanomolar-micromolar range. 
Allosamidin is composed of two N-acetylhexosamine residues with an unusual D-allo-
configuration and a novel aminocyclitol aglycone, named allosamizoline, joined by two β-(1,4)-
glycosidic bonds. It was first isolated from the mycelium of Streptomyces sp.122 The 
pseudotrisaccharide has been used to investigate the physiological role of chitinases involved 
in a variety of organisms. For example, potential activity of allosamidin as a chitinase inhibitor 
is shown by inhibition of cell separation in fungi,56 toxicity towards insect larvae,79, 124 blocking 
of malaria parasite penetration into the mosquito midgut125 and easing of lung inflammation in 
a mouse model of asthma.109 It binds to human chitotriosidase (HCHT) and Coccidiodes immitis 
chitinase (CiChi) with Ki values of 40 nM and 230 nM respectively.
47 Allosamidin binds to 
different chitinases in a similar way, with the two N-acetylallosamine sugars occupying the -3 
and -2 subsites in an identical fashion to the corresponding N-acetylglucosamine substrate units. 
The allosamizoline unit binds in the -1 enzyme subsite as an exact mimic of the oxazolinium 
ion reaction intermediate, making similar hydrogen bonds from the allosamizoline nitrogen and 
oxygen to the side chains of Asp-175 and Tyr-245, respectively.40, 52, 126 Moreover, Asp-175 is 
in the “up conformation” forming an additional hydrogen bond with Glu-177, similar to that 
observed for the reaction intermediate. 
 
 
Figure 7. Structure of allosamizoline. 
 
Although the aglycone (3) itself is not an inhibitor, numerous efforts have been directed toward 
its synthesis, plus that of the carbohydrate core, in order to supply synthetic (2). The total 
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synthesis of (2) has been reported127 and the preparation of the aglycone is typically long and 
complicated (e.g. 13 steps from D-glucosamine).128 
 
 
Figure 8. Allosamidin and its derivatives. 
 
 
Table 1: Structure of allosamidin and its derivatives. 
 R1 R2 R3 R4 
  Allosamidin (ALLO) (2) CH3 H OH H 
  Demethylallosamidin (DEME) (2a) H H OH H 
  Methylallosamidin (METH) (2b) CH3 CH3 OH H 
  Glucoallosamidin B (GLCB) (2c) H CH3 H OH 
 
A number of naturally occurring analogues of (2) are also known, in which the aglycone is N-
demethylated or the sugar units modified, as seen Table 1.126 
 
Chitinases from several yeasts and also human chitinases were efficiently inhibited by these 
allosamidins. The level of inhibition was dependent on the precise inhibitor structure, as shown 
in Table 2.126  
 
 
Table 2. IC50 values of allosamidin derivatives against chitinases from different species. 
 S. 
cerevisiae 
C.albicans T. harzianum B. mori Human 
ALLO (2) 55000 10000 1300 48 40 
DEME (2a) 480 1100 1300 81 1.9 
METH (2b) 60000 14000 1900 65 2.6 




The chitinases from S. cerevisiae and C. albicans showed a 10-100-fold drop in IC50 for DEME 
(2a) compared with ALLO (2), whereas chitinases from Trichoderma harzianum and Bombyx 
mori did not show this effect. In addition, HCHT (Human chitinase) and the chitinase from T. 
harzianum and B. mori bind ALLO (2) 10-100-fold better than the fungal chitinase from S. 
cerevisiae and C. albicans. These different affinities for the substrate are related to the 
construction of the active site groove. S. cerevisiae and C. albicans chitinases are similar to the 
relatively small plant chitinase hevamine, which lacks the extra α/β domain.69 By contrast, HTC 
contains the extra α/β domain and two conserved hydrophobic residues Met-210 and Met-356 
which interact with the methyl groups of the allosamizoline.126  
 
Since the availability of (2) is limited and also the scope for design of novel allosamidin-derived 




R1 = R2 = H           (Psammaplin A)   (4) 
R1= H, R2= OH     (Psammaplin K)   (5) 
R1= OH, R2= OH  (Psammaplin L)   (6) 
 
Figure 9. Structures of Psammaplins. 
 
Psammaplin A (4) is a member of a family of compounds with antibacterial and antitumour 
properties that are derived biosynthetically from bromotyrosine and cysteine. It was originally 
extracted from the sponge Psammaplysilla purpurea129 and has biological properties against a 
Bacillus sp. chitinase with an IC50 of 68 µM and Serratia marcescens chitinase B (SmChiB) 
with a Ki of 148 µM and an IC50 of 100 µM.
47  The structure of SmChiB in complex with (4) 
shows undefined electron density in the active site consistent with conformational flexibility 
and disordered binding of the inhibitor. Asp-175 is partially in the “up conformation” pointing 
towards Glu-177 indicating partial binding in the -1 subsite of the enzyme. The precise binding 







Scheme 3. Synthesis of Psammaplin A.130 
 
Reagents and conditions: (i) KBrO3, KBr, HCl, MeOH; (ii) TFAA, reflux; (iii) aq. TFA; (iv) THPONH2; (v) NHS, 
EDC, 1,4-dioxane; (vi) Et3N, cystamine, 1,4-dioxane/MeOH; (vii) HCl, CH2Cl2/MeOH. 
 
Nicolau et al.130 reported the synthesis of psammaplin A (4) starting from the commercially 
available amino acid L-tyrosine (7), which was monobrominated, then was converted to 
trifluoromethyloxazolone (9) by treatment with trifluoroacetic acid anhydride and subsequently 
hydrolyzed to give an α-keto acid (10). To complete the synthesis, the α-oxime (11) was formed 
by condensation of (10) with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine, followed by the 
symmetric amide coupling of the α-oxime with cystamine and cleavage of the THP group to 
give (4), as seen in Scheme 3. 
 
Hong et al.131 have subsequently reported an alternative approach to the key protected oxime 
derivative shown in Scheme 3 above, starting from a non-amino acid precursor. This potentially 






                                       R1=R2=H        Styloguanidine (12) 
                                       R1=H, R2=Br  Monobrominated styloguanidine (13) 
                                       R1=R2=Br       Dibrominated styloguanidine (14) 
                                              
Figure 10. Styloguanidine structures. 
 
The styloguanidines (Figure 10) are a small group of natural products that possess a unique 
hexacyclic bis-guanidine structure. Styloguanidines and brominated analogues were isolated by 
Kato et al.132 from the sponge Stylotella aurantium. They reported that styloguanidines showed 
activity towards a bacterial chitinase from Schwanella sp. and also inhibited the moulting of 
cyprid larvae of barnacles. 
 
Chang et al.133 have recently reported the synthesis of styloguanidines and related compounds. 
Lanman et al.134 first reported the synthesis of the tetracyclic core of styloguanidines and 
several other advanced intermediates have also been reported by this group.134Other synthetic 
efforts towards the styloguanidines and related bis-guanidine natural products have also been 
reported by Hoffmann and Lindel.135  
 
3.4. Cyclic Dipeptides 
Although carbohydrate oligomers and their derivatives are good candidates for the design of 
glycosyl hydrolase inhibitors, they are often difficult to synthesize and too large to cross cell 
membranes. An alternative class of compounds which are readily available for the construction 
of chitinase inhibitors are peptides. Peptides have been used to mimic carbohydrate-protein 
interactions and bind to enzymes and lectins.136, 137 While carbohydrates are critical molecules 
in the interaction between microbes and the host cell, they are not readily studied molecularly 
using genetic vectors and are poorly immunogenic. Therefore, the use of peptides (easy to 
produce, characterize and manipulate) as substitutes for natural polysaccharides has been 
developed. For example, in MethA tumour, a peptide mimetic of O-β-linked N-
acetylglucosamine present on the tumour surface-expressed glycoproteins stimulates the 
regression of the tumour via the activation of specific antitumour cellular responses.138 
 
CI-4, argifin and argadin (see section 3.5) are all peptide-based inhibitors that mimic chitinase-








Figure 11. Structure of CI-4. 
 
The cyclic peptide, cyclo (L-Arg-D-Pro) named CI-4 (Figure 11), produced by the marine 
bacterium Pseudomonas sp. IZ208, was isolated and identified as a chitinase inhibitor by 
Izumida et al.139 CI-4 (15) and two stereoisomers were evaluated against SmChiB, with cyclo 
(L-Arg-D-Pro) showing a Ki of 0.65 mM and an IC50 of 1.2 mM, whereas an IC50 value of 6.3 
mM was reported for the (D-L) isomer. Compound (15) inhibits separation of daughter cells in 
cultures of Saccharomyces cerevisae and prevents the progression of the human pathogenic 







Figure 12. Comparison of X-ray structure of SmChiB with allosamidin, CI-4 and cyclo-(L-Arg-L-Pro).141 
Amino acids bordering the active site are shown as stick models and potential hydrogen bonds between the ligands 
(in the -1 subsite) and protein (including water- or glycerol-mediated) are represented as black dashed lines. The 
carbon atoms of the catalytic residue (Glu144) are yellow and those of the ligands are purple. The figure was made 
using PYMOL software (DeLano, W. L. The PyMOL MolecularGraphicsSystem (2002) http://www.pymol.org). 
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The structure of CI-4 mimics the intermediate formed in the reaction mechanism of all Family 
18 chitinases - the five-membered oxazoline ring fused to a pyranose ring, The structure of 
SmChiB in complex with CI-4 (Figure 12) shows that it mimics the reaction intermediate and 
compared to allosamidin, CI-4 also makes the same interactions with the chitinase. 141 The six-
membered ring of the CI-4 dipeptide backbone overlaps with the pyranose ring of the reaction 
intermediate. The proline ring occupies the same hydrophobic pocket as the oxazoline ring in 
the intermediate. The arginine side chain then occupies the same space as the N-
acetylglucosamine in the -2 subsite. Hydrogen bonds are formed with Glu-144 (the catalytic 
acid of SmChiB), Trp-97, Tyr-214 and Asp-215 (water-mediated). Hydrophobic interactions 
are made with Ala-184, Met-212 and most notably the completely conserved Trp-408.  
 
Compound (15) is a relatively weak inhibitor against Serratia marcescens chitinase with an 
IC50 = 1.2 mM but because of its easy synthesis, it is a potential scaffold for derivatization.
140 
The crystal structure of this compound in complex with SmChiB shows the Arg side chain does 
not make any significant interactions with the protein. This suggests that it could potentially be 
replaced with other groups that could stack against the hydrophobic amino acids present in the 
catalytic groove of the protein. Interestingly, the crystal structure of cyclo(L-Arg-D-Pro) 
showed that the orientation of the inhibitor in the active site depends on the stereochemical 
configuration of Pro. By changing the conformation, cyclo(L-Arg-L-Pro) is rotated 180° and 
subsequently the Arg side chain is pointed towards to the + subsites, rather the – subsites as in 




Cyclopentapeptide derivatives have been found to effectively inhibit the activity of chitinases 











Figure 13. Structure of argifin. 
 
The cyclopentapeptide argifin (16) (Figure 13) was isolated from the fungal Gliocladium sp. 
FTD-0668142 and was the first non-sugar molecule to show chitinase inhibition in the sub-
micromolar range. Its structure consists of an N-methylcarbamoyl-derivatised L-Arg (Arg(MC) 
an N-methyl-L-Phe residue (MePhe), two β-linked Asp residues and a D-Ala residue. The 
unusual acylated Arg residue plays a key role in the binding of (16) to Family 18 chitinases. 
IC50 values of 3.7, 1.1 and 4.5 µM were obtained against Lucilia cuprina (blowfly) chitinase, 






Figure 14.  X-ray crystal structure of Argifin-AfChiB1complex, with key active site residues indicated.  
(Image courtesy of Prof. D. M. F. van Aalten, University of Dundee). 
 
Compound (16) binds to subsites -1, +1 and +2, interacting with residues Trp-384, Trp-137 and 
Phe-251 that are conserved hydrophobic residues in the Family 18 chitinases AfChiB1 (see 
Figure 14). The N-methylcarbamoyl moiety in the -1 subsite interacts with the side chain of 
Tyr-48 and Trp-384; its nitrogen hydrogen-bonds to the carboxyl groups of Asp-175 and Glu-
177, whereas its oxygen hydrogen bonds to the hydroxy group of Tyr-245. The Arg residue 
also forms a salt-bridge-like interaction with the catalytic acid Glu-177. The N-
methylcarbamoyl group, which resembles the N-acetyl group of the distorted -1 sugar in the 
SmChiB-GlcNA5 structure, retains the hydrogen bonds to Asp-175 and Tyr-245. Likewise, one 
of the hydrogen bonds to the catalytic acid is preserved, while Asp-175 is retained in the “up 
conformation” pointing towards the catalytic acid.47 Linear peptides containing an Arg(MC) 
residue and N-methylguanylurea itself are also chitinase inhibitors.118, 143 Andersen et al.143 
discovered through X-ray analysis that the ability of the guanylurea moiety to penetrate fully 










activity. The synthesis of (16) by a combination of solution and solid-phase methods144, 145 and 
all solid-phase methods has been reported.146, 147 
 3.5.2. Banyasin A 
 
Figure 15.  Banyasin A. 
 
Banyasin A (17) (Figure 15) is a cyclopentapeptide isolated from the water bloom of the 
cyanobacterium Nostoc sp. (IL-235).148 As for (16), the structure of (17) consists of an L-(N-
methylcarbamoyl)-Arg (Arg-MC) residue, a L-MePhe residue, L-Asp and L-Ala residues and 
a novel amino acid, 3-amino-2-methyl-5E-octenoic acid (Amoa). The stereochemistry 
configuration at C2 and C3 in Amoa remain unresolved. The Arg (MC) unit contained in 
banyasin A is the essential feature that allows argifin to make key interactions with the enzyme 
AfChiB. Therefore it is of considerable interest to synthesize (17) and evaluate its potential 














Figure 16. Argadin structure. 
 
The cyclopentapeptide argadin (18) was isolated from a fungal strain Clonostachys sp. FO-
7314149 and is composed of an acetylated L-Arg residue, a D-Pro residue, a backbone cyclised 
L-Asp-β-semialdehyde, an L-His residue and an L-aminoadipic acid residue. Its inhibitory 
potency against typical bacterial chitinases is greater compared to argifin (16) with IC50 values 
of 150 nM against Lucilia cuprina chitinase,150 0.5 µM against AfChiB1117 and 13 nM against 
HCHT.117 Compound (18) has also shown to arrest the moulting of cockroach larvae upon 
injection into the ventral abdominal part. The hemiaminal unit and the D-Pro residue restrict 
the rotation involving the main chain thus possibly contributing to a more rigid structure. 
 
Dixon et al.144 reported the synthesis of (18), with the peptide assembly being carried out by 
solid-phase synthesis, starting from the histidine residue. A homoserine residue was 
incorporated, which then was oxidised in solution to give an hemiaminal derivative, followed 
by the introduction of the derivatised Arg side chain. Hirose et al.151 also achieved the synthesis 




Methylxanthines (Figure 17) have been found in plants and include the well-known compounds 
caffeine (1,3,7-trimethylxanthine) (19), theophylline (1,3-dimethylxanthine) (20) and 
theobromine (3,7-dimethylxanthine) (21). These are purine alkaloids and are produced from 
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coffee (Coffea arabica), tea (Camelia sinensis), mate (Ilex paraguariens), guarana (Paullinia 
cupana), cola (Cola nitida) and cacao (Theobroma cacao).  
 
 
Figure 17. Structures of methylxanthines. 
 
These compounds have a wide range of medical applications, including the treatment of asthma, 
bronchitis and chronic obstructive pulmonary disease and are also used as diuretics, cardiac 
stimulants and renal protective agents. Rao et al.152 used a fluorescence-based assay of a 
commercially available library of 800 molecules screened at 100 µM against the Family 18 
chitinase, chitinase B1 from A. fumigatus. This identified the xanthine derivatives, theophylline 
(20) and caffeine (19) as competitive inhibitors of bacterial, fungal and human Family 18 
chitinases.152 They were shown to be competitive inhibitors of AfChiB1 with (19) and (20) 
having IC50 values of 469 µM and 1500 µM, respectively. They were crystallographically 
determined to bind to the active site of AfChiB1, again mimicking the oxazolinium ion 
intermediate by hydrogen-bonding to the side chains of Asp-175 and Tyr-245, as well as the 
main chain of Tyr-137. The 1,3-dimethylxanthine substructures of these inhibitors also stack in 
the active site, making hydrophobic interactions with the conserved tryptophan residues in the 
active site of the protein.  
 
4. Synthetic chitinase inhibitors 
4.1. Bacterial-type chitinase inhibitors 
 
In the high-throughput screen described above,149 the most promising compounds identified 
were the natural methylxanthine, caffeine (19) and the synthetic  derivative, pentoxifylline (22) 
is the most potent of the three methylxanthine inhibitors identified against AfChiB1 with a Ki 
of 37 µM. The AfChiB1-(22) complex reveals several unusual interactions which may explain 
the increase of magnitude in potency compared to caffeine. Strikingly Trp--137 rotates 93° 
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around (22), sandwiching the xanthine moiety with extensive π-π stacking interactions. The 
rotation of Trp--137 excludes an ordered water molecule seen in the complexes with (20) and 
(19). Additionally the alkyl tail of (22) extends to the -3 subsite, replacing the second ordered 
xanthine seen in both the complexes of (19) and (20), stacking with Trp52 and hydrogen 
bonding two ordered water molecules. 
 
Compound (20) is the weakest of the three inhibitors with an IC50 1500 µM.
152 The inhibitor 
binds in a position equivalent to the allosamidin allosamizoline unit. Allosamizoline is known 
to mimic the oxazolinium intermediate. The methylxanthine mimics this intermediate by 
forming hydrogen bonding with Asp-175, Tyr-245 and the backbone nitrogen of Trp-137, 
residues all conserved in Family 18 chitinases. In addition, the methylxanthine moiety makes 
favourable π-π stacking interactions with Trp-387. Compared to (20), (19) contains an 
additional 7-methyl group, which appears to increase the inhibition 3-fold to an IC50 460 µM. 
This results in the loss of the hydrogen bond for the xanthine-N7 with Asp-175 but also forces 
Asp-175 in to a down conformation compared to the up conformation observed in the AfChiB1-
allosamidin. Similarly Glu-177 moves away to avoid steric clashes of the terminal carboxylate 
with the N-7 methyl. As well as the methylxanthine in the -1 subsite, an additional ordered 
inhibitor molecule is observed in the AfChiB1-(19) complex occupying a position equivalent to 
the -3 sugar observed in the AfChiB1-allosamidin complex. This addititional methylxanthine 
molecule also makes stacking interactions with Trp-52, which is conserved in the other 
bacterial-type chitinases, such as human chitotriosidase, AMCase and chitinase A from Serratia 
marcescens. 
 
The largest of the methylxanthine inhibitors, (22), only covers a small part of the AfChiB1 
active site, from the −1 to just beyond the −2 subsite. By comparison, other more potent 
chitinase inhibitors, such as allosamidin (2) (which covers the −1 to −3 subsites) and 
argifin/argadin (16)/(18) (which cover the −1 to +2 subsites) occupy further subsites. It should 
be noted that nearly all residues in the −1 subsite are identical in the “bacterial”- and “plant”-
types of chitinases, suggesting that these inhibitors may also reduce activity of the latter class 
of enzymes. The simple xanthines thus have a rather poor affinity for chitinases, with a Ki of 
37 µM for (22) against fungal chitinase AfChiB1.152 However, it was recognised that it should 
be possible to extend the methylxanthine scaffold to address additional available chitinase 
subsites and increase chitinase affinity and selectivity through synthetically accessible purine 
chemistry. Molecules of this nature may help elucidate the role that chitinases play in fungal 
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morphology, growth and virulence. Similarly, this approach may extend to the study of the 
precise functions of the mammalian chitinases, which share sequence homology with AfChiB1. 
In this regard, targets could be chitotriosidase and acidic mammalian chitinase, as well as 
several structurally related Family 18 chitinase-like lectins (chilectins), purported to be 
involved in carbohydrate recognition, such as HCgp-39, YM-1 and YM-2 that have been 
implicated in the pathophysiology of inflammation.  
 
The three 1,3-dimethylxanthine derivatives, (19), (20) and (22), possess a common binding 
mode with Family 18 chitinases, whether making π-π interactions, or mimicking the hydrogen 
bonds of the reaction intermediate in the active site of the enzyme. The xanthine moiety of the 
three compounds always binds in the same orientation as observed for the AfChiB1 in the active 
site. Additionally (22) offers good ligand efficiency, ΔG = -0.43 Kcal mol−1 atom−1, suggesting 
that it should be an ideal starting point for further optimization.153 
 
Schüttelkopf et al.153 screened a database of 5.1 million commercially available compounds for 
molecules containing the 3-methylxanthine substructure, as this moiety makes the key 
interactions with the enzyme (AfChiB1). 50,193 candidate ligands were identified. The most 
promising hits were evaluated by docking with PRODRG/LIGTOR and twelve compounds 
were then selected for evaluation in vitro. Compounds (23) and (24), shown in Figure 18 
showed significant inhibition, but for (23), its activity was worse than caffeine, so it was not 













Figure 18. 3-Methylxanthine scaffolds as potential inhibitors of AfChiB1. 
 
Compound (24) showed an IC50 = 4.8 ± 1.4 µM, improving inhibition by 2 orders of magnititude 
compared to caffeine (19) and nearly 25- fold compared to pentoxifylline (22), the most potent 
xanthine-based chitinase inhibitor. “C2-dicaffeine” (24) is a competitive inhibitor of chitinase 
38 
 
with an extensive π-π stacking binding mode. Defined electron density for (24) shows the 
“primary” caffeine moiety is sandwiched between Trp-137 and Trp-384, whereas the “second” 
stacks with Trp-52.153   
 
Compound (24), C2-dicaffeine or bisdionin B, inhibits several bacterial type Family 18 
chitinases.153  The complex of AfChiB1-(24) showed significant stacking interactions between 
the   three tryptophan residues, Trp-52, Trp-137 and Trp-384 residues. . This suggested that 
(24) can be used as ligand to test for inhibition of bacterial-type chitinases. Subsequently, three 
additional Family 18 chitinases were screened against (24), namely human macrophage 
chitotriosidase (HCHT), acid mammalian chitinase activity from mouse lung (mAMCase) and 
a bacterial-type enzyme from S. marcescens (SmChiB). The IC50 values were 107 µM, 90 µM 
and 71 µM, respectively. The substitutions of the amino acids within the catalytic site of each 
protein which do not interact directly with the xanthine units seem to affect more or less the 
activity of (24) against these enzymes. This suggested that dicaffeine molecules could be used 
as scaffolds to design inhibitors of bacterial type chitinases in general and selectively target 
individual enzymes.153 
 
In the crystal structure of the AfChiB1-(24) complex,153 the active site Asp175 is in the down 
conformation into the catalytic core, like in other complexes with xanthine derivatives. 
Furthermore there are two major differences from the previously known xanthine binding mode 
and the docked conformation: first, (24) is shifted out of the active site by about 1.5 Å and 
second, both purine rings are flipped by 180° around their N-1 linker bond. This binding mode 
significantly improves π-π-stacking between the secondary caffeine and Trp-52 compared with 
the docked orientation.153 
 
 
                                        R1 = R2 = CH3, R3 = H      Bisdionin C    (25) 
R1 = CH3, R2, R3 = H  Bisdionin F        (26) 
R1= CH3, R3= CH3-CH2  Bisdionin G   (27) 
 




C3-dicaffeine also known as bisdionin C, (25) is also a drug-like molecule based on Lipinski’s 
rule of five. Compound (25) is more active against AfChiB1 compared to (24) due to its longer 
linker between the two xanthines. Bisdionins C (25) and F (26) showed inhibitory activity 
against AfChiB1 and AMCase with IC50 values of 0.20 µM and 2.2 µM respectively.
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Bisdionin G (27), a derivative of bisdionin F (26) carrying an ethyl substituent on the 8-position 
of the second xanthine moiety, has recently been identified as an effective ligand of chitinase-
like protein YKL-39, with a Ki value of 120 ± 2 µM.
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4.1.2. Closantel plus related derivatives 
The neglected tropical disease, river blindness or Onchocerciasis is caused by the filarial 
parasitic nematode Onchocerca volvulus, which is transmitted to humans by blackfly. Its 
symptoms are the result of the death of the microfilarae in the skin and eyes. Recently, one 
chitinase from O. volvulus, OvCHT1, has been identified and it is expressed in larvae and stored 
within cells of the oesophageal glands of the nematode. This larval chitinase has a role in 
parasite transmission, ecdysis and remodelling of cuticle. Consequently deregulation of this 
metabolism is a potential therapeutic target to develop inhibitors of OvCHT1. Gloeckner et 
al.116 used a fluorescence-based assay, to screen the Johns Hopkins Clinical Compounds 
Library (JHCCL), a commercially available library of 1514 known drugs, against OvCHT1. 
They found that the veterinary anthelmintic drug closantel (28) is a chitinase inhibitor with an 
IC50 1.6 µM.  Additionally, closantel was also found to inhibit the L3 to L4 larval moult in O. 
volvulus in the same manner as had been observed with cysteine protease and transglutaminase 
inhibitors cultured with this parasitic species. Structure retrofragmention of (28) led to 
compound (29), which was identified as a chitinase inhibitor with an IC50 = 5.8 µM, similar to 
(28).  
                           
Figure 20. Structure of closantel (28) and its derivative (29). 
 
Because of the role of (28) as a protonophore and its chitinase inhibitor activity, this suggests a 




To investigate the molecular fragment responsible for the individual and or dual biochemical 
activities of (28), a series of compounds based on the closantel fragment (29) was screened for 
chitinase inhibition and protonophore activity. These studies revealed that (30) has a better 
chitinase inhibition with IC50 = 0.63 µM compared to (28) and has no protonophore activity. 
Additionally compound (31) showed no chitinase inhibition but was found to be a more potent 
ionophore than (28). 
 
Figure 21. Structure of OvCHT1 inhibitors. 
 
4.1.3. AMCase inhibitors from high throughput screening 
The Acidic Mammalian Chitinase (AMCase), which is a member of the Family 18 chitinases, 
has been recently demonstrated to be implicated in the pathophysiology of asthma. Several 
natural products or novel synthetic derivatives  have been shown to be inhibitors of AMCase.155 
To identify new small molecule inhibitors of AMCase, Cole et al.156 applied a combination of 
high-throughput screening (HTS), fragment based screening (FBS) and virtual screening (VS) 
techniques. 
 
The AMCase HTS assay based on hydrolysis of the fluorescent-based substrate, 4-
methylumbelliferyl(β-D-N,N’-diacetylchitobioside) was used to screen a library of 446,000 
compounds at a concentration of 10 µM.156 The structures of the most promising hits from HTS 






Figure 22. Structure of AMCase inhibitors. 
 
The X-ray structure of these inhibitors in complex with AMCase revealed that (32) was a potent 
inhibitor.156 Its structure was compared to the previous structure of AMCase with 
methylallosamidin (2a). The aminotriazole moiety of (32) was found to bind in the active site 
forming hydrogen bonds with catalytic residues Asp-138, Glu-140 and Tyr-212 and to stack 
against the conserved residues Trp-360 and Met-210. The rigid bromophenyl ring interacts with 
hydrophobic residues Tyr-237, Ala-295 and Ile-300. 
 
The compound (33) binds to AMCase in the same manner as for the compound (32), with the 
pyridine ring occupying the conserved residues Trp-360 and Met-210 and the piperazine moiety 
overlapping with Tyr-237, Ala-295 and Ile-300. The indole ring by extension makes 
hydrophobic interactions with Tyr-267, Ala-295, Ile-300 and Leu-364. 
 
Cole et al.156 screened other hits identified by FBS shown in Figure 23 that are weaker inhibitors 
than (32) and (33) but have lower molecular weights and clogP. This means that the ligand 
efficiency (LE) and ligand-lipophilic efficiency (LLE) of these compounds (34) and (35) are 
comparable, plus they are equally good (hits of IC50 < 0.1-100 µM), so they can be used as 









4.2. Plant chitinase inhibitors 
Plant-type chitinases are involved in fungal cell-wall remodelling during cell division. 
Deregulation of this process may result in a decrease of fungal viability as well as virulence, 
making inhibitors of plant-type chitinases potential tools as antifungal agents.   
 
To date, mainly bacterial-type chitinase inhibitors have been reported and most of them are 
weak inhibitors against fungal plant-type Family 18 chitinases. The crystal structure of the 
plant-type fungal chitinase, Saccharomyces cerevisae CTS1 (ScCTS1) was established by 
Hurtado-Guerrero et al.157 This protein displays four domains: a signal peptide, a catalytic 
domain, a Ser/Thr-rich domain and high-affinity chitin-binding regions. The active site consists 
of six sugar-binding subsites, numbered from -4 (the nonreducing end) to +2 (the reducing end) 
with hydrolysis taking place on the glycosidic bond between the -1 and +1 subsites. 
 
In order to design antifungal compounds and to understand the role of plant chitinases in cell 
wall morphogenesis, Hurtado-Guerrero et al.157 screened ScCTS1 against the Prestwick 
chemical library of 880 drug-like molecules. From this, three significant hits were identified: 
8-chlorotheophylline (Ki of 600 µM), acetazolamide (36) a well-known carbonic anhydrase 
inhibitor and kinetin (37) (a plant hormone). Both (36) and (37) were competitive inhibitors, 
with Ki values of 21 and 3.2 µM, respectively. 
 
 
Figure 24. Competitive inhibitors of ScCTS1. 
 
Allosamidin (2), a potent Family 18 chitinase of both plant and bacterial-type chitinases,122 
inhibits ScCTS1 with a Ki of 0.61 µM
157 and hevamine with a Ki of 3.1 µM
158 but it is a weak 
inhibitor for the plant-type chitinase A1 in A. fumigatus with an IC50 of 127 µM.
159 Based on 
these studies, (36) and (37) were screened against AfChiA1. The results showed that (37) failed 
to display any activity against AfChiA1, even at higher concetrations. Compound (36) on the 




The X-ray structure of AfChiA1-(36) shows that the thiadiazole ring stacks with the conserved 
Trp-312, while its ring nitrogens form hydrogen bonds with Ala-124 and Tyr-125. The 
acetamido moiety enters and fills the shallow active site pocket of AfChiA1, by forming 
hydrogen bonds with Tyr-238, Gln-230, Met-310, Ala-205, Tyr-34 and Asp-172. The 
sulfonamide group makes a poor hydrogen bond with Trp-312.159 
 
These investigations showed that (36) is a weak inhibitor of both ScCTS1 and AfChiA but, 
because of its synthetically accessibility and high ligand efficiency (-0.40 kcal mol-1atom-1), it 
is an interesting lead for future inhibitor development.159 
 
4.2.1. Guanylurea and derivatives 
The structure of argifin (16) in complex with AfChiB1 has been used to design peptide 
fragments that contain the dimethylguanylurea unit, which penetrate fully into the active site 
groove.117, 160 The potency of the argifin peptide fragments can be ranked tetrapeptides  > 
tripeptide > monopeptide > dimethylguanylurea. Crystallography studies of these peptide-
protein complexes and enzymology showed that these argifin fragments conserved their mode 
of binding and are still competitive inhibitors of Family 18 chitinases but with better ligand 
efficiency than (16), with BEI values 11.7 and 10.2 for (16) and the tetrapeptide, Ac-Arg(MC)-
MePhe-β-Asp-OH, respectively. Surprisingly, the simple dimethylguanylurea derivative (38) 
shown in Figure 25 and Table 3 forms most of the key interactions with AfChiB1 and represents 
an unsually efficient binder and an attractive scaffold for structure-based optimization. In the 
(38)-AfChiB1 complex, the fragment is well ordered in the same manner as the Arg(MC) side 




Figure 25. Structure of alkylguanylureas (see Table 3). 
 
As the catalytic groove of Family 18 chitinases is strongly conserved,41-44 it was speculated that 
a guanylurea derivative could also inhibit the plant-type Family 18 enzymes and that it should 





Remarkably, compound (38) was found to inhibit the plant-type enzyme AfChiA1 with an IC50 
of 79 µM, confirming that effective inhibitors for this class of chitinases can be generated based 
on the guanylurea structure. A small series of simple “argifin-derived” fragments were 
synthesized and tested against AfChiA1 as seen in Table 3. Note that three of the derivatives, 
(38), (40) and (41) are significantly more active than the best inhibitor of plant-type enzymes, 
allosamidin (2) with an IC50 of 127 µM against AfChiA1.
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Table 3. Alkylguanylurea biological activities against AfChiA1 
Compound R AfChiA1 IC50 (µM) 
38 CH3 79 ± 8 
39 CH3CH2 310 ± 7 
40 CH3(CH2)3 38 ± 7 
41 Cyclo hexane 42 ± 1.3 
42 PhCH2 299 ± 4 
 
The exposed site of AfChiB1 contains a larger β/α-loops plus the incorporation of an entire α/β 
domain and this is lined by the several solvent-exposed aromatic residues, including Trp 137. 
Whereas in the AfChiA1 the active site is defined by very short β/α-loops, the extra α/β domain 
is lacking.  
 
Table 3 shows that the alkylguanylureas (38-42) are efficiently accommodated in the shallow 
active site of the AfChiA1. 
 
 It is these differences in construction of the active site  that explain the different affinities for 








4.3. Objectives of the project:  
This project is focused on the synthesis and development of peptide-based chitinase inhibitors. 
Our specific objectives were to: 
 
 Develop an improved synthesis of the cyclic pentapeptide argifin. Specifically, 
herein aim to develop a synthesis which is suitable for larger-scale preparation 
of the natural product and avoids side reactions that may occur in existing 
syntheses. 
 
 Investigate the synthesis of new reagents for the direct conversion of amines to 
the key guanylurea unit of argifin and related peptides. 
 
 Develop an efficient synthetic route to Amoa (3-amino-2-methyl-5-E-octenoic 
acid), the novel amino acid component of the cyclic peptide banyasin A. It was 
aimed to develop a synthesis that is suitable for the preparation of all four 
diastereoisomers of Amoa for incorporation into peptide synthesis. 
 
















5. Results and discussion 
5.1. Approaches to argifin and related peptides 
As already highlighted, argifin is a cyclic pentapeptide isolated from Gliocladium fungal 
culture,142 which is an effective inhibitor of bacterial-type chitinases. Its key features 
synthetically are two β-linked Asp residues and an unusual N-methylcarbamoyl-L-Arg residue. 
The latter forms hydrogen bonds with the catalytic residues of the active site, mimicking those 
formed by the natural substrate in the -1 pocket. No inhibition is observed in the absence of this 
Arg(MC) residue.143 
 
5.1.1 Strategy avoiding aspartimide formation 
The first synthesis of argifin was carried out by a combination of solid-phase and solution 
chemistry, as shown in Scheme 4.161 
 
 
Reagents and conditions: (i) PyBOP, DIPEA, CH2Cl2, 16 h, [peptide] = 1 mM, quantitative yield; (ii) 
TFA/thioanisole/H2O/CH2Cl2 (16:2:1:1, v/v/v), 2 h, 28% or TFA/CH2Cl2/H2O; (iii) 3 eq, MeNHCO2Su, 6 eq, 
DBU, DMF, 40 °C, 2 h, 65% for (16). 
 
Scheme 4. First total synthesis of argifin. 
 
The partially protected linear peptide was obtained by Fmoc-solid phase synthesis using 2-
chlorotrityl resin. The choice of Asp derivative as the starting amino acid was found to be 
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critical in the assembly of the linear precursor. The use of tert-butyl protection for the non-
resin-linked Asp residue rather than benzyl ester protection reduced based-induced aspartimide 
formation162 during the Fmoc deprotection. The cyclisation of the linear peptide was then 
performed in dilute CH2Cl2 solution using PyBOP activation and DIPEA as base. 
 
The cyclisation was effective as the choice of the linear precursor sequence maximises the 
possibility of favourable precyclised conformations, by having the MePhe and D-Ala residues 
in the second and fourth positions respectively. To complete the synthesis, the removal of tert-
butyl and Pmc protecting groups was required. These acid-labile protecting groups were 
cleaved using a mixture of TFA/thioanisole/CH2Cl2/water (16:2:1:1, v/v/v). However the 
deprotection proved to be problematic leading to several products, including aspartimide 
formation.162 Preparative HPLC was required in order to isolate the fully deprotected cyclic 
pentapeptide (45) in 28% yield. Finally, the derivatisation of the Arg residue was carried out 
using succinimidyl N-methylcarbamate in the presence of DBU as base. Mono-acylation gave 
the required the Arg(MC) moiety. HPLC was again required in order to isolate the desired 
compound argifin (16), in 17% overall yield, based on the loading of the first amino acid in the 
solid-phase synthesis. 
 
In summary, in the first synthesis of argifin,161 removal of acid-labile Asp and Arg side chain 
protecting groups proved to be problematic, leading to aspartimide formation upon side chain 
deprotection and, as a consequence, two HPLC purifications were required during the synthesis. 
This is both time-consuming and reduces the overall yield of the cyclic peptide that can be 
obtained. In order to improve the efficiency of production of argifin and develop SAR on 
analogues of the cyclopentapeptide, another synthesis was therefore developed by Dixon et 






Reagents and conditions: (i) 2-chlorotrityl chloride polystyrene resin, DIPEA, CH2Cl2, 60 min; (ii) Fmoc SPPS; 
(iii) Pd(Ph3P)4, PhSiH3, CH2Cl2, 3 x 20 min; (iv) piperidine/DMF (1:4, v/v), 4 x 3 min; (v) PyBOP, DIPEA, 
CH2Cl2, 2 x 60 min; (vi) N2H4/DMF (1:49, v/v), 2 x 15 min; (vii) 1H-pyrazole-1-carboxamidine hydrochloride, 
DIPEA, DMF, 16 h; (viii) MeNHCO2Su, DBU, DMF, 2 h; (ix) TFA/CH2Cl2 (1:99, v/v), 10 x 20 min; (x) 1 M aq. 
HCl, 60 °C, 90 min; (xi) DIPEA, DMF, 2 x 16 h. 
 
Scheme 5. Dixon’s on-resin synthesis of argifin.146 
 
The alternative synthesis of argifin as outlined in Scheme 5 was carried out by all solid-phase 
chemistry.146 The acid-labile 2-chlorotrityl chloride polystyrene resin was again chosen for 
Fmoc-solid phase synthesis. The linkage to the resin was achieved through the -carboxyl of 
one of the Asp residues in the linear peptide precursor, with allyl ester protection on the -
carboxyl of this residue. The Orn side chain was Dde-protected, as Dde is removable by 
hydrazinolysis but stable to both Fmoc and allyl ester deprotection conditions. The non-resin-
linked Asp residue was again protected as a tert-butyl ester (on the -carboxyl) in order to 
eliminate aspartimide formation during assembly of the linear peptide precursor (48). The use 
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of 2-chlorotrityl resin also helped suppress aspartimide formation when the resin-bound cyclic 
peptide intermediate (50) was exposed to the basic conditions required for the final Arg 
acylation step (step (viii) in Scheme 5). 
 
After removal of the Fmoc group on the N-terminal Asp residue and removal of the allyl ester 
protection at the C-terminal Asp, the cyclisation of the linear pentapeptide intermediate (48) 
was performed on resin in CH2Cl2 solution using PyBOP activation and DIPEA as base. 
Cleavage of Dde from the resin-bound cyclic pentapeptide (50) gave the free side-chain amino 
group on the Orn residue ready to be derivatised. The conversion of Arg(MC) was attempted 
by two different approaches. The approach involved a one-step reaction using the known 
reagent (53) to convert the Orn residue directly to Arg(MC). This was unsuccessful, however; 
15 eq of the reagent and prolonged reaction time gave poor conversion. The second approach 
involved a two-step sequence carried out on the Orn residue in (50). This involved first 
guanidination of the side-chain amino function with 1H-pyrazole-1-carboxamidine 
hydrochloride to give the Arg derivative, then acylation with succinimidyl N-methylcarbamate 
in the presence of DBU to give the Arg(MC)-containing intermediate (51). The method of 
introduction of Arg(MC) in this latter step was thus essentially the same as that used in the first 
reported synthesis. Analysis by HPLC on the crude cyclic peptide (52) that was obtained after 
cleavage from the resin revealed 70% of the mono-acylated compound, plus some doubly 
acylated material and also unreacted starting material. 
 
To complete the synthesis, the tert-butyl ester protection at Asp in (52) had to be removed 
independently of cleavage from the resin in order to avoid aspartimide formation. The treatment 
of the resin-bound peptide (51) with TFA/CH2Cl2 (1:99, v/v) gave the cyclic peptide (52) 
without any side-chain deprotection. The remaining tert-butyl ester was then finally cleaved 
using 1M aq. HCl.  One single HPLC purification had to be done in order to isolate the desired 
fully deprotected argifin (16), in 18% overall yield, over a 17-step sequence.146  
 
These results demonstrated that the choice of the resin and also the combination of the 
protecting groups during the linear peptide assembly was effective to eliminate the issue of 
aspartimide formation but introduced a potential problem of double acylation in the Arg to 




Aspartimide formation is a well-known problem in the synthesis of Asp-containing peptides 
and it may occur under acidic or basic conditions, leading to the formation α or β-peptides,162 




Scheme 6.  Aspartimide formation from β-Asp peptides. 
 
It appears that argifin (16) with its two β-linked Asp residues is particularly sensitive. In this 
case, the Asp residue followed by D-Ala (“Asp-D-Ala” unit) is probably at most risk of 
aspartimide formation. 162 
 
In a subsequent synthesis of (16) by solid phase methods, Sunazuka et al.147 developed a 
specific guanidinylating agent (54), shown in Figure 26,  that can be used  to  convert an Orn 
residue directly to Arg(MC) on resin, using a similar protection strategy to that used in Dixon’s 
synthesis.146 One minor difference was that in the coupling to the hindered MePhe residue, 
HATU was used, which proved to be more efficient than PyBOP or PyBrOP. After Fmoc and 
allyl ester deprotections at the N and C-termini of the linear resin-bound peptide, the cyclisation 
was carried out in CH2Cl2 using HATU in the presence of base. Dde was then removed with 
2% hydrazine/DMF, followed by the conversion of Orn to Arg(MC) in a one-step reaction. This 
crucial transformation in the synthesis using (54) to modify the Orn side chain gave only a 
monoacylated Arg intermediate. To complete the synthesis, the protected cyclic peptide was 




This synthetic was achieved in 15-steps from the loading of the first amino acid to resin and 




Figure 26. Sunazuka’s guanidination reagent.147  
 
As with the previous reported on-resin synthesis,143 one single HPLC purification was used. 
However strategies involving on-resin cyclisation are inherently limited in the scale of peptide 
that may be synthesised, plus it has been observed that exposure of the final peptide to acidic 
conditions leads to some risk of aspartimide formation. 162 
 
The aim was therefore to establish a new approach to (16) that is suitable for producing larger 
quantities of the cyclic peptide, as would be required for in vivo studies. To achieve this, the 
aim was to synthesise a suitable linear peptide by SPPS with cyclisation done by solution 
chemistry, as in the first synthesis of (16).161 To improve the efficiency of the synthesis, two 
different approaches were also attempted to introduce the Arg(MC) side-chain, via a 
combination of side-chain protecting groups that should allow   avoidance of side reactions seen 
in previous syntheses. 
 
In order to overcome aspartimide formation,162  benzyl ester and benzyl carbamate (Z) 
protecting groups were envisaged for the Asp and Arg residues, respectively, which are 
removable under neutral conditions by hydrogenolysis. As outlined in Scheme 7, the synthesis 
of the linear precursor peptide (59), does not involve the risk of aspartimide formation as the 
first Asp residue (Asp-OBn) incorporated is directly attached to the solid support (see 
intermediate (56)). Boc-Asp-OBn was chosen to incorporate the second Asp residue at the N-
terminus for similar reasons. In this way, the N-terminal protecting group is removed upon 
cleavage from the solid support with TFA. This avoids the risk of aspartimide formation which 
would occur if Fmoc-Asp-OBn was used, where exposure to basic conditions would be required 




For the synthetic approach in Scheme 7, the fully protected linear pentapeptide (59) was 
assembled on Wang resin using 2 eq of Fmoc-protected amino acids and PyBOP (1.9 eq) 
activation and DIPEA as base, except for the coupling to the hindered MePhe residue where 
HATU (2 eq) was used. This proved to be more efficient than PyBrOP.158 The cleavage of the 
linear peptide from the resin and removal of the Boc protecting group from the N-terminus was 
achieved with TFA/H2O/CH2Cl2 (95:2.5:2.5, v/v/v) to give (59) in quantitative yield, based on 
the calculated  resin loading. The cyclisation of (59) was then performed in dilute CH2Cl2 
solution using HATU activation and DIPEA as base and gave the cyclic pentapeptide (60) in 
55% yield. The cyclisation proceeded efficiently to give exclusively (60), without the need for 
further purification, as judged by HPLC, shown in  Figure 27. 
 
 
Reagents and conditions: (i) Wang Resin DIC, DMAP, CH2Cl2/DMF (1:1, v/v), 90 min; (ii) piperidine/DMF (1:4, 
v/v), 4 x 3 min; (iii) Fmoc-MePhe-OH, PyBOP, DIPEA, DMF, 90 min; (iv) Fmoc-Arg(Z)2-OH, HATU, DIPEA, 
DMF, 90 min; (v) piperidine/DMF (1:4, v/v), 4 x 3 min; (vi) Fmoc-D-Ala-OH, PyBOP, DIPEA, DMF, 90 min; 
(vii) piperidine/DMF (1:4, v/v), 4 x 3 min; (viii) Boc-Asp-OBn-OH; (ix) TFA/H2O/CH2Cl2 (95:2.5:2.5, v/v/v), 1 
h; (x)  HATU, DIPEA, DMF, 48 h. 
 







    Figure 27. HPLC trace of isolated cyclic pentapeptide (60) and the linear peptide (59). 
 
In summary, the careful choice of alternative  protecting groups for the Asp and Arg residues 
in this synthesis  allowed us to obtain the linear peptide (59) effectively, which could be cyclised 
directly with no further HPLC purification required (Figure 27). 
 
A further positive feature of our modified approach is the replacement of the moisture-sensitive 
2-chlorotrityl resin, with the cheaper, more robust Wang resin for the linear SPPS. 
 
With the fully protected cyclic peptide (60) in hand, the removal of all the hydrogenolysable 
































Reagents and conditions: A:  H2, Pd(OH)2/C, AcOH/PriOH, r.t., 1 h; B: H2, Pd black, AcOH/PriOH, r.t., 18 h; C 
H2, Pd(OH)2/C, AcOH/PriOH, r.t., 16 h.; D: H2, Pd(OH)2/C, AcOH/PriOH, r.t., 18 h; E: H2 (4 bar, ), Pd(OH)2/C, 
AcOH, r.t, 72 h.  
                                           
Scheme 8. Hydrogenolysis of (60). 
 
First, the fully cyclic protected peptide (60) was submitted to hydrogenolysis, with Pd(OH)2/C 
in AcOH/iPrOH and 1 atm of hydrogen. The reaction was monitored by TLC and, after 
disappearance of the starting material, analysis by HLPC showed a single new peak at 9.83 min, 
but mass spectrometry showed the presence of two different compounds (62) and (63), shown 
in Figure 28. These corresponded to the full deprotection of the Arg residue (removal of both 
Z groups), with either both benzyl ester protecting groups intact as in (62), or one benzyl ester 




Figure 28. Compounds resulting from the hydrogenolysis of protected cyclic peptide (60). 
 
The mixture of the two cyclic peptides (62) and (63) obtained was again submitted to 





It was speculated that the use of a more reactive catalyst, such as palladium black, should 
improve the hydrogenolysis; therefore, the same sample was submitted to hydrogenolysis, with 
this catalyst, under a hydrogen balloon. Once again, no further change was observed. Although 
the removal of the Z protection was expected to occur more easily than the benzyl esters, the 
difficulty to achieve full deprotection was unexpected.163 Repeating the initial deprotection with 
a fresh sample of the cyclic peptide (60) and new catalyst again gave a mixture of (62) and (63), 
which were inseparable on HPLC (Figure 29). 
 
 
Figure 29. HPLC trace of the partially deprotected cyclic pentapeptides (62) and (63). 
 
Full deprotection of (60) was finally achieved using Pd(OH)2/C, in AcOH under medium 
hydrogen pressure (4 bar). HPLC analysis after 72 h now showed a clear conversion to a single 
new product (61) (Figure 30) which was confirmed as the fully deprotected cyclic peptide (60) 
by mass spectrometry. 



















Figure 30. HPLC trace of the fully deprotected cyclic pentapeptide (61). 
 
To complete the synthesis, the introduction of the N-methylcarbamoyl group onto the Nω 
position of the Arg side chain was performed according to the method used in Dixon’s first 
synthesis of argifin.161 The compound (61) was treated with 3 eq of succinimidyl N-
methylcarbamate in DMF at 40 °C in the presence of DBU as base. This gave (16) in 19% 
overall yield from (61), after purification by preparative HPLC, as shown in Figure 31. 
 
The final yield of argifin from the fully protected cyclic peptide (61) is a slight improvement 
on Dixon’s original approach (19% against 18%). Importantly, only one HPLC purification is 
























Figure 31. HPLC trace of argifin (16). 
 
 
5.1.2. Introducing the guanylurea group of argifin; strategy avoiding the double acylation 
A critical step in all published syntheses of argifin to date is the introduction of the guanylurea 
unit of the natural product. When this is effected by treatment of the Arg residue with an 
activated ester, there is the potential for double acylation to occur.146 Sunazuka avoided the 
problem of the double acylation by conversion of an Orn residue to Arg(MC) with a suitable 
guanidinylating agent. It was decided to explore an alternative one-step approach to the 
guanylurea moiety of argifin via a doubly protected arginine side chain, Arg(Z)2. This would 
avoid again the use of any acid-labile protection. 
 
In previous work in our laboratory, it had been showed that di-Boc-protected guanidines may 
be converted to the corresponding guanylureas by aminolysis with methylamine.118 It was 
envisaged that this type of reaction could be a way of converting an Arg(Z)2 side chain into the 
Arg(MC) unit of argifin  in one step, so avoiding the problem of double acylation.   
 

















As a first step, the Boc-protected compound,  N,N’-di-Boc-N’-benzylguanidine  (65) was first 
prepared according to the method of Feichtinger et al.164 by reaction of benzylamine with 1,3-
di-Boc-2-(trifluoromethanesulfonyl)guanidine (64) in CH2Cl2, in the presence of  triethylamine 
(5 eq), for 30 min at room temperature (Scheme 5). This gave (65) in 72% yield, which was 
then converted to (66) by aminolysis with methylamine (5 eq) in THF at reflux overnight. 
Analysis of the reaction mixture by TLC showed the presence of the starting material and two 
other components. The crude product was purified to give unchanged starting material and the 




Reagents and conditions : (i) Benzylamine (1.1 eq), CH2Cl2, rt, 30 min, 72%; (ii)  MeNH2 (5 eq), THF, reflux, 
overnight, 55%. 
 
Scheme 9. Aminolysis of the Boc-protected guanidine (65) to give guanylurea (66). 
 
In order to investigate the scope of the aminolysis reaction with other carbamate protecting 
groups, the di-Z guanidine (68) was synthesised in an analogous fashion to (65). It was first 
necessary to synthesise the appropriate guanidinylating reagent (69), as described by 
Feichtinger et al.164 (see Scheme 10). First, guanidine hydrochloride (67) was converted to the 
N,N’-di-Z-guanidine derivative (68) in 59% yield by treatment with benzyl chloroformate (3 
eq) in aqueous sodium hydroxide (5 eq).  Next, (68) was deprotonated with sodium hydride in 
anhydrous chlorobenzene at -45 °C, followed by treatment of the resulting anion with triflic 
anhydride to give (69) in 84% yield. The use of chlorobenzene as solvent was essential for the 
success of this step; the corresponding reaction in THF gave none of the desired product. 
 
With (69) in hand, the guanylurea (71) was obtained via a two step procedure as before. First, 
a solution of benzylamine and (69) in CH2Cl2 was treated with triethylamine (5 eq) for 1 h at 
room temperature, to give (70) in 81% yield. Compound (70) was then treated with 
methylamine (7.5 eq) in THF at reflux overnight. Analysis of the reaction mixture by TLC 
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showed the presence of the starting material and two other components. The crude product was 




Reagents and conditions : (i) NaOH (5 eq) CH2Cl2, H2O, 0 °C, 1h; (ii) benzyl chloroformate (3 eq), 0 °C -rt, 
overnight, 59%; (iii) NaH (3.3 eq) chlorobenzene, 0 °C, 1h, triflic anhydride (1 eq), -45 °C -rt, overnight, 84%; 
(iv) benzylamine (1.1 eq), CH2Cl2, rt, 1h, 81%; (v) MeNH2 (7.5 eq), THF, reflux, overnight, 98%. 
 
Scheme 10. Aminolysis of the Z-protected guanidine (70). 
 
Miel and Rault165 reported that the conversion of Boc-protected guanidines into ureas with 
various primary and secondary amines occurs via an isocyanate intermediate as shown in 
Scheme 11. In our case an excess of methylamine was used, which should act both a base to 
promote the formation of the isocyanate and as a nucleophile, according to Miel and Rault. 
 
 
Scheme 11.  Mechanism of aminolysis via an isocyanate proposed by Miel and Rault.162 
 
The N-H protons of the di-Boc-protected guanidine are expected to be more acidic than those 
of the benzylamino unit,165 due to the possibility of delocalizing negative charge through the 
guanidine and carbonyl functional groups. The isocyanate intermediate is then generated by the 
removal of the Boc-protected N-H, followed by the expulsion of a tBuO- group. If such a 
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mechanism also operates for N,N’-di-Z-guanidines such as (70), a more efficient conversion (as 
observed) might be expected, based on the fact that benzyloxy is potentially a better leaving 
group than tert-butoxy, as seen in Scheme 11. 
 
This aminolysis method165 was then applied to our Arg(Z)2 protected cyclic pentapeptide (60) 
prepared previously. Compound (60) was treated with excess methylamine in THF solution and 
the reaction heated at reflux. After 24 h and 48 h respectively, the reaction was incomplete as 
shown by HPLC and extra MeNH2 (5 eq) was added. After 72 h of reaction, a single main 
product appeared to be formed by HPLC with very little starting material (60) remaining (Figure 
32). Analysis of the crude reaction mixture by mass spectrometry did not show the formation 
of the desired product (72), but rather a compound m/z 933.4 [M+Na+] corresponding to the 




Reagents and conditions: (i) MeNH2, THF, reflux, 72 h. 
 





Figure 32.  HPLC trace of the aminolysis reaction with (60) after 72 h. 
 
In order to investigate whether the aminolysis reaction165 occurred just at the Arg(Z)2 side chain 
or also at aspartic acid, two model tripeptides were prepared. The tripeptide (74) may only 
undergo reaction at Arg, while (77) may react at both Arg and Asp (see Scheme 13), to give a 
product (78) with incorporation of two equivalents of methylamine. 




































Reagents and conditions: (i) MeNH2, THF, 65 °C, 72 h. 
 
Scheme 13. Investigation of aminolysis reaction on the tripeptides (74) and (77).  
 
The tripeptides (74) and (77) were synthesised by Fmoc SPPS using Wang resin. These models 
were then submitted to the aminolysis reaction with 2 eq of MeNH2 and the reaction was 
monitored by HPLC.  For the reaction of methylamine with (74), HPLC analysis showed no 
change after 48 h reaction. An excess of 5 eq of methylamine was added to the reaction, but 
after 72 h the HPLC still indicated that no reaction was occurring. In the case of (77) with 
MeNH2 after 48 h reaction, HPLC showed partial consumption of the starting material, 
therefore another 5 eq of MeNH2 were added to the reaction mixture but again after 72 h HPLC 
showed no further change. Although the analysis by HPLC did indicate a new compound, mass 
spectrometry did not support the formation of the desired compound (78). 
 
Because of the inconclusive results with these models, a simpler argifin-related fragment was 
chosen for study. It was speculated that the desired aminolysis reaction might be sterically 







Reagents and conditions: (i) EDC.HCl, HOBt, MeNH2.HCl, DIPEA, CH2Cl2, rt, 16 h, 89%; (ii) EtNH2, DMF, rt, 
30 min; (iii) Ac2O, DMAP, CH2Cl2, 16 h, 78% ; (iv) MeNH2, THF, 16 h;  (v) BnNH2, CHCl3, reflux, 16 h. 
 
Scheme 14. Synthesis of model compound (81) and attempted aminolyses. 
 
The synthesis of this model compound (81) is shown in Scheme 14. First, the amide derivative 
(80) was prepared by coupling of (79) with methylamine using EDC.HCl and HOBt as 
activating agents and DIPEA, to give (80) in quantitative yield. This was followed by Fmoc 
deprotection using diethylamine and acetylation with acetic anhydride in the presence of a 
catalytic amount of DMAP, to give (81) in 78% yield. The aminolysis of (81) was first 
attempted in THF with an excess of methylamine but the reaction was unsuccessful and the 
HPLC indicated the presence of the starting material. The reaction was repeated according to 
the method of Miel and Rault165 using CHCl3 as solvent but this again gave the unchanged 
starting material. Finally, repeating the reaction with a non-volatile primary amine, 
benzylamine, also failed to give the desired compound and only the starting material was 
recovered. 
 
The failure to convert the di-Z-guanidine function of (81) into the expected guanylurea with 
methylamine implies that the reaction may not proceed in the same fashion as for the Boc 
derivatives. This proposition requires further investigation. In the light of this, it was decided 
to investigate the preparation of alternative reagents that could be used to effect the conversion 
Orn→Arg(MC), which would not introduce protecting groups on Arg(MC) that required 




5.1.3. Approaches to alternative reagents for the direct conversion of Orn to Arg(MC) 
Guanidine-containing molecules have a wide range of biologically important roles, for 
example, zanamivir, the influenza inhibitor, possesses a guanidine moiety in its structure.166 
 
The most commonly used reagents for the conversion of amines to guanidines include pyrazole-
1-carboxamidine derivatives,167 diprotected triflylguanidines and diprotected thioureas,164 as 
well as S-methylisothiourea derivatives, which need to be activated by toxic mercury salts168 or 
by Mukaiyama’s reagent.169 The choice of guanidinylating reagent usually depends on the 
synthetic strategy as well as on the reactivity of the starting amine. For reagents such as 
isothiouronium salts and pyrazoles, it appears that the presence of at least one alkoxycarbonyl 
group is required on the guanidinyl unit for useful reactivity. 
 
Sunazuka et al.147 reported the synthesis of argifin where the Arg(MC) side chain is introduced 
on-resin by modifying an Orn side chain. For this they developed a pyrazole reagent (86), 
activated with a Boc group and the acid-labile PMB group, both of which could be removed 




Reagents and conditions: (i) (85), NaH, THF, 0-80 °C; (ii) R-NH2, Et3N, rt. 
 
Scheme 15. Pyrazole-based guanidinylating reagent (87) developed by Sunazuka.147 
 
It was decided to modify this approach, to generate instead a pyrazole reagent (91) containing 
all hydrogenolysable protecting groups. Our attempted preparation of such a reagent is shown 






Reagents and conditions: (i) pyridine, CH2Cl2, N2, -78 h, (89), 2 h; Method A. (ii) (91), NaH, THF, N2, 0 °C to rt; 
Method B. (ii) as A but used new NaH; Method C (ii) (91), DMAP, DIPEA, CH2Cl2, rt, 16 h.  
 
Scheme 16. First attempted preparation of pyrazole-based guanidinylating agent (92) with hydrogenolysable 
protecting groups. 
 
N-Benzyl-N-methylcarbamoyl chloride (90) was first prepared according to the method of 
Yoakim et al.,170 by the reaction of bis(trichloromethyl)carbonate (89) with benzylmethylamine 
(88) in the presence of  pyridine for 2 h at -78 °C (Scheme 16). This gave (90) in quantitative 
yield. Conversion to (92) by acylation of the pyrazole derivative (91) was carried out with (90) 
in the presence of NaH as base in THF. The reaction was carried out at room temperature 
overnight. Although analysis of the reaction mixture by TLC showed a new component, on 
purification by analogy with Sunazuka,147 the two starting materials (84) and (85) were isolated 
unchanged. Repeating the reaction with a fresh sample of NaH also gave only unchanged 
starting materials.  
 
An alternative approach was explored in which (90) was further activated with DMAP (0.2 eq) 
and then reacted with (88) in the presence of base. However this was unsuccessful and analysis 
by proton NMR was not consistent with the formation of the expected compound. 
 
Since both reactants were recovered unchanged when the reaction with NaH was performed at 







Reagents and conditions: Method D: (i) (91), NaH, THF, 0 °C to rt, then reflux 16 h. 
 
Scheme 17. Second attempted preparation of pyrazole-based guanidinylating agent (93). 
 
Pyrazole derivative (91) was treated with (90) and NaH in THF at reflux for 16 h. In this case, 
analysis of the reaction mixture by TLC showed a new component, which was isolated by 
column chromatography and shown by  1H NMR to be the acylated pyrazole (93) lacking the 
Z protection (Scheme 17). 
 
It seems likely that under these conditions, the expected product is formed but is then 
decomposed via an isocyanate intermediate. Hirose et al.145 have in fact subsequently reported 
the preparation of (92) by these methods but in very low yield (19%).  
 
Due to the difficulty in obtaining the desired pyrazole reagent (92), it was decided to explore 
the preparation of related reagents based on the diprotected triflylguanidine reagents and 
triurethane guanidines reported by Feichtinger.164 
 
Goodman has shown that reagents such as (64) react effectively with a range of amines to give 




Reagents and conditions: (i) R-NH2, CH2Cl2. 
 




Triprotected urethanes have been less exploited but a report by Prabhakaran and Sanjayan 
suggests that these compounds may be selectively converted to guanidines or guanylureas, with 




Reagents and conditions: (i) R-NH2, CH2Cl2. 
 
Scheme 19. Formation of guanidines or guanylureas from tri-Boc guanidine.  
 
Precursors for Goodman-type guanidinylating reagents were prepared as outlined in Scheme 
20.171 These molecules all contain a guanylurea unit, which may then be potentially activated 
for reaction with various amines. 
 
 
Reagents and conditions: (i) Boc2O, NaOH, H2O, 1,4-dioxane, 0 °C-rt, 16 h, 22%; (ii) MeNH2, THF, reflux 16 h, 
4%; (iii) (88), THF,  reflux, 16 h, 76%; (iv) 4-methoxybenzylmethylamine (94), THF, reflux, 16 h, 86%. 
 
Scheme 20. Boc-protected guanidine derivatives. 
 
The di-Boc guanidine (95) was prepared from guanidine hydrochloride and Boc anhydride in a 
one-pot procedure, to give (95) in 22% yield plus the unchanged starting material. Having 
already synthesised the di-Boc guanidine, it was hoped that we could then prepare the 
corresponding guanylureas with a range of methylamine derivatives. For this (95) was first 
treated with 10 eq of MeNH2 in THF at reflux for 16 h giving (96) in a low yield of 4%. 
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Promising results were obtained when (95) was treated with only 3 eq of benzylmethylamine 
(88) in THF at reflux for 72 h; this gave the guanylurea (97) in 78% yield. The best results were 
obtained when (95) was treated with 3 eq of (94) in THF at reflux for 16 h, to give (98) in 86% 
yield, as outlined in Scheme 20. 
 
We also wanted to investigate the same set of reactions with Z-containing compounds, as this 
could give a guanidinylating agent that would generate a protected guanylurea that might be 
deprotected under neutral conditions. This would be particularly useful for the synthesis of 
argifin. 
 
Reagents and conditions: (i) Benzyl chloroformate, NaOH, H2O, 0 °C-5 °C, 16 h, 59%; (ii) MeNH2, THF, reflux, 
18 h 30 min; (iii) (88), THF, reflux, 16 h, 9%; (iv) (94), THF, reflux, 16 h, 13%. 
 
Scheme 21. Synthesis of guanylureas (99)-(101): precursors for guanidinylating agents.  
 
The di-Z-guanidine derivative (68) was prepared from guanidine hydrochloride and benzyl 
chloroformate under basic conditions, to give (68) in 59% yield. As for the di-Boc-guanidine 
(64), it was hoped that (68) could be converted to the corresponding guanylureas by a reaction 
with methylamine or a benzylamine derivative. The attempted preparation of (99) was first 
carried out by treating (68) with 5 eq of methylamine in THF at reflux for 16 h. After 2 h 30 
min reaction, TLC indicated only the starting material, so another 2.5 eq of methylamine were 
added to the reaction mixture. After 16 h reaction, TLC showed no change and 1H NMR of the 
crude product indicated only starting material. It was hypothesized that the volatile amine 
methylamine was not efficiently delivered in order for the reaction to take place but on repeating 
the process with 10 eq of methylamine in THF at reflux for 16 h, this again was not successful 
and 1H NMR indicated the starting material once more. In contrast, when (68) was treated with 
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10 eq of (88) in THF at reflux for 16 h, the reaction did proceed and gave the guanylurea (100), 
although in very poor yield (9%), plus the unchanged starting material in 72% yield. Finally 
when (68) was treated with only 3 eq of (94) in THF at reflux for 16 h, this gave (101) in 13 % 
yield plus the unchanged starting material (68) (66%) as outlined in Scheme 21. 
 
In summary, reactions of the di-Boc-guanidine (95) with a methylamine equivalent were more 
effective than for the corresponding di-Z-guanidine (68) with yields ranging from 4% to 86% 
yield. In the case of using an amine with an electron-rich, alkyl substituent (methoxybenzyl), 
the highest yield was obtained (86%). 
 
We subsequently investigated the conversion of (98) into the corresponding di-Boc (103), or 1-
Boc-3-triflate (102) derivatives (Scheme 22), which would be analogues of the guanidinylating 




Figure 33 (102) and (103); potential reagents for the direct conversion of amines to protected 
methylguanylureas. 
 
For the attempted preparation of (102), (98) was treated with NaH in chlorobenzene at 0 °C and 
then triflic anhydride was added at -45 °C to the reaction mixture, which was allowed to warm 
up to room temperature for 16 h. Although the TLC showed the consumption of the starting 
material, analysis by 1H NMR was not consistent with the formation of the desired compound, 






Reagents and conditions: (i) NaH, chlorobenzene, 0 °C, 1 h, then -45 °C Tf2O, 16 h ; or (ii) DIPEA, CH2Cl2,  then 
Tf2O, -45 °C to rt, 16 h; (iii) Boc2O, DIPEA, CH2Cl2, 0 °C to rt, 14%, 16 h. 
 
Scheme 22 Attempted preparation of potential guanidinylating agents (102) and (103). 
 
It was suspected that the desired product might be unstable under strongly basic conditions and 
so we substituted DIPEA as base. (98) was treated with DIPEA in CH2Cl2 at 0 °C and then 
triflic anhydride was added at -45 °C to the reaction mixture which was again allowed to warm 
up to room temperature for 16 h. The 1H NMR spectrum of the crude product was again not 
consistent with the expected product. 
 
For the preparation of (103), (98) was treated with DIPEA in CH2Cl2 and then Boc anhydride 
was added at 0 °C and the reaction mixture was allowed to warm up to room temperature and 
stirred for 16 h. This gave the desired compound (103) in 14% yield, plus unchanged starting 
material (66%), as shown in Scheme 22.  
 
5.1.4. Conclusion and future work: 
An improved synthesis of argifin has been investigated using a combination of solid phase and 
solution methods. The use of hydrogenolysable protecting groups avoids the risk of aspartimide 
formation during final deprotection which is a potential problem in other argifin syntheses. The 
overall yield by the approach developed here is slightly improved compared to the original 
synthesis of Dixon et al.161 with only one single HPLC purification being required to isolate the 
natural product. This method should now be applicable for the large-scale synthesis of argifin 




The preparations of several reagents for the direct conversion of an amine into a guanylurea 
derivative have been investigated. An analogue (103) of the diurethane reagents described by 
Goodman has been successfully prepared for this purpose. Future work should focus on 
studying the reaction of various amines with (103) to test its usefulness as an agent to introduce 






























5.2. Approaches to Amoa: key component of banyasin A 
5.2.1. Introduction to banyasin A 
 
Banyasin A (104) (Figure 34), isolated from the water bloom of the cyanobacterium Nostoc 
sp.,148 is a cyclic pentapeptide consisting of L-Ala, L-Asp, L-MePhe, L-Arg(MC) and a rare β-
amino acid,  3-amino-2-methyl-5E-octenoic acid (Amoa). As (104) contains the essential 
Arg(MC)-MePhe dipeptide motif as argifin142 it would be of considerable interest to synthesise 
and evaluate banyasin A as a potential Family 18 chitinase inhibitor and to investigate the mode 




Figure 34. Structure of banyasin A (104). 
 
The stereochemistries configuration of  Amoa at C-2 and C-3 in the structure reported by 












β-Methylamino acid derivatives such as Amoa (105) occur quite widely in a number of peptide 
natural products and the syntheses of several examples have been achieved using 
diastereoselective aldol chemistry.173 
 
5.2.2. Diastereoselective aldol reactions 
 
The asymmetric aldol addition mediated by chiral auxiliaries is one the most important and 
general methods for asymmetric carbon-carbon bond formation. Dibutylboron enolates of N-
acyl oxazolidinones, pioneered by Evans, are the most commonly utilized enolates and are 




Reagents and conditions: Method A: (i) TiCl4, 1 eq amine, RCHO; Method B: (i) TiCl4, 2 eq TMEDA or (-)-
sparteine. 
 
Scheme 23. Transition states to access (A) “non-Evans syn” aldol adducts, (B) “Evans syn” aldol adducts via 
chlorotitanium enolates.  
 
Crimmins has shown that chlorotitanium enolates of oxazolidinones provide a high 
diastereoselectivity as well the ability to produce either “Evans” or “non-Evans” syn aldol 
adduct, depending on the stoichiometry of the TiCl4 or the nature of the base employed as 
shown in Scheme (23).175  Formation of the chlorotitanium enolate of an N-acyloxazolidinone 
with 1.1 eq of TiCl4 and 2.5 eq of (-)-spartine followed by the addition of 1.1 eq of the aldehyde 
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at 0 °C gave the Evans-syn adduct as a major diastereoisomer in high yield with excellent 
diasterocontrol. High selectivity and excellent yields were also observed when N- 
acyloxazolidinone was enolized with 1.05 eq of TiCl4, 1.0 eq of (-)-sparteine and 1.0 eq of N-
methylpyrrolidinone (NMP). The non-Evans syn aldol adduct was obtained when the 
enolization was carried out with 2 eq of TiCl4 and 1 eq of DIPEA. Furthermore the use of 2 eq 
of TiCl4, 1 eq of DIPEA, TMEDA or (-)-sparteine, gave the non-Evans syn adduct. Titanium 
(IV) enolates of N-acyl oxazolidinones and oxazolidinethiones and titanium (II) enolates of 
thiazolidinethiones have all been shown to have highly organized chelated transition state 
structures which result in predictable diastereocontrol in reactions with various aldehydes. 
 
5.2.3. Previous approaches to Amoa 
 
In previous work in this laboratory to establish the stereochemistry present in banyasin A (104), 
a strategy for the synthesis of all four stereoisomers of Amoa was devised based on chemistry 
developed by Crimmins and She.176 This involves a modified Evans reaction, where the 
titanium enolate of an optically pure N-propanoyl-oxazolidinone was combined with an 
aldehyde to obtain enantiomerically pure syn aldol products. 
 
Using this approach, one stereoisomer of Amoa (105) suitable for application in Fmoc SPPS 
was obtained as follows. The (4R,5S)-oxazolidinone derivative (106) was acylated with 
propanoyl chloride, to give N-propanoyl derivative (107) in 88%. Following Crimmins’s 
procedure,173 the acylated auxiliary (107) was treated with 1.05 eq TiCl4, 1.10 eq DIPEA, 1.00 
eq NMP and 2.0 eq of hex-3-enal, to give the syn aldol product (108) in 72% as a single 
diastereoisomer. Compound (108) was converted into the azide with inverted configuration 
using a Mitsunobu reaction. The reaction proved to be successful with the use of DPPA as a 
nucleophilic source of azide, to give the desired azide (109) in 34% yield, plus some eliminated 
material (110) in 32% yield. Cleavage of the chiral auxiliary from (109) with alkaline hydrogen 
peroxide, followed by Staudinger aza-Wittig reduction of the azido (109) and N-protection 
using Fmoc-OSu, provided the β-amino acid (111) in overall 21% over three steps, as outlined 
in Scheme 24. 
 
It is important to note that the removal of the auxiliary from (109), preceded by the reduction 
of the azido function dramatically increased the yield of the conversion of (109) to (111). 
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Furthermore using Fmoc-OSu avoided the formation of the mixed anhydride intermediate and 
ester by-product, which seemed to occur when Fmoc-Cl was used. 
 
 
Reagents and conditions: (i) n-BuLi, propanoyl chloride, N2, -78 °C to rt, 16 h, 88%; (ii) TiCl4, DIPEA, NMP, hex-3-enal, N2, 
0 °C, 6 h, 72%; ( iii) PPh3, DEAD, N2, -20 °C for 1 h, DPPA, -20 °C to rt, 16 h, 34%; ( iv) LiOH/ H2O2, 3 h, 0 °C; (v) PPh3, 
N2, rt, 30 min then H2O, 60 °C, 16 h (vi) Dioxane, 10% Na2CO3, Fmoc-OSu, 0 °C to rt, 16 h, 21%.  
 
Scheme 24. Synthesis of one diastereoisomer of (105) based on diastereoselective aldol chemistry. 
 
Following on from Nathubhai’s work,177 we also aimed to prepare all 4 stereoisomers of (105) 
by a strategy used by Kimura in the preparation of kulokekahilide 173 In this work four 
stereoisomers of 3-amino-2-methylhexanoic acid (111) were obtained from two syn aldol 
products, introducing the N-function with either inversion of configuration or net retention, as 














5.2.4. New approach to Amoa using Evans chemistry 
To avoid the problems of elimination observed in Nathubhai’s work177 when an azido function 
was introduced by Mitsunobu chemistry, we aimed to investigate the introduction of the alkene 
function of Amoa at the end of the synthesis. The unsaturated chain would be introduced by 
Julia-Kocienski olefination, after cleavage of the Evans auxiliary as outlined in Scheme 27. 
Here, (106) would be acylated with propanoyl chloride and then the N-propanoyl derivative 
(107) would be subjected to a Crimmins aldolization with 3-(benzyloxy)propanal (112). The 
enantiomerically pure (2R,3S)-aldol product (113), would then be converted into the azide (114) 
by inversion of configuration using a Mitsunobu reaction. Cleavage of the chiral auxiliary from 
(114) with alkaline hydrogen peroxide, followed by catalytic reduction of the azido function 
and debenzylation, would then provide the β-amino acid (115) which could be transformed into 
the Boc-protected derivative (116). To complete the synthesis of (105), the hydroxyl group 
would be oxidised to the aldehyde (117) by Swern oxidation, followed by the introduction of 
the alkene function carried out via E-selective Julia-Kocienski olefination to give (119). Ester 
hydrolysis and protection of the amino function with the Fmoc group would then give one 







Reagents and conditions: (i) propanoyl chloride, n-BuLi, THF, -78 °C; (ii) TiCl4, DIPEA, (112), NMP, 0 °C-, 7 h; 
(iii) DPPA, Ph3P, DEAD, THF, -20 °C-rt; (iv) H2O/THF, LiOH/H2O2, 0 °C; (v) H2, Pd/C; (vi) MeOH, HCl, (vii) 
Boc2O, NaHCO3, H2O-dioxane; (viii) (COCl)2, DMSO, Et3N, CH2Cl2, (ix) (118), Julia Kocienski reagent, 
KHMDS (0.5 M in DME), DME. 
 
Scheme 27. Proposed synthetic approach for the preparation of one single diastereoisomer of (105) - the Fmoc-
protected derivative (119) 
 
The first stage in our synthetic approach was the preparation of the protected aldehyde (112) 
from the diol (120), as this aldehyde was not commercially available. 
 
Reagents and conditions: (i) Benzyl bromide, TBAI, NaH, THF, 0°C then warming to rt, 16 h, 76%; (ii) (ClCO)2, 
DMSO, 30 min, -78 °C, Et3N then warming to rt, 16 h, 24%. 
 
Scheme 28. Synthesis of aldehyde (112). 
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The diol (120) was treated with benzyl bromide with TBAI, giving the monoprotected alcohol 
(121) in 76% yield.178 Compound (121) was subjected to Swern oxidation; this was attempted 
by two different methods. The first attempted involved treating (121) with oxalyl chloride and 
DMSO according to the method of Davis and Qi.179 This gave the desired aldehyde (112) in 
24% yield, plus unchanged starting material. Repeating the oxidation according to the method 
reported by Davis180 with a more diluted solution of (120) in CH2Cl2 gave (112) in an improved 
yield of 46% but still with some unchanged starting material remaining. The aldehyde proved 
to be unstable at room temperature and decomposed on standing. It was therefore freshly 
prepared for the aldol chemistry. The aldehyde (112) was subjected to the Crimmins aldol 
reaction176 with the acylated chiral oxazolidinone (107), as shown in Scheme 29. 
 
Reagents and conditions: (i) propanoyl chloride, n-BuLi, THF, -78 °C to rt, 16 h, 84%; (ii) TiCl4, DIPEA, CH2Cl2, 
-5 °C, then NMP, (112), 4 h, 39%.   
 
Scheme 29. Synthesis of the syn aldol product (113). 
 
The (4R,5S)-oxazolidinone derivative (106) was acylated with propanoyl chloride,  to give  N-
propanoyl derivative (107) in 84% yield. The diastereoselective aldol addition reaction between 
(107) and (112) of was carried out using the optimised Crimmins procedure.173 The reaction 
was first  effected with 1.05 eq of TiCl4, 1.10 eq of DIPEA, 1.00 eq of NMP and 2.00 eq of 
aldehyde (112) at 0 °C, then warming up to room temperature for 16 h.  This reaction was 
unsuccessful and both starting materials were recovered unchanged. Compound (107) was 
again subjected to the Crimmins aldol reaction but this time the titanium enolate was formed at 
-5 °C and allowed to react with 2 eq of the freshly made aldehyde (112) and stirred at -5 °C for 
4 h. The aldol reaction proceeded smoothly in this case and gave the (2R,3S)-aldol product 
(113) in 39% yield, plus both unchanged starting materials. The stereochemical assignment of 
(113) is based on three pieces of evidence. Firstly, the 1H NMR obtained for (113) is identical 
to that reported by Kigoshi et al.,181 for the same syn aldol product prepared from (4R,5S)-
oxazolidinone (106) using Evans boron enolate chemistry. The optical rotation obtained for 
(113) was also consistent with that reported by Kigoshi.181 Finally, in the 1H NMR spectrum 
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obtained for (113), the H-2 signal at  3.85 shows the expected dq pattern, with a coupling 
constant JH2-H3 of 3.8 Hz, which is consistent with the syn aldol configuration. Reports by 
Mukaiyama and others indicate that in non-polar media,182, 183 a larger coupling constant should 
be expected for an anti aldol product (e.g. 9 Hz).
 
Because of its potential biological activity against Family 18 chitinases, we intended to focus 
our attention on the unsaturated chain of Amoa, in order to determine the importance of this 
unit within (105). Thus in parallel, we planned to investigate the synthesis of some analogues 
of (105), both linear and cyclic, in which the unsaturated side chain would be replaced by a 
saturated group. This would be achieved using Crimmins aldolization as shown in Scheme 30, 
since the appropriate required aldehyde hexanal was stable and commercially available. The 
aldehyde would be subjected to Crimmins procedure to give the enantiomerically pure syn aldol 







Reagents and conditions: (i) propanoyl chloride, n-BuLi, THF, -78 °C; (ii) TiCl4, DIPEA, NMP, hexanal; (iii) 
DPPA, Ph3P, DEAD, THF, -20 °C-rt; (iv) H2, Pd/C (v) H2O/THF, LiOH/H2O2, 0 °C;  
 
Scheme 30. Synthetic approach to reduced Amoa analogue (125) and banyasin A analogue (126). 
 
The diastereoselective aldol addition of the acylated auxiliary (107) and hexanal was again 
carried out under Crimmins optimised conditions.176 The reaction was  effected with 1.05 eq of 
TiCl4, 1.10 eq of DIPEA, 1.00 eq of NMP and 2.00 eq of freshly distilled hexanal, at 0 °C then 
warming up to room temperature for 7 h. This gave the Evans syn aldol product (122) in 74% 






Reagents and conditions: (i) TiCl4, DIPEA, CH2Cl2, 0 °C, then NMP, hexanal, 7 h, 74%.   
 
Scheme 31. Synthesis of the syn aldol product (122). 
 
The stereochemical assignment of (122) could again be confirmed by comparison of the 1H 
NMR and optical rotation of the product obtained with that previously reported by Sone184 for 
the same syn aldol that was prepared using Evans boron enolate chemistry. Once again, the 1H 
NMR of (122) showed the expected dq at δ 3.78 for the H-2 signal, with a coupling constant 
JH2-H3 of 2.7 Hz, consistent with the syn aldol configuration reported by Sone.
184 In Sone’s 
study,184 the syn configuration of (122)  was further supported by conversion to a corresponding 
β-amino acid whose 1H NMR could be compared with a closely related material of known 
configuration derived from the natural product dolabellin (see Scheme 32). 
 
Reagents and conditions: (i) LiOH, H2O2, THF, H2O, rt; (ii) CH2N2, ether, rt. 









The Mitsunobu reaction185 allows the conversion of primary and secondary alcohols into esters, 
phenyl ethers, thioethers and various other compounds. It involves the condensation of an 
alcohol R1-OH and acidic compound H-Nu to form R1-Nu, with the aid of a 
trialkyl/triarylphosphine reagent and an azodicarboxylate. The nucleophile Nu used should be 
acidic, since the azodicarboxylate should be protonated during the course of the reaction, to 
prevent side reactions. The trialkyl/triarylphosphine combines with an azodicarboxylate (e.g. 
diethyl azodicarboxylate – DEAD) to generate a phosphonium intermediate that deprotonates 
the hydroxyl function of the alcohol, which is then converted into a good leaving group. 
 




Scheme 33. Mitsunobu reaction between an alcohol and nucleophilic species, Nu (Nu = N3).  
 
Mechanism of the Mitsunobu reaction: 
 
 
The phosphine reduces the weak N=N bond of the diethyl azodicarboxylate (DEAD) to give a 
betaine intermediate. The nitrogen anion produced is stabilized by the delocalization of charge 





The betaine intermediate removes a proton from the nucleophile, to give an ion pair, as shown 




Next, the phosphorus species from step b interacts with the alcohol component. Oxygen and 
phosphorus have a strong mutual affinity, therefore they form the key oxyphosphonium ion, as 




Finally, the attack of the nucleophile anion upon the oxyphosphonium intermediate generated 
in step c gives the desired product and the triphenylphosphine oxide, as shown Scheme 34 in 
step d. 
 
Scheme 34. Mitsunobu reaction mechanism. 
 
A possible mechanism for the conversion of the aldol (122) to azide (123), by Mitsunobu 






Scheme 35. Mechanism of the Mitsunobu reaction occuring on (122) with DPPA. 
 
Thompson et al.186 were the first to report the Mitsunobu reaction using DPPA as a source of 
azide. In this reaction, formation of an activated oxyphosphonium ion intermediate involves 
liberation of azide ion from DPPA, which is then available for subsequent SN2 reaction. (see 
Scheme 35).   
 
 
A: Ph3P, DEAD, DPPA, CH2Cl2, r.t. 16 h; B: as A, 0 °C to r.t. 16 h; C: as A, using THF, 16 h. 
 
Scheme 36. Mitsunobu reactions with (122) and DPPA as azide source.  
 
Having successfully reproduced the Crimmins syn aldol product (122), in the next step the 
introduction of a nitrogen function was attempted through Mitsunobu reaction. Three sets of 
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conditions were attempted as shown in Scheme 36. Firstly (122) was treated with DEAD, PPh3 
and DPPA in CH2Cl2 at room temperature for 16 h. This gave the desired azide (123) in only 
7% yield and the unchanged starting material (122) in 93% yield, after purification by column 
chromatography. In the next attempt, the reaction was repeated with PPh3 and DEAD added at 
0 °C, followed by addition of DPPA, then the reaction was warmed up to room temperature for 
16 h. This again gave the azide (123) in very low yield (6%), together with the unchanged 
starting material (122) in 94% yield. The reaction was again repeated with all the reagents added 
at room temperature but using anhydrous THF as a solvent. This reaction was unsuccessful and 
gave only the unchanged starting material (123). 
 
The 1H NMR spectrum obtained for (123) was consistent with the introduction of the azide 
function at C-2 with inversion of configuration and a resulting anti relationship for H-2 and H-
3. This assignment was based on the coupling constant JH2-H3 = 9.3 Hz associated with the H-2 
signal at  = 3.86. This is consistent with the value reported by Kimura et al.,173 in the analogous 
conversion of a syn (2R, 3S) aldol to the anti (2R, 3R) azide, via SN2 displacement of an 
intermediate mesylate (see Scheme 38). The intermediate tosylate with syn configuration shows 
a correspondingly smaller JH2-H3. 
5.2.6. Synthesis of (123) via a tosylate 
Due to the lack of success in the production of the azido derivative (123) via Mitsunobu 
reaction, an alternative strategy was explored. It was decided to activate the hydroxy of (122) 
followed by nucleophilic displacement with azide. To achieve this, formation of the tosylate 
from (122) was attempted.  
 
 
Reagents and conditions: (i) TsCl, pyridine, 0 °C, 3 h; (ii) TsCl, pyridine, 0 °C to 50 °C, 16 h.  
 
Scheme 37. Attempted conversion of aldol (123) to tosylate (129). 
 
In the first attempt, (122) was treated with tosyl chloride at 0 °C in anhydrous pyridine then 
warmed up to room temperature. The reaction was monitored by TLC, which showed a new 
higher running material, although after work up of the reaction, the 1H NMR spectrum of the 
87 
 
crude product indicated unchanged starting material (122). The reaction was repeated under the 
same conditions as before but after adding all the reagents at 0 °C, the reaction mixture was 
heated at 50 °C for 16 h. The appearance of the TLC was similar to before and the 1H NMR 
spectrum of the crude product again indicated unchanged starting material (122), as outlined in 
Scheme 37. 
 
5.2.7 Synthesis of (122) via the mesylate 
In the next attempt, the hydroxy group from (122) was activated as a mesylate. For this (122) 
was treated with Et3N and methanesulfonyl chloride to give the corresponding mesylate (130), 
as confirmed by the 1H NMR spectrum of the crude product. (130) was treated with NaN3 at 70 
°C for 3 h and this gave the desired azide (123) in 27% yield plus the eliminated material (131) 
in 42% yield. The reaction was repeated under the same conditions as before but at a lower 
temperature, 40 °C, and it was monitored by TLC. After 15 min reaction TLC showed a new 
higher running material. In this case, after work up of the reaction, the 1H NMR spectrum of 
the crude product revealed no (123) but only the eliminated product (131), which was isolated 




Reagents and conditions: (i) MeSO2Cl, Et3N, CH2Cl2, 0 °C, 3 h; (ii) NaN3, 15-crown-5, DMF, 70 °C, 3 h. 
 
Scheme 38. Preparation and attempted displacement of mesylate (130). 
5.2.8. Synthesis of (123) via the triflate 
A solution of (122) was treated with pyridine and triflic anhydride in CH2Cl2, to give the 
corresponding triflate derivative (132) in 62% yield, confirmed by the 1H NMR spectrum of the 
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crude product. The nucleophilic displacement was attempted with NaN3 at 60 °C in DMF for 
16 h Analysis by 1H NMR showed only elimination products (131) alongside some other 




Reagents and conditions: (i) Tf2O, pyridine, CH2Cl2, 0 °C, 2 h 30 min; (ii) NaN3, DMF, 60 °C, 16 h. 
 
Scheme 39. Synthesis and attempted displacement of triflate (132). 
 
5.2.9. Conclusion and future work on aldol reactions 
A potential approach to the novel amino acid (105) and its diastereoisomers has been studied 
based on the Crimmins modification of the Evans aldol reaction. Aldol intermediates (113) and 
(122) were both successfully prepared following Crimmins titanium enolate conditions and the 
syn stereochemistry of the two products was deduced primarily based on the value of the JH2-
H3 coupling constants observed in the 
1H NMR spectra obtained and by comparison of the NMR 
data with those reported for the same compounds prepared by Evans boron enolate chemistry.  
 
Although aldol derivatives (122) and (113) were successfully prepared, introduction of the 
nitrogen function by nucleophilic displacement proved to be problematic, leading to eliminated 
products. It was therefore decided to pursue an alternative approach which would involve 








5.3. Chiral pool approach towards the synthesis of Amoa 
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5.3.1. Summary on the aldol strategy 
Our first strategy depended upon the specific and high-yielding Crimmins modification of the 
Evans aldol reaction.176 We successfully obtained syn adducts by this method as single 
diastereoisomers. The initial route involved the introduction of the nitrogen function at the 
beginning of the synthesis via an inversion procedure on an aldol product (122) through a 
Mitsunobu reaction,187 which gave poor results. Subsequently we focused on alternative routes 
via nucleophilic substitution reactions of a mesylates, tosylate, or triflate. The best conditions 
for introducing an azido function into (122) were via the mesylate (130). However, under 
optimized conditions, significant amounts of eliminated material were obtained along with the 
desired product (123). It was therefore decided that it would not be useful to attempt the same 
strategy with aldol compound (113), which has an α-substituent of similar steric bulk to (122). 
 
Because of the limited success in introducing the nitrogen function of the desired amino acid 
via displacement reactions, it was decided to explore an alternative approach using a chiral 
starting material with the key nitrogen function already in place.  
 
5.3.2. Aspartic and glutamic acid starting scaffolds 
Aspartic and glutamic acids play important roles as general acids in enzyme active centres,188 
as well as in maintaining the solubility and ionic character of proteins. They have also been 
used extensively as enantiomerically pure starting materials or building blocks for the 
preparation of natural products or novel biologically active molecules. 
 
The purpose of using aspartic and glutamic acids as starting materials in organic synthesis is to 
introduce one or more defined stereogenic centres within a biological active target. The 
possibility to generate a β- or γ-enolate in the side chain provides many possibilities to develop 
more complex structures, starting with a fixed configuration at the α -carbon, according to 
whether D- or L- starting materials are chosen. The β- or γ-carboxylic acid function also 
provides a way to simply attach novel side chain groups. A few examples are outlined below. 
 
The N-aryl-N-hydroxycarbamoyl derivative (137) is a competitive inhibitor of glyoxalase І, 
which is involved in the prevention of cell apoptosis in tumours.189 The molecule is an analogue 
of glutathione (γ-Glu-Cys-Gly-OH) in which a Glu residue is used to replace cysteine. The 
carboxylic acid function is then converted to a hydroxamide, which is able to chelate Zn 2+. 
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More and Vince189 have reported the synthesis of the tripeptide Glu-Glu-Gly, which began with 
coupling of Boc-Glu(OBn)-OH (133) with H-Gly-OtBu to give the dipeptide (134). The Boc 
group was selectively cleaved, then the resulting dipeptide was coupled to Boc-Glu-OtBu to 
give the tripeptide. Finally the hydrogenolysis of the side-chain benzyl ester of the tripeptide 
provided acid (135). To complete the synthesis, p-bromophenylhydroxylamine was coupled to 
the acid (135) using DCC and DMAP to give (136), followed by deprotection of the acid-labile 
groups to give (137), as outlined in Scheme 40. 
 
 
Reagents and conditions: (i) HCl. H-Gly-OtBu, EDC, HOBt, NMM, CH2Cl2, 91%; (ii) 4M HCl/dioxane, 0 °C, 
99%; (iii) Boc-Glu-OtBu, EDC, HOBt, CH2Cl2, 84%; (iv) H2, Pd/C, MeOH, 86%; (v) p-
bromophenylhydroxylamine, EDC, CH2Cl2, 52%; (vi) TFA, CH2Cl2 (1:1), 76%. 
 
Scheme 40. Synthesis of an S-(N-aryl-N-hydroxamate) analogue of glutathione.189 




5.3.3. Aspartic acid as a scaffold in alkaloid synthesis 
 
 
Reagents and conditions: (i) acetyl chloride, MeOH, 8 °C 30 min, then rt, 15 h, 77%; (ii) TMSCl, CHCl3, rt, 2 h, 
then Et3N, Pb(NO3)2, 9-bromo-9-phenylfluorene 3 d, 92%; (iii) O-tert-butyl-N,N’diisopropylisourea, CH2Cl2, rt, 
44 h, then H2O, 1 h, 84%; (iv) KHMDS in toluene, THF, -78 °C 45 min, then 3-chloropropyl triflate, 1 h 30 min, 
76%; (v) NaHCO3, CH3CN, reflux  10 min, then NaI, 48 h, 81%; (vi) DIPEA, n-BuLi in hexanes, THF, -78 °C, 
40 min, then ethyl iodide, 2 h 30 min, 59%; (vii) 10% Pd/C, AcOH, H2, rt, 2 h 30 min, 98%; (viii) tryptophyl 
bromide, NaHCO3, CH3CN, 70 °C 21 h, 93%; (xi) iPrOH/H2O (v/v), AcOH, 100 °C 15 h, then PhPOCl2, 15 min, 
74%.  
 
Scheme 41. Synthetic route to (+)-vincamine, based on  L-Asp diesters.190  
 
The synthetic route to (+)–vincamine, which is an alkaloid possessing cerebral vasodilatory 
effects, is outlined in Scheme 41.190 An aspartate derivative with different protecting groups at 
the α- and β- carboxyl functions was first mono-C-alkylated on the enolate of the β-ester with 
the three-carbon bis-electrophile, 3-chloropropyl trifluoromethanesulfonate to give (139), as a 
mixture of diastereoisomers. This was followed by an intramolecular cyclisation to give a 
piperidine derivative (140). A second alkylation of the ester enolate was then used to introduce 
the ethyl group in (140). The PhFI group was removed to give (141) and then N-alkylation with 
tryptophyl bromide was carried out. The synthesis of the key tetracyclic intermediate (142) was 
then finally accomplished by cyclisation of an intermediate iminium ion generated after the 




5.3.4. Aspartic acid for formation of lactams 
Aspartic acid has been used as the starting material to synthesize lactam (149), which is an 
inhibitor of tumour necrosis factor-α converting enzyme (TACE).191  Boc-Asp-OMe (144) was 
first esterified with MeI and DBU to give the diester. This was then alkylated with allyl bromide 
to give anti-product (145). After ozonolysis, the resultant aldehyde formed a Schiff base with 
4-benzyloxyaniline, followed by reduction of the imine by NaBH(OAc)3 and cyclisation in 
toluene at reflux to provide lactam (146). After removal of the benzyl ether protection, the 2-
methyl-4-quinolinyl)methyl group was incorporated, followed by Boc deprotection to give the 
free amine (148). To complete the synthesis, acetylation and hydroxamic acid formation were 
carried out on the free amine and on the C- terminal carboxylic acid, respectively to give (149). 
Here the Asp starting material fixes the C-2 stereocentre and also allows the generation of the 
C-3 stereocentre. 
 
     
Reagents and conditions: (i) MeI, DBU, toluene, at reflux, 96%; (ii) allyl bromide, LiHMDS, toluene, THF, 61%, 
(iii) O3, CH2Cl2, PPh3, 71%; (iv) 4-benzyloxyaniline, toluene, at reflux; (v) NaBH(OAc)3, ClCH2CH2Cl; (vi) 
toluene at reflux 46% for 3 steps; (vii) H2, Pd(OH)2/C, MeOH, 74%; (viii) 4-chloromethyl-2-methylquinoline, 
Cs2CO3, DMSO, 86%; (ix) CF3CO2H, CH2Cl2, quantitative yield; (x) Ac2O, i-Pr2NEt, CH2Cl2, 87%; (xi) NH2OH, 
KOH, MeOH, 51%. 
 
Scheme 42. Preparation of a lactam inhibitor (149) of tumour necrosis factor-α converting enzyme from L-
Asp.191 
 
5.3.5. Aspartic acid in the synthesis of the novel amino acid NMeOHIle  
The N-methyl amino acid  N-methyl-δ-hydroxyisoleucine (NMeOHIle) is found in halipeptin 
A, a peptide which has a potent anti-inflammatory activity.192 The synthetic route presented by 
Yu et al.,193 was based on a highly diastereoselective methylation of a selectively protected 
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aspartate, Z-Asp(OAll)-OtBu, followed by building up the molecule to the desired NMeOHIle 
(see Scheme 43 ). 
 
 
 Reagents and conditions: (i) LiHMDS, THF, HMPA then MeI (ii) TFA, CH2Cl2, then CH2N2, Et2O, rt, 95%; (ii) 
[Pd(PPh3)], NMA, CH2Cl2, rt; (iii) ClCOiBu, NMM, THF, -20 °C, then CH2N2, Et2O, 20 °C to rt; (iv) AgNO3, 
H2O, THF; (v) ClCO2Et, NMM, THF, 0 °C then NaBH4, MeOH, 0 °C to rt, 35% yield for the 4 steps; (vi) TIPSCl, 
imidazole, DMAP, CH2Cl2, rt, 89%; (vii) Pd/C, H2, Boc2O, MeOH, rt; (viii) Ag2O, MeI, DMF, 50 °C, 94% yield 
for 2 steps; (ix) aq. LiOH, THF, MeOH, then allyl bromide, K2CO3, DMSO, rt, 92%. 
 
Scheme 43. Synthesis of NMeOHIle from L-Asp.193 
 
Here Asp as a starting material allows the β-methyl group to be introduced into the amino acid 
structure with control of stereochemical configuration.  
 
5.3.6. Aspartic acid used in our strategy towards the synthesis of Amoa 
The approach of  Yu et al.,193 and similar work suggested to us that this might be a suitable 
strategy for the preparation of Amoa. This seemed promising for,if L-aspartic acid was chosen 
as the chiral educt for (119), its nitrogen function, which was problematic to introduce and also 
one of the stereogenic centres necessary for the future (105), would already be in place. The β-
carboxyl group should allow introduction of an alkyl group via the β-ester enolate and this 
should lead to the formation of the second asymmetric carbon, required in (119). The α-
carboxyl group could then be derivatized to an aldehyde function which could be elongated to 






Scheme 44. Planned retrosynthesis of compound (119). 
 
The retrosynthetic analysis of (119) is described in Scheme 44. The key steps are the 
stereoselective introduction of the side-chain methyl group and the homologation of an α-
aminoaldehyde derivative to a β-aldehyde. We envisaged that a suitable aldehyde could be 
prepared by chemoselective reduction of a Weinreb amide194 or similar Asp derivative.195  For 
the conversion of an α-aldehyde into the β-aldehyde, we anticipated using a Wittig reaction 
with (methoxymethylene)triphenylphosphorane to generate an enol ether, followed by acidic 
hydrolysis, to give the β-aldehyde. This approach has been applied by Ying et al.,196 for the 
synthesis of the antitubercular agent elisapterosin B, in which the key intermediate, a cis alkene, 




Reagents and conditions: MeOHC=PPh3, acetone, water, p-toluenesulfonic acid, 15 min, rt. 
 
Scheme 45. Wittig reaction, using an enol ylide for aldehyde homologation.196 
 
In our synthesis, the alkene function could be introduced into the molecule by a modified Julia-
Kocienski reaction. Recently Pospíšil has developed new conditions for the Julia-Kocienski 
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olefination, which uses specific metal cation-chelating agents to enhance the E-selectivity, as 




Reagents and conditions: KHMDS, 18-crown-6, THF, -78 °C. 
 
Scheme 46. Modified Julia-Kocienski olefination by Pospíšil.197 
 
Our initially adopted approach via (159a) is outlined in Scheme 47. The advantage of this 
synthesis is that starts with a readily available Asp diester, easily produced in large quantities. 
Park et al.,198 reported that the alkylation of (158) gave a 1:1 mixture of diastereoisomers but 
this was considered not to be necessarily a problem. In our case if we could separate both 
isomers (159a) and (159b) by column chromatography, this would provide ultimately a route 
to the synthesis of all four stereoisomers of Amoa, starting from L- or D-aspartic acid, using 
the approach in Scheme 47. 
 
 
Reagents and conditions: (i) MeOH, TMSCl, 0 °C, then warm up to rt, 48 h; (ii) Boc2O, Et3N, MeOH, 0 °C, then 
warm up to rt, 16 h; (iii) MeI, LiHMDS, THF, -78 °C, 6 h, then warm up to rt, 16 h. 
 
Scheme 47. Synthesis of the β-methyl-L-Asp derivatives (159a) and (159b).198 
 
Our first synthesis of (159a) began by dissolving commercial L-aspartic acid (1) in MeOH and 
treating with TMSCl. After 48 h reaction, all volatiles were removed in vacuo and the crude 
diester salt (157) was directly N-acylated using Boc anhydride in the presence of triethylamine 
to give (158) in 53% yield. The enolate dianion that was obtained by treating (158) with 2 eq 
of lithium hexamethyldisilazane (LiHMDS) at -78 °C was then allowed to react with 
iodomethane to give (159a) in 17% yield as a single isomer isolated by column 
chromatography. The methylation gave a mixture of diastereoisomers in a ratio of 3:1 (159a: 
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159b), based on the 1HNMR spectrum of the crude product. The overall isolated yield of (159a) 
and (159b) was 49% , consisting of pure (159a) in 17% yield, a 1:1 mixture of (159a) and 
(159b)  in 25% yield and (159b) in 7% yield. 
 
The NMR spectrum of (159a) obtained was identical to that reported by Park et al.198 In this 
study, the (2S, 3R) configuration of the alkylation product was confirmed by conversion of 
(159a) to the lactone (160). The stereochemical configuration was confirmed by 1H NMR, with 




Scheme 48. Proof of the stereochemical configuration of (159a).198 
 
The ratio of isomers was calculated based on the relative integrals of the Hβ protons for the two 
isomers in the 1H NMR crude mixture. The preference for the anti isomer (159a) is in contrast 
to Park’s report198 but consistent with other studies.199 Park et al.,198 reported (159a) and (159b) 
as a 1:1 mixture of diastereoisomers, which were  separable by column chromatography, (see 
above).  
 
With (159a) from the first key transformation in hand, the next step was the selective removal 
of the α-ester, in order to carry out the proposed homologation. This involved first removal of 
the Boc group in acidic conditions, then treatment with basic copper carbonate.  
 
 
Reagents and conditions: (i) 4 M aq. HCl 30 min, rt; (ii) CuCO3.Cu(OH)2, thioacetamide, 70 °C, 3 h  
Scheme 49. Attempted α-ester hydrolysis (159a).200 
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The selective hydrolysis of dimethyl L-aspartate hydrochloride has been reported by   Gmeiner 
et al.190 but this method uses hydrogen sulfide to remove the copper salts at the end of the 
reaction. In our case when the selective hydrolysis was attempted with work-up with 
thioacetamide,200 the desired compound (162) could not be isolated, as shown in Scheme 49. 
 
Although the alkylation reaction was successfully achieved, the differentiation of the α- and β-
carboxylic acid functions was an issue and therefore we decided to change the protecting 
groups. It is known that the diastereoselectivity in β-alkylation reactions of Asp acid derivatives 
depends on the protecting groups on the α- and β-acids and nitrogen functions,199, 201 as 
demonstrated in Table 4. The diastereoselectivities observed in our experiments with (158) are 
consistent with those reported for Boc-Asp(OBn)-OMe193 (entry 2), which is the closest 




Reagents and conditions: (i) LiHMDS, HMPA, THF, 45 min, distilled MeI, -78 °C, 3 h. 





















































































































Typical procedure: A stirred solution of LiHMDS (39 mL, 39 mmol) and HMPA (20 mL), was treated with a 
solution of Asp derivative (6.72 g, 18.6 mmol)  in dry THF (80 mL), added dropwise. After 45 min, freshly distilled 
MeI (3.5 mL, 56.2 mmol) was added to the reaction mixture at -78 °C and stirring continued for 3 h. 
 
Yu et al.,193 reported the methylation of protected aspartate derivatives under Hanessian’s 
reaction conditions,199 using the strong base, LiHMDS, and a mixture of solvents, THF/HMPA 
and LiHMDS, as outlined in Table 4. The alkylation reaction showed poor diastereoselectivity 
when bulky protecting groups on the β-carboxylic acid were used, this applied for (163), (165) 
and (167). In a different study Humphrey et al.,202 demonstrated that bulkier N-protecting 
groups favour the anti selectivity and this rule seems to fulfil the model proposed by Yu et 
al.;193 when α-tert-butyl ester (167) was used, the ratio for anti and syn isomers was then 
enhanced to 3.5:1. Excellent diastereoselectivity could be achieved by reducing the size of the 
β-ester moiety (entries 4 et 5). The conclusion was, therefore, that, in the methylation reaction, 
larger α- and small β-esters in the aspartate are favoured for anti selectivity. However, although 
compound (169) gave higher anti selectivity, the hydrolysis of the alkylated product (170) with 
aqueous LiOH in methanol gave a mixture of the acid plus the 3-epimer. For this reason, Yu et 
al.,193 preferred the allyl ester derivative (150).  
 
Our particular attention was attracted to (150), this N-benzyloxycarbonyl derivative should 
favour anti selectivity, as shown in entry 5 on Table 4.199 We therefore decided to use (171) for 
our synthetic approach, with its particular combination of protecting groups that should give 
mainly one stereoisomer, to allow us to put our planned Scheme 51 into action. The α- and the 
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β-carboxylic acid groups are also selectively protected which should allow us to build 















Scheme 51. Planned synthesis for Amoa from L-aspartic acid. 
 
 
Preparation of (2S)-4-allyl-1-tert-butyl-2-(((benzyloxy)carbonyl)amino)succinate (150) 
 
 Figure 36.  Compound (150) 
 
The success of this strategy hinged on the availability of an allyl ester 
derivative. Allyl ester groups can be removed by the use of 
tetrakis(triphenylphosphine)palladium(0) and so can be removed independently of 
benzyloxycarboxyl groups which are removable by catalytic hydrogenolysis and tert-butyl 
groups which are acid-labile.  
 
 
Method A. Reagents and conditions : (i) Allyl alcohol, TMSCl, 0 °C-rt, 18 h, 53%. 
 







Reagents and conditions: (i) Allyl alcohol, acetyl chloride, 0 °C-rt, 83%; (ii) Z-Cl, K2CO3, H2O, rt, 16 h, 56%. 
 
Scheme 53. Preparation of Z-Asp(OAll)-OH - Method B.204 
 
The preparation of the H-Asp(OAll)-OH, (180) was attempted by two methods.  The first 
method (A) according to the procedure of Lajoie,203 involved treatment with 
chlorotrimethylsilane in allyl alcohol; this appeared to give the dipeptide derivative (179), 
according to 1H  NMR analysis, as shown in Scheme 52. In the second method (B),204 L-Asp 
was esterified by treatment with acetyl chloride in allyl alcohol to give (180) in 83% yield. The 
amino group of (180) was then N-protected, with benzyloxycarbonyl, using benzyl 
chloroformate, under basic conditions to give Z-Asp(OAll)-OH (181) in 56% yield, as shown 
in Scheme 53. 
 
As noted above, it was important to protect (181) at the α-carboxyl group with tert-butyl for the 
methylation reaction in order to ensure the formation of a single major diastereoisomer in the 
alkylation reaction. For this transformation several attempted reactions were carried out. We 
chose to avoid the classic isobutene/H2SO4 method employed by Baldwin,
204 as this would 
require the use of specialised apparatus (pressure vessel) which was not available to us.  
 
Methods using Boc anhydride 
Nuijens et al.205 have reported the β-esterification of Z-Asp-OMe using Boc anhydride in 




Reagents and conditions: (i) Boc2O, CH3CN/tBuOH (v/v: 4:2), pyridine, DMAP, rt, 24 h, 94%. 
 
Scheme 54. β-esterification of  Z-Asp-OMe.205 
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We tried to use this method for the α-esterification of (181), as outlined in Scheme 55. 
The reaction was monitored by TLC and this showed the formation of a new higher running 






Method A. Reagents and conditions: (i) Boc2O, CH3CN/tBuOH (v/v: 4:2), pyridine, DMAP, rt, 18 h, 19%. 
 
Scheme 55. α-Esterification of (181).205 
 
The expected α-ester (150) was isolated in only in 19% yield after column chromatography. 
During the course of this reaction, the mixed anhydride obtained by activation with Boc 
anhydride of the carboxyl group liberates tert-butyl alcohol as a by-product. This may then 
itself react with the activated acid to give the corresponding ester, making thus an efficient one-




Scheme 56. Mechanism of synthesis of α-aspartate esters via Boc2O/DMAP. 
 
It is known that the addition of a catalytic amount of 4-dimethylaminopyridine (DMAP) is 
exceedingly effective in the conversion of mixed anhydrides formed with dicarbonate reagents 




Method B. Regeants and conditions: (i) Boc2O, tBuOH, DMAP, rt, 16 h, 24%.  
 
Scheme 57. α-Esterification of Z-Asp(OAll)-OH.206 
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The reaction of Scheme 57 was repeated according to Takeda et al.,206 using tBuOH as the only 
solvent but the yield was only slightly improved, giving the desired compound (150) in 24% 
yield, as shown in  Scheme 57. 
 
Due to the initially disappointing results with the Boc anhydride mixed anhydride procedure, 
we examined an alternative approach that has also been reported to be effective for preparing 
the tert butyl esters of amino acids. 
 
Using isopropenyl chloroformate 
Zeggaf et al.,207 have reported the esterification of the N-protected α-amino acid using 
isopropenyl chlorocarbonate (IPCC) activation. The mixed anhydride generated in situ reacts 
with the alcohol in the presence of DMAP (Scheme 58). 
 
 
Scheme 58. Mechanism of synthesis of α-aspartate esters via IPCC/DMAP method. 
 
Two methods were attempted as described by Zeggaf et al.,207 as outlined in Schemes 58 and 
59. 
 
Method C. Reagents and conditions: (i) IPCC, tBuOH, Et3N, DMAP, CH2Cl2, 35 °C, 16 h.  
 
Scheme 59. α-Esterification of Z-Asp(OAll)-OH.207 
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Firstly, Z-Asp(OAll)-OH (181) was treated with 1.1 eq of IPCC, in the presence of 1 eq of 
triethylamine and 3 eq of alcohol in CH2Cl2, at 35 °C. However only poor conversion to the 
ester was observed, plus several other products were visible on TLC. The crude ester (150) was 
isolated in only 10% yield (Scheme 59). 
 
 
Method D. Reagents and conditions: (i) IPCC, tBuOH, Et3N, DMAP, 35 °C, 16 h. 
 
Scheme 60. α-Esterification of Z-Asp(OAll)-OH.208  
 
In the previous example, the reaction was attempted at 35 °C, rather than room temperature as 
described by Zeggaf.208 They also described esterification of some amino acids where tert- butyl 
alcohol is used as a solvent at 35 °C which has been shown to enhance the yield. We decided 
to apply the latter conditions, using the alcohol as a solvent. Furthermore, as the mixed 
anhydride prepared from IPCC releases the enolate of acetone, so having an excess of alcohol 
would favour the reaction. Compound (181) was subjected again to the esterification reaction 
but this gave the desired ester (150) in only a slightly improved yield (25%) as shown in Scheme 
60. 
 
Using carbodiimide reagents 
We used another method for mild one-pot esterification applicable to N-protected amino acids 
for the formation of the tert butyl ester (150). The acylation reaction again required one 
equivalent of DCC for one equivalent of carboxylic acid and a catalytic amount of DMAP, plus 
















Reagents and conditions: (i) DCC, tBuOH, DMAP, rt 91%.189 
 
Scheme 61. α-Esterification using DCC-DMAP.  
 
Compound (181) was first treated with 1.2 eq of DCC and then with 10 eq of tert-butyl alcohol 
in the presence of a catalytic amount of DMAP (Scheme 62). The reaction was unsuccessful 





Method E. Reagents and conditions: (i) DCC, DMAP, tBuOH, 0 ºC to rt, 16 h. 
 
Scheme 62. Attempted α-esterification of (181) using DCC-DMAP. 
 
Based on the previous results with the use of DCC, we decided to use a method including HOBt, 
which should form a benzotriazole ester as intermediate, as shown in Scheme 63 . 
 








Method F. Reagents and conditions: (i) HOBt, DCC, DMAP, tBuOH, CH2Cl2/DMF, rt, 16 h. 
 
Scheme 64. Attempted α-esterification of (181) with DCC-HOBt. 
 
 
Compound (181) was first treated with 1.4 eq of HOBt and 1 eq of DCC, then with 10 eq of 
alcohol in the presence of DMAP as the catalyst. However no ester (150) was formed and the 
starting material was recovered, as shown in Scheme 64. 
 
As the attempts with DCC were unsuccessful and the ipcc-promoted esterification of amino 
acids proved no more effective than the Boc2O method, we put all our effort into synthesizing 
compound (150) by the latter route.  
 
After several attempts, the best conditions found to carry out the reaction with Boc anhydride 
were consistent with tert-butyl alcohol as a solvent in the presence of DMAP at 40 °C, for 48 
h. This gave (150) in 45% yield, following column chromatography, plus unchanged starting 
material, as outlined in Scheme 65. 
 
 
Method G. Regeants and conditions: (i) Boc2O, tBuOH, 
DMAP, 40 ºC, rt, 48 h, 45%. 
 




The next step was the alkylation of the β-enolate generated from the protected aspartic acid 









Method A. Reagents and conditions: (i) LiHMDS, THF, -78 °C, then MeI, warm up to rt, 18 h. 
 
Scheme 66.  β-Alkylation reaction on (150) according to Park et al.198 
 
Compound (150) was subjected to the alkylation method used by Park et al.,198 as it had been 
previously successful with (159a). The enolate dianion was obtained by treating (150) with 2 
eq of lithium hexamethyldisilazide at -78 °C and was allowed to react with 1.2 eq of 
iodomethane. This gave a mixture of diastereoisomers of C+N-alkylated product (182) and 
(183), as shown in Scheme 66. These could not be separated by column chromatography in this 
initial study. 
Because of these disappointing results, we then decided to apply directly the alkylation 






Method B. Reagents and conditions: (i) LiHMDS, THF, HMPA, -78 °C 45 min, then MeI, warm up to rt, 16 h. 
 
Scheme 67. β-Alkylation reaction on (150) according to Yu et al.193 
 
Following the method developed by Yu et al.,193 the enolate dianion was obtained by treating 
(150) with 2 eq of lithium hexamethyldisilazide at -78 °C and 6.2 eq of HMPA. This was 
allowed to react with 3 eq of iodomethane. The methylation reaction gave 40% of the C+N-
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alkylated product (183) isolated as a single diastereoisomer and a mixture of diastereoisomers 
of C+N-alkylated product (12%) (182), plus N-alkylated product (17%) (184), as shown in 
Scheme 67. 
 
The stereochemical configuration of (183) was inferred from that of (171) for which the 
configuration has been determined unambiguously by Yu et al.193 As in (171) and (159a) (both 
anti alkylation products), the Hβ proton resonates at δ ca 3.20. For the syn alkylation product 
(159b), the corresponding signal appears at δ ca 3.00.   
 
Beatty et al.,209 have shown that the successful alkylation of Asp derivatives may be 
significantly affected by the temperature. We therefore speculated that the formation of the 
unwanted isomer, the N-alkylated product, might be avoided by stopping the alkylation at -78 






Method C. Regeants and conditions: (i) LiHMDS, THF,  HMPA, -78 °C, 30 min, MeI, 3 h, then quench. 
 
Scheme 68. β-Alkylation reaction on (150) – modification of Yu’s method. 193 
 
Compound (150) was alkylated under Yu’s procedure,193 as outlined Scheme 68, with the 
modified quench procedure. However even with this precaution, we failed to reproduce the 
highly diastereoselectivity in the alkylation from Yu. The methylation reaction gave once again 
C+N-alkylated product (183), the diastereoisomeric C+N-alkylated product (182), plus N-
alkylated product (184), with none of the desired compound observed, as shown in Scheme 68. 
 
Prior to the next attempted alkylation, we ensured that all the reagents used were completely 
anhydrous, including the HMPA, which was dried over heated molecular sieves. Iodomethane 








Method D. Reagents and conditions: (i) LiHMDS, HMPA, THF, -78 °C, 30 min, MeI, 3 h, then quench. 
 
Scheme 69. β-Alkylation reaction of (150) – repeat of Method C with purified reagents. 
 
The methylation reaction using distilled iodomethane and dried HMPA gave the desired 
compound (171) in 55% yield but still contaminated with a small amount of C+N-alkylated 
product (183), as well as a mixture of the two C+N-alkylated diastereoisomers (182) and (183), 
as outlined in Scheme 69. The 1H NMR of (171) isolated from this preparation was identical to 
that reported by Yu193 and the optical rotation was also consistent with that reported previously. 
In Yu’s study, the configuration of (171) was confirmed by conversion to the lactone (185). 
The configuration was confirmed by 1H NMR NOESY experiments. Strong NOEs were 
observed between Ha-Hc and Hb-Hd, in the lactone which is consistent with the proposed 
configuration in (171).193 
 
 
Scheme 70. Proof of configuration of (171).193 
 
 
Reactions either using HPMA or not were therefore found to produce C- and N-alkylated 
product. The report of Yu193 postulated that the stereoselectivity of the alkylation is driven by 
the 1,2-asymmetric induction of the enolate dianion from the aspartate derivative. 
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A chelated transition state which leads to the observed stereochemical 
outcome is possibly due to lithium-π-olefin coordination based on a 
Zimmerman-Traxler-type model,210 as shown in Figure 37.  
 
Figure 37.  Proposed chelated transition state in alkylation of (171).210 
 
In contrast, Baldwin et al.,204 have reported that the reaction of MeI with aspartate dianion  gave 
a mixture of C- and N-alkylated products and the addition of HMPA to the reaction had no 
effect on the diastereomeric ratios. A similar study by Hanessian199 also supports this 
observation. 
 
After these disappointing results, it was decided to improve the method previously used for the 
synthesis of (171) without HMPA. The requirement here was to find the best alkylation 






Method E. Reagents and conditions: (i) LiHMDS, THF, -78 °C, 45 min, MeI, 3 h, then quench. 
 
Scheme 71. β-Alkylation reaction of (150) according to Yu et al.,193 without HMPA. 
 
Several alkylation reactions were carried out on different scales, using rigorously dried and 
distilled reagents. When 0.44 mmoles of the ester (150) was used, a mixture of diastereoisomers 
in a ratio of 3:1 was obtained, which was separated by column chromatography. The compounds 
eluting from the column in order of increasing polarity were: 41% of the desired isomer (171) 
and then 17% of a 1:1 mixture with (186). The enolate dianion was obtained by treating (150) 
with 2 eq of lithium hexamethyldisilazide at -78 °C and was allowed to react with 3 eq of 
anhydrous iodomethane.  On a 1.65 mmole scale, the crude material had the following 
composition: major/minor/starting material (2:1:0.5). The compounds were isolated by column 
chromatography eluting as follows: the C-alkylated product (171) in 48% yield, plus 200 mg 
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of mixture of (171) and diastereoisomer (186) (2:1), along with starting material (150), as 




Reagents and conditions: (i) LiHMDS, THF, -78 °C, 45 min, MeI, 3 h, then quench. 
 
Scheme 72. Large scale β-alkylation reaction of (171) under optimised conditions. 
 
The preparation of (171) was thus achievied in moderate yield compared to the 91% yield 
reported by Yu.193 Our results seem to rather correlate with the β-methylation of (158) to give 
compounds (159a) and (159b), reported by Park et al.198 
 
Having successfully introduced the second stereocentre, (171) was ready to be used as a 
scaffold to build up the Amoa side chain. The next stage was to deprotect the α-carboxyl group 
for further elongation of the molecule via the α-aldehyde. 
 
Unexpectedly the standard removal of the tert-butyl ester of (171) with 4M HCl in dioxane 
failed, giving the unchanged starting material, however the deprotection was effective using 
TFA/CH2Cl2 (3:8, v/v) at room temperature, which gave the expected product (173) in 91% 











Reagents and conditions: (i) TFA/CH2Cl2 (v/v: 3:8), rt, 2 h. 
 




Esters and amides undergo reduction to the corresponding aldehydes using DIBAL-H at low 
temperature followed by acidic quench. The reactions occurs in three steps, first the lone pair 
of oxygen coordinates with aluminium, then the hydride is delivered to the carbonyl carbon, to 
give the tetrahedral intermediate, which is stable at low temperature and whose breakdown is 




Scheme 74. Reduction of an ester by DIBAL-H. 
 
The development of N-methoxy-N-methylamides, Weinreb amides,211 allows the conversion of 
carbonyl compounds at the carboxylic acid oxidation level to the corresponding aldehydes and 
ketones.212 The efficiency of this transformation is attributed to the exceptional stability of the 




Scheme 75. Weinreb amide reduction by DIBAL-H. 
 
Even with a large excess of the organometallic reagent, no over-addition occurs due to the 
chelation of a metal ion between the resulting alkoxide and the oxygen atom of the N-methoxy 
group. This prevents the premature release of the ketone functionality or formation of an 
iminium intermediate until the acidic work-up has been performed. This remarkable feature of 
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Weinreb amides allows them to be converted into aldehydes when treated with aluminium or 
boron hydrides, as shown in Scheme 75.213  
 
Bayer et al,.194 have successfully achieved the preparation of an aspartic acid aldehyde (189) 




Reagents and conditions: (i) HCl. HNOMeMe, NEM, PPA, CH2Cl2, rt; (ii) DIBAL-H, THF, -78 °C; then acidic 
work-up with KHSO4, 63% yield (over two steps). 
 
Scheme 76. Preparation of the aldehyde using Weinreb amide.194 
 
To apply this approach for our system, activation of the Asp derivative (173) with HOBt/EDC 
for conversion to the methoxymethylamide (174) was carried following the method of 




Reagents and conditions: (i) EDC.HCl, HOBt/H2O, CH2Cl2/DMF, then MeNHOMe.HCl, rt, 53% yield. 
 
Scheme 77. Preparation of the Weinreb amide (174).194 
 
The reduction of (174) was carried out with 1.2 eq of DIBAL-H and the reaction was monitored 
by TLC. After 2 h reaction, TLC showed starting material, therefore another 1.2 eq of DIBAL-
H was added to the reaction mixture. After 2 h reaction, TLC showed partial consumption of 
the starting material, therefore another 0.44 eq of DIBAL-H was added to the reaction mixture. 





Reagents and conditions: (i) DIBAL-H, THF, -78 °C and then acidic quench. 
 
Scheme 78. Attempted reduction of the Weinreb amide (174) with DIBAL-H.194 
 
After work-up under acidic conditions, the crude 1H NMR spectrum revealed a mixture of the 
desired aldehyde (176) plus the unchanged starting material The ratio of (176):(174) was 
approximately 1:3, as judged by 1H NMR.  Unfortunately the aldehyde (176) co-eluted with the 
starting material (174), so it was not possible to separate them, after repeated attempts at column 
chromatography. 
 
After this unsuccessful attempt to prepare the aldehyde (176), we then turned our attention to 
the reduction of a thiol ester. Fukuyama et al.,215 have reported the reduction of ethyl thiol esters 
with triethylsilane and palladium on carbon. This method is suitable for the conversion of 
optically active amino acids into α-amino aldehydes. As these intermediates are known to 
racemize even under mild conditions, they must be carefully handled or converted to more 










Reagents and conditions: (i) Et3SiH, 10% Pd/C, acetone, rt; (ii) CSA, MeOH, 95%. 
 




Compound (173) was first converted to the ethyl thiol ester (175) using DCC as an activating 
agent in the presence of a catalytic amount of DMAP. This gave the corresponding ester (175) 








Method A. Reagents and conditions: (i) EtSH, DCC, DMAP, CH2Cl2, rt, 52%. 
 
Scheme 80. Preparation of thiol ester (175) using DCC/DMAP activation.  
 
When the coupling was carried out with EDC.HCl and DMAP, the thiol ester (175) was 
obtained in 40% yield, a slightly lower yield compared to coupling with DCC. 
 
Method B. Reagents and conditions: (i) EtSH, 
EDC.HCl, DMAP, DMF, 40%. 
 
Scheme 81. Preparation  of the thiol ester (175)  using 
EDC.HCl, DMAP.215 
 
Compound (175) was subjected to reduction under Fukuyama conditions,215 using 5 eq of 
Et3SiH and  Pd/BaSO4 (Scheme 82). After 2 h reaction all the starting material was consumed 
and the oil obtained was purified by column chromatography. This did not give the expected 
compound (176) but a mixture of two reduced compounds (190) and (191), which were 
separable by column chromatography. In order to prevent the reduction of the allyl group, a less 
reactive catalyst, Pd/BaSO4, was used in place of Pd/C employed by Fukuyama.
215 However, 
although the thiol ester group was reduced to the aldehyde function, olefin reduction could not 
be avoided. On prolonged reaction time (48 h), only the reduced aldehyde (191) was isolated 





Reagents and conditions: Method A: (i) Pd/BaSO4, Et3SiH, acetone, rt, 2 h; or Method B: as A, reaction for 48 h. 
 
Scheme 82. Attempted reductions of the thiol ester (175).215 
 
As Pd/BaSO4 appeared to result in faster reduction of the allyl group of (175) than the thiol 
ester, in the next attempt, we tried Lindlar catalyst, Pd/CaCO3/PbO and a monosubstituted 
alkene as an additive in the reaction mixture. This was based on the work of Evans et al.,195 
who  reported that the reduction of a thiol ester to the aldehyde using Pd(0)/triethylsilane led to 
concomitant reduction of an alkene within the same molecule. Subsequently they used an excess 
of sacrificial alkene, as shown in Scheme 83, to suppress this side reaction. 
 
Reagents and conditions: (i) Et3SiH, 
5%Pd/CaCO3/PbO/quinoline, 1-
decene, acetone, rt, 2 h.  
 
 
Scheme 83. Selective reduction of a thiol ester in the presence of an alkene according to Evans.195 
 
Following the method used by Evans et al.,195 (175) was again subjected to selective reduction, 
in the presence of quinoline and 1-decene. This gave unchanged starting material, even when 
an excess of triethylsilane was used. 
 
 
Method C. Reagents and conditions: (i) 5% 




Scheme 84. Attempted eduction of (175) according to Evans’ procedure.195  
 
Attempts to reduce selectively (175) using a Pd catalyst/triethylsilane in the presence of 
quinoline and 1-decene were, therefore, unsuccessful. However, when we used only Pd/BaSO4 
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in the presence of 1-decene, the TLC revealed a mixture of the two reduced compounds (190) 








Method D. Reagents and conditions: (i) Pd/BaSO4, Et3SiH, 1-decene, acetone, rt, 2h. 
 
Scheme 85. Further attempted selective reduction of (175). 
 
Because of the problems encountered in producing the required aldehyde (176) through the 
Weinreb amide (174) or selective reduction of thiol ester (175), this discouraged us from 
pursuing the synthetic approach using the α-aldehyde (176). Subsequently we turned our efforts 
to producing the homologated carboxylic acid at (173) via a more conventional but slightly less 
direct route.  
 
The Arndt-Eistert216 procedure allows the conversion of activated carboxylic acids to 
diazoketones by the action of diazomethane, followed by Wolff rearrangement in the presence 
of nucleophiles such as water, alcohols or amines. The method is used for the synthesis of 
homologated carboxylic acids and their derivatives such as esters or amides. Recently this has 
become widely used in the synthesis of β-peptide and β-amino acid derivatives from the 
protected α-amino acids.217 
  
The transformation requires the use of diazomethane and since it is highly toxic, labile and 
explosive, a less hazardous substitute, trimethylsilydiazomethane (TMSCHN2) has been 
developed by Aoyama and Shioiri.218 The application of TMSCHN2 in the classical Arndt-
Einstert reaction starting from acyl chlorides is efficient. However, in the case of amino acid 
chemistry, other activation methods for activation, such as mixed anhydrides and the use of 
coupling reagents, are preferred. 
 
Van Nguyen et al.,219 have reported the Arndt-Eistert reaction using the activated ester formed 
by 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU), a coupling 
agent, followed by treatment with TMSCHN2. 
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Following the method used by van Nguyen et al.,219 (173) was activated with 1 eq of TBTU, 
followed by treatment with 2 eq of TMSCHN2. After 3 h 30 min reaction, TLC showed 
disappearance of the starting material and the resulting crude product was purified by column 
chromatography. This intermediate was subjected to Wolff rearrangement but the desired 




Reagents and conditions: Method A:  (i) TBTU, THF/DMF, DIPEA, 0 °C, 30 min, then TMSCHN2, 0 °C, 3 h 30 
min; (ii) silver benzoate, dioxane:water (2:1), reflux 16 h. 
 
Scheme 86. Attempted Arndt-Eistert homologation of (173) using TBTU as coupling reagent.  
 
Further examination of the 1H NMR spectrum of the supposed diazomethylketone (192) 
showed an absence of the expected H methane signal. We speculated that the intermediate 
formed might in fact be the trimethylsilylmethyl ester derivative (194) isolated after silica gel 




 Figure 38. Trimethylsilylmethyl ester derivative formed during attempted Arndt-Eistsert synthesis.220 
 
Compound (173) was again subjected to an Arndt-Eistert synthesis but this time using the 
method of Patil et al. 217 Compound (173) was activated as the mixed anhydride, prepared with 
ClCOOEt/DIPEA and was allowed to react with 2 eq of TMSCHN2. This was followed by the 
Ag+/base-catalysed Wolff rearrangement of diazoketone (192) in water, which proceeded 






Reagents and conditions:  Method B: (i) ClCOOEt, DIPEA,THF, -15 °C to -4 °C, 30 min, then TMSCHN2, 4 °C, 
48 h; (ii) silver benzoate, dioxane:water (2:1), reflux, 16 h. 
 



























5.3.7. Conclusion and future work  
A selectively protected β-methyl-substituted Asp derivative (173) was successfully prepared, 
suitable for the incorporation of the Amoa side chain. The key step of homologating the α-
carboxylic function has been achieved by Arndt-Eistert chemistry. The next steps would be to 
convert the new carboxylic function to the corresponding aldehyde. This might be achieved via 
the anhydride, followed by reduction to the primary alcohol and then selective re-oxidation. 
The alkene function might then be introduced by E-selective Julia-Kocienski olefination to give 
the protected Amoa diastereoisomer. This chemistry is outlined in Scheme 88.  
 
 
Scheme 88. Planned synthetic route to protected Amoa diastereoisomer. 
 
Using this overall approach, all four Amoa diastereoisomers may now be prepared, starting 
from L- or D-aspartic acid as appropriate. Selective deprotections and Fmoc protection of the 














5.4. 2,5-Diketopiperazines : proline-containing cyclodipeptides as potential 
Family 18  chitinase inhibitors. 
5.4.1. DKP in nature 
Innumerable natural product molecules containing the 2,5-diketopiperazine (2,5-DKP) ring 
have a wide range of interesting biological activities, such as antitumour,221 antimicrobial222 
and antiviral223 activities. The sulfur-bridged 2,5-DKPs are a class of metabolites with 
epipolythiodioxopiperazine (ETP) structures  and are mainly found in fungi and lichens, as 
shown in Figure 39.224 The toxicity of these ETPs rings in 2,5-DKP is due to the presence of 
the disulfide bridge which can inactivate proteins via reaction with a thiol group and by 




Figure 39. Natural  2,5-DKP- and  epithiodiketopiperazines 
 
The best known ETP is the lipid-soluble 2,5-DKP gliotoxin (195) which has  toxic effects on 
phagocytic cells and T-lymphocytes at low concentrations in vitro.226 The 15-membered 
antifungal macrolide MPC1001 (196) possesses antiproliferative activity against the human 
prostate cancer line (DU14S) with an IC50 = 9.3 nM.
227 Rostratin (197) showed in vitro 
cytotoxicity against human colon carcinoma (HCT-116) with an IC50 = 1.57 μM.228 
 
5.4.2. Diketopiperazines as potential drug leads 
The 2,5-DKPs are a class of compounds that are useful in medicinal chemistry, combinatorial 
chemistry and targeted organic chemistry. This is because these small cyclic dipeptides are 
conformationally rigid chiral templates with multiple H-bond acceptors and donor 
functionality. Furthermore they possess multiples sites for structural elaboration of diverse 
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functional groups with defined stereochemistry.  In this regard, SAR has been explored in many 
2,5-DKP templates to move from a lead to a clinical drug.  
 
Cyclic dipeptides, DKPs, have been developed to obtain DNA-binding agents that overcome 
multidrug resistance, as shown by the quinone-based anticancer agents. Tryptophan is 
commonly incorporated into 2,5-DKP natural products based on the tryptophan-proline, cyclo 
(L-Trp-L-Pro) moiety found in the tryprostatin mammalian cell-cycle inhibitors and the 
fumitremorgin multidrug-resistant transport inhibitors, which are possible candidates for the 
development of anticancer drugs.229, 230 In addition, 2,5-DKP cores are found in naturally 
occurring peptide antibiotics. 
 
DKP Derivatives as DNA-Binding agents: 
 
 
Figure 40. Spirodikepiperazine (198) and its derivatives. 
 
DNA-binding agents that exhibit selective cytotoxicity are potential leads for the treatment of 
cancer. The spirodiketopiperazines (198) have been developed as potentially new anticancer 
agents related to the quinone-based anticancer agents, doxorubicin and mitoxantrone and they 
are active against multidrug resistant tumour cell lines, unlike the parent compound.231 SAR 
studies on these compounds showed that substitution at the C3-position and the stereochemical 
configuration at C3 and C3’ were important in order to obtain high potency. Preparation of 
derivatives of (198) substituted at the C3-position showed that the (3S,3’R) (199) isomer 
derived from L-Met and the (3R,3’S) (200) isomer from D-Pro had cytotoxicity comparable or 
greater than that of doxorubicin against human breast and colon carcinoma cell lines, with (200) 
being the most potent across both cell lines.231 Furthermore substitution on the nitrogen showed 
that (201) and (202) were the most promising compounds, with activity comparable to that of 





Figure 41. Spirodiketopiperazine derivatives. 
 
All these compounds (199-202) showed the ability to overcome potential multiple drug-
resistance mechanisms, which was demonstrated by their high cytotoxicity against doxorubicin- 
and cisplatin-resistant cell lines. Their mode of binding to DNA was determined by STD-NMR 
spectroscopy which showed that the interaction with DNA occurs in a dual-binding mode: first 
the tricyclic planar core binds with DNA by intercalation and then the 2,5-diketopiperazine ring 
and its substituents bind externally to the double-stranded DNA.231 
 
DKP: Cell-cycle inhibitors 
 
 
Figure 42. Tryprostatins A and B. 
 
The tryprostatins A (203) and B (204) were isolated from a marine fungal strain of Aspergillus 
fumigatus and have attracted attention as potential anticancer drugs.229 Compound (204) for 
example is a mammalian cell-cycle inhibitor,229 whereas (203) is an inhibitor of the multidrug-
resistance protein (BCRP/AGCG2) that mediates resistance to chemotherapeutics in breast 
cancer.230 All four diastereoisomers of both tryprostatin A (203) and B (204) have been 







Figure 43. Tryprostatin C with D-Pro-L-Trp configuration. 
 
Only the DL diastereoisomer (205) of tryprostatin A showed 
potent cytotoxicity against all the cancer cell lines.229 The L-
Trp unit was clearly required because none of the other 
tryprostatins that contained the D-Trp unit showed activity. 
Further investigation included the N-mono- and dialkylated indole ring derivatives of 
tryprostatin A (204). Replacing the isopropenyl substituent in (204) (IC50 = 68 µM) gave (206) 
(IC50 = 60 µM) with a similar level of potency towards inhibition of the growth of tsFT210. 




Figure 44. Trypostatin A analogues:  modification at the indole ring. 
 
Substitution of the L-proline ring gave the most promising compounds in these series, with L-
valine and L-phenylalanine, analogues (207) (IC50 = 19 µM ) (208) (IC50 = 10 µM), being 3.5-













DKP: Antibiotics and Antibacterials 
 
 
Figure 46. DKP structure in natural peptide antibiotics. 
 
DKP structures are found among several naturally occurring peptide antibiotics. They range 
from simple cyclic dipeptides to more complex fused structures. For instance, the simple 
antibiotic structure, the cycloserine dimer (209), showed activity against Mycobacterium 
tuberculosis.233 The highly complex DKP derivative bicyclomycin (210) was isolated from 
Streptomyces sapporonesis and inhibits a broad spectrum of Gram-negative bacteria and the 
Gram-positive bacterium, Micrococcus luteus.234 It possesses a low toxicity and it is rapidly 
absorbed in man when given intramuscularly. This antibiotic (210) (bicyclomycin) is used 
clinically to treat gastroenteritis. Bicyclomycin is the only known selective inhibitor of rho, a 
RecA-type ATPase. A crystal structure of bicyclomycin-rho complex was obtained in order to 
design new synthetic derivatives of bicyclomycin. SAR studies showed that the C(1) triol and 
[4.2.2]-bicyclic ring were essential for the bicyclomycin-rho inhibitory activity, whereas the 
C(5)-C(5a) exomethylene moiety was not necessary. Recently the bicyclomycin derivative, 5a-
(3-formylphenylsulfanyl)dihydrobicyclomycin (211) was shown to inhibit rho by an order of 
magnitude more efficiently than (210).235 
 
Many Gram-positive and Gram-negative bacteria communicate via the production and sensing 
of small, diffusible signal molecules that coordinate virulence-determinant production and 
regulate expression of specific genes responsible for communal behaviour. This is known as 
quorum sensing (QS).236 Recently the 2,5-DKP based (cyclic Xaa-Pro) have been shown to 
both activate and inhibit (QS) in certain Gram-negative bacteria.222 
 
5.4.3. Proline-containing DKP derivatives and their biological activities 
Proline-based 2,5-DKPs are widely distributed in nature because the peptide bond to the proline 
amino acid residue has significant cis character favouring the intramolecular cyclization of Xaa-
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Figure 47. Proline-based DKPs with antimicrobial activity. 
 
Cyclo(L-Phe-L-Pro) (212) is produced by the lactic acid bacteria L. corynniforms and L. 
plantarum and has been shown to possess antifungal activity against A. fumigatus. Its 
enantiomer (213), produced by a marine bacterium, inhibits the growth of the fish pathogen 
Vibrio anguillarum and was also shown to have antifouling activity. Furthermore (212) was 
active as a signal molecule, controlling the expression of genes important for the pathogenicity 
of the bacteria Vibrio spp.238 The isomer cyclo(L-Phe-D-Pro) (214), isolated from Bacillus 
subtilis sp., has been shown to be active against V. anguillarum.239  
 
The symmetrical cyclo(L-Pro-L-Pro) DKP (215) was isolated from the bacterium 
Pseudoalteromonas haloplanktis TAC125 and the blowfly Lucillia sericata and has been 









Cyclo(L-His-L-Pro) (216) is a metabolite from tryrotropin-releasing hormone (TRP) in 
mammals and is a part of the complicated neuroendocrine control system. This facilitates 
central dopamine and suppresses food intake. It has been shown that (216) has  neuroprotective 
effects in PCI2 cells stressed by serum deprivation and can prevent neuronal death induced by 
free radicals and calcium mobilization.241 Due to the effect of imidazole acting as a scavenger 
of reactive oxygen species, a novel 2,5-DKP (217) based on cyclo(L-His-L-Pro) was designed. 
The imidazole moiety was replaced by a di-tert-butylphenol, as such phenols have the ability 
to act as scavengers for reactive oxygen species (ROS) in order to increase the neuroprotective 
effect of these DKPs.242 
 
Antifungal chitinase inhibitors 
 
Cyclo(L-Arg-D-Pro) CI-4 (15), was isolated from a marine bacterium Pseudomonas sp. and 
has biological activity against yeast cell separation and also against human pathogenic fungi.   
For instance, it has been found to inhibit chitinase activity and normal cell separation of S. 
cerevisiae. Its isomer cyclo(L-Arg-L-Pro) (218) had comparable modest enzyme activity 
against chitinase from Bacillus sp. whereas its isomer cyclo(D-Arg-L-Pro) (219) was much less 
active. A similar activity profile was obtained against S. cerevisiae with these three isomers. A 
crystal structure of the complex of (15) in SmChiB showed that (15) inhibits Family 18 
chitinases, with its bicyclic structure mimicking the reaction intermediate of substrate-assisted 
catalysis.243  
 
As it has already discussed in Section 1 CI-4, (15) is an interesting lead chitinase inhibitor, due 
to its low molecular weight, simple structure and drug-like properties compared to other known 
inhibitors. It inhibits SmChiB competitively with Ki = 0.65 mM.
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CI-4 (15) and argifin (16) have comparable binding efficiency indices (BEI) of 2.58 and 6.31, 
respectively.244 Although these cyclic dipeptides are weak inhibitors, they are potential starting 
scaffolds to elaborate new classes of chitinase inhibitors.  Studies by Houston et al.,140 have 
demonstrated that changing the stereochemical configuration of the proline ring changes the 
orientation of binding of the DKP but approximately similar interactions with the key active 
site residues are maintained. The arginine side in the CI-4 structure is less ordered and does not 
make any significant interaction within the chitinase, so this could be a site for derivatization 
and/or a change of configuration. By retaining the cyclic dipeptide substructure and extending 
the molecule along the groove-shaped active site, which is so effectively occupied by 
allosamidin, an increase in favourable interactions with the enzyme might then be achieved. 
Such extensions should be composed of groups that mimic the interaction between the N-
acetylallosamine sugars of allosamidin and the -2/-3 subsites, establishing stacking interactions 
with the solvent-exposed aromatic residues. In support of this idea, crystal structure analysis on 
cyclo(L-Arg-L-Pro) (218), cyclo(L-His-L-Pro) (216), cyclo(L-Tyr-L-Pro) (220) and 
cyclo(Gly-L-Pro) (221) in SmChiB, showed that the common (221) substructure is sufficient 
for binding.140 These studies suggested that modification of the side-chain of the non-proline 
residue could be a possible way to improve potency against chitinase activity in the design of 
new 2,5-DKPs based on a proline residue. In this series, (216) showed significant activity but 
only comparable to CI-4 itself with an IC50 = 1.2 mM. 
 
In original studies on CI-4 (15) by Izumida et al.139 the D-D enantiomer of CI-4 was not 
explored. However studies in our laboratory245 have shown that this compound and its protected 
analogue are surprisingly effective inhibitors. Based on this observation, some new cyclo (Xaa-
Pro)-based dipeptides were designed, with different Xaa such as L/D-Pro, Gly, L-Ser, D-Arg, 
D-His, D-Phe. Protected Arg(Pmc), His(Trt) and Ser(Bn) were chosen in order to potentially 
increase active site interactions with the bacterial chitinases, by forming π-π stacking 
interactions with conserved tryptophan residues within the chitinase activesite.  
 
5.4.4. Approaches to the synthesis of 2,5-diketopiperazines 
Dipeptide formation and cyclization 
At its simplest, the preparation of a DKP involves the formation of a dipeptide between an N-
protected α-amino acid and α-amino acid ester, then the deprotection of the dipeptide to give a 
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dipeptide ester with a free N-terminus. To achieve the cyclization, the amide bond must assume 
the cis-configuration. Most often the cyclization is carried out by heating in an inert medium, 
such as MeOH, toluene or DMF. Recently an efficient and environmentally benign one-pot 
solution-phase synthesis of 2,5-DKPs using microwave-assisted heating in water has been 
reported.246 In this route the N-deprotection occurs via microwave irradiation followed by the 
cyclization, giving high yields of 2,5-DKP, as shown in Scheme 89. 
 
 





Scheme 90. DKP formation upon cleavage-induced cyclization. 
 
The cleavage-induced cyclization of linear dipeptides is one the most common strategies for 
the solid-phase synthesis of 2,5-DKP libraries. High yields of cyclic dipeptides have been 
obtained using both thermal and microwave-assisted heating. The PEGA-Ser resin was found 





Preparation of DKP by the Ugi reaction uses an isonitrile, a Boc-protected amino acid aldehyde 
and an amine (Scheme 91). The main advantage of this approach is that it does not require the 
use of homochiral amino acids and coupling reagents, as in the peptide coupling routes above 
and the reactant amines, carboxylic acids and aldehydes are usually all readily available. The 
terminal amide produced from the isonitrile moiety is often removed during the formation of 




Reagents and conditions: (i) MeOH, rt; (ii) 10% TFA/DCE.  
 
 








Reagents and conditions: (i) K2CO3, CH2Cl2/H2O; (ii) NaN3, DMF; (iii) PPh3, THF, rt. 
 
 
Scheme 92. Aza-Wittig cyclization route to DKPs.249 
 
An intramolecular aza-Wittig reaction followed by hydrolysis of the resulting imine ether has 
been used to prepare the 2,5-DKP ring as shown in Scheme 92. Acylation of the amino acid 
with chloroacetyl chloride gives the azide, following displacement with sodium azide. This is 
then converted into an iminophosphorane intermediate. This undergoes cyclization at C-2 to 
give the ester imino ether which, in the presence of moist THF, gives a good yields of 2,5-
DKP.249 
 
For our work the CI-4 analogues were prepared via the dipeptide ester cyclization route. A 
linear dipeptide was first prepared by coupling proline methyl ester to the corresponding Fmoc 
amino acid or Boc amino acid using PyBOP or EDC/HOBt as activating agents (see Scheme 
93).  
 
Reagents and conditions: (i) coupling reactions in CH2Cl2 or DMF/CH2Cl2. 
 





Table 5. Preparation of dipeptides 




Fmoc-D-Pro-OH (222) D-Pro-OMe (223) Fmoc-D-Pro-D-Pro-OMe (224) a 59 
Fmoc-L-Pro-OH (225) L-Pro-OMe (226) Fmoc-L-Pro-L-Pro-OMe (227) a 51 
Fmoc-Gly-OH (228) D-Pro-OMe (223) Fmoc-Gly-D-Pro-OMe (229) b 57 
Boc-L-Pro-OH (230) L-Pro-OMe (226) Boc-L-Pro-L-Pro-OMe (231) b 
 
60 
Boc-D-Pro-OH (232) D-Pro-OMe (223) Boc-D-Pro-D-Pro-OMe (233) b 51 
Boc-Gly-OH (234) D-Pro-OMe (223) Boc-Gly-D-Pro-OMe (235) b 
 
42 
Boc-D-Ser(OBn)-OH (236) D-Pro-OMe (223) Boc-D-Ser(OBn)-D-Pro-OMe 
(237) 
b 75 






Fmoc-D-His(Trt)-OH (240) D-Pro-OMe (223) Fmoc-D-His(Trt)-D-Pro-OMe 
(241) 
a 95 
Fmoc-D-Phe-OH (242) D-Pro-OMe (223) Fmoc-D-Phe-D-Pro-OMe (243) a 
 
79 






















D-Pro-OMe (226) Fmoc-D-Arg(Pmc)-D-Pro-OMe 
(251) 
a 76 
a Coupling reaction carried out with PyBOP, DIPEA. 




The compounds were isolated after purifications by column chromatography (MeOH/CH2Cl2 
gradient) giving the dipeptides in 59-95% yield. In the case of coupling Gly, L/D-Pro and D-
Ser, it was difficult to remove the by-product from the PyBOP coupling, so EDC/HOBt was 
preferred. 
 
For the cyclisation of the dipeptides, the linear protected dipeptides were treated with 
diethylamine in DMF for the removal of the Fmoc group. In the case of Boc-dipeptides 
(231),(233), (235), (237), (239) and  (245), treatment with 4 M aq HCl in dioxane was carried 





Reagents and conditions: (i) Et2NH/DMF or HCl-dioxane; (ii) cyclisation. 
 
Scheme 94. Cyclisation of dipeptides to CI-4 analogues. 
 
In an initial attempt to prepare the cyclic dipeptides cyclo(L-Pro-L-Pro) (215), cyclo(D-Pro-D-
Pro) (252) and cyclo(Gly-D-Pro) (253), the corresponding linear dipeptides were prepared from 
the Fmoc amino acids (224), (227), (229). However, after the cyclization, the desired cyclic 
dipeptides were found to be contaminated by the by-product from the Fmoc deprotection, which 
was difficult to remove even on repeated column chromatography. 
      

















Table 6. Preparation of cyclic dipeptides 







(252) D-Pro (D-Pro-D-Pro) MeOH (a) 
65 °C, 24 h 
33 
(215) L-Pro (L-Pro-LPro) MeOH (a) 
65 °C, 24 h 
33 
(253) D-Pro (Gly-D-Pro) MeOH (a) 
65 °C, 24 h 
45 
(254) D-Pro (D-Ser(OBn)-D-Pro) DMF (a) 
65 °C, 24 h 
46 
(255) L-Pro (L-Ser(OBn)-L-Pro) DMF (a) 
65 °C, 24 h 
 
53 
(256) D-Pro (D-His(Trt)-D-Pro) Toluene (b) 
110 °C, 24 h 
 
38 
(213) D-Pro (D-Phe-D-Pro) Toluene (b) 
110 °C, 96 h 
 
12 
(257) D-Pro (D-Tyr(OBn)-D-Pro) DMF (a) 
80 °C, 24 h 
64 
 
             a Deprotection of Boc with 4M HCl/dioxane, neutralize with DIPEA, before the cyclization. 
          b Deprotection of Fmoc with Et2NH/DMF before the cyclization. 
 
After the Fmoc deprotection of (241), (243), (247), (248), (250) and (251) using 
diethylamine/DMF solution, the cyclisation of the dipeptides proceeded in dilute methanol or 
toluene solution to give the cyclo(Xaa-Pro) in 12-89% yield. As noted above for Boc-
dipeptides, DIPEA had to be used in order to neutralize the salt formed after the Boc 
deprotection with HCl/dioxane. For (213) and (256), the reaction did not proceed in MeOH at 
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65 °C, so toluene had to be used and heating at 110 °C, giving (213), (256) in yields of 12% 
and 38% respectively.  
 
As noted above, to achieve the cyclization of a dipeptide intermediate, the amide bond must 
assume the cis-configuration. This may be hindered by sterically bulky groups adjacent to Cα, 
resulting in poor yields of cyclization. In these cases heating in high boiling solvents such as 
toluene or xylene may be needed to force the reaction to completion. 
 
Although proline should favour a cis amide bond in the Xaa-Pro sequence desirable for 
formation of 2,5-DKPs, we did indeed obtain a poor yield in some cases. For the His(Trt) (256) 
and Phe (213) analogues, cyclisation was much less efficient, probably due to the size of the 
Cβ-substituents.  
 
For  cyclo(L-Arg(Pmc)-D-Pro) (259), carrying the reaction out at 65 °C gave two compounds 
with close retention times on HPLC, in 80% yield (see Figure 50). However, at room 




Scheme 95. Synthesis of cyclo (Arg(Pmc)-Pro) diastereoisomers. 
 
Table 7. Synthesis of cyclo(Arg(Pmc)-Pro) 
No Arg(Pmc) Pro Yield % 
(258) L L 89 
(259) L D 84 
(260) D L 87 
(261) D D 77 
 
Cyclisation of all four diastereoisomeric Arg(Pmc)-Pro-OMe derivatives at room temperature 
gave a single isomer as judged by HPLC and 1H NMR. Compounds (258)/(261) and (259)/(260) 
could be clearly resolved by analytical HPLC. For the case of (250), the product obtained from 
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reaction at 65C shows evidence of othe diastereoisomers both by HPLC (Figure 50) and 1H 
NMR. 
 
 (a)                                                                                      (b) 
Figure 50. (a) HPLC trace of (259) plus epimer from the reaction at 65 °C in MeOH; (b) pure (259) from the 
reaction at rt. 
 
Removal of Trt, OBn and Pmc groups  
Deprotection of (256), (257) and (261) was done under acidic conditions using TFA/TIPS/H2O 
(95/2.5/2.5, v/v/v). For the His derivative (256) more iPr3SiH (2 eq) was added in order to 
quench the trityl cation generated. 
 
 
Table 8. Deprotection of cyclic dipeptides 
Comp. Cyclo(Xaa-Pro) Cyclo(Xaa-Pro) Yields (%) 
(262) Cyclo (D-Arg(Pmc)-D-Pro) (261) Cyclo (D-Arg-D-Pro) (262) 
 
Qt yield 
(263) Cyclo(D-His(Trt)-D-Pro (256) Cyclo(D-His(Trt)-D-Pro) (263) 
 
Qt yield 
(264) Cyclo(D-Tyr(OBn)-D-Pro) (257) Cyclo(D-Tyr-D-Pro) (264) 66 
 
 
5.4.5. Biological data 
Selected cyclic dipeptides were evaluated against the bacterial chitinase, SmChB1 from S. 
marcescens. This work was performed by Dr Gustav Vaaje-Kolstad (Norwegian University of 
Life Sciences, Ǻs, Norway). 

































Table 9 shows the results obtained with (215), (252), (253) and (262), prepared in this study, 
and alongside IC50 values reported in the literature for related cyclic dipeptides.  
 
 
Table 9. IC50 of the DKPs against SmChiB1 
Compound IC50 (µM) 
Cyclo (D-Arg(Pmc)-D-Pro) (262) 63.5 ± 26 
Cyclo (D-Pro-D-Pro) (252) 136.9 ± 38 
Cyclo(L-Pro-L-Pro) (215) 469.4 ± 72 
Cyclo(Gly-D-Pro) (253) 1334 
Cyclo(Gly-L-Pro) (266) 5000140 
CI-4 Cyclo(L-Arg-D-Pro) (15) 1200140 
Cyclo(L-Arg-L-Pro) (267) 6300140 
 
The limited data available suggest that DKPs with the D-D template are the more potent 
compounds. (262) is more than 100-fold more potent than the natural product, CI-4, (15).   
 
Cyclo(L-Arg-L-Pro) (267) is a weaker inhibitor still compared to (15). This confirms the 
important of D-configuration for the proline residue and also the potential for modifying the 
non-proline residue suggested by Houston et al.140 This observation about the D-configuration 
is supported by the activity of cyclo(Gly-D-Pro) (253) which is significantly better than the L-
Pro derivative. As expected, cyclo(D-Pro-D-Pro) (252) is a better inhibitor than its enantiomer 
cyclo(L-Pro-L-Pro) (215). Surprisingly however, although (215) is 4-fold weaker than (252), it 
is a better inhibitor than (253) which does have a D-proline residue. This may suggest a new 
binding mode for (215) with SmChiB not seen with other DKPs,140 which should be revealed 
by further X-ray studies. 
 
 Based on the initial data obtained, it seems possible that DKPs such as cyclo(D-Ser(OBn)-D-
Pro) (254) cyclo(D-Tyr(OBn)-D-Pro) (257) and cyclo(D-His(Trt)-D-Pro) (256) will also be 
significantly more potent than CI-4 (15). This is based on the presence of a D-proline residues 
and a non-proline residue with a side chain bearing a bulky hydrophobic group, as in (262) 
which could potentially make hydrophobic interactions with the conserved tryptophan residues 
within the active site of the enzyme. 
 
Data on further compounds should confirm these preliminary findings and provide the basis for 
design of other inhibitors based around DKP motifs with D-D configuration. 
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5.4.6. Conclusion and future work 
A series of DKPs related to the natural product CI-4 has been synthesised. CI-4 has a very weak 
activity against the bacterial type chitinase SmChiB from S. cerevisae. By changing the Pro 
configuration from L to D, compounds with promising activity have been obtained. Further 
compounds have been synthesized based on the D,D-template with the Arg residue replaced by 
a hydrophobic group to interact with the hydrophobic regions of chitinase active site. Biological 
data on these analogues should confirm our initial findings and provide the basis for the design 
of other inhibitors based around DKP motifs. 
 
 



















6. Overall conclusions 
 
This project focused on the synthesis and development of peptide-derived chitinase inhibitors. 
In Section 5, part 1, an improved synthesis of the cyclic pentapeptide inhibitor argifin was 
investigated. The synthesis was carried out by a combination of solution and solid phase 
methods in order to provide a synthetic route that might be suitable for scale-up. The linear 
peptide was synthesised by SPPS and was cyclised efficiently in solution. By choosing 
hydrogenolysable protecting groups for the side chains of Asp and Arg residues, it was possible 
to avoid a final deprotection of the final cyclic peptide under acidic conditions, which has been 
shown to lead to the generation of aspartimide products. The final yield of the natural product 
from the linear peptide was 19%, which compares very favourably with previously reported 
syntheses. Importantly, only one HPLC purification was required at the final step of the 
synthesis, which should allow the synthetic route to be easily applied for the preparation of mg-
g quantities of the natural product. 
New methods have also been studied for the preparation of the guanylurea side chain unit of 
argifin and related chitinase inhibitors. In Section 5, part 1, the synthesis of reagents for the 
direct conversion of amines to guanylureas were also explored. The direct conversion of a bis-
benzyloxycarbonyl-protected arginine residue, Arg(Z)2 to the corresponding guanylurea was 
first investigated, based on the observation that such a transformation could be successfully 
achieved by reaction of simple guanidine derivatives with methylamine. The result of such an 
aminolysis reaction was inconclusive when applied to a protected cyclic pentapeptide related 
to argifin and when similar reactions were investigated with shorter peptides containing the 
benzyloxycarbonyl protecting group, there was no success. Therefore we looked at building 
blocks that could be converted to potential guanidinating agents, which could then be applied 
for the conversion of an Orn side chain into Arg(MC). 
A range of Boc- and Z-protected guanylureas were obtained by reaction of bis-Boc and bis-Z 
guanidines with methylamine, N-methylbenzylamine and 4-methoxy-N-methylbenzylamine in 
poor to good yields. The aim was to generate guanidinylating agents related to previously 
reported bis-urethane-trifluoromethylsulfonamides and tris-Boc/Z compounds. One of the 
guanylureas prepared was successfully converted to a bis-Boc derivative, which, in the future,  
could be used to test the reactivity of compounds of this type with different amines. 
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In Section 5, parts 2 and 3, the synthesis of a key component of the cyclic peptide banyasin A 
was investigated. Banyasin A is a natural product which contains the Arg(MC)MePhe dipeptide 
motif of argifin, which therefore suggests that it may be an interesting chitinase inhibitor. It 
also contains   the novel amino acid, Amoa (3-amino-2-methyl-5-E-octenoic acid), in which the 
stereochemical configurations at C-2 and C-3 are unresolved. In these sections of the work, the 
synthesis of four diastereoisomers of Amoa was studied in some detail. 
A potential approach to the novel amino acid Amoa and its diastereoisomers was first studied 
based on the Crimmins modification of the Evans aldol reaction. Although aldol derivatives 
were successfully prepared using this Ti-based chemistry, introduction of a nitrogen function 
by nucleophilic displacement with azide and Mitsunobu chemistry proved to be problematic. 
The desired products were only obtained in low yields and significant amounts of eliminated 
products were observed. It was therefore decided to pursue an alternative chiral pool approach 
which would involve introducing the C-2 methyl group of Amoa into an enantiomerically pure 
α-amino derivative. 
 
L-Aspartic acid was chosen as the chiral starting material with the key nitrogen function already 
in place. The combination of different protecting groups on the nitrogen and α and β- carboxylic 
acid groups were found to be important for the diastereoselectivity of the methylation reaction, 
in accordance with the literature. The best results were obtained using distilled reagents, 
iodomethane and litium hexamethyldisilazane, which gave the desired anti β-methyl aspartate 
in 48% yield. Surprisingly, the use of HMPA in the alkylation reaction did not improve the 
diastereoselectivity as has been previously reported but instead led to the formation of both N- 
and C-alkylated products. 
 
Two routes were considered for the conversion of the selectively protected β-methyl aspartate 
to Amoa. The key transformation to be achieved was a homologation reaction at the -acid 
group. Selective reduction of the -acid to the aldehyde via the thiol ester or Weinreb amide 
was first attempted – the aldehyde could then be reacted with a suitable phosphorane in a Wittig-
type reaction. Although the Weinreb amide could be selectively reduced with DIBAL-H, it was 
not possible to separate the desired aldehyde from unchanged starting material. Reduction of 
the thiol ester using triethylsilane and a Pd catalyst was also unsuccessful, as parallel reduction 
of the allyl ester group could not be avoided. Finally, a successful and selective route was 
devised, via Arndt-Eistert chemistry. This led to the desired homologated β-amino acid 
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derivative, (3R,4R)-3-(((benzyloxy)carbonyl)amino)-4-methyl-5-oxo-5-allyloxypentanoic acid 
in 27% yield over 8 steps from L-aspartic acid. 
 
With this key intermediate in hand, the synthesis of Amoa may be completed as follows. 
Conversion of the new carboxylic function to the corresponding aldehyde maybe achieved by 
reduction to the primary alcohol and then selective re-oxidation under Swern conditions. The 
alkene function of Amoa might then be introduced by E-selective Julia-Kocienski olefination 
to give the protected Amoa (2R, 3R)-diastereoisomer. Since we have observed that changing 
the protecting groups on the L-aspartic acid starting material leads to differing ratios of 
separable diastereoisomers in the methylation reaction with iodomethane, it should be possible 
to  obtain readly the other isomer to generate the (2S, 3R) Amoa diasteroisomer. Similarly, by 
changing to suitable protected D-aspartic acid starting materials, it should also be possible to 
generate the two other (2S, 3S) and (2R, 3S) diastereoisomers of Amoa. With all  four 
diastereoisomers of Amoa in hand, it will then be possible to apply these intermediates for the 
synthesis of banyasin A itself and identify the one present in the natural product synthesised. 
 
In Section 5, part 4, several analogues of CI-4 cyclo(L-Arg-D-Pro), were synthezised, with a 
D-D template. It is known from the literature that cyclo(L-Arg-L-Pro), a diastereoisomer of CI-
4, is a weaker inhibitor than CI-4 Itself. X-ray data show that changing the stereochemical 
configuration at the proline residue changes the binding orientation of the DKP in the active 
site of a typical bacterial chitinase, while the arginine residue does not make any significant 
contacts with the enzyme in CI-4. It has been suggested therefore that the arginine residue might 
be replaced with alternatives that present a hydrophobic group that can interact with conserved 
hydrophobic tryptophan residues in the chitinase active site. 
 
We chose to prepare DKPs with hydrophobic amino acid side chains, or side chains with bulky 
protecting groups such as Ser(OBn), Tyr(OBn), His(Trt) and Phe in order to favour these 
interactions. DKPs with an all-D stereochemical configurations were synthesized in yields of 
12% to 89%.  Preliminary biological data obtained with the bacterial chitinase SmChiB showed 
that some of these compounds, were as expected, more potent than CI-4  and significantly more 
potent than related DKPs with all-L configuration in the literature.  
 
Based on the results obtained in this work, further studies on CI-4 analogues may now provide 





Chemical reagents were purchased from Sigma, Aldrich, Fluka, Acros, Lancaster and 
Novabiochem. Anhydrous CH2Cl2 was obtained by distillation over calcium hydride, 
anhydrous THF and Et2O over sodium/benzophenone. All other solvents were purchased from 
Fisher Scientific. DMF peptide grade was purchased from Rathburn Chemicals Ltd, 
Walkerburn, Scotland.  
 
Analytical TLC was performed using silica gel 60 F254 pre-coated on aluminium sheets (0.25 
mm thickness). They were viewed using UV light of wavelength 254 nm and stained with 
iodine, ninhydrin, and phosphomolybdic acid. Column chromatography was performed on 
silica gel 60 (35-70 micron) from Fisher Scientific.  
 
Melting points were recorded on a Reichert-Jung Kofler block heated-stage microscope and 
are uncorrected.  
 
Optical rotations were measured at ambient temperature using an Optical Activity Ltd. AA-10 
polarimeter in a cell volume of 5 mL and specific rotations are given in 10-1 deg. mL g-1. 
 
Infrared spectra were recorded on a Perkin-Elmer RXI FT-IR system and values are given in 
cm-1. 
 
1H NMR spectra were obtained on JEOL Eclipse (270 MHz), Varian Mercury VX (400 MHz), 
Bruker Avance III (400 MHz) or Bruker Avance III (500 MHz) spectrometers. 13C NMR 
spectra were obtained on JEOL Eclipse (67.9 MHz), Varian Mercury VX (100 MHz) Bruker 
Avance III (100 MHz) or Bruker Avance III (125 MHz) spectrometers. The chemical shifts are 
recorded in parts per million (ppm) with reference to tetramethylsilane. The coupling constants 
J are quoted in Hz. The multiplicities are assigned as a singlet (s), doublet (d), triplet (t), quartet 
(q), quintuplet (qn), doublet of doublets (dd), triplet of doublets (td), broad (br), and multiplet 
(m). 
Mass Spectrometry was carried out on a micrOTOFTM from Bruker Daltonics (Bremen, 
Germany), using an electrospray source (ESI-TOF). This is a Time-of-Flight mass spectrometer 
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coupled with an electrospray source (ESI-TOF). This instrument can be used to measure 
accurate mass to 5 ppm externally calibrated and 2 ppm internally calibrated. Samples are 
introduced by injection using an autosampler system.  The instrument is calibrated using a 
sodium formate solution, which is applicable to both positive- and negative-ionisation modes. 
These samples were analysed under standard conditions for small molecules in positive 
electrospray ionisation mode. The instrument acquires both accurate mass and true isotope 
patterns, therefore both of these dimensions of information are used to help determine or 
confirm the molecular formula. Ions are most often present as protonated or sodiated molecules. 
Data were processed using external calibration with the Bruker Daltonics software, 
DataAnalysisTM as part of the overall hardware control software, Compass 1.1TM. 
Analytical RP-HPLC was performed on a a Dionex UltiMate 3000 HPLC system equipped with 
a Phenomenex Gemini 5µm C-18 (150 x 4.6 mm) column with a flow rate of 1 mL/min. 
Preparative RP-HPLC was performed on a Dionex HPLC system equipped with a Phenomenex 
Gemini 5µm C-18 (250 x 30 mm) column with a flow rate of 22.5 mL/min. Mobile phase A 
was 0.1% TFA in water, mobile phase B was 0.1% TFA in acetonitrile.  
Gradient 1 was T = 0 min, B = 5%; T = 10 min, B = 95%; T = 15 min, B = 95%; T = 15.1 min, 
B = 5%; T = 18.1 min, B = 5%.  
 
Gradient 2 was T = 0 min, B = 5%; T = 20 min, B = 40%; T = 22 min, B = 95%; T = 27 min, B 
= 95%; T = 27.1% B= 5%; T = 32 min, B = 5%.  
 
Gradient 3 was T = 0 min, B = 5%; T = 30 min, B = 12%; T = 32 min, B = 95%; T = 37 min, B 
= 95%; T = 38 min, B = 5%; T = 42 min, B = 5%; T = 42.1, B = 5%.  
 
 
Qualitative tests for the presence or absence of free primary amino groups during deprotection 
or coupling in SPPS were carried out with the Kaiser method.250 The beads are treated with 
ninhydrin in ethanol, phenol in ethanol, and potassium cyanide, then heated. A positive result 
is indicated by the beads turning dark blue. For secondary amines, the chloranil test was used.251 
The beads are treated with acetaldehyde in DMF, and p-chloranil in DMF. The presence of 
secondary amines is indicated by the beads turning to bright orange/red. 
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Enzyme activities of ChiB in the presence of the different cyclic dipeptides were determined 
using 4-methylumbelliferyl-alpha-D-N,N-diacetylchitobioside as a fluorogenic substrate in a 
standard assay. 
 
Reaction mixtures consisted of purified ChiB (2.75 nM), substrate (20 íM), BSA (0.1 mg/mL), 
and inhibitor (0-10 mM) in 50 íL citrate/phosphate buffer pH 6.3. The mixtures were incubated 
for 10 min at 37 °C (product formation is known to be linear over time under these conditions) 
and the reaction was stopped by addition of 0.2M Na2CO3 (1.95 mL). The amount of liberated 
4-methylumbelliferone (4-MU) was determined using a DyNA 200 fluorimeter (Hoefer 
Pharmacia Biotech, San Francisco, CA). Each measurement was performed in triplicate, 
yielding standard deviations that in all cases were below 5% of the average. IC50 values were 






7.2. Approaches to argifin and related peptides 
7.2.1. Improved synthesis of argifin by use of hydrogenolysable protecting groups. 




Synthesis was carried out manually by Fmoc SPPS. Wang resin (0.354 g nominal loading 1.21 
mmol/g, 0.390 mmol) was pre-swollen in dry CH2Cl2 (7 mL) for 30 min.  The loading of the 
resin was achieved as follows: Fmoc-Asp-OBn (0.523 g, 1.17 mmol) was dissolved in dry 
CH2Cl2 (4 mL) and DMF (3 mL), DIC (0.75 g, 0.59 mmol) in dry CH2Cl2 (3 mL) was added 
and the mixture was stirred for 20 min at 0° C. All the solvents were evaporated and the residue 
of Fmoc-Asp anhydride was dissolved in DMF (7 mL). The resin (0.354 g, 0.390 mmol) was 
suspended in anhydrous CH2Cl2 (5 mL) and was treated with DMAP (10.2 mg, 78.0 µmol) plus 
the solution of Fmoc-Asp anhydride and stirring was continued at room temperature for 90 min. 
The resin was washed with DMF (4 x 7 mL), CH2Cl2 (4 x 7 mL), MeOH (4 x 7 mL), Et2O (4 x 
7 mL).  Fmoc deprotection was achieved by treatment with piperidine/DMF (1:4, v/v) (3 x 7 
mL), for 4 x 3 min. Peptide couplings were performed based on the nominal loading, using 
Fmoc-amino acid (2 eq), PyBOP (1.9 eq) and DIPEA (8 eq) in peptide grade DMF (5 mL) for 
90 min, except for the case of coupling to MePhe when Fmoc-Arg(Z)2-OH (2 eq), HATU (2 
eq) and DIPEA (4 eq) in DMF peptide grade (5 mL) for 150 min was used. The last Asp 
derivative coupled was Boc-Asp-OBn. The resin was washed with DMF (4 x 7 mL), CH2Cl2 (4 
x 7 mL), MeOH (4 x 7 mL), Et2O (4 x 7 mL). Cleavage from the resin and the side chain 
deprotection were achieved by treatment with TFA/TIPS/H2O (95:2.5:2.5, v/v/v) (10 mL). All 
the solvents were evaporated under vacuum and the residue was dissolved in TFA and cold 
Et2O was added. The precipitated white solid was isolated by centrifugation, to give (59) as a 
white solid (371 mg, 80% yield); RP-HPLC (analytical system, gradient 1) Rt= 9.1 min), 
[found (ES+) 1085.4630 [M+H]+, C57H65N8O14  requires 1085.4615]. 
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Compound (59) (371 mg, 0.310 mmol), and HATU (118 mg, 0.310 mmol) were dissolved in 
anhydrous CH2Cl2 (20 mL), and the solution was adjusted to pH 9 by addition of DIPEA (520 
L, 1.43 mmol) and stirred for 48 h at room temperature. The reaction mixture was concentrated 
under vacuum and the residue dissolved in EtOAc (20 mL) and extracted with 5% aq. citric 
acid (2 x 40 mL), sat. aq. NaHCO3 (2 x 40 mL and brine (2 x 40 mL). The organic extract was 
filtered and dried over MgSO4 to give a yellow oil (192 mg). The HPLC of the crude cyclic 
pentapeptide was run and showed two peaks, RP-HPLC (analytical system, gradient 1)  Rt = 
8.6 min, and Rt = 10.8 min. The crude material was precipitated from CH2Cl2/petroleum ether, 
to give (60) as a pale yellow solid (182 mg, 55%); RP-HPLC (analytical system, gradient 1) 
Rt = 10.8 min. [found (ES+) 1089.4381 [M+Na]





A:  H2, Pd(OH)2/C, AcOH/iPrOH, rt, 1 h; B: H2, Pd black, AcOH/iPrOH, rt, 18 h; C H2, Pd(OH)2/C, AcOH/iPrOH, 
rt, 16 h; D: H2, Pd(OH)2/C, AcOH/PriOH, rt, 18 h; E: H2 (4 Bar, hydrogenator), Pd(OH)2/C, AcOH, rt, 72 h.  
                                           
 Method A: Compound (60) (40.0 mg, 37.0 mol), was dissolved in AcOH/PriOH (20 mL, 1:1 
v/v), the solution was degassed and purged three times with nitrogen. The solution was treated 
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with Pd(OH)2/C  (40 mg). The reaction was degassed three times with nitrogen before treating 
with H2 (1 atm) and stirring continued at room temperature for 1 h. The reaction mixture was 
monitored by TLC (10% MeOH/CH2Cl2), until consumption of the starting material was 
observed. The reaction mixture was filtered through Celite, then coevaporated with Et2O, then 
MeOH and finally with toluene to give a pale white solid (31.4 mg). HPLC indicated the 
disappearance of the starting material and formation of a new compound, RP-HPLC (analytical 
system, gradient 1) Rt = 9.9 min.  
Mass spectrometry indicated two compounds, corresponding respectively to the deprotection 
of the arginine residue (62), [found (ES+) 799.3774 [M+H]+ , C41H50N8O9  requires 799.3740] 
and arginine deprotection plus removal of the one of two Bn group on the aspartic acid residues 
(63), [found (ES+) 731.3123 [M+Na]+, C34H44N8O9Na requires 731.3133]. 
 
Method B: The mixture of those two cyclic pentapeptides (62) and (63) from method A was 
again submitted to hydrogenolysis using Pd(OH)2/C (31 mg). The reaction was run for 18 h at 
room temperature but no further change was observed by RP-HPLC.  
Method C: Same sample from Method B. A mixture of partially deprotected cyclic 
pentapeptide (31 mg) was dissolved in AcOH/iPrOH (20 mL, 1:1 v/v) and the solution was 
degassed and purged three times with nitrogen. The reaction mixture was then treated with Pd 
black (31 mg), and was degassed three times with nitrogen before treating with H2 (1 atm), and 
stirring continued at room temperature, for 16 h. RP-HPLC  showed no further change. 
Method D: Compound (60) (20.0 mg, 19.0 mol) was dissolved in AcOH/iPrOH (3 mL, 1:1 
v/v), the solution was degassed and purged three times with nitrogen. The reaction mixture was 
then treated with a fresh sample of Pd(OH)2/C (20 mg) and  was degassed and purged three 
times with nitrogen before treating with H2 (1 bar) and stirring at room temperature for 18 h. 
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The reaction mixture was monitored by TLC (MeOH/CH2Cl2), which showed the consumption 
of the starting material. The reaction was filtered through Celite, then coevaporated with Et2O 
then MeOH and finally toluene to give a pale white solid (31.4 mg); RP-HPLC (analytical 
system, gradient 1) Rt = 9.9 min. 
 
Method E: Compound (60) (20.0 mg, 19.0 mol) was dissolved in AcOH (7 mL), the solution 
was degassed and purged three times with nitrogen. The reaction mixture was then treated with 
Pd(OH)2/C (60 mg) and hydrogenated at  4 bar pressure and stirred at room temperature for 72 
h. HPLC indicated the disappearance of the starting material and formation of a new compound, 
RP-HPLC (analytical system, gradient 1) Rt = 4.2 min). This gave the fully deprotected cyclic 
pentapeptide (61) (30 mg), which was used directly in the subsequent acylation step.  [found 










A solution of (61) (30.0 mg, 19.0 mol) in DMF (0.8 mL) and DBU (24.0 L, 0.162 mmol) 
was stirred at 40 °C and was treated with N-succinimidyl-N-methylcarbamate (14.0 mg, 0.810 
mol) in DMF (0.4 mL). The reaction mixture was stirred at 40°C for 48 h. The acylated 
compound was then purified by preparative HPLC, to give (72) as a solid (3.5 mg, 19%, from 
(60); RP-HPLC (analytical system, gradient 1) Rt = 6.8 min. [found (ES+) 676.3046 [M+H]
+, 
C29H42N9O10 requires 676.3054].  
7.2.2.  Approaches to alternative reagents for the direct conversion of Orn to Arg(MC) 




A stirred solution of benzylamine (53.0 mg, 0.50 mmol) and 1,3-di-Boc-2-
(trifluoromethanesulfonyl)guanidine (64) (176 mg, 0.450 mmol) in CH2Cl2 (2 mL) was treated 
with triethylamine  (70 µL, 0.50 mmol) and the reaction mixture was stirred at room 
temperature for 30 min after which time the starting material was consumed, as shown by TLC 
(10% EtOAc/petroleum ether). The reaction mixture was diluted into CH2Cl2 (3 mL), and was 
washed with 2M aq. sodium bisulfate (10 mL), sat. aq. sodium carbonate (10 mL)  and brine 
(10 mL). The organic extract was dried, filtered and the solvent was evaporated to give (64), as 
a white solid (114 mg, 72%); Mp 121-122 °C  (lit,161 126-127 °C); IR υmax (KBr disc ) 3442, 
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3334 (NH),  2978, 2929 (CH), 1741, 1653, 1624 (C=O), 1366, 1334 (NH), 1153 (CO); 1H 
NMR (270 MHz, CDCl3) δ 1.27 (9H, s, (C(CH3)3)), 1.28 (9H, s, (C(CH3)3),  4.60 (2H, d, J 4.9 
Hz, PhCH2), 7.29-7.33 (5H, m, Ph ), 8.57 (1H, br, NH), 11.53  (1H, s, NH). 
 




A solution of (65) (100 mg, 0.286 mmol) was treated with a solution of 2M methylamine in 
THF (720 L, 1.43 mmol). The reaction mixture was stirred at reflux overnight. The solvent 
was evaporated to give a colourless oil. The residue was pre-adsorbed onto silica using CH2Cl2 
as solvent and was purified by column chromatography, (EtOAc /petroleum ether gradient) to 
give (66) as a colourless oil, which solidified (48 mg, 55%);  Mp 88-90 °C; 1H NMR (270 
MHz, CDCl3) δ 1.40 (9H, s, (C(CH3)3) 2.79 (3H, d, J 7.7 Hz, NHCH3)  4.51 (2H, d, J 5.5 Hz, 
CH2Ph), 7.24-7.29  (5H, m, Ph), 8.42 (1H, br, NH), 12.16 (1H, s, NH); 13C NMR  (101 MHz, 
CDCl3) δ 27.93 (CH3), 45.12 (CH2Ph), 127.42, 127.74, 128.06, 128.75  (CH Ar), 137.81  (C 
quaternary), 152.86 C=N, 163.28  (C=O). [found (ES+) 329.1565 [M+Na], C15H22N4O3Na 
requires 329.1589]. 
 





A suspension of guanidine hydrochloride (67) (3.82 g, 40.0 mmol) in CH2Cl2 (80 mL), was 
treated with sodium hydroxide (8.0 g, 0.20 mmol) and water (40 mL) and the reaction mixture 
was cooled to 0 °C. Benzyl chloroformate (17.1 mL, 120 mmol) was added dropwise with 
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vigorous stirring over 45 min. Stirring was continued at 0 °C - 5° C overnight. The reaction was 
checked by TLC (1% MeOH/CH2Cl2), showing disappearance of the starting material and the 
reaction mixture was diluted in CH2Cl2 (100 mL). The aqueous phase was extracted with 
CH2Cl2 (100 mL). The organic fractions were washed with water (2 x 100 mL), were dried, 
filtered and the solvent was evaporated to give a white solid. The crude product was 
recrystallised from CH2Cl2/petroleum ether, to afford (68) as a white solid (7.77 g, 59%); Mp 
148-150 °C (lit, 164 149-150 °C); IR υmax (KBr disc) 3401, 3240 (NH),  3034,  2953 (CH), 1734, 
1622, 1561 (C=O), 1443, 1384 (Ar), 1294, 1223 (CO), 755 (CH Ar);  1H NMR (270 MHz, 
DMSO-d6) δ 5.16 (4H, s, 2 x CH2, PhCH2),  7.34-7.36 (10H, m, 2xPh), 8.68 (1H, br, NH), 10.89 











A suspension of (68) (0.83 g, 2.5 mmol) in anhydrous chlorobenzene (25 mL) was treated with 
60% sodium hydride (0.2 g, 8.3 mmol assumed) at 0 °C under a nitrogen atmosphere. After 
being stirred for 1 h at 0 °C, the mixture was cooled to -45 °C. Triflic anhydride (0.42 mL, 5.0 
mmol) was added and the reaction mixture was allowed to warm to room temperature and stir 
overnight. The reaction was checked by TLC, Rf 0.81 (5% Et2O/CH2Cl2), showing 
disappearance of the starting material. The solvent was evaporated, and the residue was 
dissolved in a mixture of EtOAc (50 mL) and 2M aq.  sodium bisulfate (15 mL). The organic 
layer was washed with water (50 mL) and brine (50 mL), was dried, filtered and the solvent 
was evaporated to give a colourless oil. This residue was co-evaporated with toluene (3 x100 
mL) to remove traces of chlorobenzene and the solvent was  evaporated, to afford (69) as a  
white solid (0.98 g, 84%); Mp 70-72 °C (lit, 164  74-75 °C); 1H NMR (270 MHz, CDCl3) δ 5.21 
(4H, s, 2 x PhCH2),  7.24-7.26 (10H, m, 2 x Ph),  10.35 (1H, br, NH). 
 




A stirred solution of (69) (230 mg, 0.500 mmol) and benzylamine (60 µL, 0.55 mmol) in CH2Cl2 
(8 mL) was treated with triethylamine (77 µL, 0.55 mmol) and the reaction mixture was stirred 
at room temperature. The reaction was continued until the starting material was consumed, as 
shown by TLC (20% Et2O/petroleum ether). The reaction mixture was washed with 2M aq. 
sodium bisulfate (10 mL), sat. aq. sodium carbonate (10 mL) and brine (10 mL). The organic 
extract was dried, filtered and evaporated to give (70) as a yellow solid (169 mg, 81%); Mp 
150-152 °C161; 1H NMR  (270 MHz, CDCl3) δ 4.63 ( 2H, d, J 5.5 Hz, NHCH2Ph),  5.14 (2H, 
153 
 
s, OCH2Ph), 5.16 (2H, s, OCH2Ph), 7.32-7.36, (15H, m, 3 x Ph), 8.72 (1H, br, NH),  11.79 (1H, 
br, NH). 
 




A solution of (70) (100 mg, 0.239 mmol) in CH2Cl2 (5 mL) was treated with a solution of 2M 
methylamine in THF (0.60 mL, 1.20 mmol). The reaction mixture was stirred at reflux 
overnight. The solvent was evaporated to give a colourless oil. The residue was pre-adsorbed 
onto silica using CH2Cl2 as a solvent and was purified by column chromatography, (EtOAc 
/petroleum ether gradient) to give (71) as white solid (80 mg, 98%); Mp 162-165 °C; 1H NMR 
(270 MHz, DMSO-d6) δ 2.51 (3H, d, J 5.5 Hz, NHCH3), 4.53 (2H, d, J 5.5 Hz, PhCH2), 5.03 
(2H, s, CH2, OCH2Ph) 7.30-7.32  (10H, m, 2 x Ph), 8.15 (1H, br, NH), 9.64 (1H, br, NH), 11.04 
(1H, s, NH); 13C NMR (CDCl3, 101 MHz) δ 28.34 (CH3), 45.12 (CH2Ph), 53.40 (CH2Ph), 
127.41, 127.73, 128.06, 128.64, 128.75 (CH Ar), 137.81 (C quaternary), 152.86 (C=N), 163.28 









A solution of (60) (48 mg, 45 µmol) was dissolved in THF (2 mL) and was then treated with a 
2M solution of methylamine in THF (113 L, 0.225 mmol). The reaction mixture was stirred 
at 65 °C overnight. The reaction was followed by HPLC and 5 eq of MeNH2 were added each 
day during 5 days in order to complete the reaction. After running the reaction for 24 h, a new 
peak appeared at Rt =10.3 min. After 48 h and 72 h the new peak had increased compared to 
the starting material Rt = 10.7 min. After running the reaction for 5 days the HPLC showed the 
relative area of the peak at Rt 10.3 min was significantly greater compared to the starting 
material. The solvents were evaporated, to give crude material as an oil (20 mg). Mass 
spectrometry showed the presence of starting material plus a new component corresponding to 
the incorporation of 2 eq of methylamine with loss of 2 benzyloxy groups [found (ES+) 






Synthesis was carried out manually, by Fmoc SPPS. The 2-chlorotrityl resin (0.20 g, 0.22 
mmol) was pre-swollen in dry CH2Cl2 (7 mL) for 30 min. The resin was added to a solution of 
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Fmoc-Asp-OtBu (73) (0.32 g, 0.78 mmol), and DIPEA (1.1 mL, 6.2 mmol) in anhydrous 
CH2Cl2 (5 mL), with stirring continued at room temperature for 90 min. The resin was washed 
with DMF (4 x 7 mL), CH2Cl2 (4 x 7 mL), MeOH (4 x 7 mL), Et2O (4 x 7 mL), then treated 
with CH2Cl2 /MeOH/DIPEA (17: 2: 1, v/v/v) (7 mL) for 40 min. Fmoc deprotection was 
achieved by treatment with piperidine/DMF (1:4, v/v) (3 x 7 mL), for 4 x 3 min. Peptide 
couplings were performed relative to the nominal loading, using Fmoc-amino acid (2 eq), 
PyBOP (1.9 eq) and DIPEA (8 eq) in DMF (5 mL) for 90 min, except for the case of coupling 
to MePhe when Fmoc-Arg(Z)2-OH (2 eq), HATU (2 eq) and DIPEA (4 eq) in DMF  (5 mL) for 
150 min were used. The resin-bound peptide was N-α-deprotected and acetylated by treatment 
with Ac2O/CH2Cl2/DIPEA (5 mL, 1:8:1 v/v/v), for 45 min at room temperature. The Kaiser test 
was carried out and the beads were brown, therefore the tripeptide was treated again with 
Ac2O/CH2Cl2/DIPEA (5 mL, 1:8:1 v/v/v), for 160 min. The resin was washed with DMF (4 x 
7 mL), CH2Cl2 (4 x 7 mL), MeOH (4 x 7 mL), Et2O (4 x 7 mL). Cleavage from the resin and 
side-chain protection were achieved by treatment with TFA/TIPS/H2O (10 mL, 95:2.5:2.5 
v/v/v). All of the solvent was evaporated under vacuum and the residue was dissolved in TFA 
and precipitated with cold Et2O. The solid was isolated by centrifugation, to give (74) as a white 
solid (18 mg, 15%); RP-HPLC (analytical system, gradient 1) Rt = 8.7 min. [found (ES+) 
761.3108 [M+H]+, C38H45N6O11  requires 761.3141]. 
 





The synthesis was carried out manually by Fmoc SPPS. Wang resin (0.354 mg, 0.300 mmol) 
was pre-swollen with CH2Cl2 (7 mL), for 30 min. Fmoc-Asp-OBn (76) (0.522 g, 1.17 mmol) 
was dissolved in dry CH2Cl2 (4 mL), DMF (3 mL) and DIC (0.75 g, 0.59 mmol) in dry CH2Cl2 
(3 mL) was added and then the mixture was stirred for 20 min at 0 °C. All the solvent was 
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evaporated, and the residue was dissolved in DMF (7 mL). The resin and DMAP (9.5 mg, 78 
mol) were added to the mixture and stirring was continued at room temperature for 90 min. 
The resin was washed with DMF (4 x 7 mL), CH2Cl2 (4 x 7 mL), MeOH (4 x 7 mL), Et2O (4 x 
7 mL). The loading was determined to be 59% based on UV absorption after the Fmoc 
deprotection.  Fmoc deprotection was achieved by treatment with piperidine/DMF (1:4, v/v) (3 
x 7 mL), for 4 x 3 min. Peptide couplings were performed using Fmoc-amino acid (2 eq), 
PyBOP (1.9 eq) and DIPEA (8 eq) in DMF (5 mL) for 90 min, except for the case of coupling 
to MePhe when Fmoc-Arg(Z)2-OH (2 eq), PyBrOP (2 eq) and DIPEA (4 eq) in DMF (5 mL) 
for 4 x 90 min were used. The resin-bound peptide was N-α-deprotected and acetylated by 
treatment with Ac2O/CH2Cl2/DIPEA (5 mL, 1:8:1 v/v/v), for 1 h at room temperature. The resin 
was washed with DMF (4 x 7 mL), CH2Cl2 (4 x 7 mL), MeOH (4 x 7 mL), Et2O (4 x 7 mL). 
Cleavage from the resin was achieved by treatment with TFA/TIPS/H2O (10 mL, 95:2.5:2.5, 
v/v/v) for 1 h. All of the solvent was removed under vacuum and the tripeptide was dissolved 
in the minimum quantity of TFA and precipitated with cold Et2O. The solid was isolated by 
centrifugation, to give (77) as a yellow solid (52 mg, 68%); RP-HPLC (analytical system, 
gradient 1) Rt = 10.0 min. [found (ES+) 873.3380 [M+Na]
+, C45H50N6O11Na requires 
873.3429]. 
 
Attempted preparation of Ac-Arg( Z, CONHMe)-MePhe-Asp-OBn (75)  
 
 
A solution of (74) (6.0 mg, 7.8 µmol) in THF (0.5 mL) was treated with a solution of 2M 
methylamine in THF (19 µL, 39 µmol). The reaction mixture was stirred at 65 °C overnight. 
After 24 h and 48 h respectively, the reaction showed no change as shown by HPLC and extra 
methylamine (5 eq) was added. After 72 h, HPLC again showed no further change. Mass 
spectrometry at this stage also showed only the starting material. 
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A solution of (77) (21 mg, 24 µmol) in THF (1 mL) was treated with a 2M solution of 
methylamine in THF (60 µL, 0.12 mmol). The reaction mixture was stirred at 65°C overnight. 
After 24 h and 48 h respectively, HPLC showed the partial disappearance of the starting 
material and formation of a new peak. Extra methylamine (5 eq) was added.  After 72 h, little 








Fmoc-Arg(Z)2-OH (79) (113 mg, 0.170 mmol), EDC.HCl (67 mg, 0.30 mmol), HOBt (87 mg, 
0.23 mmol) and MeNH2.HCl (116 mg, 0.24 mmol) were dissolved in anhydrous CH2Cl2 (7 
mL). The reaction mixture was then treated with DIPEA (0.9 mL, 0.56 mmol) and stirring was 
continued at room temperature for 16 h. After disappearance of the starting material as shown 
by TLC (10% MeOH/CH2Cl2), all of the solvents were evaporated and the crude material was 
purified by column chromatography using 3-4% MeOH/CH2Cl2 eluent. The desired compound 
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was isolated (80) as a white solid (102 mg, quantitative yield); Mp 180-182 °C; IR υmax (KBr 
disc) 3392, 3300 (NH),  2952 (CH), 1721, 1656, 1610 (C=O),  1445 (NH), 1259 (CO); 1H NMR 
(CDCl3, 400 MHz) δ  1.57-1.78 (4H,  m, 2 x Hβ, 2 x Hγ),  2.34 (3H, d, J 4.6 Hz, NH CH3), 
3.56-3.63 (1H, m, 1 x Hδ), 3.89-3.91 (1H, m, 1 x Hδ), 4.16 (1H, t, J 6.3 Hz, Fmoc-CH), 4.19-
4.27 (1H, m, Fmoc-CH2), 4.35-4.39 (1H, m, Fmoc-CH2), 4.53-4.58 (1H, m, Hα), 4.90 (1H, d, 
J 12.3 Hz, CH2Ph), 5.05 (1H, d, J 12.3 Hz, CH2Ph), 5.21-5.28 (2H, m, CH2Ph ), 6.41 (2H, br, 
NH), 7.19-7.41 (10H, m, 2 x Ph), 7.44-7.58 (2H, m,  Ar-H Fmoc), 7.70-7.75 (2H, m, Ar-H 
Fmoc), 9.36 (1H, br, NH), 9.48(1H, br, NH); 13C NMR  (CDCl3, 101 MHz) δ 24.35 (CH2β), 
25.79 (CH2γ), 47.22 (CH2δ), 54.23 (CH3N), 66.33 (CH Fmoc), 67.20 (CHα), 69.01 (CH2 
Fmoc), 119.83, 119.98, 124.77, 127.00, 127.50, 127.62, 128.17, 128.27, 128.32, 128.55, 
128.81, 128.93, 128.93 (CH=CH Ar), 134.47, 136.03, 141.31, 143.76, 143.88, 155.68, 156.05, 







Compound (80) (73 mg, 0.11 mmol) was dissolved in anhydrous DMF (6 mL) and was treated 
with Et2NH (124 µL, 1.10 mmol) at room temperature for 30 min. After consumption of the 
starting material as shown by TLC, the reaction mixture was then co-evaporated with toluene.  
The crude material (50 mg, 0.11 mmol) was dissolved in anhydrous CH2Cl2 (5 mL) and Ac2O 
(22.0 mg, 0.22 mmol) and DMAP (13.4 mg, 0.110 mmol) were added and then stirring was 
continued at room temperature. The reaction was checked by TLC (10% MeOH/CH2Cl2). After 
running the reaction for 16 h, the starting material was consumed and all the solvents were 
evaporated and the crude material purified by column chromatography using 5-10% 
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MeOH/CH2Cl2 eluent. The desired compound (81) was isolated as a white solid (46 mg, 78%); 
Mp 185-187°C; IR υmax (KBr disc) 3403, 3287 (NH), 2949 (CH), 1722, 1641 (C=O), 1254 
(CO); 1H NMR  (CDCl3, 400 MHz) δ  1.59-1.76 (4H,  m, 2 x Hβ, 2 x Hγ) 1.91 (3H, s, CH3CO),   
2.49 (3H, d, J 4.6 Hz, CH3NH), 3.81-3.88 (1H, m, 1 x Hδ), 4.05-4.12 (1H, m, 1 x Hδ), 4.48-
4.53 (1H, m, Hα),  5.11 (2H, d, J 12.3 CH2Ph), 5.18 (2H, J 12.3 Hz, CH2Ph) 5.24 (2H, s, 
CH2Ph), 6.57-6.58 (1H, br, NHCH3), 6.99 (1H, d, J 8.2 Hz, NHα), 7.31-7.39 (10H, m, 2 x Ph), 
9.37 (1H, br, NH), 9.49 (1H, br, NH); 13C NMR (CDCl3, 101 MHz) δ 21.27, 22.89, 24.12, 
26.48, 42.37, 50.66, 65.49, 67.28, 126.47, 126.52, 126.83, 127.02, 127.09, 132.72, 134.39, 
153.96, 159.34, 161.61, 168.16, 170.19; [found (ES+) 498.2356 [M+H]+, C25H32N5O6 requires 
498.2352]. 
 





A stirred solution of (81) (20 mg, 40 µmol) in anhydrous CHCl3 (2 mL), was treated with 
benzylamine (8.7 µL, 0.08 mmol) and stirring was continued at reflux for 16 h. The solvent was 
evaporated to give a white solid. The residue was dissolved in CH2Cl2 and purified by column 
chromatography (MeOH/CH2Cl2 gradient) to give a white solid (18 mg, 92%); Rf 0.4 (10% 








A: MeNH2, THF, rt, 16 h; B: as A, using CHCl3. 
 
Method A:  A stirred solution of (81) (20 mg, 40 µmol) in anhydrous THF (2 mL), was treated 
with 2M solution of methylamine in THF (0.1 mL, 0.2 mmol) and stirring was continued at 
room temperature. The reaction was monitored by TLC. After 4 h the the reaction showed no 
change by TLC and an extra 5 eq of 2M solution of methylamine in THF (0.1 mL, 0.2 mmol) 
was added. After 16 h, no further change had been indicated by HPLC.  Analysis by HPLC and 
1H NMR showed unchanged starting material.  
 
Method B: A stirred solution of (81) (20 mg, 40 µmol) in anhydrous CHCl3 (2 mL), was treated 
with 2M solution of methylamine in THF (0.1 mL, 0.2 mmol) and stirring was continued at 
room temperature. The reaction was monitored by TLC. After 4 h the reaction showed no 
change and further 2M methylamine in THF (0.1 mL, 0.2 mmol), was added.  After 16 h, again 






7.2.3. Approaches to alternative reagents for the direct conversion of Orn (or simple 
amines) to Arg(MC) and analogues 




A solution of bis(trichloromethyl)carbonate (0.78 g, 26 mmol) in anhydrous CH2Cl2 (10 mL) 
was cooled to -70 °C under N2 and pyridine (0.62 mL, 7.8 mmol) and N-methylbenzylamine 
(88) (1.0 mL, 7.8 mmol) were added. The reaction mixture was allowed to warm up to room 
temperature and was monitored by TLC (10% MeOH/CH2Cl2). After running the reaction for 
2 h the starting material was consumed, then the reaction was neutralized with 1M aq. HCl (10 
mL) and it was extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried 
over MgSO4, filtered and the solvent was evaporated to give an oil that crystallised at room 
temperature (90) (1.56 g, quantitative yield); 1H NMR  (CDCl3, 400 MHz) δ two rotamers: 2.99 
(1.25H, s, minor rotamer CH3N), 3.06 (1.75H, s, major rotamer CH3N), 4.56 (1.17H, s, major 










A:  (90), NaH, THF, 0 °C to rt, 3 h; B: as A, but using fresh NaH; C: (90), DMAP, DIPEA, CH2Cl2, rt, 16 h; D: 
(90), NaH, THF, 0 °C to rt, 16 h. 
 
Method A: A stirred solution of (91) (0.22 g, 0.90 mmol) in anhydrous THF (9 mL) was purged 
under N2 and was cooled to 0 °C. 60% NaH (55 mg, 1.4 mmol) was then added. The reaction 
mixture was stirred at 0 °C for 10 min, then warmed up to room temperature, after which (90) 
(0.50 g, 2.7 mmol) in anhydrous THF (3 mL) was added to the reaction mixture, then the stirring 
was continued with heating at reflux. The reaction was monitored by TLC (30% 
EtOAc/petroleum ether). After running the reaction for 3 h, a new spot appeared on TLC. The 
reaction mixture was diluted into EtOAc (50 mL), then neutralized with sat. aq. NH4Cl (30 
mL). The organic layer was separated and extracted with H2O (50 mL), dried over Na2SO4, 
filtered and the solvent evaporated to give a white solid. The crude material was purified by 
column chromatography using 5-25% EtOAc/ petroleum eluent. Analysis by 1H NMR indicated 
the presence of both starting materials. 
 
Method B: A stirred solution of (91) (110 mg, 0.45 mmol) in anhydrous THF (4.5 mL), was 
purged under N2, cooled to 0 °C, then fresh 60% NaH ( 26 mg, 0.68 mmol) was added. The 
reaction mixture was stirred at 0 °C for 10 min, then warmed up to room temperature, after 
which  (90) (250 mg, 1.36 mmol) in anhydrous THF (3 mL) was added to the reaction mixture 
via a cannula. Stirring was continued overnight. The reaction was monitored by TLC (30% 
EtOAc/petroleum). After running the reaction for 16 h, a new spot appeared. The reaction 
mixture was diluted into EtOAc (50 mL), then neutralized with sat. aq. NH4Cl (30 mL) and the 
organic layer was separated and extracted with H2O (50 mL), dried over Na2SO4, filtered and 
the solvent evaporated to give a white solid. The crude material was purified by column 
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chromatography using 30-40% EtOAc/ petroleum ether eluent. Analysis by 1H NMR revealed 
both starting materials: (90) and (91). 
 
Method C: A stirred solution of (91) (96 mg, 0.39 mmol) in anhydrous CH2Cl2 (20 mL), was 
purged under N2, then (90) (180 mg, 0.93 mmol), DMAP (9.6 mg, 78 µmol) and DIPEA 
(171µL, 0.983 mmol), were added to the reaction mixture. Stirring was continued at room 
temperature overnight, and the reaction was monitored by TLC (30% EtOAc/petroleum ether). 
After running the reaction for 16 h, a new spot with a lower Rf appeared. The reaction mixture 
was neutralized with 1M aq. solution of HCl (30 mL), then extracted with CH2Cl2 (2 x 20 mL). 
The combined organic extracts were dried over Na2SO4, filtered and the solvents evaporated to 
give a yellow solid.  Analysis by 1H NMR was not consistent with formation of the expected 
product. 
 
Method D: A stirred solution of (91) (220 mg, 0.90 mmol) in freshly distilled THF (9 mL), was 
purged under N2 and cooled to 0°C. Fresh NaH  (131 mg, 3.28 mmol assumed) was added to 
the reaction mixture, then the stirring was continued at 0 °C for 10 min, followed by warming 
up to room temperature. Compound (90) (500 mg, 2.73 mmol) in anhydrous THF (3 mL) was 
added to the reaction mixture via a cannula and then stirring was continued overnight. The 
reaction was monitored by TLC (30% EtOAc/petroleum ether). After running the reaction for 
16 h, a new spot with a lower Rf appeared. The reaction mixture was diluted into EtOAc (50 
mL) and then neutralized with sat. aq. NH4Cl (30 mL). The organic layer was separated and 
extracted with H2O (50 mL), dried over Na2SO4, filtered and the solvents evaporated to give a 
brown oil. The crude material was purified by column chromatography using 7-10% 
EtOAc/petroleum ether eluent to give a yellow oil (193 mg, 84%). Analysis by 1H NMR showed 








IRυmax (thin film): 3150, 3128, 3030 (NH), 1650; 1H NMR  (CDCl3, 400 MHz) δ 3.14 (3H, br, 
CH3N ), 4.84 (2H, br, NH2),  6.34-6.36 (1H, m, pyrazole ring), 7.29-7.37 (5H, m, Ar), 7.63 (1H, 
br,  pyrazole ring), 8.17-8.19 (1H, m, pyrazole ring); 13C NMR (CDCl3, 101 MHz) δ 35.69 
(CH3N), 53.43 (CH2 benzylic), 106.42, 125.83, 126.63, 126.85, 127.64, 127.99 (CH Ar), 
130.19, 130.85, 135.42, 140.82, 151.33 (C quaternary and pyrazole ring) (C=O); [found (ES+) 






A stirred solution of guanidine hydrochloride (67) (2.39 g, 25 mmol) in H2O (25 mL) was 
treated with sodium hydroxide (4 g, 0.1 mol) and the reaction mixture was cooled to 0 °C, then 
1,4-dioxane (50 mL) was added. Di-tert-butyl dicarbonate (12 g, 55 mmol) was added in one 
portion with vigorous stirring.  After 2 h, the reaction was allowed to warm up to room 
temperature overnight. The solvents were evaporated and then the crude material was purified 
by column chromatography, using 2% MeOH/CH2Cl2 eluent, to give (95) as a white solid (1.4 
g, 22%); Mp 140-142 °C (lit,161 144°C); IR υmax (KBr disc) 3415, 3120 (NH), 2983, 2937 (CH), 
1732 (C=O), 1681, 1643, 1457, 1401 (NH), 1148 (CO); 1H NMR (CDCl3, 400 MHz) δ 1.40 






A stirred solution of   (95) (200 mg, 0.760 mmol) in anhydrous THF (1 mL) was purged under 
an N2 atmosphere for 10 min, then treated with 2M methylamine  in THF (3.8 mL, 7.6 mmol). 
The reaction mixture was heated at reflux and the reaction was monitored by TLC. After 
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running the reaction for 16 h, a new spot appeared, as shown by TLC (4% MeOH/CH2Cl2). The 
solvent were removed under vacuum to give an oil, which was purified by column 
chromatography, using MeOH/CH2Cl2 eluent. This gave (96) (6.7 mg, 4%) plus unchanged 
starting material (175 mg, 87%). 1H NMR (CDCl3, 400 MHz) δ 1.47 (9H, s, (C(CH3)3), 2.79 
(3H, d, J 4.8, NHCH3), 5.60 (2H, br, 2 x NH), 8.40 (2H, br, 2 x NH); [found (ES+) 224.1006 
[M+Na]+, C8H16N3NaO3 requires 224.1006]. 
 




A stirred solution of (95) (200 mg, 0.760 mmol) in anhydrous THF (2 mL) was purged under 
an N2 atmosphere, then was treated with N-benzylmethylamine (88) (276 mg, 2.26 mmol) and 
the reaction mixture was stirred at reflux overnight. The reaction was monitored by TLC. After 
running the reaction for 72 h, TLC showed that the starting material was replaced by a new 
lower running spot Rf 0.62 (4% MeOH/CH2Cl2). The solvent were evaporated and the residue 
was purified by column chromatography using 0-2% MeOH/CH2Cl2 eluent, to give (97) as an 
oil (182 mg, 78%); IR υmax (thin film): 3397, 3251, 3205 (NH), 2977, 2936 (CH), 1719, 1642 
(C=O), 1152 (CO);  1H NMR (CDCl3, 400 MHz) δ two rotamers: 1.47-1.49 (9H, m, (C(CH3)3), 
2.87-3.02 (3H, m, NCH3), 4.57 (1H, br, CHPh) 4.71 (1H, br, CHPh), 7.18-7.27 (5H, m, Ph), 
7.95 (2H, br,  2 x NH), 9.40 (1H, br, NH); 13C NMR  (CDCl3, 101 MHz) δ two rotamers 27.92 
(C(CH3)3), 28.00 (C(CH3)3), 32.92 (N-CH3), 34.59 (N-CH3), 50.99 (CH2-Ar), 52.70 (CH2-Ar), 
82.46 (C(CH3)3), 82.82 (C(CH3)3), 126.92, 127.06, 127.46, 128.39 (CH Ar), 138.18, 138.47 (C 
quaternary), 153.18, 156.57, 164.65 (C=O, C=N); [found (ES+) 329.1591 [M+Na]+, 














A stirred solution of (95) (200 mg, 0.76 mmol) in anhydrous THF (2 mL) was purged under an 
N2 atmosphere, then was treated with 4-methoxy-N-benzylmethylamine (94) (345 mg, 2.28 
mmol) and the reaction mixture was stirred at reflux overnight. The reaction was monitored by 
TLC (5% MeOH/CH2Cl2). After running the reaction for 16 h the starting material disappeared. 
The solvent was evaporated and the residue was purified by column chromatography using 0-
2% MeOH/CH2Cl2 gradient, to give an oil (282 mg). Analysis by 
1H NMR revealed the desired 
compound plus the presence of the starting material (94). The material was again purified using 
20-40% EtOAc/petroleum ether eluent to give an oil, which crystallised (97) (219 mg, 86%); 
Mp 125-127 °C; 1H NMR  (CD3OD, 500 MHz) δ two rotamers 1.49 (4.5H, s, (C(CH3)3), 1.50 
(4.5H, s, (C(CH3)3), 2.78 (1.5H, br, NCH3 rotamer),  2.94 (1.5H, br, NCH3 rotamer), 3.31 (1H, 
br, NH), 3.76 (3H, s, OCH3), 4.45 (1H, br, CH2Ar rotamer) 4.68 (1H, br, CH2Ar rotamer), 6.85 
(2H, d, J 8.2 Hz, HAr), 7.16 (2H, d, J 8.2 Hz, ArH); 13C NMR  (CDCl3, 101 MHz) δ two 
rotamers 27.91 (C(CH3)3), 28.00 (C(CH3)3), 32.73 (N-CH3), 34.40 (N-CH3), 50.38 (CH2-Ar), 
52.08 (CH2-Ar), 55.20 (OCH3), 82.37 (C(CH3)3), 82.52 (C(CH3)3), 113.78, 113.80, 128.39, 
128.52, 128.81 130.43 (CH Ar), C quaternary),  156.48, 158.61, 159.01, 164.51 (2 x C=O, 2 x 
C=N); [found (ES+) 359.1688 [M+Na]+, C16H24N4NaO4 requires 359.1690]. 
 






Method A: A stirred solution of (68) (1.00 g, 3.05 mmol) in anhydrous THF  (20 mL) was 
purged under an N2 atmosphere for 10 min, then was treated with 2M solution of methylamine 
in THF (7.6 mL, 15 mmol) and the reaction mixture was stirred at reflux. The reaction was 
monitored by TLC (5% MeOH/CH2Cl2). After running the reaction for 2 h 30 min TLC still 
showed remaining starting material, therefore another 2.5 eq of methylamine (3.8 mL, 7.6 
mmol) was added to the reaction mixture. After running the reaction for 16 h, the solvent was 
evaporated. Analysis by 1H NMR revealed the starting material. 
 
Method B: A stirred solution of (68) (200 mg, 0.611 mmol) in anhydrous THF  (1 mL) was 
purged under an N2 atmosphere for 10 min, then it was treated with a 2M solution of  
methylamine in THF (3.05 mL, 6.11 mmol) and the reaction mixture was stirred at reflux 
overnight. The reaction was monitored by TLC (5% MeOH/CH2Cl2). After running the reaction 
for 16 h no change was noticed on TLC. Analysis by 1H NMR revealed the unchanged starting 
material. 
 




A stirred solution of (68) (200 mg, 0.611 mmol) in anhydrous THF (4 mL) was purged under 
an N2 atmosphere for 10 min, then it was treated with (88) (0.24 mL, 6.11 mmol) and the 
reaction mixture was stirred at reflux. The reaction was monitored by TLC (2% 
MeOH/CH2Cl2). After running the reaction for 16 h a new spot appeared on TLC. The solvent 
was evaporated. The residue was dissolved in CH2Cl2 and purified by column chromatography, 
using 2-4% MeOH/CH2Cl2 as eluent, to give (100) as  an oil (18.4 mg, 9%), plus unchanged 
starting material (144 mg 72%); 1H NMR (CDCl3, 400 MHz) δ two rotamers: 2.87 (1.5H, s, 
NCH3), 2.91 (1.5H, s, NCH3), 4.50 (2H, br, CH2Ph),  5.19 (2H, s, CH2Ph), 7.17-7.51 (10H, m, 
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2 x Ph); 13C NMR  (CDCl3, 101 MHz) δ 52.29 (N-CH3), 52.57 (N-CH3), 67.21 (CH2-Ar), 
127.26, 127.34, 127.55, 127.81, 127.93, 128.07, 128.15, 128.43, 128.55, 136.72, 137.36 (CH 
Ar, C quaternary, C=NH), 156.30 (C=O), 156.72 (C=O); found [(ES+) 363.1428 [M+Na]+, 
C18H20N4O3Na requires 363.1430]. 
 




A stirred solution of (68) (500 mg, 1.53 mmol) in anhydrous THF (10 mL) was purged with N2, 
then treated with (94) (693 mg, 4.59 mmol) and the stirring continued at reflux overnight. The 
solvent was evaporated. The residue was dissolved in CH2Cl2 and then purified by column 
chromatography using petroleum ether to give a white solid (71.7 mg, 13%), 1H NMR  (CDCl3, 
400 MHz) δ two rotamers: 2.85 (1.5H, s, N-CH3  rotamer), 2.88 (1.5H, s, N-CH3 rotamer), 3.80 
(3H, s, OMe), 4.44 (2H, br, CH2-Ar), 5.19 (2H, s, CH2-Ar), 6.85-6.87 (2H, m, ArH), 7.10-7.22 
(2H, m, ArH), 7.30-7.38 (5H, m, Ph). 13C NMR (CDCl3, 101 MHz) δ two rotamers 33.34 (N-
CH3), 34.14 (N-CH3), 51.68 (CH2-Ar), 51.96 (CH2-Ar), 55.22 (OCH3), 67.14 (CH2-Ar), 113.90,  
127.80, 127.93, 128.44, 128.70, 129.23, 129.38, 129.49, 136.78, 136.85 (CH Ar, C quaternary), 











A stirred solution of (98) (200 mg, 0.600 mmol) in anhydrous CH2Cl2 (5 mL) was cooled to 0 
°C under an N2 atmosphere, then Boc2O (143 mg, 0.650 mmol) and DIPEA (115 µL, 0.658 
mmol), were added to the reaction mixture. The resulting solution was allowed to warm up to 
room temperature overnight. The reaction was monitored by TLC. After running the reaction 
for 48 h a new spot with higher Rf 0.80 (1% MeOH/CH2Cl2) appeared. The solvent was 
evaporated and the residue was purified by column chromatography using 10-30% 
EtOAc/petroleum ether eluent. Compound (103) was isolated as a white solid (36 mg, 14%), 
plus the unchanged starting material (132 mg, 66%); Mp 120-122 °C; 1H NMR  (CDCl3, 400 
MHz) δ two rotamers: 1.47 (9H, s, (C(CH3)3), 1.49 (9H, s, (C(CH3)3), 2.84 (1.5H, s, N-CH3), 
3.16 (1.5H, s, N-CH3 ), 3.78 (3H, s, OMe), 4.49 (1H, s, Ar-CH2), 4.83 (1H, s, Ar-CH2), 6.83 
(2H, d, J 8.4 Hz, ArH), 7.19 (1H, d, J 8.5 Hz, ArH), 7.23 (1H, d, J 8.5 Hz, ArH), 10.01-10.21 
(1H, m, NH), 12.17-12.47 (1H, m, NH);  13C NMR  (CDCl3, 125 MHz) δ two rotamers: 27.01 
(C(CH3)3 ), 27.03 (C(CH3)3), 31.62 (N-CH3) 33.85 (N-CH3), 49.40 (Ar-CH2), 51.58 (Ar-CH2), 
55.23 (OMe), 80.88(C(CH3)3), 82.57 (C(CH3))3), 112.70, 112.83,  128.02, 128.44, 147.72, 
148.19, 148.49, 151.86 (CH Ar, C quaternary), 157.78, 162.30, 162.38  2 x C=O, C=N); [found 





Attempted preparation of tert-butyl (N-(4-methoxybenzyl)(methyl)carbamoyl-N’-




A: NaH, chlorobenzene, 0 °C, then Tf2O, -45 °C to rt, 16 h; B: as A, using DIPEA in CH2Cl2. 
Method A: A stirred solution of (98) (69 mg, 0.20 mmol) in anhydrous chlorobenzene (4 mL) 
was cooled to 0 °C under an N2 atmosphere, then was treated with 60% NaH (27 mg, 0.66 
mmol) and the stirring continued at 0 °C for 1 h, after which the reaction mixture was cooled 
to -45 °C and triflic anhydride was added and stirring continued for 1 h. The mixture was then 
allowed to warm to room temperature overnight. TLC showed that the starting material was 
replaced by a lower running spot Rf 0.50 (4% MeOH/CH2Cl2). The reaction was quenched with 
2M aq. KHSO4 (7 mL) and extracted with CH2Cl2 (4 x 20 mL). The combined organic extracts 
were dried over MgSO4, filtered and the solvent evaporated to give an oil (47 mg). Analysis by 
1H NMR of the crude product was not consistent with formation of the expected compound. 
 
Method B: A stirred solution of (98) (500 mg, 1.49 mmol) in anhydrous CH2Cl2 (10 mL) was 
cooled to 0 °C under nitrogen atmosphere, then it was treated with DIPEA (0.27 mL, 1.56 
mmol) and the stirring continued at 0 °C for 1 h. The reaction mixture was then cooled to -45 
°C and triflic anhydride was added and stirring continued for 1 h and then was allowed to warm 
to room temperature overnight. TLC showed that the starting material was replaced by a lower 
running spot Rf 0.60 (6% MeOH/CH2Cl2). The reaction was quenched with 2M aq. KHSO4 (7 
mL) and extracted with CH2Cl2 (4 x 20 mL). The combined organic extracts were dried over 
MgSO4, filtered and the solvent evaporated to give an oil (360 mg). Analysis by 
1H NMR of 
the crude product was not consistent with formation of the expected compound. 
 
 
7.3. Approaches to Amoa- Key component of banyasin A. 
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A stirred solution of (106) (3.00 g,1.70 mmol) in anhydrous THF (30 mL) was cooled to -78 
°C under a N2 atmosphere, then 2.5 M BuLi in hexanes (7.0 mL,18.0 mmol) was added 
dropwise and stirring continued for 30 min. Freshly distilled propanoyl chloride (1.62 mL,19.0 
mmol) was added dropwise to the clear reaction mixture. The resulting solution was left to stir 
at -78 °C for 30 min and then was allowed to warm to room temperature overnight. TLC showed 
that the starting material was replaced by a new higher running spot, Rf 0.80 (20% 
EtOAc/petroleum ether). The reaction was quenched with sat. aq. NH4Cl (40 mL), then the 
organic layer was extracted with aq. NaOH (2 x 20 mL) and brine (2 x 20 mL). The combined 
organic extracts were dried over MgSO4, filtered and the solvent evaporated to give a colourless 
oil. The crude material was purified by column chromatography (15-30% EtOAc/petroleum 
ether gradient) to give (107) as an oil (3.33 g, 84%); [α]20D = +54.1 (c 0.8 in CHCl3), (lit [α]20D 
= +44.8 (c 0.25 in CHCl3)
252; IR υmax (thin film): 2983, 2940 (CH), 1781, 1703 (C=O), 1361, 
1246 (CO) 1H NMR  (CDCl3, 270 MHz) δ 0.90 (3H, d, J 6.6 Hz, CH3-oxazolidinone ring), 
1.19 (3H, t, J 7.4 Hz, CH3-CH2), 2.90-3.04 (2H, m, CH3-CH2), 4.76 (1H, qn, J 6.6 Hz, CH3-











A stirred solution of (107) (369 mg, 1.58 mmol) in anhydrous CH2Cl2 (20 mL), undera N2 
atmosphere was cooled to 0 °C, 1M TiCl4 in CH2Cl2 solution (1.66mL, 1.66 mmol) was added 
dropwise and the  solution was allowed to stir for 15 min at 0 °C. Freshly distilled DIPEA (303 
µL, 1.74 mmol) was added dropwise to the reaction mixture and stirring continued for 40 min. 
Anhydrous N-methylpyrrolidin-2-one (151 µL, 1.58 mmol) was added at 0 °C, followed by the 
addition of freshly distilled hexanal (379 µL, 3.16 mmol). The deep red colour of the enolate 
solution disappeared and was replaced by a pale yellow colour. The reaction was monitored by 
TLC (10% EtOAc/petroleum ether). After 5 h, the starting material was consumed. The reaction 
was quenched with half-sat. aq. NH4Cl (40 mL), then the aqueous layer was extracted with 
CH2Cl2 (2 x 40 mL). The combined organic extracts were dried over Na2SO4, filtered and the 
solvent evaporated. The crude material was dissolved in CH2Cl2, then purified by column 
chromatography using 15-20% EtOAc/petroleum ether eluent to give (122) (388 mg, 74%) as 
a pale yellow oil, which crystallized at room temperature; [α]20D = +23.4 (c 0.6  in CHCl3),  (lit 
[α]19D = +24.9 (c 0.6 in CHCl3)184 ); Mp 82-84 °C,  lit Mp 90-91.5 °C184; IR υmax (KBr disc): 
3452 (OH),  2939, (CH), 1792, 1689 (C=O), 1460 (Ar), 1370, 1343, 1249, 1190 (CO); 1H NMR  
(CDCl3, 400 MHz) δ 0.89-0.92 (6H, m, CH3-CH2, CH3-oxazolidinone ring), 1.24 (3H, d, J 7.0 
Hz, CH3-CH-CHOH), 1.36-1.58 (8H, m, (CH2)4), 2.83 (1H, br, CH-OH), 3.78 (1H, qd, J  7.0, 
2.7 Hz, CH3-CH-CHOH ), 3.95-3.97 (1H, m, CH3-CH-CH-OH), 4.80 (1H, qn, J 6.8 Hz, CH3-
CH-oxazolidinone ring), 5.68 (1H, d, J 7.3 Hz, Ph-CH-oxazolidinone ring), 7.30-7.44 (5H, m, 
Ph); 13C NMR  (CDCl3, 101 MHz) δ 10.20 (CH3-CH2-CH2), 14.02 (CO-CH(CH3)-CH), 14.37 
(CH3-oxazolidinone ring), 22.58 (CH3-CH2-CH2), 25.69 (CH3-CH2-CH2), 31.78 (CH2-CH2-
CHOH), 33.91 (CH2-CH2-CHOH), 42.21 (CO-CH-(CH3)-CHOH), 54.78 (CO-CH-(CH3)-
CHOH), 71.62 (CH from oxazolidinone), 78.96 (CH from oxazolidinone), 125.64, 128.76, 
128.86 (CH Ar), 133.20 (C quaternary), 152.64 (C=O), 177.45 (CO ester); [found (ES+) 




Via Mitsunobu reaction 





A: Ph3P, DEAD, DPPA, CH2Cl2, rt, 16 h; B: as A, 0 °C to rt, 16 h; C: as A, using THF, 16 h. 
 
Method A:  A stirred solution of (122) (150 mg, 0.45 mmol), in anhydrous CH2Cl2 (4 mL), was 
stirred at room temperature. Triphenylphosphine (130 mg, 0.50 mmol) and diethyl 
azodicarboxylate (78 µL, 0.50 mmol) were added and stirring was continued at room 
temperature for 15 min. The reaction mixture was then treated with diphenylphosphoryl azide 
(107 µL, 0.50 mmol) and stirring was continued at room temperature overnight. After running 
the reaction for 16 h, a new spot with a higher Rf appeared, as shown on TLC (15% 
EtOAc/petroleum). The solvent was evaporated and the crude material was purified by column 
chromatography, using 0-5% EtOAc/petroleum. This gave (123) as a colourless oil (12 mg, 
7%) plus unchanged starting material (140 mg, 93%); IR υmax (thin film): 2935, 2864 (CH), 
2104 (N3), 1783, 1699 (CO), 1457, 1345, 1242, 1195 (CO); 1H NMR (CDCl3, 400 MHz) δ 
0.78-0.93 (6H, m, CH3-CH2, CH3-oxazolidinone ring), 1.20 (3H, d,  J 7.0 Hz, CH3-CH-CHN3), 
1.23-1.70 (8H, m, (CH2)4), 3.69 (1H, td, J 9.0, 2.9 Hz, CH-CH(N3)-CH2), 3.86 (1H, dq, J 9.3, 
6.9 Hz,  CH3-CH-CH(N3), 4.82 (1H, qn, J 6.7 Hz, CH3-CH-oxazolidinone ring), 5.70 (1H, d, J 
7.1 Hz, Ph-CH-oxazolidinone ring), 7.30-7.42 (5H, m, Ph); 13C NMR  (CDCl3, 101 MHz) δ 
12.99 (CH3-CH2), 13.32 (CH3-CO), 13.61 (CH3 oxazolidinone), 21.50 (CH3-CH2), 24.24 (CH2-
CH2), 30.24 (CH2-CH2) 30.56 (CH2-(CH)-N3), 41.28 (CH(C=O)), 54.01 (CH2-(CH)-N3), 63.81 
(CH oxazolidinone), 78.00 (CH oxazolidinone), 124.58, 127.73 127.78 (CH Ar), 132.13 (C 
quaternary), 151.59 (C=O), 173.68 (C=O ester); found [(ES+) 381.1913 [M+Na]+, 




Method B:  A stirred solution of (122) (140 mg, 0.420 mmol) in anhydrous CH2Cl2 (4 mL), 
was purged with N2, then cooled to 0 °C. Triphenylphosphine (121 mg, 0.46 mmol) and diethyl 
azodicarboxylate (73 µL, 0.46 mmol) were added and stirring was continued at 0 °C, for 15 
min. The reaction mixture was then treated with diphenylphosphoryl azide (100 µL, 0.462 
mmol) and allowed to warm up to room temperature overnight. After running the reaction for 
16 h, a new spot with a higher Rf appeared, as shown on TLC (10% EtOAc/petroleum ether). 
The solvent was evaporated and the crude material was purified by column chromatography, 
using 0-5% EtOAc/petroleum ether eluent. This gave (123) as an oil (9.4 mg, 6%) plus the 
unchanged starting material (136 mg) alongside with some impurities. 
 
Method C: A stirred solution of triphenylphosphine (102 mg, 0.43 mmol) in anhydrous THF 
(4 mL), was purged with N2. Diethyl azodicarboxylate (75 µL, 0.43 mmol) was added and 
stirring was continued at room temperature for 20 min. The reaction mixture was treated with 
(122) (130 mg, 0.39 mmol) and stirred for 15 min, followed by addition of diphenylphosphoryl 
azide (93 µL, 0.43 mmol). The reaction was stirred at room temperature overnight. After 
running the reaction for 16 h, a new spot with a higher Rf appeared, as showed on TLC (10% 
EtOAc/petroleum ether). The solvent was evaporated and the crude material was dissolved in 
CH2Cl2 and purified by column chromatography, using 0-30% EtOAc/petroleum ether eluent. 
Only starting material was recovered (80 mg, 78%).  
 
Via the tosylate 
Attempted preparation of (2R,3S)-2-methyl-1-((4R,5S)-4-methyl-2-oxo-5-




A: TsCl, pyridine, 0 °C, 3 h; B: TsCl, pyridine at 0 °C then heated at 50 °C. 
 
Method A: A stirred solution of (122) (76 mg, 0.23 mmol) in anhydrous pyridine (4 mL) under 
a N2 atmosphere was cooled to 0 °C and treated with tosyl chloride (48 mg, 0.25 mmol). After 
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running the reaction for 3 h, a new spot with a higher Rf appeared, as showed on TLC (10% 
EtOAc/petroleum ether). The reaction was quenched with 1M aq.  HCl (20 mL) at 0 °C and 
was extracted with CHCl3 (2 x 20 mL). The combined organic layers were washed with brine 
(2 x 20 mL). The combined organic extracts were dried over MgSO4, filtered and the solvent 
evaporated to give a brown oil (73 mg). Analysis by 1H NMR indicated the presence of 
unchanged starting material.   
 
Method B: Recovered from method A (122) (73 mg, 0.22 mmol) in anhydrous pyridine (2 mL) 
under a N2 atmosphere was cooled to 0 °C and treated with a solution of tosyl chloride (46 mg, 
0.24 mmol) diluted in anhydrous pyridine (2 mL). Stirring was continued at 0 °C for 5 min and 
then the mixture was heated at 50 °C, overnight. The reaction was monitored by TLC (10% 
EtOAc/petroleum ether). After running the reaction for 4 days, a new spot with a higher Rf 
appeared. The reaction was quenched with 1M aq. HCl (20 mL) at 0 °C and was extracted with 
CHCl3 (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL). The 
combined organic extracts were dried over MgSO4, filtered and the solvent evaporated to give 
a yellow oil (66 mg). Analysis by 1H NMR indicated the presence of unchanged starting 
material only.  
 
Via the mesylate 
(2R,3S)-2-Methyl-1-((4R,5S)-4-methyl-2-oxo-5-phenyloxazolidin-3-yl)-1-oxooctan-3-yl 




A stirred solution of (122) (100 mg, 0.30 mmol) in anhydrous CH2Cl2 (1 mL), was cooled to 0 
°C under a N2 atmosphere then treated with anhydrous Et3N (84 µL, 0.60 mmol). After 3 min, 
methanesulfonyl chloride (24 µL, 0.30 mmol) was added. After running the reaction for 3 h, 
the reaction mixture was extracted with sat. aq. NaCl (2 x 10 mL) and the aqueous phase was 
separated, then extracted with CH2Cl2 (2 x 10 mL). The combined organic extracts were dried 
over MgSO4, filtered and the solvent evaporated to give (130) (121 mg, 98%)  as a brown oil, 
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which was used for the next step; IR υmax (thin film) 1774, 1702 (C=O), 1365, 1174 (SO2); 1H 
NMR  (CDCl3, 400 MHz) δ 0.80-0.85 (6H, m, CH3-CH2, CH3-oxazolidinone), 1.14 (3H, d,  J 
6.9 Hz, CH3-CH-CH(OSO2), 1.24-1.78 (8H, m, (CH2)4), 2.95 (3H, s, CH3-SO2), 3.96 (1H, qd, 
J 7.0, 2.8 Hz, CH3-CH-CH(OSO2)), 4.59-4.66 (1H, m, CH3-CH-CH(OSO2)), 5.02-5.06 (1H, m, 
CH3-CH-oxazolidinone ring), 5.66 (1H, d, J 7.2 Hz, Ph-CH-oxazolidinone ring), 7.21-7.34 (5H, 
m, Ph).  
 
Attempted preparation of (4R,5S)-3-((2R,3R)-3-azido-2-methyloctanoyl)-4-methyl-5-




Method A: A stirred solution of (130) (120 mg, 0.30 mmol) in anhydrous DMF (2 mL), under 
N2, was treated with sodium azide (57 mg, 0.87 mmol), dissolved in DMSO (1 mL) and 15-
crown-5 (6.0 µL, 0.03 mmol). Stirring was continued at 70 °C and the reaction was monitored 
by TLC (20% EtOAc/petroleum ether). After running the reaction for 3 h, the starting material 
was consumed. The reaction mixture was allowed to cool to room temperature, then sat. aq. 
NaCl (5 mL) was added, the mixture was extracted with CH2Cl2 (2 x 10 mL). The combined 
organic extracts were dried over Na2SO4, filtered and the solvent evaporated to give a yellow 
oil. The crude material was purified by column chromatography using 1-5% EtOAc/petroleum 
ether eluent) to give (123) as an oil (28 mg, 27%) and the eliminated product (131) as an oil (40 
mg, 42%); IR υmax (thin film): 2929, 2861 (CH), 2103 (C-C), 1786, 1683 (C=O), 1456 (Ar), 










1H NMR  (CDCl3, 400 MHz) δ 0.79-0.88 (6H, m, CH3-CH2, CH3-oxazolidinone ring), 1.22-
1.29 (4H, m, CH2-CH2), 1.35-1.41 (2H, m, CH2), 1.83 (3H, d, J 1.3 Hz, CH3-C(C=O)=CH), 
2.11 (2H, q, J 7.2 Hz C=CH-CH2-CH2), 4.62-4.68 (1H, m, CH3-CH-oxazoline ring), 5.58 (1H, 
d, J 7.4 Hz, Ph-CH-oxazolidinone ring), 5.97-6.01 (1H, m, CH3-C(C=O)=CH-CH2), 7.20-7.23 
(2H, m, H-Ar), 7.29-7.36 (2H, m, H-Ar); [found (ES+) 316.1892 [M+H]+, C19H26NO3 requires 
316.1907]. 
 
Method B: A stirred solution of (130) (66 mg, 0.16 mmol) in anhydrous DMF (3 mL), under 
N2, was treated with sodium azide (31 mg, 0.87 mmol), followed by 15-crown-5 (334 µL, 0.016 
mmol). Stirring was continued at 40 °C and the reaction was monitored by TLC (20% 
EtOAc/petroleum ether). After running the reaction for 15 min, a TLC showed a new spot with 
higher Rf, plus the starting material. The reaction mixture was allowed to cool to room 
temperature, then sat. aq. NaCl (5 mL) was added and the mixture was extracted with CH2Cl2 
(2 x 10 mL). The combined organic extracts were dried over Na2SO4, filtered and the solvent 
evaporated to give a yellow oil. The crude material was purified by column chromatography 
using 1-7% EtOAc/petroleum eluent to give eliminated product (131) as an oil (9 mg, 18%) and 
also unchanged (127) (26 mg, 39%). 
 






A stirred solution of (122) (50 mg, 0.15 mmol) in anhydrous CH2Cl2 (2 mL) under N2, was 
cooled to 0 °C and then was treated with anhydrous pyridine (14 µL, 0.18 mmol).  Triflic 
anhydride (28 µL, 0.16 mmol) was added to the reaction mixture and the stirring was continued 
at 0 °C. The reaction was monitored by TLC (10% EtOAc/petroleum ether). After running the 
reaction mixture for 2 h 30 min, the starting material was consumed as shown by TLC. The 
reaction was quenched with cold 1M aq. HCl (10 mL) and sat. aq. NaHCO3 (10 mL), then the 
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aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined organic extracts were 
dried over Na2SO4, filtered and the solvent was evaporated to give (132) (43 mg, 62%) as an 
oil, which was used immediately. 
 





A stirred solution of (132) (43 mg, 0.09 mmol) in anhydrous DMF (5 mL), was treated with 
sodium azide (120 mg, 1.84 mmol) and stirring was continued at 60 °C. The reaction was 
monitored by TLC (15% EtOAc/petroleum ether). After running the reaction for 16 h, the 
starting material was consumed as shown by TLC. The reaction mixture was diluted in H2O (10 
mL), then extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were dried over 
Na2SO4, filtered and the solvent evaporated to give a brown oil. The crude material was 
dissolved in CH2Cl2, then purified by column chromatography (EtOAc/petroleum ether 
gradient). Analysis by 1H NMR revealed mostly eliminated products.  
 





A stirred solution of propane-1,3-diol (120) (15.0 mL, 214 mmol) in anhydrous THF (130 mL), 
was cooled to 0 °C and benzyl bromide (8.50 mL, 71.5 mmol),  tetra-n-butylammonium iodide 
(5.28 g,  14.0 mmol) and  NaH 60% dispersion in mineral oil  (3.0 g, 75 mmol) were added. 
The reaction mixture was allowed to warm to room temperature overnight. The reaction mixture 
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was washed with sat. aq.  NH4Cl (100 mL) and extracted with EtOAc/Et2O (1:1) (4 x 100 mL). 
The organic extracts were dried over MgSO4, filtered and the solvents evaporated. The crude 
material was purified by column chromatography using 35-60% EtOAc/petroleum ether eluent 
to give (121) as an oil (9.1 g, 76%); 1H NMR  (CDCl3, 400 MHz) δ 1.87 (2H, qn, J 5.8 Hz, O-
CH2-CH2-CH2OH), 2.31 (1H, br, OH), 3.66 (2H, t, J 5.9 Hz, O-CH2-CH2-CH2OH), 3.78 (2H, 
t, J 5.8 Hz, O-CH2-CH2-CH2OH), 4.52 (2H, s, O-CH2-Ph), 7.26-7.37 (5H, m, Ph).  
  




Method A179: A stirred solution of oxalyl chloride (3.28 mL, 6.56 mmol) in anhydrous CH2Cl2 
(20 mL) was cooled to -50 °C, DMSO (0.94 mL, 13 mmol) was added dropwise, and stirring 
continued for 5 min. A solution of 3-(benzyloxy) propanol (121) (1.00 g, 6.02 mmol) in 
anhydrous CH2Cl2 (5 mL) was added to the reaction mixture via a cannula. After  15 min Et3N 
(4.17 mL, 30.1 mmol) was added dropwise to the reaction mixture and the stirring continued  
at -50 °C for 10 min, then the reaction was allowed to warm up to room temperature. The 
reaction was monitored by TLC (15% EtOAc/petroleum ether). After running the reaction for 
18 h, a new spot with the higher Rf appeared on TLC. The reaction was quenched with sat. aq. 
NH4Cl (10 mL), then the aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic layers were washed with sat aq. NaHCO3 (2 x 10 mL) and brine (10 mL). The combined 
organic layers were dried over Na2SO4, filtered and the solvent evaporated to give a yellow oil. 
The crude material was dissolved in CH2Cl2, then purified by column chromatography, using 
EtOAc/petroleum ether eluent, to give (112) (236 mg, 24%), plus unchanged starting material. 
 
Method B180: A stirred solution of oxalyl chloride (3.3 mL, 6.6 mmol) in anhydrous CH2Cl2 
(60 mL) was cooled to -78 °C, DMSO (0.94 mL, 13.2 mmol) was added then stirring continued 
for 10 min. (121) (1.00 g, 6.02 mmol) was added via cannula and stirring continued for 15 min. 
Et3N (4.2 mL, 30.0 mmol) was added and stirring continued at -78 °C, for 5 min, then the 
reaction mixture was allowed to warm up to room temperature. The reaction was monitored by 
TLC (15% EtOAc/petroleum ether). After running the reaction for 16 h, a new spot with higher 
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Rf appeared on TLC. The reaction was quenched with sat. aq. NH4Cl (10 mL), then the aqueous 
layer was extracted with CH2Cl2 (2 x 20 mL). The combined organic layers were washed with 
sat. aq. NaHCO3 (2 x 10 mL) and brine (10 mL). The combined organic layers were dried over 
Na2SO4, filtered and the solvent evaporated to give a yellow oil. The crude material was 
dissolved in CH2Cl2, then purified by column chromatography, using EtOAc/petroleum ether 
eluent, to give (112) (456 mg, 46%), plus unchanged starting material (283 mg, 28%);  1H NMR  
(CDCl3, 400 MHz) δ 2.68 (2H, td, J 6.1, 4.0 Hz, O-CH2-CH2-CHO), 3.81 (2H, t, J 6.1 Hz, O-
CH2-CH2-CHO), 4.52 (2H, s, O-CH2-Ph), 7.26-7.37 (5H, m, Ph), 9.79 (1H, t, J 4.0 Hz, CHO). 






A stirred solution of (107) (164 mg, 0.70 mmol) in anhydrous CH2Cl2 (2 mL), under a N2 
atmosphere was cooled to -5 °C. 1M TiCl4 in CH2Cl2 solution (0.730 mL, 0.735 mmol) was 
added dropwise and the solution was allowed to stir for 15 min at 0 °C. Freshly distilled DIPEA 
(134 µL, 0.77 mmol) was added dropwise to the reaction mixture and stirring continued for 40 
min. Anhydrous N-methylpyrrolidin-2-one (67 µL, 0.70 mmol) was added at -5 °C, followed 
by the addition of freshly made (112) (230 mg, 1.40 mmol). The deep red colour of the enolate 
solution disappeared and was replaced by a pale yellow colour. The reaction was monitored by 
TLC (10% EtOAc/petroleum ether). After 4 h of reaction the starting material was consumed. 
The reaction was quenched with half-sat. aq. NH4Cl (2 x 20 mL), then the aqueous layer was 
extracted with CH2Cl2 (2 x 40 mL). The combined organic layers were dried over Na2SO4, 
filtered and the solvent evaporated to give a pale yellow solid. The crude material was dissolved 
in CH2Cl2, then purified by column chromatography using EtOAc/petroleum ether eluent to 
give (113)  (108 mg, 39%), as an oil, and a mixture of both starting materials (144 mg); [α]29D 
= +5.9 (c 1  in CHCl3),  (lit [α]29D = +8.6 (c 1.2 in CHCl3)181   IR υmax (thin film): 3498 (OH), 
2943, 2864 (CH), 2319, 2253 (C=C), 1777, 1694 (C=O), 1357 (CO); 1H NMR  (CDCl3, 400 
MHz) δ 0.88 (3H, d,  J 6.6 Hz, CH3-oxazoline ring), 1.26 (3H, d, J 7.0 Hz, CH3-CH), 1.74-1.92 
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(2H, m, -CHOH-CH2-CH2-O-), 3.28 (1H, br, CH-OH), 3.64-3.75 (2H, m, CH2-CH2-O-CH2-
Ar), 3.85 (1H, dq, J 7.0, 3.8 Hz, CH3-CH-CHOH), 4.17-4.19 (1H, m, CH-CH(OH)-CH2), 4.52 
(2H, s, CH2-Ph), 4.76 (1H, qn, J 7.0 Hz, CH3-CH-oxazolidinone ring), 5.63 (1H, d, J 7.2 Hz, 
Ph-CH-oxazolidinone ring), 7.26-7.43 (10H, m, 2 x Ph); 13C NMR (CDCl3, 101 MHz) δ 10.96 
(CH3-oxazolidinone ring), 14.34 (CH3-CH), 30.90 (CH2-CH2-O), 33.73 (CH2-CH2-O), 54.81 
(PhCH2-O-), 68.32 (CH-CO), 70.46 (-CHOH-), 73.21 (CH3-CH-oxazolidinone ring), 78.84 
(Ph-CH-oxazolidinone ring), 125.58, 127.65, 127.82, 128.39, 128.69, 128.75, (CH Ph), 133.16, 
138.03 (C quaternary), 152.66 (C=O), 176.38 (C=O ester); [found (ES+) 398.1959 [M+H]+, 



















7.4. Chiral pool route towards synthesis of Amoa 
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A stirred anhydrous of MeOH (15 mL), was cooled to 0 °C and TMSCl (47.6 mL, 376 mmol) 
was added, then L-aspartic acid (156) (10 g, 75 mmol) was added in small fractions to the 
reaction mixture and the stirring continued at room temperature. After 48 h reaction, the solvent 
was evaporated, to give the crude diester. A solution of diester (75 mmol) in anhydrous MeOH 
(200 mL), was cooled to 0 °C and the reaction mixture was treated with Et3N (68 mL, 488 
mmol) and Boc2O (18 g, 83 mmol). The reaction was allowed to warm up to room temperature, 
overnight. After running the reaction for 16 h,  TLC showed disappearance of the starting 
material and the reaction mixture was diluted in EtOAc (150 mL) and H2O (150 mL). The 
aqueous phase was separated and extracted with CH2Cl2 (100 mL). The combined organic 
layers were then extracted with H2O (3 x 100 mL), dried over MgSO4, filtered and the solvent 
was evaporated to give a pale yellow solid. The crude material was dissolved in CH2Cl2 and 
then was purified by column chromatography using 2% MeOH/CH2Cl2 eluent to give (158) as 
a pale yellow solid (10.4 g, 53%); IR υmax (KBr disc): 3407, (NH), 2981(CH), 1741, 1705 
(C=O), 1349, 1163 (CO); Mp 58-60 °C, (lit255 56 °C); 1H NMR  (CDCl3, 400 MHz) δ 1.43 
(9H, s, (C(CH3)3), 2.80 (1H, dd, J 16.9, 4.7 Hz, 1Hβ), 2.95-3.00 (1H, m, 1Hβ), 3.67 (3H, s, 
CO2Me), 3.74 (3H, s, CO2Me), 4.55-4.56 (1H, m, Hα), 5.46-5.47 (1H, m, NH).  
 
(2S,3R) and (2S,3S)-dimethyl-2-((tert-butoxycarbonyl)amino)-3-methylsuccinate198 






A stirred solution of  (158) (1.00 g, 3.82 mmol) in anhydrous THF (10 mL) was cooled to -78 
°C under a N2 atmosphere, then  1M LiHMDS in THF (7.64 mL, 7.64 mmol) was added to the 
reaction mixture and stirring continued for 2 h. Iodomethane (4.58 mmol, 0.28 mL) was added 
to the reaction mixture. The resulting solution was left to stir at -78 °C for 6 h and then was 
allowed to warm up at room temperature overnight. TLC showed that the starting material was 
replaced by two new higher running spots, Rf 0.60 and Rf 0.70 (30% EtOAc/petroleum ether). 
The reaction was quenched with 3M aq.  HCl (10 mL) to pH 2-3 and then the organic layer was 
washed with 2M aq. Na2S2O3 (10 mL). The combined organic extracts were dried over MgSO4, 
filtered and the solvent evaporated to give a brown coloured oil. The crude material was 
dissolved in CH2Cl2 and then purified by column chromatography using 0-12% 
EtOAc/petroleum ether eluent to give (159a) as a yellow oil (183 mg, 17%); Rf  0.60 TLC (30% 
EtOAc/petroleum ether); 1H NMR  (CDCl3, 400 MHz) δ 1.24 (3H, d, J 7.2 Hz, 
CH(CH3)CO2Me) 1.43 (9H, s, (C(CH3)3), 3.21-3.24 (1H, m, 1Hβ), 3.66 (3H, s, CO2Me), 3.72 
(3H, s, CO2`Me), 4.49-4.53 (1H, m, 1Hα), 5.39-5.42 (1H, m, NH); 13C NMR (CDCl3, 101 MHz) 
δ 13.46 (CH(CH3)CO2Me), 28.20 ((C(CH3)3), 41.38 (CH(CH3)CO2Me), 51.96 (C O2Me), 52.45 
(CO2Me), 55.30 (CHNHBoc), 79.98 (C(CH3)3), 155.90 (C=O), 171.47 (C=O), 174.16 (C=O); 
[found (ES+) 298.1253 [M+Na]+, C12H21NO6Na requires 298.1261]. 
 
Minor isomer as an oil  (159b) Rf 0.7 TLC (30% EtOAc/petroleum ether) (13 mg, 7%); 1H 
NMR  (CDCl3, 400 MHz) δ 1.20 (3H, d, J 7.3 Hz, CH(CH3)CO2Me) 1.43 (9H, s, (C(CH3)3), 
2.95-2.98 (1H, m, 1Hβ), 3.69 (3H, s, CO2Me), 3.74 (3H, s, C O2Me), 4.63-4.64 (1H, m, Hα), 
5.23-5.25 (1H, m, NH).   





 Compound (159a) (160 mg, 0.58 mmol) was treated with 4M HCl in dioxane (1 mL) and stirred 
at room temperature for 30 min. The reaction was checked by TLC (15% EtOAc/petroleum 
ether), which showed that the starting material disappeared, to give the amine hydrochloride 
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salt. The solvents were evaporated.  A stirred solution of the crude salt in H2O (10 mL) was 
treated with basic copper carbonate (154 mg, 0.70 mmol) and stirred at 70 °C for 3 h. The 
reaction mixture was then filtered through Celite and washed with H2O (20 mL). Thioacetamide 
(79 mg, 1.05 mmol) was added to the reaction mixture and the stirring continued at room 
temperature overnight. After running the reaction for 16 h, the reaction mixture was quenched 
with 3M aq. HCl (4 mL) and then the resulting mixture was filtered through Celite. The filtrate 
was then basified with 3M aq. NaOH (7 mL) and then the precipitate formed was removed by 
filtration. The solvents were evaporated to give a white solid. Analysis by 1H NMR was not 
consistent with formation of the expected product. 
 
(2S)-4-(Allyloxy)-2-amino-4-oxobutanoic acid (180)203, 204 
 
 
A: Allyl alcohol, TMSCl, 0 °C to rt, 18 h; B: as A, using acetyl chloride, 18 h. 
 
Method A203: A stirred solution of L-aspartic acid (172) (5.3 g, 40 mmol) in distilled allyl 
alcohol (30 mL, 441 mmol) was was cooled to 0 °C and TMSCl (15.2 mL, 120 mmol) was 
added. The resulting mixture was allowed to warm to room temperature overnight. After 
running the reaction for 18 h, the reaction mixture was cooled to 0 °C and then cold diethyl 
ether (200 mL) was added to the reaction mixture. The white precipitate formed was collected 
by filtration and washed with cold diethyl ether (2 x 20 mL)  to give a white solid (6.7 g, 
quantitative yield); Mp above 230 °C; IR υmax (KBr disc) 3397 (NH),  3088,  2987 (OH), 1730,  








1H NMR (D2O, 400 MHz) δ 3.13-3.15 (4H, m, 2 x 2Hβ), 4.37-4.40 (2H, m, 2 x Hα), 4.76 (2H, 
m, O-CH2-CH=CH2), 5.30-5.40 (2H, m, O-CH2-CH=CH2), 5.93-6.06 (1H, m, O-CH2-
CH=CH2). 
 
Method B204: Distilled allyl alcohol (50.0 mL, 735 mmol) was cooled to 0 °C, then acetyl 
chloride (7.0 mL, 99 mmol) was added dropwise to the reaction mixture and the resulting 
mixture was stirred at 0 °C for 1 h.  Compound (172) (3.3 g, 25 mmol) was added to the reaction 
mixture and stirring continued at 0 °C, then the suspension was allowed to warm to room 
temperature overnight. After running the reaction for 18 h, the reaction mixture was cooled to 
0 °C, then cold diethyl ether (250 mL) was added and the stirring continued at 0 °C for 1 h. The 
white precipitate was collected by filtration and washed with cold diethyl ether (2 x 20 mL) to 
give (180) as a white solid (4.3 g, 83%); Mp 170-174 °C (lit204 184-186 °C); IR υmax (KBr disc): 
3422 (NH), 2945 (CH),  2643 (OH), 1735 (C=O), 1503 (C=C), 1230 (CO)  1H NMR (D2O, 400 
MHz) δ 3.12-3.17 (2H, m, 2Hβ), 4.35-4.37 (1H, m, Hα), 4.70-4.74 (2H, m, O-CH2-CH=CH2), 








A stirred solution of (180) (4.0 g, 19 mmol) in H2O (90 mL) was treated with diethyl ether (40 
mL), K2CO3 (4.3 g, 31 mmol) and benzyl chloroformate (4.3 mL, 31 mmol), then the reaction 
mixture was stirred at room temperature for 16 h. The reaction was checked by TLC (10% 
MeOH/CH2Cl2) and a new spot with a higher Rf appeared. The aqueous layer was extracted 
with diethyl ether (2 x 100 mL) and then it was acidified to pH 1 with concentrated aq. HCl. 
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The resulting opaque solution was extracted with diethyl ether (2 x 100 mL). The combined 
organic extracts were dried over MgSO4, filtered and the solvent was evaporated to give an oil. 
The crude material was dissolved in CH2Cl2 and was purified by column chromatography using 
7% MeOH/CH2Cl2 eluent to give (181) as a  colourless oil (3.3 g, 56%); IR υmax (thin fim): 
3337 (NH), 3068, 2951(CH), 1727 (C=O), 1215 (CO);  1H NMR (CDCl3, 400 MHz) δ 2.90 
(1H, dd, J  17.2, 4.5 Hz, 1Hβ), 3.08 (1H, dd, J 17.3, 4.2 Hz, 1Hβ), 4.57-4.59 (2H, m, O-CH2-
CH=CH2), 4.69-4.72 (1H, m, Hα), 5.12 (2H, s, CH2-Ph), 5.21-5.32 (2H, m, O-CH2-CH=CH2), 
5.82-5.92 (2H, m, O-CH2-CH=CH2, NH), 7.30-7.35 (5H, m, Ph), 10.17 (1H, br, OH); 13C NMR  
(CDCl3, 101 MHz) δ 36.37 (CH2β), 50.16 (CHα), 65.81 (O-CH2-CH=CH2), 67.28 (O-CH2-Ph), 
118.76 (CH=CH2), 128.05, 128.19, 128.48, (CH Ar), 131.47 (CH=CH2), 135.93 (C quaternary), 
156.13, 170.63, 175.09 (C=O). 




A: Boc2O, CH3CN/tBuOH (v/v: 2/1), pyridine, DMAP, rt, 18 h; B: Boc2O, tBuOH, DMAP, rt, 16 h; C: IPCC, 
DMAP, tBuOH, Et3N, CH2Cl2, 35 °C, 16 h; D: as C, using only tBuOH, 16 h; E: tBuOH, DCC, DMAP, CH2Cl2, 
0 °C to rt; F: tBuOH, HOBt, DCC, DMAP, DMF/CH2Cl2, rt, 16 h; G: as B, heating at 40 °C, 48 h. 
 
Method A: A stirred solution of (181) (268 mg, 0.87 mmol) in acetonitrile/tBuOH (2:1, v/v) 
(60 mL) was treated with Boc2O (190 mg, 0.87 mmol), pyridine (70 µL, 0.87 mmol) and DMAP 
(5.0 mg, 0.043 mmol) then the reaction mixture was stirred at room temperature for 18 h. The 
reaction mixture was checked by TLC (10% MeOH/CH2Cl2) which showed the starting 
material plus presence of a new spot with a higher Rf. The solvents were evaporated and the 
residue was dissolved in EtOAc (50 mL) and then was extracted with sat. aq.  NaHCO3 (50 
mL), 1M aq. HCl (2 x 50 mL) and brine (50 mL). The organic extract was dried over MgSO4, 
filtered and the solvent was evaporated to give an oil. The crude material was dissolved in 
CH2Cl2 and then purified by column chromatography using 2% MeOH/CH2Cl2 eluent to give 




Method B: A stirred solution of (181) (184 mg, 0.60 mmol) in tBuOH (6 mL, 0.06 mmol) was 
treated with Boc2O (258 mg, 1.18 mmol) and DMAP (5.0 mg, 0.043 mmol) then the reaction 
mixture was stirred at room temperature for 16 h. The reaction mixture was checked by TLC 
(10% MeOH/CH2Cl2) which showed the starting material plus the presence of a new spot with 
a higher Rf. The reaction mixture was diluted in EtOAc (50 mL) and then was extracted with 
5% aq. citric acid (2 x 20 mL), 5% aq. NaHCO3 (2 x 20mL) and brine (20 mL). The organic 
extract was dried over MgSO4, filtered and the solvent was evaporated to give the desired 
compound (150) as an oil (52 mg, 24%). 
 
Method C: A stirred solution of (179) (150 mg, 0.50 mmol) in distilled CH2Cl2 (2 mL) was 
stirred at 35 °C and then triethylamine (74 µL, 0.54 mmol), DMAP (12 mg, 0.10 mmol), tBuOH 
(138 µL, 1.47 mmol) and IPCC (60 µL, 0.54 mmol) were added to the reaction mixture, which 
was stirred at 35 °C, for 16 h. The reaction mixture was checked by TLC (10% MeOH/CH2Cl2), 
which showed the starting material plus the presence of a new spot with a higher Rf. All the 
solvents were evaporated. The residue was dissolved in EtOAc (30 mL) and then was extracted 
with 5% aq. citric acid (2 x 20 mL), 5% aq.  NaHCO3 (2 x 20mL) and brine (20 mL). The 
organic extract was dried over MgSO4, filtered and the solvent was evaporated to give the 
desired compound (150) as an oil (17 mg, 10%).  
Method D: A stirred solution of (181) (150 mg, 0.50 mmol) in  freshly distilled tBuOH (3 mL, 
32 mmol) was stirred at 35 °C and then triethylamine (74 µL, 0.54 mmol), DMAP (12 mg, 0.10 
mmol) and IPCC (60 µL, 0.54 mmol) were added to the reaction mixture and stirred at 35 °C, 
for 16 h. The reaction mixture was checked by TLC (10% MeOH/CH2Cl2), which showed the 
starting material plus the presence of a new spot with a higher Rf. All the solvents were 
evaporated. The residue was dissolved in EtOAc (30 mL) and then was extracted with 5% aq. 
citric acid (2 x 20 mL), 5% aq. NaHCO3 (2 x 20mL) and brine (20 mL). The organic extract 
was dried over MgSO4, filtered and the solvent was evaporated to give (150) as an oil (95 mg, 
25%). Analysis by 1H NMR showed the desired compound, plus the unchanged starting 
material.  
 
Method E: A stirred solution of DCC (121 mg, 0.60 mmol) and DMAP (6 mg, 0.05 mmol) in 
anhydrous CH2Cl2 (5 mL) was cooled to 0 °C. tBuOH (460 µL, 4.9 mmol) and (181) (152 mg, 
0.50 mmol) were added to the reaction mixture, which was then stirred at 0 °C for 1 h, then at 
25 °C for 16 h. The reaction mixture was diluted in EtOAc (30 mL) and then was extracted with 
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5% aq. citric acid (2 x 20 mL), 5% aq. NaHCO3 (2 x 20mL) and brine (20 mL). The organic 
extract was dried over MgSO4, filtered and the solvent was evaporated to give a yellow solid. 
Analysis by 1H NMR was not consistent with formation of the expected product.  
 
Method F: A stirred solution of (181) (150 mg, 0.50 mmol) in DMF/CH2Cl2  (1:1, v/v) (10 
mL) was treated with DCC (101 mg, 0.50 mmol) and HOBt  (93 mg, 0.69 mmol) and the 
resulting mixture was stirred at room temperature for 40 min. tBuOH (460 µL, 4.9 mmol) and 
DMAP (6 mg, 0.050 mmol) were added and then the reaction mixture was stirred at room 
temperature for 16 h. The reaction mixture was checked by TLC (10% MeOH/CH2Cl2), which 
showed the starting material plus the presence of a new spot with a higher Rf. The reaction 
mixture was diluted in EtOAc (30 mL) and then was extracted with 5% aq. citric acid (2 x 20 
mL), 5% aq. NaHCO3 (2 x 20 mL) and brine (20 mL). The organic extract was dried over 
MgSO4, filtered and the solvent evaporated to give an oil. Analysis by 
1H NMR was not 
consistent with formation of the expected product. 
 
Method G: A stirred solution of (181) (3.9 g, 0.013 mol) in freshly distilled tBuOH (95 mL, 
1.01 mmol) was treated with Boc2O (5.6 g, 0.025 mmol) and DMAP (460 mg, 4x10
-3 mmol), 
then the reaction mixture was stirred at 40 °C for 48 h. The reaction mixture was checked by 
TLC (10% MeOH/CH2Cl2) which showed the disappearance of the starting material and the 
formation of a new spot with a higher Rf. The solvents were evaporated. The residue was 
dissolved in EtOAc (100 mL) and was then extracted with 5% aq. citric acid (2 x 100 mL), 5% 
aq. NaHCO3 (2 x 100 mL) and brine (100 mL). The organic extract was dried over MgSO4, 
filtered and the solvent was evaporated to give an oil. The crude product was dissolved in 
CH2Cl2 and was purified by column chromatography using 1% MeOH/CH2Cl2, to give (150) 
(2.1 g, 45%) as a colourless oil; 1H NMR   (CDCl3, 400 MHz) δ 1.44 (9H, s, C(CH3)3), 2.81 
(1H, dd, J 16.8, 4.4 Hz, 1Hβ), 3.00 (1H, dd, J  16.8, 4.4 Hz,  1Hβ), 4.49-4.60 (3H, m, O-CH2-
CH=CH2 and Hα), 5.11 (2H, s, CH2-Ph), 5.21-5.32 (2H, m, O-CH2-CH=CH2), 5.70-5.72 (1H, 
m, NH), 5.83-5.93 (1H, m, O-CH2-CH=CH2), 7.30-7.35 (5H, m, Ph); 13C NMR  (CDCl3, 101 
MHz) δ 27.79 (C(CH3)3), 36.83 (CH2β), 50.91 (CHα), 65.48 (O-CH2-CH=CH2), 66.91 (O-CH2-
Ph), 82.53 (C(CH3)3), 118.58 (CH=CH2), 127.99, 128.07, 128.44 (CH Ph), 131.68 (CH=CH2), 
136.24 (C quaternary), 155.87 (C=O), 169.43 (C=O), 170.35 (C=O); [found (ES+) 386.1625 




(2R,3S)-1-Allyl 4-tert-butyl 3-(benzyloxycarbonylamino)-2-methylbutanedioate193(171) 
 
A: LiHMDS, THF, MeI, -78 °C to rt, 18 h; B: LiHMDS, THF, HMPA, MeI, -78 °C to rt, 18 h; C: as B, using 
anhydrous reagents; D: as B, at -78 °C for 3 h; E: as A, using anhydrous reagents and reaction at -78 °C, 3 h. 
 
Method A: A stirred solution of (150) (320 mg, 0.88 mmol) in anhydrous THF (3 mL)  under 
a N2 atmosphere was cooled to -78 °C, then 1M LiHMDS  in THF (1.8 mL, 1.8 mmol) was 
added to the reaction mixture and stirring was continued at -78 °C for 2 h. Iodomethane (66 µL, 
1.05 mmol) was then added to the reaction mixture and the stirring was  continued at -78 °C for 
6 h, then the reaction was allowed to warm up to room temperature overnight. After running 
the reaction for 18 h, the reaction mixture was cooled to 0 °C and then it was quenched with 
cold 3 M aq. HCl to pH 4 and brine (5 mL) and was extracted with EtOAc (2 x 10 mL). The 
combined organic extracts were dried over MgSO4, filtered and the solvent was evaporated to 
give a yellow oil. The crude material was purified by column chromatography using 5% 
EtOAc/petroleum ether eluent to give (182) as a pale yellow oil (223 mg), a mixture of C- and 
N-alkylated products.  
 
Method B: A stirred solution of (150) (320 mg, 0.88 mmol) in anhydrous THF (3 mL)  under 
an N2 atmosphere was cooled to -78 °C, then 1M LiHMDS  in THF (1.8 mL, 1.8 mmol) and 
HMPA (0.95 mL, 5.46 mmol) were added to the reaction mixture and the resulting solution was 
allowed to stir at -78 °C for 45 min. Iodomethane (170 µL, 2.64 mmol) was added at -78 °C 
and the reaction mixture was allowed to warm up to room temperature overnight. After running 
the reaction for 18 h, a new spot with higher Rf appeared, as shown by TLC (6% 
EtOAc/petroleum ether). Brine (20 mL) was added to the reaction mixture and then it was 
extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over MgSO4, 
filtered and the solvent was evaporated to give a brown oil. The crude material was purified by 
column chromatography using 6-7% EtOAc/petroleum ether eluent to give a pale yellow oil. 









(2S, 3R)-4-Allyl 1-tert-butyl N-benzyloxycarbonyl-N,3-dimethyl-L-aspartate (183) 
 
An oil (117 mg, 40%), Rf 0.41 TLC (10% EtOAc/petroleum ether); IR υmax (thin film): 3451 
(NH), 2978, 2942 (CH), 1734 (C=O), 1455, 1153 (CO); 1H NMR  (CDCl3, 400 MHz) δ two 
rotamers: 1.24-1.28 (3H, m, CH(CH3)CO), 1.42 (4.5H, s, C(CH3)3), 1.43 (4.5H, s,  C(CH3)3), 
2.88-2.93 (3H, m, N(CH3)), 3.16-3.23 (1H, m, Hβ), 4.49-4.51 (2H, m, O-CH2-CH), 4.61-4.64 
(0.5H, m, Hα), 4.81-4.84 (0.5H, m, Hα), 5.05-5.29 (4H, m, O-CH2-CH=CH2, CH2-Ph), 5.78-
5.87 (1H, m, O-CH2-CH=CH2), 7.29-7.35 (5H, m, Ph); 13C NMR (CDCl3, 101 MHz) δ two 
rotamers: 14.39, 14.84 (CH3), 27.78, 27.81 (C(CH3)3), 31.87, 32.04 (NCH3), 40.26 (CHβ), 
61.68, 62.02 (CHα), 65.32, 65.40 (O-CH2-CH=CH2),  67.34, 67.42 (O-CH2-Ph), 77.18 
(C(CH3)3), 118.43, 118.63 (CH=CH2), 127.71, 127.87, 128.35 (CH Ar), 131.76, 131.86 
(CH=CH2), 136.47, 136.64 (C quaternary), 155.85, 156.53, 168.29, 168.55 (C=O), 173.01, 
173.09 (C=O ester); [found (ES+) 414.1881 [M+Na]+, C21H29NO6Na, requires 414.1887]. 
 





As an oil (56 mg, 17%); IR υmax (thin film): 3452 (NH), 2976, 2934 (CH), 1734 (C=O), 1153 
(CO); 1H NMR   (CDCl3, 400 MHz) δ two rotamers: 1.37 (4.5H, s, C(CH3)3), 1.41 (4.5H, s, 
C(CH3)3), 2.69-2.83 (1H, m, Hβ), 2.94 (3H, s, N(CH3)), 2.96-3.11(1H, m, Hβ), 4.57-4.62 (2H, 
m, O-CH2-CH), 4.74-4.80 (1H, m, CHα), 5.05-5.34 (4H, m, O-CH2-CH=CH2, CH2-Ph), 5.83-
5.93 (1H, m, O-CH2-CH=CH2), 7.29-7.34 (5H, m, Ph); 13C NMR (CDCl3, 101 MHz) δ two 
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rotamers: 27.78, 27.81, (C(CH3)3), 33.47, 33.59 (N-CH3), 34.64, 35.12 (CH2β), 57.69, 58.22 
(CHα), 65.38, 65.48 (O-CH2=CH=CH2), 67.25, 67.45 (O-CH2-Ph), 82.06, 82.23 (C(CH3)3), 
118.31, 118.49 (CH=CH2), 127.67, 127.76, 127.92, 128.39 (CH Ar), 131.76, 131.88 
(CH=CH2), 136.29, 136.62 (C quaternary), 155.85, 156.16 (C=O), 168.89, 168.97 (C=O ester), 
170.30, 170.54 (C=O ester); [found (ES+) 400.1784 [M+H]+, C20H28NO6 requires 400.1731]. 
  
 
A mixture of both diastereoisomeric C/N-alkylated products (182) and 




Method C: A stirred solution of (150) (160 mg, 0.44 mmol), in anhydrous THF (2 mL) under 
a N2 atmosphere was cooled to -78 °C. 1M LiHMDS in THF (0.92 mL, 0.92 mmol) and HMPA 
(0.47 mL, 2.73 mmol) were added to the reaction mixture and the resulting solution was allowed 
to stir at -78 °C for 45 min. Iodomethane (94 µL, 1.32 mmol) was added at -78 °C.  After 
running the reaction for 3 h 30 min, the starting material was consumed and a new spot with 
higher Rf appeared. The reaction was stopped by pouring into aqueous solution of 3M aq. HCl 
(15 mL) at room temperature and then the resulting mixture was extracted with EtOAc (3 x 20 
mL). The combined organic extracts were dried over MgSO4, filtered and the solvent was 
evaporated to give a brown oil. The crude material was purified by column chromatography 
using 6% EtOAc/petroleum ether eluent to give a pale yellow oil. Analysis by 1H NMR 
indicated both diastereisomeric C/N-alkylated products (182) and (183) and N-alkylated 
product (184). 
 
Method D: A stirred solution of (150) (160 mg, 0.44 mmol), in anhydrous THF (2 mL) under 
a N2 atmosphere was cooled to -78 °C. 1M LiHMDS in THF (0.92 mL, 0.92 mmol) and 
anhydrous HMPA (0.47 mL, 2.73 mmol) were added and the solution was allowed to stir at -
78 °C for 45 min.  Freshly distilled iodomethane (94 µL, 1.32 mmol) was added at -78 °C. The 
reaction was checked by TLC (8% EtOAc/petroleum ether) and after running the reaction for 3 
h, the starting material was consumed and a new spot with higher Rf appeared on TLC. The 
reaction was stopped by pouring into 3M aq. HCl (15 mL) at room temperature, and then the 
resulting mixture was extracted with EtOAc (4 x 20 mL). The combined organic extracts were 
dried over MgSO4, filtered and the solvent was evaporated to give a brown oil. The crude 
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product was purified by column chromatography using 4-10% EtOAc/petroleum ether eluent 
to give a pale yellow oil. Analysis by 1H NMR indicated the desired C-alkylated product (171a) 
(92 mg, 55%) but contaminated with the C/N-alkylated N-alkylated products.  
 
 Method E: A stirred solution of (150) (600 mg, 1.65 mmol), in anhydrous THF (2 mL) under 
N2 atmosphere was cooled to -78 °C. 1M LiHMDS in THF (3.5 mL, 3.5 mmol) was added and 
the solution was allowed to stir at -78 °C for 45 min. Freshly distilled iodomethane (0.301 mL, 
4.95 mmol) was added at -78 °C. After running the reaction for 3 h, the starting material was 
consumed and a new spot with higher Rf appeared on TLC. The reaction was stopped by pouring 
into 3M aq. HCl (50 mL) at room temperature and then the resulting mixture was extracted with 
EtOAc (4 x 20 mL). The combined organic extracts were dried over MgSO4, filtered and the 
solvent was evaporated to give a brown oil. The crude material was purified by column 
chromatography using 8-9% EtOAc/petroleum ether eluent. This gave the desired compound 
C-alkylated product (171) (301 mg, 48%) as a pale yellow oil; [α]22 D = -6.2 (c 1.1, CHCl3), (lit 
[α]22 D =  -6.2, c 1.2, CHCl3)193; IR υmax (thin film): 3433, 3368, (NH), 2960, 2941 (CH), 1729 
(C=O), 1505 (C=C), 1218, 1160 (CO); 1H NMR   (CDCl3, 400 MHz) δ 1.21 (3H, d, J 7.3 Hz, 
CH(CH3)CO), 1.42 (9H, s, C(CH3)3), 3.18-3.23 (1H, m, Hβ), 4.51-4.60 (3H, m, O-CH2-CH, 
Hα), 5.12-5.33 (4H, m, O-CH2-CH=CH2, CH2-Ph), 5.63-5.65 (1H, m, NH), 5.84-5.94 (1H, m, 
O-CH2-CH=CH2), 7.29-7.37 (5H, m, Ph); 13C NMR (CDCl3, 101 MHz) δ 13.02 (CH3), 27.79 
(C(CH3)3), 41.43 (CHβ), 56.21 (CHα), 65.41 (O-CH2-CH=CH2), 66.93 (O-CH2-Ph), 82.47 
(C(CH3)3), 118.31 (CH=CH2), 127.04, 128.15, 128.43 (CH Ar), 131.78 (CH=CH2), 136.30 (C 
quaternary), 156.44, 169.37 (C=O), 173.12 (C=O ester); [found (ES+) 400.1748 [M+H]+, 
C20H28NO6 requires 400.1731]. 
 
A mixture of both diastereoisomeric C-alkylated products (171) and (186) plus the starting 
material (150) (200 mg, 33%) was also isolated. 
 
Preparation of (2S,3R)-4-(allyloxy)-2-((benzyloxy)carbonyl)amino)-3-methyl-4-




      
 
(171) (96 mg, 0.25 mmol) was treated with 4 M aq. HCl in dioxane (2 mL) at room temperature 
for 30 min. The reaction mixture was then co-evaporated with diethyl ether to give an oil. 







A stirred solution of (171) (228 mg, 0.60 mmol) in anhydrous CH2Cl2 (60 mL) was treated with 
TFA (20 mL) and the stirring was continued at room temperature. The reaction was monitored 
by TLC and a new spot with a lower Rf 0.60 (5% MeOH/CH2Cl2 + 0.1%AcOH) appeared. After 
running the reaction for 2 h, the solvent was evaporated, to give (173) (176 mg, 91%) as an oil; 
IR υmax (thin film):  3342 (NH), 2946 (CH), 1717, 1703 (C=O), 1221 (CO);  1H NMR (CDCl3, 
400 MHz) δ 1.30 (3H, d, J 7.4 Hz, CH3(CH)CO), 3.26-3.36 (1H, m, Hβ), 4.53-4.68 (3H, m, O-
CH2-CH, Hα), 5.10-5.32 (4H, m, O-CH2-CH=CH2, CH2-Ph), 5.70-5.99 (2H, m, O-CH2-
CH=CH2, NH), 7.15-7.38 (5H, m, Ph), 9.12 (1H, br, COOH); 13C NMR (CDCl3, 101 MHz) δ 
13.73 (CH3-CHβ), 41.16 (CHβ), 55.50 (CHα), 65.83 (O-CH2-CH=CH2), 67.32 (O-CH2-Ph), 
118.76 (CH=CH2), 127.99, 128.18, 128.49 (CH Ph), 131.40 (CH=CH2), 135.97 (C quaternary), 
156.77 (C=O), 173.79, 175.13 (C=O ester); [found (ES+) 344.1124 [M+Na]+, C16H19NO6Na 







A stirred solution of (173) (207 mg, 0.65 mmol) in anhydrous CH2Cl2 (2.5 mL) and DMF (2.5 
mL) was cooled to 0 °C and HOBt (123 mg, 0.91 mmol) and EDC.HCl (125 mg, 0.65 mmol) 
were added and the stirring continued at 0 °C for 30 min. N,O-Dimethylhydroxylamine 
hydrochloride (63 mg, 0.65 mmol) and DIPEA (0.6 mL, 3.4 mmol) were added to the reaction 
mixture. The resulting solution was allowed to warm up to room temperature overnight. After 
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running the reaction for 16 h, TLC showed a new spot with a lower Rf 0.50 (15% 
EtOAc/petroleum ether). All the solvent was evaporated and the residue was dissolved in 
EtOAc (20 mL) and extracted with 5% aq. citric acid (2 x 20 mL), 5%  aq.  NaHCO3 (2 x 20 
mL) and brine (20 mL). The organic layer was dried over MgSO4, filtered and the solvent was 
evaporated to give an oil. The crude material was purified by column chromatography using 
90% EtOAc/petroleum ether eluent to give (174) as oil (127 mg, 53%); 1H NMR (CDCl3, 400 
MHz) δ 1.21 (3H, d, J 7.1 Hz, CH(CH3)CO), 2.90-3.02 (1H, m, Hβ), 3.20 (3H, s, NCH3), 3.77 
(3H, s, OCH3) 4.50-4.60 (2H, m, O-CH2-CH2=CH), 4.90-4.94 (1H, m, Hα), 5.05-5.32 (4H, m, 
O-CH2-CH=CH2, CH2-Ph), 5.78-5.92 (2H, m, O-CH2-CH=CH2 and NH), 7.26-7.37 (5H, m, 
Ph); 13C NMR (CDCl3, 101 MHz) δ 13.99 (CH(CH3)CO), 32.20 (NCH3), 41.57 
(CHβ(CH3)CO), 53.07 (CHα), 61.60 (OCH3), 65.48 (O-CH2-CH2=CH), 66.90 (CH2-Ar), 
118.33 (O-CH2-CH2=CH), 127.92, 128.03, 128.41 (CH Ph), 131.91 (O-CH2-CH2=CH), 136.21 
(C quaternary), 156.15 (C=O ester), 173.21 (C=O amide); [found (ES+) 387.1517 [M+Na]+, 
C18H24N2O6Na requires 387.1527].  
 




Via reduction of Weinreb amide 
 
A stirred solution of (173) (124 mg, 0.34 mmol) in anhydrous THF (4.3 mL) under N2 was 
cooled to -78 °C, then DIBAL-H (0.41 mL, 0.41 mmol) was added and the stirring continued 
at -78 °C. The reaction was monitored by TLC (35% EtOAc/petroleum ether) and after running 
the reaction for 2 h, the starting material remained and another 1.2 eq of DIBAL-H (0.41 mL, 
0.41 mmol) was added. After 2 h reaction, 0.85 eq of DIBAH-L (0.29 mL, 0.29 mmol) was 
added to the reaction mixture. After running the reaction for 9 h, the reaction mixture was 
poured into 5% aq. citric acid (10 mL) and then extracted with EtOAc (3 x 40 mL). The 
combined organic layers were dried over Na2SO4, filtered and the solvent evaporated to give 
196 
 
an oil (238 mg). Analysis by 1H NMR showed the presence of the aldehyde (176). The crude 
material was then dissolved in MeOH and pre-absorbed onto silica, then purified by column 
chromatography using EtOAc/petroleum ether eluent, plus 0.1% pyridine. The desired 






A: EtSH, DCC, DMAP, CH2Cl2, rt, 16 h; B: EtSH, EDC.HCl, DMAP, rt, 16 h. 
 
Method A: A stirred solution of (173) (138 mg, 0.43 mmol) in anhydrous CH2Cl2 (10 mL), was 
treated with DCC (97 mg, 0.47 mmol). EtSH (333 µL, 0.43 mmol) (0.96 µL of EtSH dissolved 
in 1 mL of anhydrous CH2Cl2) and DMAP (5.2 mg, 0.043 mmol) were added to the reaction 
mixture. The resulting mixture was allowed to stir at room temperature for 16 h. After 
consumption of the starting material as shown by TLC (30% EtOAc/petroleum ether), the 
solvent was evaporated. The residue was dissolved in EtOAc (30 mL), then extracted with 5% 
aq. citric acid (2 x 20 mL), 5% aq. NaHCO3 (2 x 20 mL) and brine (20 mL). The organic layer 
was dried over Na2SO4, filtered and the solvent was evaporated to give an oil. The crude 
material was purified by column chromatography using 20% EtOAc/petroleum ether eluent to 
give (175) (81 mg, 52%) as an oil, [α]22 D = -0.90 (c 1.4, CHCl3).  1H NMR   (CDCl3, 400 MHz) 
δ 1.22 (3H, t, J 7.4 Hz, CH3-CH2), 1.26 (3H, d, J 7.6 Hz, CH(CH3)CO), 2.81-2.90 (2H, m, CH3-
CH2-S), 3.37-3.44 (1H, m, Hβ), 4.50-4.60 (3H, m, O-CH2-CH, Hα), 5.12-5.33 (4H, m, O-CH2-
CH=CH2, CH2-Ph), 5.81-5.98 (2H, m, O-CH2-CH=CH2, NH), 7.30-7.39 (5H, m, Ph); 13C NMR   
(CDCl3, 101 MHz) δ 14.18 (CH(CH3)CO), 23.41 (CH3-CH2), 27.80 (CH3-CH2), 40.72 
(CHβ(CH3)CO), 62.63 (CHα), 65.56 (O-CH2-CH2=CH), 67.30 (CH2-Ph), 118.52 (O-CH2-
CH2=CH), 127.93, 128.15, 128.47 (CH Ph), 131.52 (O-CH2-CH2=CH), 136.15 (C quaternary), 
156.15 (C=O ester), 173.21 (C=O amide), 200.37 (C=O thiol ester); [found (ES+) 387.1170 




Method B: A stirred solution of (173) (178 mg, 0.55 mmol) in peptide grade DMF (3 mL), was 
treated with EDC.HCl (94 mg, 0.60 mmol). EtSH (441 µL. 0.55 mmol) and DMAP (9.0 mg, 
55 mol) were added to the reaction mixture. The resulting mixture was allowed to stir at room 
temperature for 16 h. After consumption of the starting material as showed on TLC (30% 
EtOAc/petroleum ether) the solvent was evaporated. The residue was dissolved in EtOAc (30 
mL), then was extracted with 5% aq. citric acid (2 x 20 mL), 5% aq. NaHCO3 (2 x 20 mL) and 
brine (20 mL). The organic layer was dried over Na2SO4, filtered and the solvent was 
evaporated to give an oil. The crude product was purified by column chromatography using 10-
12% EtOAc/petroleum ether eluent to give (175) 81 mg, 40%) as an oil. 
 
 
Attempted preparation of (2R,3S)-allyl 3-(benzyloxycarbonylamino)-2-methyl-4-
oxobutanoate (176) 




A: Pd/BaSO4, Et3SiH, acetone, rt, 48 h; B: as A, reaction for 2 h; C: 5%Pd/CaCO3/PbO, quinoline, 1-decene, 
Et3SiH, acetone, 4 h; D: Pd/BaSO4, 1-decene, Et3SiH, 2 h. 
 
Method A: A stirred solution of (175) (72 mg, 0.20 mmol) in distilled acetone (2 mL) was 
treated with 20% w/w Pd/BaSO4 (17 mg, 20) and triethylsilane (160 µL, 0.98 mmol) and then 
the stirring was continued at room temperature for 48 h. After consumption of the starting 
material, three new spots appeared by TLC (30% EtOAc/petroleum ether). The reaction mixture 
was filtered through Celite and then washed with acetone (10 mL) to give an oil (86 mg). The 
crude material was purified by column chromatography using 50% EtOAc/petroleum ether 







Method B: A stirred solution of (175) (44 mg, 0.12 mmol) in distilled acetone (1.5 mL), was 
treated with 20% Pd/BaSO4 (9 mg) and triethylsilane (96 µL, 0.60 mmol) and then the stirring 
was continued at room temperature. The reaction was monitored by TLC (20% 
EtOAc/petroleum ether). After running the reaction for 2 h 15min, all the starting material was 
consumed and then the reaction mixture was filtered through Celite, then washed with acetone 
(10 mL) to give an oil (69 mg). The crude material was purified by column chromatography 
using 5-100% EtOAc/petroleum ether eluent, to give the following compounds: 
 
Propyl (2R,3S)-3-(benzyloxycarbonylamino)4-(ethylthio)-2-methyl-4-oxobutanoate 
 (191) (13.4 mg, 30%) 
 
1H NMR  ( CDCl3, 400 MHz) δ  0.91 (3H, t, J 7.4 Hz, CH3-CH2), 1.16-1.28 (6H, m, CH3-CH2 
and CH(CH3)CO)), 1.54-1.68 (2H, m, CH3-CH2-CH2), 2.81-2.90 (2H, m, CH3-CH2-S), 3.35-
3.41 (1H, m, Hβ), 3.97-4.07 (2H, m, O-CH2-CH2), 4.50 (1H, dd, J 10.2, 3.6 Hz, Hα), 5.19 (2H, 
s, CH2-Ph), 5.97-5.99 (1H, m, NH), 7.31-7.40 (5H, m, Ph); [found (ES+) 390.1329 [M+Na]
+, 
C18H25NO5SNa requires 390.1346]. 
 
 
(2R,3S)-propyl-3-((benzyloxy)carbonyl)amino)-2-methyl-4-oxobutanoate (190a) plus its 




1H NMR  (CDCl3, 400 MHz) δ 0.92 (3H, td, J 1.6, 7.4 Hz, CH3-CH2), 1.29 (1.5H, d, J 7.4 Hz, 
CH(CH3)CO), 1.34 (1.5H, d, J 7.4 Hz, CH(CH3CO), 1.57-170 (2H, m, CH2-CH2-CH3), 3.05-
3.08 (0.45H, m, Hβ), 3.29-3.35 (0.55H, m, Hβ), 3.91-4.11 (2H, m, O-CH2-CH2), 4.38-4.41 (1H, 
m, Hα), 4.43-4.46 (1H, m, Hα),  5.12 (1H, s, CH2-Ph), 5.19 (1H, s, CH2-Ph), 5.60-5.64 (0.45H, 
m, NH), 5.83-5.86 (0.55H, m, NH), 7.30-7.38 (5H, m, Ph), 9.66 (0.5H, s, HC=O), 9.70 (0.5H, 
s, HC=O).    
 
Method C: A stirred solution of (175) (37 mg, 0.10 mmol) in distilled acetone (2 mL), was 
treated with 5% Pd/CaCO3/PbO (403 mg), a few drops of quinoline and 1-decene (382 µL, 2.02 
mmol) and then the reaction mixture was stirred vigorously at room temperature. Triethylsilane 
(40 µL, 0.25 mmol) was added over 2 min and the stirring continued at room temperature. The 
reaction was monitored by TLC (20% EtOAc/petroleum ether). After running the reaction for 
1 h 40 min, 3 drops of triethylsilane were added to the reaction mixture in order to complete the 
reaction. After running the reaction for 4 h a new spot with lower Rf appeared and then the 
reaction mixture was filtered through Celite, which washed with acetone to give an oil (146 
mg). The crude material was purified by column chromatography using 5-100% 
EtOAc/petroleum ether eluent, to give only the unchanged (175) (30 mg). 
 
Method D: A stirred solution of (175) (14 mg, 0.038 mmol) in distilled acetone (1 mL), was 
treated with 20% w/w Pd/BaSO4 (7 mg, 20%) and 1-decene (382 µL, 2.02 mmol) and then the 
reaction mixture was stirred at room temperature. Triethylsilane (40 µL, 0.25 mmol) was added 
to the reaction, which was stirred vigorously at room temperature. The reaction was monitored 
by TLC (20% EtOAc/petroleum ether). After running the reaction for 2 h, the starting material 
was consumed. The reaction mixture was filtered through cotton wool, which was washed with 
acetone to give an oil (15 mg). The crude product was analysed by 1H NMR showing the 








 A: TBTU, DIPEA, THF/DMF, 0 °C, then TMSCHN2, 3 h 30 min; B: isopropyl chloroformate, DIPEA, THF, -15 
°C to –5 °C, then TMSCHN2, 4 °C, 48 h.  
 
Method A: A stirred solution of (173) (307 mg, 0.96 mmol) in THF (3 mL) and DMF (2 mL) 
was cooled to 0 °C and was treated with distilled DIPEA (170 µL, 0.96 mmol), TBTU (308 mg, 
0.96 mmol) and the stirring was continued at 0 °C for 30 min. 2M TMSCHN2 in Et2O (0.96 
mL, 1.92 mmol) was added to the reaction mixture, and the resulting solution was stirred at 0 
°C. The reaction was monitored by TLC (1% MeOH/CH2Cl2 + 0.1% AcOH). After running the 
reaction for 3 h 30 min, the starting material was consumed. The reaction mixture was diluted 
in EtOAc (150 mL) then extracted with 5% aq. citric acid (20 mL), 5% aq.  NaHCO3 (20 mL) 
and brine (20 mL). The organic layer was dried over Na2SO4, filtered and the solvent was 
evaporated to give a brown oil (452 mg) l. Analysis by 1H NMR of the crude product showed 
the lack of a Hβ signal. 
 
Method B: A stirred solution of (173) (196 mg, 0.61 mmol) in anhydrous THF (3 mL), under 
a N2 atmosphere was treated with DIPEA (109 µL, 0.63 mmol), then the reaction mixture was 
cooled to -15 °C. The resulting mixture was treated with isobutyl chloroformate (82 µL, 0.63 
mmol) and the stirring continued at -5 °C for 30 min. The white precipitated solid was filtered 
off and the filtrate was diluted in acetonitrile (2 mL) and treated with 2M TMSCHN2 in Et2O 
(0.61 mL, 1.22 mmol) and stirring continued at 4 °C, for 48 h. TLC (4% MeOH/CH2Cl2) 
showed the disappearance of the starting material and formation a new spot at higher Rf. The 
reaction mixture was diluted in EtOAc (40 mL), then extracted with 5% aq. citric acid (20 mL), 
5% aq. NaHCO3 (20 mL) and brine (20 mL). The organic layer was dried over Na2SO4, filtered 
and the solvents evaporated to give (192) (170 mg, 83%) as a brown oil. Analysis by 1H NMR 
of the crude product showed the desired compound which was used directly in the next step. 
1H NMR (CDCl3, 400 MHz) δ 1.23 (3H, d, J 7.4 Hz, CH(CH3)CO)), 3.28-3.33 (1H, m, Hβ), 
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4.39-4.52 (1H, m, Hα), 4.54-4.67 (2H, m, O-CH2-CH=CH2), 5.15 (2H, s, CH2-Ph), 5.21-5.35 
(2H, m, O-CH2-CH=CH2), 5.59 (1H, s, CH=N=N), 5.82-5.92 (1H, m, O-CH2-CH=CH2), 6.02-
6.05 (1H, m, NH), 7.31-7.37 (5H, m, Ph). 
 
(3R,4R)-3-(Benzyloxycarbonylamino)-4-methyl-5-oxo-5-allyloxypentanoic acid (193) 
 
 
A stirred solution of diazomethylketone (192) (67 mg, 0.19 mmol) in 1,4-dioxane (2 mL) and 
H2O (1 mL), was treated with silver benzoate (7.0 mg, 0.03 mmol) and then the reaction mixture 
was stirred at 70 °C, for 48 h. The reaction was checked by TLC (4% MeOH/CH2Cl2) which 
showed the disappearance of the starting material and the formation of a new spot at lower Rf. 
The reaction mixture was then diluted in 5% aq. NaHCO3 (10 mL), then it was extracted with 
Et2O (20 mL). The aqueous layer was then acidified with saturated aq. citric acid to pH 2 and 
it was extracted with EtOAc (3 x 30 mL) to give a colourless oil (109 mg). The crude material 
was pre-adsorbed into silica and purified by column chromatography using 1% MeOH/CH2Cl2 
eluent to give (193)  (19 mg, 27%); 1H NMR   (CD3OD, 400 MHz) δ 1.24 (3H, d, J 7.6 Hz, 
CH(CH3)CO), 2.53-2.66 (2H, m, CH2-COOH), 2.82-2.94 (1H, m, CH-CHNHZ), 4.27-4.35 
(1H, m, CH-CHNHZ), 4.57-4.66 (2H, m, O-CH2-CH=CH2), 5.09-5.39 (4H, m, O-CH2-
CH=CH2, CH2-Ph), 5.93-6.03 (1H, m, O-CH2-CH=CH2 ), 7.33-7.41 (5H, m, Ph); 13C NMR 
(CD3OD, 101 MHz) δ 14.09 (CH(CH3)CO), 38.09 (CH), 44.63 (CH2-CO2H), 66.36 (O-CH2-
CH=CH2 and CH2-Ph), 67.48 (CH), 118.52 (O-CH2-CH=CH2), 128.76, 128.97, 129.48 (CH 
Ar), 133.61 (O-CH2-CH=CH2), 138.36 (C quaternary), 158.13 (C=O acid), 175.55 (C=O ester); 












Fmoc-D-Pro-OH (222) (507 mg, 1.50 mmol), H-D-Pro-OMe.HCl (223) (249 mg, 1.50 mmol) 
and PyBOP (785 mg, 1.50 mmol) were dissolved in anhydrous CH2Cl2 (5 mL). The reaction 
mixture was treated with DIPEA (0.8 mL, 4.5 mmol) and then stirred at room temperature 
overnight when the starting material was consumed, as shown by TLC (10% MeOH/CH2Cl2). 
The reaction mixture was concentrated under vacuum, and the residue dissolved in EtOAc (20 
mL) and extracted with 5% aq. citric acid (2 x 20 mL), sat. aq. NaHCO3 (2 x 20 mL) and brine 
(2 x 20 mL). The organic extract was dried, filtered and the solvent was evaporated to give a 
yellow oil. The crude material was pre-adsorbed onto silica using CH2Cl2 as a solvent and 
purified by column chromatography (80-90% EtOAc/petroleum ether eluent) to give (224) as 
a colourless oil  (399 mg, 59%) (lit261 Mp 118-120 °C); RP-HPLC (analytical system, gradient 
1) Rt  6.3 min; IR υmax (thin film) 3279 (NH), 3009, 2981, 2956, 2882 (CH), 1743, 1699, 1658 
(C=O), 1433 (Ar, NH), 1355, 1191, 1123 (CO), 752 (CH Ar);  1H NMR (270 MHz, CDCl3) two 
rotamers δ 1.91-2.20 (8H, m, 4 x Hβ Pro, 4 x H Pro), 3.44-3.63 (4H, m, 4 x Hδ  Pro), 3.68 
(1.5H, s, CO2Me), 3.70 (1.5H, s, CO2Me), 4.15-4.30 (2H, m, Fmoc-CH2), 4.33-4.41 (1H, m, 
Fmoc-CH), 4.45-4.60 (2H, m, 2 x Hα Pro), 7.24-7.40 (4H, m, Ar-H Fmoc), 7.51-7.63 (2H, m, 
Ar-H Fmoc), 7.66-7.75 (2H, m, Ar-H Fmoc); 13C NMR  (CDCl3, 101 MHz) δ 22.90, 24.14, 
24.72, 24.74, 24.83 (2 x CH2γ Pro), 28.45, 28.62, 28.94, 29.81 (2 x CH2β Pro), 45.97, 46.45, 
46.64, 47.06 (2 x CH2 δ  Pro), 47.09 (CH Fmoc), 52.01 (OCH3), 58.01, 58.61 (2 x CHα Pro), 
67.28 (CH2 Fmoc), 119.59, 119.77, 124.99, 125.14, 126.87, 126.91, 127.49 (CH Ar), 141.12, 
143.36 (C quaternary), 154.81 (C=O), 170.79 (C=O), 172.45 (C=O ester); [found (ES+) 







Fmoc-L-Pro-OH (225) (507 mg, 1.50 mmol), (226) (249 mg, 1.50 mmol) and PyBOP (785 mg, 
1.50 mmol), were dissolved in anhydrous CH2Cl2 (5 mL). The reaction mixture was treated 
with DIPEA (0.8 mL, 4.5 mmol) and then stirred at room temperature overnight when the 
starting material Fmoc-L-Pro-OMe was consumed by TLC (10% MeOH/CH2Cl2). The reaction 
mixture was concentrated under vacuum and the residue dissolved in EtOAc (20 mL) and 
extracted with 5% aq. citric acid (2 x 40 mL), sat. aq. NaHCO3 (2 x 40 mL) and brine (2 x 40 
mL). The organic extract was dried, filtered and the solvent was evaporated to give a yellow 
oil. The crude material was dissolved in CH2Cl2 and purified by column chromatography (4% 
MeOH/CH2Cl2 eluent) to give (227) as a colourless oil, which crystallised on standing (342 mg, 
51%),( lit 118-120 °C); 1H NMR  (CDCl3, 270 MHz) two rotamers δ 1.70-2.25 (8H, m, 4 x H 
Pro, 4 x H γ  Pro), 3.47-3.55 (4H, m, 4 x Hδ  Pro), 3.63 (1.5H, s, CO2Me),  3.65 (1.5H, s, 
CO2Me), 4.11-4.35  (3H, m, Fmoc-CH2, Fmoc-CH), 4.44-4.50 (2H, m, 2 x Hα Pro), 7.21-7.34 









Fmoc-Gly-OH (228) (446 mg, 1.50 mmol), HOBt (283 mg, 2.10 mmol) and EDC.HCl (287 
mg, 1.50 mmol) were dissolved in anhydrous CH2Cl2 (5 mL) and DMF (5 mL). The resulting 
solution was stirred for 30 min at 0 °C, then   (223) (249 mg, 1.50 mmol) and DIPEA (0.5 mL, 
3 mmol) were added and the resulting mixture was allowed to warm gradually to room 
temperature overnight. The reaction mixture was concentrated under vacuum and the residue 
dissolved in EtOAc (20 mL) and extracted with 5% aq. citric acid (2 x 40 mL), sat. aq. NaHCO3 
(2 x 40 mL) and brine (2 x 40 mL). The organic extract was dried, filtered and the solvent was 
evaporated to give an oil. The crude material was purified by column chromatography (4% 
MeOH/CH2Cl2 eluent) to give (229) as a colourless oil which crystallised on standing (347 mg, 
57%); Mp 82-85°C; IR υmax (thin film) 3359 (NH), 3016, 2955, 2884 (CH), 1727, 1651 (C=O), 
1447 (Ar, NH), 1223, 1178 (CO), 754 (CH Ar); 1H NMR  (CDCl3, 270 MHz) δ 1.84-2.20 (4H, 
m, 2 x Hβ  Pro, 2 x H Pro), 3.38-3.64 (2H, m, 2 x H Pro), 3.70 (3H, s, CO2Me), 3.99 (2H, t, 
J 4.4 Hz, Fmoc-CH2), 4.15-4.20 (1H, m, Fmoc-CH), 4.31 (2H, d, J 7.1 Hz, CH2 Gly), 4.43-
4.54 (1 H, m, Hα Pro), 5.80-5.86 (1 H, m, NH), 7.25 (2H, t, J 7.3 Hz, Ar-H Fmoc), 7.35 (2H, t, 
J 7.3 Hz, Ar-H Fmoc), 7.57 (2H, d, J 7.4 Hz, Ar-H Fmoc), 7.71 (2H, d, J 7.1 Hz, Ar-H Fmoc); 
13C NMR  (CDCl3, 101 MHz) δ 24.62 (CH2γ Pro), 29.00 (CH2β Pro), 43.35 (CH2δ Pro), 45.93, 
(CH2α Gly) 47.08 (CH Fmoc), 52.41 (OCH3), 58.93 (CHα Pro), 67.19 (CH2 Fmoc), 119.93, 
125.16, 126.59, 127.07 (CH Ar), 141.26  , 143.87 (C quaternary), 156.23 (C=O), 167.02 (C=O), 









Boc-L-Pro-OH (230) (323 mg, 1.50 mmol), HOBt (283 mg, 2.10 mmol) and EDC.HCl (287 
mg, 1.50 mmol) were dissolved in anhydrous CH2Cl2 (5 mL). The resulting solution was 
allowed to stir for 30 min at 0 °C.  H-L-Pro-OMe.HCl (226) (249 mg, 1.5 mmol) and DIPEA 
(0.52 mL, 3 mmol) were added and the resulting mixture was allowed to warm gradually to 
room temperature overnight. The reaction mixture was concentrated under vacuum and the 
residue dissolved in EtOAc (20 mL) and extracted with 5% aq. citric acid (2 x 40 mL), sat. aq. 
NaHCO3 (2 x 40 mL) and brine (2 x 40 mL). The organic extract was dried, filtered and the 
solvent was evaporated to give an oil. The crude material was purified by column 
chromatography using 1-5% MeOH/CH2Cl2 eluent, to give (231) as oil (292 mg, 60%); 1H 
NMR  (CDCl3, 270 MHz) δ two rotamers 1.35 (3.5H, s, C(CH3)3 minor rotamer), 1.41 (5.5H, 
s, C(CH3)3 major rotamer), 1.79-2.18 (8H, m, 4 x HPro, 4 x Hβ Pro), 3.32-3.61 (3.4H, m, 3.4 
x Hδ Pro both rotamers), 3.66 (1.7H, s, OMe major rotamer), 3.68 (1.3H, s, OMe minor 
rotamer), 3.70-3.74 (0.6H, m, 0.6 x Hδ Pro major rotamer), 4.36  (0.4H, dd, J 8.0, 4.0 Hz, 0.4 
x Hα Pro minor rotamer), 4.47 (0.6H, dd, J 8.0, 4.0 Hz, 0.6 x Hα Pro major rotamer), 4.49-4.56 









Boc-D-Pro-OH (232) (323 mg, 1.50 mmol), HOBt (283 mg, 2.10 mmol) and EDC.HCl (287 
mg, 1.50 mmol) were dissolved in anhydrous CH2Cl2 (5 mL). The resulting solution was 
allowed to stir for 30 min at 0 °C. Compound (223) (249 mg, 1.50 mmol) and DIPEA (0.52 
mL, 3.0 mmol) were added and the resulting mixture was allowed to warm gradually to room 
temperature overnight. The reaction mixture was concentrated under vacuum and the residue 
dissolved in EtOAc (20 mL) and extracted with 5% aq. citric acid (2 x 40 mL), sat. aq. NaHCO3 
(2 x 40 mL) and brine (2 x 40 mL). The organic extract was dried, filtered and the solvent was 
evaporated to give an oil. The crude material was purified by column chromatography using 1-
3% MeOH/CH2Cl2 eluent, to give (233) as an oil (252 mg, 51%); 1H NMR  (CDCl3, 400 MHz) 
δ two rotamers 1.33 (3.7H, s, C(CH3)3 minor rotamer), 1.39 (5.3H, s, C(CH3)3 major rotamer), 
1.75-2.16 (8H, m, 4 x Hγ Pro, 4 x Hβ Pro), 3.32-3.59 (3.7H, m, 3.7 x Hδ Pro both rotamers), 
3.64 (1.7H, s, OMe major rotamer), 3.66 (1.3H, s, OMe minor rotamer),  3.71-3.73 (0.3H, m, 
0.3 x HδPro minor rotamer), 4.32-4.35 (0.4H, dd, J 8.0, 4.0 Hz, 0.4 x Hα Pro minor rotamer), 










Boc-Gly-OH (234) (263 mg, 1.50 mmol), HOBt (284 mg, 2.10 mmol) and EDC.HCl (288 mg, 
1.50 mmol) were dissolved in anhydrous CH2Cl2 (5 mL). The resulting solution was allowed 
to stir for 30 min at 0 °C. Compound (223) (249 mg, 1.50 mmol) and DIPEA (0.52 mL, 3.0 
mmol) were added and the resulting mixture was allowed to warm gradually to room 
temperature overnight. The reaction mixture was concentrated under vacuum and the residue 
dissolved in EtOAc (20 mL) and extracted with 5% aq. citric acid (2 x 40 mL), sat. aq. NaHCO3 
(2 x 40 mL) and brine (2 x 40 mL). The organic extract was dried, filtered and the solvent was 
evaporated to give an oil. The crude material was purified by column chromatography using 1-
4% MeOH/CH2Cl2 eluent, to give (235) as oil (180 mg, 42%) (lit
257 Mp 55.9 °C); IR υmax (thin 
film) 3399 (NH), 2977, 2884 (CH), 1746, 1715, 1659 (C=O), 1443 (NH ), 1170 (CO); 1H NMR  
(CDCl3, 400 MHz) δ 1.39 (9H, s, C(CH3)3), 1.87-2.10 (4H, m, 2 x Hβ Pro, 2 x Hγ Pro), 3.39-
3.45 (1H, m, 1 x Hδ Pro), 3.52-3.58 (1H, m, 1 x Hδ Pro), 3.68 (3H, s, OMe), 3.87-3.93 (2H, m, 






Boc-D-Ser(OBn)-OH (236) (444 mg, 1.50 mmol), HOBt (283 mg, 2.10 mmol) and EDC.HCl  
(287 mg, 1.50 mmol) were dissolved in anhydrous CH2Cl2 (5 mL) and DMF (5 mL). The 
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resulting solution was allowed to stir for 30 min at 0 °C. Compound (223) (249 mg, 1.5 mmol) 
and DIPEA (0.5 mL, 3 mmol) were added and the resulting mixture was allowed to warm 
gradually to room temperature overnight. The reaction mixture was concentrated under vacuum 
and the residue was dissolved in EtOAc (20 mL) and extracted with 5% aq. citric acid (2 x 40 
mL), sat. aq NaHCO3 (2 x 40 mL) and brine (2 x 40 mL). The organic extract was dried, filtered 
and the solvent was evaporated to give an oil. The crude material was purified by column 
chromatography (4% MeOH/CH2Cl2 eluent) to give (237) an as oil (304 mg, 75%); 1H NMR  
(CDCl3, 270 MHz) two rotamers δ 1.35 (9H, s, C(CH3)3), 1.89-2.15 (3H, m,  2 xHγ Pro, 1 x Hβ 
Pro), 3.36-3.72 (7H, m,  1 x Hβ Pro, 2 x Hδ Pro, 1 x Hβ Ser, CO2Me), 4.41-4.58 (4H, m, 1 x 
Hβ Ser, Hα Ser, CH2Ph), 4.68 (0.8H, q, J 6.1 Hz, 0.8 x Hα Pro major rotamer) 4.74 (0.2H, dd, 
J 8.0, 1.9 Hz, 0.2 x Hα Pro minor rotamer) 5.32 (0.2H, d, J 8.6 Hz,  0.2 x NH minor rotamer), 






Boc-L-Ser(OBn)-OH (238) (443 mg, 1.50 mmol), HOBt (284 mg, 2.10 mmol) and EDC.HCl 
(288 mg, 1.50 mmol) were dissolved in anhydrous CH2Cl2 (5 mL) and DMF (5 mL). The 
resulting solution was allowed to stir for 30 min at 0 °C. Compound (226) (249 mg, 1.50 mmol) 
and DIPEA (0.52 mL, 3.0 mmol) were added and the resulting mixture was allowed to warm 
gradually to room temperature overnight. The reaction mixture was concentrated under vacuum 
and the residue dissolved in EtOAc (20 mL) and extracted with 5% aq. citric acid (2 x 40 mL), 
sat. aq. NaHCO3 (2 x 40 mL) and brine (2 x 40 mL). The organic extract was dried, filtered and 
the solvent was evaporated to give an oil. The crude material was purified by column 
chromatography to give (239) as an oil (507 mg, 83%) (lit Mp ; IR υmax (thin film) 3317 (NH),  
2975,  2877 (CH), 1747, 1710, 1649 (C=O), 1446 (NH), 1170 (CO); 1H NMR  (CDCl3, 400 
MHz) δ two rotamers 1.41 (2.14H, s, C(CH3)3 minor rotamer), 1.42 (6.86H, s, C(CH3)3 major 
rotamer), 1.93-2.26 (3 H, m, 2 x Hγ Pro, 1 x Hβ Pro), 3.61-3.72 (7H, m, 1 x Hβ Pro, 2 xHδ Pro, 
1 x Hβ Ser, CO2Me), 4.46-4.70 (5H, m, 1 x Hβ Ser, CH2Ph, Hα Pro, Hα Ser), 5.35 (1H, d, J 8.0 
Hz, NH), 7.23-7.34 (5H, m, Ph); 13C NMR  (CDCl3, 101 MHz) δ two rotamers 24.80, 22.26 
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(CH2γ Pro), 28.22, 28.27 (C(CH3)3), 28.95, 30.65 (CH2β Pro), 46.37, 46.98 (CH2δ Pro), 51.97, 
52.07 (CH2β Ser), 58.93 (CHα Ser), 59.06 (CHα Pro), 70.49, 73.23 (PhCH2-O), 79.55, 79.68 
(C(CH3)3), 127.39, 127.45, 127.64, 128.25 (CH Ar), 137.79, 137.91 (C quaternary), 154.72, 






Compound (240) (309 mg, 0.500 mmol), (223) (83 mg, 0.50 mmol) and PyBOP (260 mg, 0.500 
mmol) were dissolved in anhydrous CH2Cl2 (7 mL). The reaction mixture was treated with 
DIPEA (0.17 mL, 2.0 mmol) and the reaction mixture was stirred at room temperature until the 
starting material was consumed, as shown by TLC (5% MeOH/CH2Cl2). The reaction mixture 
was concentrated under vacuum and the residue dissolved in EtOAc (20 mL) and extracted with 
5% aq. citric acid (3 x 40 mL), sat. aq. NaHCO3 (3 x 40 mL) and brine (3 x 40 mL). The organic 
extract was dried, filtered and the solvent was evaporated to give a yellow oil. The crude 
material was purified by column chromatography (4% MeOH/CH2Cl2 eluent) to give (241) as 
a white solid (348 mg, 95%); Mp 115-120°C; IR υmax (KBr disc) 3412 (NH), 3060, 3020 (CH), 
1715, 1494, 1447 (Ar, NH), 1213 (CO), 751 (CH Ar). 1H NMR  (CDCl3, 270 MHz) δ 1.89-
2.12 (3H, m, 2 x Hγ Pro, 1 x Hβ Pro), 2.83-2.91 (2H, m, 1 x Hβ Pro, 1 x Hβ-His), 3.06-3.13 
(1H, dd, J 14.7 Hz, 4.8 Hz, 1 x Hβ His), 3.51 (3H, s, CO2Me), 3.63-3.79 (2H, m, 2 x Hδ Pro), 
4.12-4.20 (1H, m, Fmoc-CH), 4.25 (2H, t, J 6.5 Hz, Fmoc-CH2), 4.54-4.56 (1H, m, Hα Pro), 
4.79-4.87 (1H, m, Hα His), 6.06 (1H, d, J 8.3 Hz, NH), 6.73 (1H, s, imidazole ring), 7.09-7.13 
(6H, m, Ar-H), 7.22-7.37 (13H, m, Ar-H, 1 x imidazole ring), 7.57 (2H, d, J 5.6 Hz, Ar-H 
Fmoc), 7.73 (2H, d, J 7.4 Hz, Ar-H Fmoc); 13C NMR  (CDCl3, 101 MHz) δ 24.85 (CH2γ Pro, 
CH2γ His), 28.97 (CH2β Pro), 31.10 (CH2δ Pro), 46.91, (CH2β His) 47.12 (CH Fmoc), 52.09 
(OCH3), 52.70 (CHα Pro), 58.68 (CHα His), 67.11 (CH2 Fmoc), 119.86, 125.31, 127.04, 
127.96, 128.03, 129.86 (CH Ar), 136.06 (CH imidazole ring), 138.63 (C=N), 141.20, 142.48, 
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143.97, 143.99, (C quaternary), 156.05, 170.50 (C=O), 172.40 (C=O); [found (ES+) 731.3166 






Compound (242) (390 mg, 1.00 mmol), (223) (167 mg, 1.00 mmol) and PyBOP (520 mg, 1.00 
mmol), were dissolved in anhydrous CH2Cl2 (7 mL). The reaction mixture was treated with 
DIPEA (0.39 mL, 2.0 mmol) and the reaction mixture was stirred at room temperature 
overnight, until the disappearance of the starting material, Fmoc-D-Phe-OH, was shown by 
TLC (10% MeOH/CH2Cl2). The reaction mixture was evaporated to dryness and the residue 
was dissolved in EtOAc (20 mL) and extracted with 5% aq. citric acid (3 x 40 mL), sat. aq. 
NaHCO3 (3 x 40 mL) and brine (3 x 40 mL). The organic extract was filtered, dried and the 
solvent was evaporated to give a yellow oil. The crude material was purified by column 
chromatography (6-8% MeOH/CH2Cl2 eluent) to give (243) as a colourless oil (393 mg, 79%); 
IR υmax (thin film) 3287 (NH), 2953, (CH), 1717, 1640, 1658 (C=O), 1443 (Ar, NH), 1250 
(CO), 748 (CH Ar); 1H NMR  (CDCl3, 270 MHz) δ 1.67-2.15 (3H, m, 1 x Hβ Pro, 2 x Hγ Pro), 
2.99-3.01 (1H, m, 1 x Hβ Pro), 3.06-3.23 (2H, m, 2 x Hδ Pro), 3.57-3.60 (1H, m, 1 x Hβ Phe), 
3.75 (3H, s, CO2Me), 4.15-4.34 (4H, m, Fmoc-CH, Fmoc-CH2, 1 x Hβ Phe), 4.48-4.52 (1H, m, 
Hα Pro), 4.72 (1H, q, J 7.6 Hz, Hα Phe), 5.69-5.75 (1H, m, NH), 7.25-7.31 (9H, m, Ar-H Fmoc, 
Ph, Phe), 7.51-7.53 (2H, m, Ar-H Fmoc), 7.74 (2H, d, J 7.4 Hz, Ar-H Fmoc ); 13C NMR  
(CDCl3, 101 MHz) δ 24.89 (CH2γ Pro), 29.01 (CH2β Pro), 39.03 (CH2δ Pro), 46.92 (CH2β Phe) 
47.08 (CH Fmoc), 52.24 (OCH3), 53.72 (CHα Pro) , 59.00 (CHα Phe), 67.06 (CH2 Fmoc), 
119.94, 125.21, 126.94, 127.67, 128.59, 129.39 (CH Ar), 136.06, 141.26, 143.81 (C 
quaternary), 155.69, 170.32 (C=O), 172.21 (C=O)); [found (ES+) 499.2239 [M+H]+, 








Compound (244) (557 mg, 1.50 mmol), HOBt (596 mg, 2.10 mmol) and EDC.HCl (431 mg, 
1.50 mmol) were dissolved in anhydrous CH2Cl2 (3.5 mL) and DMF (3.5 mL). The resulting 
solution was allowed to stir for 30 min at 0 °C. Compound (223) (373 mg, 1.50 mmol) and 
DIPEA (0.52 mL, 3.0 mmol) were added to the resulting mixture which was allowed to warm 
gradually to room temperature overnight. The reaction mixture was concentrated under vacuum 
and the residue dissolved in EtOAc (20 mL) and extracted with 5% aq. citric acid (2 x 20 mL), 
sat. aq. NaHCO3 (2 x 20 mL) and brine (2 x 20 mL). The organic extract was dried, filtered and 
the solvent was evaporated to give an oil. The crude material was purified by column 
chromatography (0-1% MeOH/CH2Cl2 eluent) to give (245) as an oil (414 mg, 57%); IR υmax 
(KBr disc) 3296, 3242 (NH),  2933, (CH), 1667 (C=O), 1511, 1441  (Ar, NH), 1240 (CO), 755 
(CH Ar); 1H NMR  (270 MHz, CDCl3) δ two rotamers 1.32 (7.1H, s, C(CH3)3), 1.39 (1.9H, s, 
C(CH3)3), 1.71-1.90 (3H, m, 2 x CHγ Pro, 1 x Hβ Pro), 2.05-2.09 (1H, m, 1 x Hβ Pro), 2.73-
3.01 (2H, m, 2 x Hβ Tyr), 3.07-3.27 (1H, m, 1 x HδPro), 3.50-3.54 (1H, m, 1 x Hδ Pro), 3.62 
(2.3H, s, CO2CH3 major rotamer ), 3.65 (0.7H, s, CO2CH3 minor rotamer), 4.29-4.38 (0.2H, m, 
0.2 x Hα Pro minor rotamer), 4.41-4.48 (0.8H, m, Hα Pro major rotamer), 4.51-4.60 (1H, m, 
HαTyr), 4.78 (2H, s, PhCH2-O-), 6.77-6.90 (2H, m Ar-H), 7.01-7.18 (2H, m, Ar-H), 7.29-7.40 







Compound (246) (994 mg, 1.50 mmol), (226) (249 mg, 1.50 mmol) and PyBOP (780 mg, 1.50 
mmol) were dissolved in anhydrous CH2Cl2 (7 mL). The reaction mixture was treated with 
DIPEA (0.52 mL, 3.0 mmol) and then stirred at room temperature overnight until the Fmoc-L-
Arg(Pmc)-OH  was consumed, as shown by TLC (5% MeOH/CH2Cl2). The solvent was 
evaporated and the residue dissolved in EtOAc (20 mL) and extracted with 5% aq. citric acid 
(3 x 50 mL), sat. aq. NaHCO3 (3 x 50 mL) and brine (3 x 50 mL). The organic extract was 
dried, filtered and the solvent evaporated to give a white solid. The crude material was purified 
by column chromatography (0-1% MeOH/CH2Cl2 eluent) to give (247) as a white solid (815 
mg, 70%); 1H NMR  (CDCl3, 400 MHz) δ 1.25 (6H, s, 2 x CH3 Pmc), 1.58-1.68 (2H, m, 2 x Hγ 
Arg), 1.74-1.79 (2H, m,  CH2 Pmc), 1.90-2.03 (5H, m, 2 x Hβ Arg, 1 x Hβ-Pro, 2 x Hγ Pro), 
2.09 (3H, s, Pmc Ar-Me), 2.16-2.21 (1H, m, 1 xH Pro), 2.55-2.62 (6H, m, Pmc 2 x Ar-Me), 
3.21-3.22 (2H, m, 2 x Hγ Arg), 3.56-3.58 (2H, m, 2 x Hδ Pro), 3.66 (3H, s, CO2Me), 4.13-4.17 
(1H, m, Fmoc-CH), 4.28-4.35 (2H, m, Fmoc-CH2), 4.48-4.51 (2H, m,  Hα Arg, Hα Pro), 5.97-
6.10 (4H, m, 4 x Arg NH), 7.24-7.29 (2H, m, Ar-H Fmoc), 7.34-7.39 (2H, m, Ar-H Fmoc), 
7.54-7.56 (2H, m, Ar-H Fmoc), 7.72-7.74 (2H, m, Ar-H Fmoc); 13C NMR  (CDCl3, 400 MHz) 
δ 12.02 (CH3 Pmc), 17.38 (CH3 Pmc), 18.41 (CH3 Pmc), 21.37 (CH2, Pmc), 25.01 (2 x CH2, 
CH2γ, Arg/Pro), 26.69 (2 x CH3, Pmc) 28.93 (2 x CH2, CH2β, Arg/Pro), 32.82 (CH2, Pmc), 
40.69 (CH2δ Arg), 47.11 (CH, Fmoc), 51.69 (CH2δ, Pro), 52.55 (OMe), 58.91 (CHα, Arg), 
67.01 (CHα, Pro), 73.49 (CH2 Fmoc), 117.80 ( SO2-CAr Pmc), 119.95, 123.87 ,124.96, 127.70 
(CH, Ar), 133.54, 134.89, 135.53, 141.27 (C quaternary from Pmc), 143.58, 143.70 (C, 








Compound (246) (994 mg, 1.50 mmol), (223) (249 mg, 1.5 mmol) and PyBOP (780 mg, 1.5 
mmol) were dissolved in anhydrous CH2Cl2 (7 mL). The reaction mixture was treated with 
DIPEA (0.52 mL, 3 mmol) and then stirred at room temperature overnight until the Fmoc-L-
Arg(Pmc)-OH  was consumed, as shown by TLC (5% MeOH/CH2Cl2). The solvent was 
evaporated and the residue dissolved in EtOAc (20 mL) and extracted with 5% aq. solution of 
citric acid (3 x 50 mL), sat. aq. solution of NaHCO3 (3 x 50 mL) and brine (3 x 50 mL). The 
organic extract was dried and filtered and evaporated to give white solid. The crude material 
was purified by column chromatography (0-2% MeOH/CH2Cl2 gradient) to give (248) as a 
white solid (985 mg, 85%); [α] 21 D = +1.44 (c 1.04, in MeOH); Mp 115-120°C; IR υmax (KBr 
disc) 3438, 3347 (NH),  2951, (CH), 1727, 1632 (C=O), 1549, 1446 (Ar, NH), 1247 (CO), 1109 
(SO2), 745 (CH Ar); 1H NMR (400 MHz, CDCl3) two rotamers δ 1.25 (6H, s, 2 x CH3 Pmc), 
1.56-1.65 (2H, m, 2 x HγArg), 1.70-1.78 (2H, m, CH2 Pmc), 1.80-2.04 (5H, m, 2 x Hβ Arg,  1 
x Hβ Pro, 2 x Hγ-Pro), 2.07 (3H, s, Pmc Ar-Me), 2.12-2.18 (1H, m, 1 x H Pro), 2.51-2.59 (6H, 
m, 2 x Pmc Ar-Me), 3.10-3.18 (2H, m, 2 x Hγ Arg), 3.48-3.58 (2H, m,  2 x Hδ Pro), 3.67 (2H, 
s, CO2Me), 3.71 (1H, s, CO2Me),  4.10-4.16 (1H, m, Fmoc-CH), 4.26-4.34 (2H, m, Fmoc-CH2), 
4.37-4.42 (1H, m, Hα Arg), 4.46-4.49 (1H, m, Hα Pro ), 5.97-6.09 (4H, m, 4 x NH, Arg), 7.22-
7.28 (2H, m, Ar-H  Fmoc), 7.34-7.37 (2H, m, Ar-H  Fmoc), 7.51-7.56 (2H, m, Ar-H Fmoc), 
7.71-7.73 (2H, m, Ar-H Fmoc); 13C NMR (CDCl3, 400 MHz) δ 12.02 (CH3 Pmc), 17.36 (CH3 
Pmc), 18.43 (CH3 Pmc), 21.33 (CH2, Pmc), 24.55 (2 x CH2, CH2γ Arg/Pro), 26.67 (2 x CH3, 
Pmc) 28.91 (2 x CH2, CH2β Arg/Pro), 32.74 (CH2, Pmc), 40.80 (CH2δ Arg), 47.05 (CH, Fmoc), 
52.28 (CH2δ Pro), 52.83 (OCH3), 59.21 (CHα Arg), 67.09 (CHα Pro), 73.54 (CH2, Fmoc), 
117.87 (SO2-C Ar Pmc), 119.85, 119.87, 125.09, 127.02, 127.66 (CH Ar), 133.32, 134.79, 
135.41, 141.18 (C quaternary from Pmc), 143.56, 143.77 (C quaternary from Fmoc), 153.52 
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Fmoc-D-Arg(Pmc)-OH (249) (994 mg, 1.50 mmol), (226) (249 mg, 1.50 mmol) and PyBOP 
(780 mg, 1.50 mmol) were dissolved in anhydrous CH2Cl2 (7 mL). The reaction mixture was 
treated with DIPEA (0.52 mL, 3.0 mmol) and the reaction mixture was stirred at room 
temperature overnight until Fmoc-D-Arg(Pmc)-OH  was consumed, as shown by TLC (5% 
MeOH/CH2Cl2). The solvent was evaporated and the residue dissolved in EtOAc (20 mL) and 
extracted with 5% aq. citric acid (3 x 50 mL), sat. aq. NaHCO3 (3 x 50 mL) and brine (3 x 50 
mL). The organic extract was dried, filtered and the solvent evaporated to give a white solid. 
The crude material was purified by column chromatography (0-2% MeOH/CH2Cl2 eluent) to 
give (250) as a white solid (985 mg, 85%); [α] 21 D = -1.41 (c 1.56, in MeOH);   Mp 105-110°C; 
IR υmax (KBr disc) 3437, 3341 (NH),  2956, (CH), 1727, 1629 (C=O), 1548, 1446  (Ar, NH), 
1244 (CO), 1108 (SO2), 751 (CH Ar); 1H NMR  (CDCl3, 400 MHz) two rotamers δ 1.26 (6H, 
s, 2 x CH3 Pmc), 1.56-1.68 (2H, m, 2 x Hγ Arg), 1.75-1.82 (2H, m,  CH2 Pmc), 1.89-2.05 (5H, 
m, 2 x Hβ Arg, 1 x Hβ Pro, 2 x Hγ Pro), 2.09 (3H, s, Me-Ar, Pmc), 2.14-2.19 (1H, m,  1 x H 
Pro), 2.55-2.61 (6H, m, 2 x Me-Ar, Pmc), 3.10-3.18 (2H, m, 2 x Hγ Arg), 3.51-3.55 (2H, m, 2 
x HδPro ), 3.67 (2H, s, CO2Me), 3.72 (1H, s, CO2Me),  4.13-4.19 (1H, m, CH-Fmoc), 4.31-
4.37 (2H, m, CH2-Fmoc), 4.40-4.42 (1H, m, Hα Arg), 4.48-4.52 (1H, m, Hα Pro), 5.85-5.87 
(1H, m, NH Arg), 6.04-6.07 (3H, m, 3 x NH, Arg), 7.25-7.29 (2H, m, Ar-H Fmoc), 7.35-7.39 
(2H, m, Ar-H Fmoc), 7.51-7.57 (2H, m, Ar-H Fmoc), 7.72-7.74 (2H, m, Ar-H Fmoc); 13C NMR  
(CDCl3, 400 MHz) δ 12.02 (CH3 Pmc), 17.36 (CH3 Pmc), 18.43 (CH3 Pmc), 21.35 (CH2, Pmc), 
24.54 (CH2, CH2γ Arg/Pro), 26.69 CH3 (2 x CH3, Pmc) 28.96 (CH2, CH2βArg/Pro), 32.76 (CH2, 
Pmc), 40.92 (CH2δ Arg), 47.10 (CH, Fmoc), 52.22 (CH2δ Pro), 55.36 (OCH3), 59.18 (CHα 
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Arg), 67.06 (CHα Pro), 73.54 (CH2, Fmoc), 117.87 (C, C-SO2, Ar Pmc), 119.89, 123.96, 125.05, 
127.03, 127.68 (CH Ar), 133.38, 134.78, 135.41 C (C quaternary from Pmc), 141.22, 143.75 C 
(C quaternary from Fmoc), 153.52 (C=N), 155.93, 156.44, 172.27 (C=O); [found (ES+) 
796.3379 [M+Na]+, requires 796.3356 C41H51N5O8SNa]. 
 
Fmoc-D-Arg(Pmc)-D-Pro-OMe (251) 
                
Compound (249) (407 mg, 0.61 mmol), (223) (101 mg, 0.61 mmol) and PyBOP (317 mg, 0.61 
mmol) were dissolved in anhydrous CH2Cl2 (7 mL). The reaction mixture was treated with 
DIPEA (0.21 mL, 1.2 mmol) and then stirred at room temperature overnight until the Fmoc-D-
Arg(Pmc)-OH  was consumed, as shown by TLC (5%MeOH/CH2Cl2). The solvent was 
evaporated and the residue dissolved in EtOAc (20 mL) and extracted with 5% aq. citric acid 
(3 x 50 mL), sat. aq. NaHCO3 (3 x 50 mL) and brine (3 x 50 mL). The organic extract was dried 
and filtered to give a white solid. The crude material was purified by column chromatography 
(0-2% MeOH/CH2Cl2 eluent) to give (251) as a white solid (357 mg, 76%); Mp 117-122 °C; 
IR υmax (KBr disc) 3438, 3341 (NH), 2951, (CH), 1727, 1634 (C=O), 1549, 1446  (Ar, NH), 
1248 (CO), 1109 (SO2), 742 (CH Ar); 1H NMR  (CDCl3, 400 MHz) δ 1.26 (6H, s, 2 x CH3 
Pmc), 1.58-1.70 (2H, m, 2 x Hγ-Arg), 1.77 (2H, t, J 8 Hz,  CH2 Pmc), 1.89-2.05 (5H, m, 2 x 
Hβ Arg, 2 x H Pro, 1 x H Pro), 2.10 (3H, s, Me-Ar, Pmc), 2.16-2.24 (1H, m, 1 x H Pro), 
2.56-2.63 (6H, m, 2 x Me-Ar, Pmc), 3.21-3.23 (2H, m, 2 x Hγ Arg), 3.54-3.60 (2H, m, 2 x Hδ 
Pro), 3.65 (3H, s, CO2Me), 4.14-4.17 (1H, m, CH-Fmoc), 4.29-4.38 (2H, m, CH2-Fmoc), 4.48-
4.51 (2H, m, Hα Arg, Hα Pro), 5.84 (1H, m, 1 x NH Arg), 5.94-5.96 (1H, m, 1 x NH Arg), 6.08 
(2H, m, 2 x NH Arg), 7.25-7.29 (2H, m, Ar-H Fmoc), 7.35-7.39 (2H, m, Ar-H Fmoc), 7.51-
7.56 (2H, m, Ar-H  Fmoc), 7.72-7.74 (2H, m, Ar-H Fmoc); 13C NMR (CDCl3, 400 MHz) δ 
12.03 (CH3 Pmc), 17.39 (CH3 Pmc), 18.43 (CH3 Pmc), 21.36 (CH2, Pmc), 23.78 (CH2γ Arg), 
24.98 (CH2γ Pro) 26.69 (2 x CH3, Pmc), 28.92 (CH2β Arg), 29.05 (CH2β Pro) 32.80 (CH2, 
Pmc), 40.68 (CH2δ Arg), 47.09 (CH, Fmoc), 51.83 (CH2δ Pro), 52.48 (OCH3), 58.96 (CHα 
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Arg), 67.00 (CHα Pro), 73.50 (CH2, Fmoc), 117.81 (CAr-SO2 Pmc), 119.88, 119.91, 123.87, 
125.03, 125.08, 126.99, 127.64 (CH, Ar), 133.55 ,134.85, 135.49 (C quaternary from Pmc), 
141.21, 143.64, 143.72 (C quaternary from Fmoc), 153.44 (C=N), 156.44, 170.46, 172.43 (C=O 
ester); [found (ESI+) 774.3550 [M+H]+, C41H52N5O8 requires 774.3536]. 
 




Compound (224) (149 mg, 0.33 mmol) was dissolved in anhydrous DMF (1.5 mL) and treated 
with Et2NH (1.5 mL, 0.14 mol), at room temperature for 10 min, until the starting material was 
consumed as shown by TLC (EtOAc/petroleum ether: 1/1). The reaction mixture was then co-
evaporated to dryness with toluene to remove residual DMF to give a brown oil. The residue 
was dissolved in MeOH (15 mL) and was stirred at 65 °C, for 2 h, until the lower UV-active 
spot was replaced by a new spot at Rf 0.42 (50% EtOAc/petroleum ether). The reaction mixture 
was concentrated under vacuum and triturated with petroleum ether. The compound was 
purified by column chromatography using MeOH/CH2Cl2 as eluent; this gave the cyclic 








Compound (233) (230 mg, 0.71 mmol) was treated with 4M HCl-dioxane (2 mL) at room 
temperature for 30 min,  until the starting material was consumed as shown by TLC. The 
reaction mixture was evaporated to dryness and the residue redissolved in anhydrous MeOH 
(10 mL) and DIPEA (0.50 mL, 2.9 mmol) and the reaction mixture was stirred at 65 °C 
overnight. The solvent were evaporated and the residue was dissolved in H2O and extracted 
with CH2Cl2 (2 x 10). The combined organic layers were filtered and dried  to give (252) as a 
white solid (45 mg, 33%) (lit259 Mp 141-143 °C); 1H NMR  (CD3OD, 400 MHz) δ 1.19-2.22 
(6H, m, 4 x Hγ Pro, 2 x Hβ Pro), 2.32-2.39 (2H, m, 2 x Hβ Pro), 3.55-3.59 (4H, m, 4 x Hδ Pro), 
4.41 (2H, t, J 8 Hz, 2 x Hα Pro).222  
 




Compound (227) (342 mg, 0.76 mmol) was dissolved in anhydrous DMF (1.5 mL) and treated 
with Et2NH (1.5 mL, 0.14 mol), at room temperature for 10 min, until disappearance of the 
starting material was shown by TLC (10% MeOH/CH2Cl2). The reaction mixture was 
evaporated to dryness and then co-evaporated with toluene to remove residual DMF to give an 
oil. The residue was dissolved in MeOH (15 mL) and was then stirred at 65 °C, for 2 h, until 
the lower UV-active was replaced by a new spot at Rf 0.86 (10% MeOH/CH2Cl2). The reaction 
mixture was concentrated under vacuum and triturated with petroleum ether. The compound 
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was purified by column chromatography using MeOH/CH2Cl2 as eluent. This gave the cyclic 
dipeptide (215), plus the by-product from Fmoc deprotection. 
 




Compound (231) (150 mg, 0.46 mmol) was treated with 4M HCl-dioxane (2 mL) at room 
temperature for 40 min,  until the starting material was consumed as shown by TLC. The 
reaction mixture was evaporated to dryness and the residue redissolved in anhydrous MeOH 
(10 mL) and DIPEA (0.40 mL, 2.3 mmol) and the reaction mixture was stirred at 65 °C 
overnight. The solvent were evaporated and the residue was dissolved in H2O and extracted 
with CH2Cl2 (2 x 10 mL). The combined organic layers were filtered and dried  to give (215) 
as a white solid (29.8 mg, 33%); Mp 138-142 °C, (lit259 141-143 °C); IR υmax (KBr disc) 3435, 
3209 (NH), 2957 (CH), 1661 (C=O), 1458 (NH); 1H NMR  (CD3OD, 400 MHz) δ 1.97-2.19 
(6H, m, 4 x Hγ Pro,  2 x Hβ Pro), 2.32-2.40 (2H, m, 2 x Hβ Pro), 3.51-3.62 (4H, m, 4 x Hδ Pro), 
4.42 (2H, t, J 8 Hz, 2 x Hα Pro); 13C NMR  (CDCl3, 101 MHz) δ 24.19 CH2γ Pro, 28.74 CH2 
CH2β Pro, 46.22 CH2δ Pro, 61.76 CHα Pro, 168.63 (C=O); [found (ESI+) 195.1111 [M+H]+, 








Compound (229) (347 mg, 0.850 mmol) was dissolved in anhydrous DMF (15 mL) and treated 
with Et2NH (1.5 mL, 0.14 mol), at room temperature for 10 min,  until the starting material was 
consumed as shown by TLC (10% MeOH/CH2Cl2) and a new lower UV-active spot appeared. 
The reaction mixture was evaporated to dryness and then co-evaporated with toluene to remove 
residual DMF to give a yellow oil. The residue was dissolved in MeOH (15 mL)  and stirred at 
65 °C, for 24 h, until the lower UV-active spot was replaced by a new spot at Rf  0.42 (10% 
MeOH/CH2Cl2). The reaction mixture was concentrated under vacuum and triturated with 
petroleum ether. The compound was purified by column chromatography using MeOH/CH2Cl2 
as eluent. This gave the cyclic dipeptide (253), plus the by-product from Fmoc deprotection. 
 




Compound (234) (157 mg, 0.55 mmol) was treated with 4M HCl-dioxane (2 mL) at room 
temperature for 45 min,  until the starting material was consumed as shown by TLC at Rf 0.73 
(5% MeOH/CH2Cl2). The reaction mixture was evaporated to dryness and the residue 
redissolved in anhydrous MeOH (10 mL) and DIPEA (0.40 mL, 2.3 mmol) and the reaction 
220 
 
mixture was stirred at 65 °C overnight. The solvent was evaporated and the residue was 
dissolved in H2O and extracted with CH2Cl2 (2 x 10 mL). The combined organic layers were 
filtered and dried to give a white solid (155 mg). The crude material was purified by column 
chromatography using 10-20% EtOAc/petroleum ether as eluent, to give (253) as a white solid 
(37.8 mg, 45%);  Mp 201-205 °C (lit264 Mp 205-208 °C); IR υmax (KBr disc) 3414 (NH), 2922, 
2852 (CH), 1655 (C=O), 1458 (NH); 1H NMR  (CD3OD, 400 MHz) δ 1.97 (3H, m, 2 x Hγ Pro, 
1 x Hβ Pro), 2.36-2.42 (1H, m, 1 x Hβ Pro), 3.56-3.65 (2H, m, 2 x Hδ Pro), 3.81 (1H, d, J 16.0 
Hz, CHα Gly), 4.15- 4.19 (1H, m, 1 x HαGly), 4.28-4.31 (1H, m, Hα Pro); 13C NMR  (CDCl3, 
101 MHz) δ 23.33 (CH2γ Pro), 29.40 (CH2β Pro), 46.34 (CH2δ Pro), 47.03 (CH2α Gly), 59.88 







Compound (237) (304 mg, 0.75 mmol) was treated with 4M HCl-dioxane at room temperature 
for 40 min, until the starting material was consumed as shown by TLC at Rf 0.77 (10% 
MeOH/CH2Cl2). The reaction mixture was evaporated to dryness and the residue redissolved 
in DMF (7 mL) and DIPEA (0.60 mL, 3.44 mmol) and the reaction mixture was stirred at 80 
°C, overnight. The reaction mixture was evaporated to dryness and then co-evaporated with 
toluene to remove residual DMF to give a brown oil. The resulting brown oil was purified by 
column chromatography (0-2% MeOH/CH2Cl2 eluent) and the oil obtained was dissolved in 
CH2Cl2 and precipitated with petroleum ether to give (254) as a brown solid (94 mg, 46%); RP-
HPLC (analytical system, gradient 1)  Rt = 6.68 min; Mp 133-135 °C; IR υmax (KBr disc) 3443, 
3237 (NH), 2929, 2883 (CH), 1677 (C=O), 1448 (Ar, NH), 1109 (CO), 741 (CH Ar); 1H NMR  
(CDCl3, 270 MHz) δ 1.90-2.07 (3H, m, 1 x H Pro, 2 x Hγ Pro), 2.32-2.38 (1H, m, 1 x Hβ Pro), 
3.51-3.64 (3H, m, 1 x Hβ-Ser, 2 x Hδ Pro), 4.05-4.10 (2H, m, 1 x Hβ Ser, Hα Ser), 4.31 (1H, 
dd, J 10.3, 3.8 Hz Hα Pro), 4.55 (2H, ABq, J 6.1, 1.6 Hz, CH2Ph), 6.25 (1H, br, NH),  7.25-
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7.35 (5H, m, Ph); 13C NMR  (CDCl3, 101 MHz) δ 22.48 (CH2γ Pro), 28.38 (CH2β Pro), 45.30 
(CH2δ Pro), 54.44 (CHα Ser), 58.93 (CHα Pro), 68.77 (CH2β Ser), 73.61 (CH2Ph), 127.93, 







Compound (239) (430 mg, 1.06 mmol) was treated with 4M HCl-dioxane (3 mL) at room 
temperature for 40 min,  until the starting material was consumed as shown by TLC at Rf  0.22 
(5% MeOH/CH2Cl2). The reaction mixture was evaporated to dryness and the residue 
redissolved in DMF (7 mL) and DIPEA (0.60 mL, 3.4 mmol) and the reaction mixture was 
stirred at 80 °C, overnight. The reaction mixture was evaporated to dryness and then co-
evaporated with toluene to remove residual DMF to give brown oil. The resulting brown oil 
was purified by column chromatography (2% MeOH/CH2Cl2 eluent), to give (255) as a pale 
brown solid (153 mg, 53%); [α]21 D = -9.06 (c 1.38, in MeOH); Mp 135-138 °C; IR υmax (KBr 
disc) 3439, 3227 (NH), 2876 (CH), 1676 (C=O), 1448 (Ar, NH), 1110 (CO), 741 (CH Ar); 1H 
NMR  (CDCl3, 400 MHz) δ 1.82-1.98 (1H, m, 1 x HγPro), 1.99-2.12 (2H, m, 1 xHγ Pro, 1 x 
Hβ Pro), 2.30-2.40 (1H, m, 1 x Hβ Pro), 3.44-3.65 (3H, m, 1 x Hβ Ser, 2 x Hδ Pro), 4.07-4.12 
(2H, m, 1 x Hβ Ser, Hα Ser), 4.30 (1H, dd, J 9.4, 3.3 Hz, Hα Pro), 4.55 (2H, ABq, J 11.6 Hz 
CH2Ph), 6.25 (1H, br, NH), 7.25-7.35 (5H, m, Ph); 13C NMR  (CDCl3, 101 MHz) δ 22.41 (CH2γ 
Pro), 28.31 (CH2β Pro), 45.22 (CH2δ Pro), 54.47 (CHαSer), 58.87 (CHα Pro), 68.75 (CH2β 









Compound (241) (348 mg, 0.48 mmol) was dissolved in anhydrous DMF (1.5 mL) and treated 
with Et2NH (1.5 mL, 0.14 mol), at room temperature for 10 min, until the starting material was 
consumed as shown by TLC (10% MeOH/CH2Cl2). The reaction mixture was evaporated to 
dryness and then co-evaporated with toluene to remove residual DMF to give a colourless oil. 
The residue was dissolved in toluene (15 mL) and was stirred at 110 °C, for 24 h, until the lower 
UV-active spot was replaced by a new spot at Rf  0.51 TLC (5% MeOH/CH2Cl2). The crude 
material was purified by column chromatography (0-3% MeOH/CH2Cl2 eluent) to give (256) 
as a pale white solid (88 mg, 38%); RP-HPLC (analytical system, gradient 1), Rt = 7.2 min; 
Mp above 230 °C; IR υmax (KBr disc) 3439, 3236 (NH), 2892 (CH), 1662 (C=O), 1431 (Ar, 
NH), 756 (CH Ar); 1H NMR  (CDCl3, 270 MHz) δ 1.82-2.06 (3H, m, 1 x Hβ Pro, 2 x Hγ Pro), 
2.30-2.35 (1H, m, 1 x Hβ Pro), 2.60-2.79 (1H, dd, J 10.7 Hz, 4.4 Hz, 1 x Hβ His), 3.34 (1H, dd, 
J 12.1 Hz, 3.0 Hz, 1 x Hβ His), 3.51-3.55 (2H, m, 2 x Hδ Pro), 4.04 (1H, t, J 7.4 Hz, Hα His), 
4.17 (1H, d, J 9.4 Hz, Hα Pro), 6.66 (1H, br, NH), 6.95-7.42 (16H, 3 x Ph, 1 x H imidazole 
ring), 7.63 (1H, s, H imidazole ring);  13C NMR  (CDCl3, 101 MHz) δ  22.58 (CH2γ Pro), 28.15 
(CH2β Pro), 28.40 (CH2β His), 45.40 (CH2δ Pro), 55.79 (CHα His), 59.05 (CHα Pro), 119.23 
(CH imidazole ring), 128.07, 129.67 (CH Ar), 137.00  (C quaternary), 138.93  (C=N), 142.20 
(C quaternary from CPh3), 165.45, 169.28 (C=O); [found (ESI+) 477.2281 [M+H]
+, 








Compound (243) (350 mg, 0.70 mmol) was dissolved in anhydrous DMF (3 mL) and treated 
with Et2NH (3.0 mL, 0.28 mol), at room temperature for 15 min, when the starting material was 
consumed as shown by TLC (10% MeOH/CH2Cl2). The reaction mixture was evaporated to 
dryness and then co-evaporated with toluene to remove residual DMF to give an oil. The residue 
was dissolved in toluene (15 mL) was stirred at 110 °C, for 96 h, until the lower UV-active spot 
was replaced by a new spot TLC (5% MeOH/CH2Cl2).The crude material was dissolved in 
CH2Cl2 and purified by column (2-3% MeOH/CH2Cl2 eluent) to give (213) as a brown oil (20 
mg, 12%), (lit260 Mp 130-132 °C); RP-HPLC (analytical system, gradient 1),  Rt = 6.3 min); 
IR υmax (thin film) 3247 (NH), 2995(CH), 1669 (C=O), 1439 (Ar, NH), 753 (CH Ar);  1H NMR  
(CDCl3, 270 MHz) δ 1.89-1.98 (3H, m, 1 x Hβ Pro, 2 x Hγ Pro), 2.28-2.33 (1H, m, 1 x Hβ Pro), 
2.77 (1H, dd, J 13.9,  10.5 Hz, 1 x Hβ Phe), 3.48-3.64 (3H, m,  1 x Hβ-Phe, 2 x Hδ Pro), 4.04 
(1H, t, J 7.6 Hz, Hα Phe), 4.25 (1H, dd, J 10.5 , 2.7 Hz, HαPro), 5.76 (1H, br, NH),  7.21-7.43 
(5H, m, Ph); 13C NMR (CDCl3, 101 MHz) δ 22.50 (CH2γ Pro), 28.31 (CH2β Pro), 36.75 (CH2β 
Phe), 45.40 (CH2δ Pro), 56.16 (CHα Phe), 59.09 (CHα Pro), 127.50, 129.01, 129.10 (CH Ar), 
135.90 (C quaternary), 165.03, 169.39 (C=O); [found (ES+) 267.1093 [M+Na]+, 





Cyclo (D-Tyr(OBn)-D-Pro) (257) 
 
 
Compound (257) (414 mg, 0.86 mmol) was treated with 4M HCl-dioxane (2 mL) at room 
temperature for 40 min, until the starting material was consumed as shown by TLC. The 
reaction mixture was evaporated to dryness and the residue redissolved in DMF (7 mL) and 
DIPEA (0.90 mL, 5.2 mmol) and stirred at 80 °C, overnight. The reaction mixture was 
evaporated to dryness and then co-evaporated with toluene to remove residual DMF to give a 
brown oil. The resulting brown oil was purified by column chromatography (0-2% 
MeOH/CH2Cl2 eluent), to give (257) as an oil (193 mg, 64%); 1H NMR (CD3OD, 270 MHz) δ 
1.67-1.94 (3H, m, 2 x Hγ Pro, 1 x H βPro), 2.12-2.35 (1H, m, 1 x Hβ Pro), 2.81 (1H, dd, J 23.2, 
8.5 1 x Hβ Tyr), 3.34-3.64 (3H, m, 1 x Hβ Tyr, 2 x Hδ Pro), 3.88-4.25 (1H, m, Hα Pro), 4.12-
4.24 (1H, m, Hα Tyr), 4.98 (2H, s, PhCH2-O), 6.38 (1H, s, NH), 6.78-6.95 (2H, m, Ar-H), 7.05-
7.18 (2H, m, Ar-H), 7.20-7.46 (5H, m, Ph). 
 




Compound (247) (808 mg, 1.04 mmol) was dissolved in anhydrous DMF (2 mL) and treated 
with Et2NH (2.0 mL, 0.19 mol), at room temperature for 30 min, until the starting material was 
consumed as shown by TLC (10% MeOH/CH2Cl2). The solvent was evaporated to dryness then 
co-evaporated with toluene to remove residual DMF to give an oil. The residue was dissolved 
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in MeOH (20 mL) and was stirred at room temperature, for 2 days, until the lower UV-active 
spot was replaced by a new spot at Rf 0.42 (10% MeOH/CH2Cl2). The crude material was 
purified by column chromatography (5-15% MeOH/CH2Cl2 eluent) to give (258) as a yellow 
solid (482 mg, 89%); RP-HPLC (analytical system, gradient 2) Rt = 12.5 min); [α] 19 D = -2.47 
(c 3.37, in MeOH); Mp 108-112 °C; IR υmax (KBr disc) 3447, 3349 (NH), 2971, 2935 (CH), 
1661, 1551 (C=O), 1441 (Ar, NH), 1298, 1245 (CO), 1110 (SO2), 749, 666, 612 (CH Ar);   1H 
NMR   (CDCl3, 400 MHz) δ 1.29 (6H, s, 2 x Me, Pmc), 1.63-1.72 (2H, m,  2 x H Arg ), 1.79 
(2H, t, J 6.8 Hz, CH2, Pmc) 1.84-2.06 (5H, 2 x H Pro, 1 x H Pro,  2 x H Arg), 2.09 (3H, s, 
Me-Ar Pmc), 2.33-2.40 (1H, m, 1 x H Pro), 2.54 (6H, m, 2 x CH3, Ar-Me, Pmc), 2.61 (2H, t, 
J 6.8 Hz, CH2, Pmc), 3.17-3.21 (2H, m, 2 x Hδ Arg), 3.47-3.60 (2H, m, 2 x Hδ Pro), 4.06-4.11 
(2H, m, Hα Arg, Hα Pro), 6.23-6.30 (3H, m, 3 x NH Arg); 13C NMR  (CDCl3, 101 MHz) δ 
12.05, 17.38, 18.43 CH3  (Pmc, Me), 21.34 (2 x CH2 Pmc), 22.49 (CH2γ Pro, CH2γ Arg), 26.70, 
26.72 (Me-Ar, Pmc) 28.19 (CH2β Pro, CH2β Arg), 32.73 (CH2δ Arg), 45.23 (CH2δ Pro), 54.86 
(CHα Arg), 59.02 (CHα Pro), 73.61 (C quaternary Pmc), 117.95, 123.95, 133.25, 134.75, 
135.32 153.51 (C quaternary), 156.40, 165.73, 170.75, 170.79  (2 x C=O, C=N).  
 




Method A:  Compound (249) (904 mg, 1.17 mmol) was dissolved in anhydrous DMF (2 mL) 
and treated with Et2NH (2 mL, 0.19 mol), at room temperature for 30 min, until the starting 
material was consumed as shown by TLC (10% MeOH/CH2Cl2). The reaction mixture was 
evaporated to dryness then co-evaporated with toluene to remove residual DMF to give an oil. 
The residue was dissolved in MeOH (15 mL) and was stirred at 65 °C, for 48 h, until the lower 
UV-active spot was replaced by a new spot at Rf 0.37 (8% MeOH/CH2Cl2). The crude material 
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was purified by column chromatography (0-3% MeOH/CH2Cl2 eluent) to give a yellow solid 
(485 mg). Analysis by HPLC showed two peaks. 
 
Method B: Compound (249) (950 mg, 1.22 mmol) was dissolved in anhydrous DMF (2 mL) 
and treated with Et2NH (2.0 mL, 0.19 mol), at room temperature for 30 min, until the starting 
material was consumed as shown by TLC (8% MeOH/CH2Cl2). The reaction mixture was 
evaporated to dryness then co-evaporated with toluene to remove residual DMF to give an oil. 
The residue was dissolved in MeOH (15 mL) and was stirred at room temperature, for 2 days, 
until the lower UV-active spot was replaced by a new spot at Rf  0.47 (10% MeOH/CH2Cl2). 
The crude material was purified by column chromatography (4-6% MeOH/CH2Cl2 eluent) to 
give (259) as a yellow solid (536 mg, 84%); RP-HPLC ((analytical system, gradient 2) Rt = 
12.4); [α]19 D = +9.05 (c 0.53, in MeOH); Mp 125-130 °C; IR υmax (KBr disc) 3439, 3348 (NH), 
2976, 2934 (CH), 1670, 1553 (C=O), 1445 (Ar, NH), 1299, 1246 (CO), 1111 (SO2), 744, 666, 
614 (CH Ar); 1H NMR  (CDCl3, 400 MHz) δ 1.28 (6H, s, 2 x Me, Pmc), 1.63-1.66 (2H, m, 2 x 
H Arg), 1.76-1.96 (7H, m, CH2 Pmc, 1 x Hβ Pro, 2 x H Pro, 2 x H Arg),  2.07 (3H, s, CH3 
from Pmc), 2.27-2.36 (1H, m, 1 x H Pro), 2.51 (6H, m, 2 x, Ar-Me, Pmc), 2.60 (2H, t, J 6.7 
Hz, CH2, Pmc), 3.14-3.26 (2H, m,  2 x Hδ Arg), 3.42-3.47 (1H, m, 1 x Hδ Pro), 3.54-3.61 (1H, 
m, 1 x Hδ Pro), 3.87-3.91 (1H, m, Hα Arg), 4.09-4.13 (1H, m, Hα Pro), 6.38 (3H, br, 3 x NH-
Arg), 7.76 (1 H, br, NH-Arg); 13C NMR  (CDCl3, 101 MHz) δ 12.05, 17.37, 18.42 CH3 (Pmc, 
Me), 21.33  (2 x CH2 Pmc), 21.99 (CH2γ Pro, CH2γ Arg), 25.31, 26.72 CH3 (Pmc, Ar-Me) 28.92 
(CH2β Pro, CH2β Arg), 31.05 (CH2δ Arg), 40.11 (CH2δ Pro), 45.51 (CHα Arg), 56.92 (CHα 
Pro), 58.04 (OCH3), 73.67 (C quaternary Pmc), 118.02, 124.09, 133.01, 134.73, 135.31, 153.66  
(C quaternary), 156.30, 166.19, 169.58 (2 x C=O, C=N);  [found (ES+) 542.2425 [M+Na]+, 








Compound (250) (843 mg, 1.09 mmol) was dissolved in anhydrous DMF (2 mL) and treated 
with Et2NH (2.0 mL, 0.19 mol), at room temperature for 30 min, until the starting material was 
consumed as shown by TLC (8% MeOH/CH2Cl2). The reaction mixture was evaporated to 
dryness then co-evaporated with toluene to remove residual DMF to give an oil. The residue 
was dissolved in MeOH (15 mL) and was stirred at room temperature, for 2 days, until the 
lower UV-active spot was replaced by a new spot at Rf  0.44 (10% MeOH/CH2Cl2). The crude 
material was purified by column chromatography (5-9% MeOH/CH2Cl2 eluent) to give (260)  
as a yellow solid (494 mg, 87%); RP-HPLC (analytical system, gradient 2) Rt = 12.4; [α]19 D 
= -9.42 (c 0.45, in MeOH); Mp 123-128 °C; IR υmax (KBr disc) 3439, 3343 (NH), 2973, 2936 
(CH), 1659, 1571 (C=O), 1447 (Ar, NH), 1299, 1245 (CO), 1110 (SO2), 747, 666, 614 (CH Ar) 
; 1H NMR   (CDCl3, 270 MHz) δ 1.28 (6H, s, 2 x Me, Pmc), 1.63-1.68 (2H, m,  2 x H Arg), 
1.76-1.99 (7H, CH2 Pmc,  1 x Hβ Pro, 2 x Hβ Arg, 2 x H Pro), 2.15 (3H, s, CH3 from Pmc), 
2.29-2.32 (1H, m, 1 x H Pro), 2.51 (6H, m, 2 x  Ar-Me, Pmc), 2.60 (2H, t, J 6.7 Hz, CH2, 
Pmc), 3.14-3.26 (2H, m, 2 x Hδ-Arg), 3.43-3.47 (1H, m, 1  x Hδ Pro), 3.54-3.61 (1H, m, 1 x 
Hδ Pro), 3.88-3.92 (1H, m, Hα Arg), 4.09-4.13 (1H, m, Hα Pro), 6.35 (3H, br, 3 x NH-Arg), 
7.71 (1 H, br, NH-Arg); 13C NMR  (CDCl3, 101 MHz) δ 12.06, 17.37, 18.42 CH3 (Pmc, Me), 
21.35  (2 x CH2 Pmc), 21.99 (CH2γ Pro, CH2γ Arg), 25.31, 26.71 CH3 (Pmc, Ar-Me) 28.89 
(CH2β Pro, CH2β Arg), 31.06 (CH2δ Arg), 40.15 (CH2δ Pro), 45.51 (CHα Arg), 56.95 (CHα 
Pro), 58.03 (OCH3), 73.67 (C quaternary Pmc), 118.03, 124.10, 133.00, 134.72, 135.28, 153.66  
(C quaternary), 156.32, 166.21, 169.52 (2 x C=O, C=N); [found (ES+) 542.2336 [M+Na]+, 
C25H37N5O5Na requires 542.2408]. 
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Cyclo (D-Arg(Pmc)-D-Pro) (261) 
 
 
Compound (251) (320 mg, 0.413 mmol) was dissolved in anhydrous DMF (2 mL) and treated 
with Et2NH (2.0 mL, 0.19 mol), at room temperature for 30 min, until the starting material was 
consumed as shown by TLC (8% MeOH/CH2Cl2). The reaction mixture was evaporated to 
dryness then co-evaporated with toluene to remove residual DMF to give an oil. The residue 
was dissolved in MeOH (15mL) and was stirred at room temperature, for 2 days, until the lower 
UV-active spot was replaced by a new spot at Rf  0.42 (10% MeOH/CH2Cl2). The crude 
material was purified by column chromatography (0-6% MeOH/CH2Cl2 eluent) to give (261) 
as a yellow oil (165 mg, 77%); RP-HPLC (analytical system, gradient 2) Rt = 12.5 min); [α]19 
D = +2.91 (c 3.81, in MeOH); IR υmax (thin film) 3442, 3337 (NH), 2976, 2936 (CH), 1670, 
1579 (C=O), 1442 (Ar, NH), 1298, 1244 (CO), 1110 (SO2), 754, 665 (CH Ar)  1H NMR   
(CDCl3, 400 MHz) δ 1.27 (6H, s, 2 x Me, Pmc), 1.61-1.74  (2H, m, 2 x H Arg), 1.76 (2H, t, J 
6.7 Hz ,CH2, Pmc), 1.82-2.04 (5H, m, 2 x H Pro, 2 x Hβ Arg, 1 x H Pro), 2.06 (3H, s, CH3 
from Pmc), 2.28-2.32 (1H, m, 1 x H Pro), 2.51 (6H, m, 2 x CH3, Ar-Me Pmc), 2.58 (2H, t, J 
6.6 Hz, CH2, Pmc), 3.16-3.17 (2H, m, 2 x Hδ Arg), 3.43-3.55 (2H, m,  2 x Hδ Pro), 4.04-4.08 
(2H, m, Hα Arg, Hα Pro), 6.32 (2.6H, br, 2.6 x NH Arg), 7.45  (0.85 H, br, 0.85 x NH Arg); 
13C NMR  (CDCl3, 101 MHz) δ 12.05, 17.39, 18.43 CH3 (Pmc, Me), 21.34 (2 x CH2 Pmc), 
22.01 (CH2γ Pro, CH2γ Arg), 26.70, 26.73 (Ar-Me, Pmc) 28.20  (CH2 Pro, CH2 Arg ), 32.74 
(CH2δ Arg), 40.70 (CH2δ Pro), 45.23 (CHα Arg), 54.86 (CHα Pro), 59.02 (OCH3), 73.60 (C 
quaternary Pmc), 117.95, 123.96  133.25, 134.75, 135.33 153.52 (C quaternary), 156.40, 









Compound (261) (37 mg, 0.071 mmol) was treated with a solution of TFA/TIPS/H2O 
(95:2.5:2.5, v/v/v) (1 mL) and stirred at room temperature for 3 h. The reaction mixture was 
concentrated under vacuum and the residue dissolved in H2O (10 mL) and extracted with 
CH2Cl2 (3 x 10 mL). The organic layer was dried, filtered and the solvent evaporated to give 
(262) as an oil (33 mg, quantitative yield); 1H NMR (CD3OD, 270 MHz) δ 1.66-1.68 (2H, m, 
2 x H Arg), 1.91-1.98 (5H, 1 x Hβ Pro, 2 x Hγ Pro, 2 x H Arg), 2.30-2.33 (1H, m, 1 x H 
Pro), 3.18-3.27 (2H, m, 2 x Hδ Arg), 3.50-3.59 (2H, m, 2 x Hδ Pro), 4.22 (2H, br, Hα Arg, Hα 
Pro); [found (ES+) 254.1592 [M+H]+, C11H20N5O2 requires 254.1617]. 
 




Compound (256)  (41 mg , 0.086 mmol) was treated with a solution of TFA/TIPS/H2O 
(95:2.5:2.5, v/v/v) (1 mL) and stirred at room temperature for 1 h; additional TIPS (252 µL, 
1.22 x 10-3 mmol) was then added until the reaction mixture was colourless. The reaction 
mixture was evaporated to dryness and the residue dissolved in H2O (10 mL) and extracted with 
CH2Cl2 (3 x 10mL). The organic layer was dried, filtered and  the solvent was evaporated to to 
give (263) as an oil (34 mg, quantitative yield); RP-HPLC (analytical system, gradient 1) Rt = 
2.6 min; IR υmax (thin film) 3306 (NH, OH), 2892 (CH), 1674 (C=O), 1437 (NH), 1198, 1136 
(CO); 1H NMR  (CDCl3, 270 MHz) δ 1.88-2.00 (3H, m, 2 x Hγ Pro, 1 x H Pro), 2.03-2.07 
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(1H, m, Hβ Pro), 2.15-2.28 (1H, m, 1 x Hβ His), 3.30-3.47 (3H, m, 1 x Hβ His, 2 x Hδ-Pro), 
4.23 (1H, br, Hα His), 4.56 (1H, br, Hα Pro), 7.42 (1H, br, NH), 7.90 (1H, br, 1H imidazole 
ring), 8.83 (1H, br, NH); 13C NMR  (CDCl3, 101 MHz) δ 22.19 (CH2Pro), 24.80 (CH2β Pro), 
28.08 (CH2β His), 45.07 (CH2δ Pro), 54.58 (CHα His), 58.9 (CHα Pro), 118.10  (CH=C), 
129.35 (C quaternary), 133.33 (CH=C), 165.04, 169.96 (C=O) 176.17 (CO2H), 205.59 (CF3); 







Compound (257) (20 mg, 0.06 mmol) was dissolved in AcOH (1 mL) and then was treated with 
Pd (black) (1.5 mg) and the reaction mixture was stirred at room temperature under a H2 
atmosphere. The reaction was monitored by TLC. After running the reaction for 4 h 30, the 
starting material was consumed and a new spot at Rf 0.55 (10%MeOH/CH2Cl2) appeared. The 
reaction mixture was filtered through Celite, diluted in EtOH (15 mL) then co-evaporated with 
Et2O to give a mixture of diastereoisomers, (264a) and (264b) as an oil (10.3 mg, 66%); IR 
υmax (thin film) 3260 (NH), 1666 (C=O),  1438 (NH), 1239 (CO);  1H NMR  (CD3OD, 400 
MHz) δ  1.80-2.02 (2H, m, 2 x Hγ Pro), 2.04-2.09 (2H, m, 2 x Hβ Pro), 3.03-3.12 (2H, m, 2 x 
Hβ Tyr), 3.35-3.56 (2 H, m,  2 x Hδ Pro), 3.91-3.98 (0.2 H, m  0.2 x Hα Pro), 4.04-4.07 (0.8 H, 
m, 0.8 x Hα Pro), 4.36 (0.8 H, m, 0.8 x Hα Tyr), 4.43 (0.2 H, m, 0.2 x Hα Tyr), 6.69-6.71 (2H, 
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